Compounds > azathioprine
Page last updated: 2024-10-23

azathioprine and Libman-Sacks Disease

azathioprine has been researched along with Libman-Sacks Disease in 668 studies

Azathioprine: An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed)
azathioprine : A thiopurine that is 6-mercaptopurine in which the mercapto hydrogen is replaced by a 1-methyl-4-nitroimidazol-5-yl group. It is a prodrug for mercaptopurine and is used as an immunosuppressant, prescribed for the treatment of inflammatory conditions and after organ transplantation and also for treatment of Crohn's didease and MS.

Research Excerpts

ExcerptRelevanceReference
"Thirty-eight patients with diffuse glomerulonephritis of systemic lupus erythematosus were randomly assigned to add cyclophosphamide, azathioprine, or nothing to low-dose corticosteroid treatment and have been followed for a mean of 21/3 years thereafter."9.04Cyclophosphamide or azathioprine in lupus glomerulonephritis. A controlled trial: results at 28 months. ( Decker, JL; Klippel, JH; Plotz, PH; Steinberg, AD, 1975)
"A 61-year-old man developed clinical lupus syndrome with positive antinuclear antibody, positive lupus erythematosus (LE) cell preparation, and diffuse proliferative glomerulonephritis following 26 months of procainamide therapy."8.76Glomerulonephritis in procainamide induced lupus erythematosus: report of a case and review of the literature. ( Erickson, DG; Foucar, E; Tung, KS, 1979)
"This observational, retrospective, single-center cohort study aimed to assess pregnancy outcome in women with antiphospholipid antibodies who were treated with hydroxychloroquine in addition to conventional treatment during pregnancy."7.83The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies. ( Cuadrado, MJ; Hunt, BJ; Khamashta, MA; Lliso, G; Sciascia, S; Talavera-Garcia, E, 2016)
"The objective of this study was to evaluate the risk of adverse fetal outcome in systemic lupus erythematosus (SLE) women exposed to azathioprine during pregnancy."7.81Azathioprine during pregnancy in systemic lupus erythematosus patients is not associated with poor fetal outcome. ( Ángeles, U; Jara, LJ; Morales, S; Saavedra, MÁ; Sánchez, A, 2015)
"The efficacy of isoniazid (INAH) prophylaxis against tuberculosis (TB) in patients taking corticosteroid remains controversial."7.73Tuberculosis in systemic lupus erythematosus in an endemic area and the role of isoniazid prophylaxis during corticosteroid therapy. ( Chan, TM; Lau, CS; Lo, Y; Mok, MY; Wong, WS, 2005)
"A patient with systemic lupus erythematosus (SLE) developed pancytopenia when azathioprine (first 2."7.68Pancytopenia in systemic lupus erythematosus related to azathioprine. ( Nossent, JC; Swaak, AJ, 1990)
"to determine the efficacy of danazol therapy in patients with systemic lupus erythematosus with severe autoimmune thrombocytopenia refractory to other therapies."7.67Danazol for the treatment of refractory autoimmune thrombocytopenia in systemic lupus erythematosus. ( Johnson, SC; West, SG, 1988)
"Intensive immunosuppression (IIS) was compared with prednisolone alone over a 2-year period in the treatment of severe connective tissue diseases."7.66Intensive immunosuppression versus prednisolone in the treatment of connective tissue diseases. ( Ansell, BM; de Vere Tyndall, A; Denman, AM; Gumpel, JM; Hollingworth, P; Mertin, J; Platts-Mills, T; Smith, DS, 1982)
"The effects of long-term treatment with azathioprine and prednisolone on T- and B-lymphocytes were studied in 52 patients with lupus nephritis (LN) and chronic glomerulonephritis (GN)."7.66The effects of azathioprine and prednisolone on T- and B-lymphocytes in patients with lupus nephritis and chronic glomerulonephritis. ( Gordovskaya, NB; Shilov, EM; Tareyeva, IE, 1980)
" Acute pancreatitis developed, which we could not relate to her lupus, prednisone administration, viral illness, or other causes."7.66Acute pancreatitis associated with long-term azathioprine therapy. Occurrence in a patient with systemic lupus erythematosus. ( Herskowitz, LJ; Lang, PG; Olansky, S, 1979)
" Chlorambucil may hold advantages over the immunosuppressive drugs normally recommended in this condition, azathioprine and cyclophosphamide, as it appears less liable to cause important marrow suppression and, unlike cyclophosphamide is not associated with alopecia and haemorrhagic cystitis."7.65Treatment of patients with systemic lupus erythematosus including nephritis with chlorambucil. ( Dunnill, MS; Halley, W; Holt, JM; Oliver, DO; Snaith, ML; Stephenson, AC, 1973)
"A 21-year-old woman with a history of systemic lupus erythematosus presented to the emergency department with acute-onset nausea, vomiting, and fevers."5.91Azathioprine-induced hypersensitivity reaction mimicking sepsis in a patient with systemic lupus erythematosus. ( Chao, Y; Kazi, S; McKenzie, PL; Pathak, S, 2023)
" As a conservative therapy for SLE-associated AAC, corticosteroid therapy combined with azathioprine might be beneficial."5.51Systemic Lupus Erythematosus-associated Acute Acalculous Cholecystitis Successfully Treated by a Corticosteroid Combined with Azathioprine. ( Fujiyama, S; Kudo, N; Shimomura, T; Suzushima, H; Takaoka, H, 2019)
"163 patients with diffuse lupus glomerulonephritis, proven by renal biopsy, were divided into four therapeutic trial groups: 67 were put on corticosteroids alone, 11 on corticosteroids and azathioprine, 32 on corticosteroids and cyclophosphamide, and 53 on corticosteroids and chlorambucil and were followed up for several years."5.04Comparison of chlorambucil, azathioprine or cyclophosphamide combined with corticosteroids in the treatment of lupus nephritis. ( Osman, LM; Sabbour, MS, 1979)
"Forty-seven SLE patients with severe renal disease characterized by renal biopsy documentation of diffuse proliferative or membranous glomerulonephritis or the nephrotic syndrome have been treated with azathioprine and prednisone in combination and followed for up to 12 years."5.04Longterm survival of lupus nephritis patients treated with azathioprine and prednisone. ( Barnett, EV; Dornfeld, L; Lee, DB; Liebling, MR, 1978)
"Thirty-eight patients with diffuse glomerulonephritis of systemic lupus erythematosus were randomly assigned to add cyclophosphamide, azathioprine, or nothing to low-dose corticosteroid treatment and have been followed for a mean of 21/3 years thereafter."5.04Cyclophosphamide or azathioprine in lupus glomerulonephritis. A controlled trial: results at 28 months. ( Decker, JL; Klippel, JH; Plotz, PH; Steinberg, AD, 1975)
" A prospective study found great success in transitioning to azathioprine from mycophenolate mofetil prior to pregnancy in patients with quiet lupus nephritis."4.90Systemic lupus erythematosus and pregnancy outcomes: an update and review of the literature. ( Clowse, ME; Peart, E, 2014)
" The earlier use of methotrexate and the introduction of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis have changed the natural characteristics of the disease."4.87[Systemic autoimmune disorders and pregnancy]. ( Kiss, CG; Kiss, E; Poór, G, 2011)
"A 61-year-old man developed clinical lupus syndrome with positive antinuclear antibody, positive lupus erythematosus (LE) cell preparation, and diffuse proliferative glomerulonephritis following 26 months of procainamide therapy."4.76Glomerulonephritis in procainamide induced lupus erythematosus: report of a case and review of the literature. ( Erickson, DG; Foucar, E; Tung, KS, 1979)
"This observational, retrospective, single-center cohort study aimed to assess pregnancy outcome in women with antiphospholipid antibodies who were treated with hydroxychloroquine in addition to conventional treatment during pregnancy."3.83The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies. ( Cuadrado, MJ; Hunt, BJ; Khamashta, MA; Lliso, G; Sciascia, S; Talavera-Garcia, E, 2016)
"The objective of this study was to evaluate the risk of adverse fetal outcome in systemic lupus erythematosus (SLE) women exposed to azathioprine during pregnancy."3.81Azathioprine during pregnancy in systemic lupus erythematosus patients is not associated with poor fetal outcome. ( Ángeles, U; Jara, LJ; Morales, S; Saavedra, MÁ; Sánchez, A, 2015)
"Azathioprine (AZA) is recognized among immunosuppressive medications as relatively safe during pregnancy for women with systemic lupus erythematosus (SLE) requiring aggressive treatment."3.79In utero azathioprine exposure and increased utilization of special educational services in children born to mothers with systemic lupus erythematosus. ( Ganser, MA; Gordon, C; Hyzy, MA; Marder, W; McCune, WJ; Romero, V; Somers, EC, 2013)
"9 g 24-h proteinuria while still in remission of the protein-losing enteropathy, receiving 5 mg prednisone and 100 mg azathioprine daily."3.78Protein-losing enteropathy as initial manifestation of systemic lupus erythematosus. ( Braga, LL; Brandão, LA; Carneiro, FO; Rocha, FA; Sampaio, LR, 2012)
" Compared to controls, cases were higher in body mass index, anti-dsDNA antibody, prevalence of hypertension, antiphospholipid syndrome, and use of immunosuppressive medication, especially azathioprine and methotrexate; they were lower in IgM."3.78Prevalence and risk factors for liver biochemical abnormalities in Canadian patients with systemic lupus erythematosus. ( Aghdassi, E; Fortin, PR; Gladman, DD; Hirschfield, GM; Huang, D; Mosko, J; Su, J; Urowitz, MB, 2012)
" In addition, the long-term results of the ALMS study have demonstrated that mycophenolate mofetil is superior to azathioprine in maintaining the remission in patients with severe lupus nephritis."3.78[Allergo-immunology. Clinical immunology]. ( Chizzolini, C, 2012)
" Serous retinal detachments were confirmed using fluorescein and indocyanine green angiography."3.76OCT follow-up of systemic lupus erythematosus choroidopathy. ( Bouillet, L; Chiquet, C; Kouprianoff, S; Romanet, JP, 2010)
"The efficacy of isoniazid (INAH) prophylaxis against tuberculosis (TB) in patients taking corticosteroid remains controversial."3.73Tuberculosis in systemic lupus erythematosus in an endemic area and the role of isoniazid prophylaxis during corticosteroid therapy. ( Chan, TM; Lau, CS; Lo, Y; Mok, MY; Wong, WS, 2005)
"In an open-label study, 6 patients with moderately active SLE (4 with nephritis and 3 with arthritis refractory to other therapies) were given 4 300-mg doses of infliximab, a chimeric anti-TNFalpha antibody, in addition to immunosuppression with azathioprine or methotrexate."3.72Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. ( Aringer, M; Graninger, WB; Smolen, JS; Steiner, G, 2004)
" We describe a patient suffering from pancytopenia following a combination therapy of azathioprine and allopurinol because of lupus erythematodes and diabetic nephropathy with hyperuricemia."3.72[Panzytopenia from combination therapy with azathioprin and allopurinol]. ( Seidel, W, 2004)
" Azathioprine was generally well tolerated, but 11 drug-associated neutropenias were detected."3.70Identification of thiopurine methyltransferase (TPMT) polymorphisms cannot predict myelosuppression in systemic lupus erythematosus patients taking azathioprine. ( Battaglia, E; Botto, M; Naughton, MA; O'Brien, S; Walport, MJ, 1999)
"This is a case report of fatal cryptococcal meningitis in a child with systemic lupus erythematosus being treated with prednisolone and azathioprine."3.68Cryptococcal meningitis in a child with systemic lupus erythematosus. ( al-Fawaz, IM; al-Rasheed, SA, 1990)
"A patient with systemic lupus erythematosus (SLE) developed pancytopenia when azathioprine (first 2."3.68Pancytopenia in systemic lupus erythematosus related to azathioprine. ( Nossent, JC; Swaak, AJ, 1990)
"A boy with microcephaly, unusual facial features, micropenis, and growth retardation was born to a 30-year-old woman who took azathioprine and prednisone before and during pregnancy for systemic lupus erythematosus."3.67Two chromosome aberrations in the child of a woman with systemic lupus erythematosus treated with azathioprine and prednisone. ( Ostrer, H; Perinchief, P; Stamberg, J, 1984)
"A 30-year-old woman, suffering from systemic lupus erythematosus and treated with azathioprine and methyl-prednisolone, developed seven molluscum contagiosum lesions of the upper part of her left calf."3.67Multiple lesions of molluscum contagiosum with metaplastic ossification. ( Lachapelle, JM; Naert, F, 1989)
"to determine the efficacy of danazol therapy in patients with systemic lupus erythematosus with severe autoimmune thrombocytopenia refractory to other therapies."3.67Danazol for the treatment of refractory autoimmune thrombocytopenia in systemic lupus erythematosus. ( Johnson, SC; West, SG, 1988)
"We evaluated retrospectively the effect of superimposed pregnancy upon the course of systemic lupus erythematosus (SLE) in patients receiving glucocorticoids or azathioprine at conception."3.67Pregnancy among patients with systemic lupus erythematosus receiving immunosuppressive therapy. ( Dorsey, JK; Meehan, RT, 1987)
"Intensive immunosuppression (IIS) was compared with prednisolone alone over a 2-year period in the treatment of severe connective tissue diseases."3.66Intensive immunosuppression versus prednisolone in the treatment of connective tissue diseases. ( Ansell, BM; de Vere Tyndall, A; Denman, AM; Gumpel, JM; Hollingworth, P; Mertin, J; Platts-Mills, T; Smith, DS, 1982)
"The effects of long-term treatment with azathioprine and prednisolone on T- and B-lymphocytes were studied in 52 patients with lupus nephritis (LN) and chronic glomerulonephritis (GN)."3.66The effects of azathioprine and prednisolone on T- and B-lymphocytes in patients with lupus nephritis and chronic glomerulonephritis. ( Gordovskaya, NB; Shilov, EM; Tareyeva, IE, 1980)
"Patients with lupus glomerulonephritis improved after various combinations of azathioprine or cyclophosphamide and prednisone treatment in uncontrolled studies reported in the early 1970s."3.66Cytotoxic drug treatment of lupus nephritis. ( Donadio, JV; Holley, KE; Ilstrup, DM, 1982)
"An infant born with preaxial polydactyly to a mother taking azathioprine throughout pregnancy is described."3.66Azathioprine teratogenicity: review of the literature and case report. ( Karp, LE; Williamson, RA, 1981)
" Acute pancreatitis developed, which we could not relate to her lupus, prednisone administration, viral illness, or other causes."3.66Acute pancreatitis associated with long-term azathioprine therapy. Occurrence in a patient with systemic lupus erythematosus. ( Herskowitz, LJ; Lang, PG; Olansky, S, 1979)
"Cord blood levels of immunoglobulin (Ig) A, IgM, IgD, and IgG classes and IgA and IgA subclasses were determined in the offspring of seven mothers who received azathioprine and/or prednisone during the entire pregnancy."3.65Fetal immunoglobulin synthesis following maternal immunosuppression. ( Cederqvist, LL; Litwin, SD; Merkatz, IR, 1977)
"Blastic transformation of peripheral blood lymphocytes following stimulation with phytohemagglutinin during immunosuppressive therapy (prednisone 2 mg/kg body weight, indomethacin 2--3-5 mg/kg, azathioprine 2--4 mg/kg, cyclophosphamide 1-5--3 mg/kg per day) was studied in 59 patients with various morpholigic forms of chronic glomerulonephritis and in 7 with lupus erythematosus nephritis."3.65Blastic transformation of lymphocytes in in vitro cultures during immunosuppressive therapy in patients with glomerulonephritis. ( Falkiewicz, K; Klinger, M; Melcer, H; Szewczyk, Z, 1975)
" Chloroquine should mainly be administered in "lupoid" rheumatoid arthritis (R."3.65[Differential indications in rheumatism therapy on the basis of well-known drug side effects]. ( Mathies, H, 1975)
" In a comparison of these children with SLE, with and without AN, with a group of patients with nephrosis treated with corticosteroids and a group with glomerulonephritis treated with azathioprine, AN was related to the duration of daily steroid therapy rather than the total duration of steroid treatment; this was not true for azathioprine."3.65A vascular necrosis of the femoral head in childhood systemic lupus erythematosus. ( Drummond, KN; Hurley, RM; Patriquin, H; Steinberg, RH, 1974)
" Chlorambucil may hold advantages over the immunosuppressive drugs normally recommended in this condition, azathioprine and cyclophosphamide, as it appears less liable to cause important marrow suppression and, unlike cyclophosphamide is not associated with alopecia and haemorrhagic cystitis."3.65Treatment of patients with systemic lupus erythematosus including nephritis with chlorambucil. ( Dunnill, MS; Halley, W; Holt, JM; Oliver, DO; Snaith, ML; Stephenson, AC, 1973)
" Among the pharmacological alternatives, there are chemically synthesized drugs whose efficacy has been evaluated, but which have the potential to generate adverse events that may compromise adherence and response to treatment."2.82Synthetic Pharmacotherapy for Systemic Lupus Erythematosus: Potential Mechanisms of Action, Efficacy, and Safety. ( Baracaldo-Santamaría, D; Poole, BD; Quaye, A; Rojas-Rodríguez, LC; Téllez Arévalo, AM; Tellez Freitas, CM, 2022)
"We conducted a 6-month open-label dose-escalation clinical study of patients with active SLE treated with azathioprine dosed by body weight and metabolite levels."2.74Use of pharmacogenetics, enzymatic phenotyping, and metabolite monitoring to guide treatment with azathioprine in patients with systemic lupus erythematosus. ( Askanase, AD; Belmont, HM; Bernstein, L; Buyon, JP; Ishimori, M; Izmirly, PM; Seidman, E; Tseng, CE; Wallace, DJ; Weisman, MH, 2009)
" Long-term therapy with infliximab, however, was associated with severe adverse events in two out of three SLE patients, which may have been provoked by infliximab and/or by their long-standing refractory SLE and previous therapies."2.74Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients. ( Aringer, M; Gordon, C; Graninger, WB; Houssiau, F; Rath, E; Smolen, JS; Steiner, G; Voll, RE, 2009)
" Retreatment with an augmented dosage of prednisolone, +/- another immunosuppressive agent, resulted in CR and PR in 15 (79%) and 4 (21%) of these flare episodes, respectively."2.74Very long-term outcome of pure lupus membranous nephropathy treated with glucocorticoid and azathioprine. ( Mok, CC; Ng, WL; Wong, WS; Yim, CW; Ying, KY, 2009)
"Chloroquine may increase complete clinical response at 12 months' follow-up compared with placebo (absence of skin lesions) (risk ratio (RR) 1."2.72Interventions for cutaneous disease in systemic lupus erythematosus. ( Bennett, C; Chen, S; Hannon, CW; Lima, HC; McCourt, C, 2021)
" The primary outcome was time to a major flare of SLE which resulted in either the institution of or an increase in the current dosage of prednisone of 10 mg/day or more, or institution of therapy with immunosuppressive agents."2.69A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. ( Choquette, D; Cividino, A; Danoff, D; Esdaile, JM; Joseph, L; Osterland, CK; Senécal, JL; Smith, CD; Tsakonas, E; Yeadon, C, 1998)
"Treatment with prednisone as soon as a significant rise in anti-dsDNA occurs prevents relapse in most cases, without increasing the cumulative dose of prednisdone given."2.68Prevention of relapses in systemic lupus erythematosus. ( Bootsma, H; de Boer, G; Derksen, R; Gmelig-Meyling, F; Hermans, J; Kallenberg, C; Kater, L; Limburg, P; Spronk, P; Wolters-Dicke, H, 1995)
"Forty-one patients with systemic lupus erythematosus and glomerulonephritis were studied in a randomized drug trial."2.65Alternative modes of cyclophosphamide and azathioprine therapy in lupus nephritis. ( Balow, JE; Decker, JL; Dinant, HJ; Klippel, JH; Plotz, PH; Steinberg, AD, 1982)
"Azathioprine was hepatotoxic in doses of 200 mg daily or more."2.64Azathioprine plus prednisone compared with prednisone alone in the treatment of systemic lupus erythematosus. Report of a prospective controlled trial in 24 patients. ( Hahn, BH; Kantor, OS; Osterland, CK, 1975)
"Acute pancreatitis is an uncommon complication that occurs in 0."2.61Corticosteroid-associated lupus pancreatitis: a case series and systematic review of the literature. ( Adarsh, MB; Dhir, V; Dhooria, A; Dwivedi, P; Jain, S; Kakkar, N; Kumar, RR; Malhotra, S; Naidu, S; Sharma, A; Sharma, SK, 2019)
" These studies provide a compelling case for a re-evaluation of the long-term use of glucocorticoids in SLE, focusing on minimizing glucocorticoid exposure as part of the strategy to improve long-term outcomes."2.55It hasn't gone away: the problem of glucocorticoid use in lupus remains. ( Apostolopoulos, D; Morand, EF, 2017)
" These agents are generally used in fixed, weight-based dosing regimens, and both incomplete response and adverse effects are common."2.52Optimizing the use of existing therapies in lupus. ( Croyle, L; Morand, EF, 2015)
"Management of patients with lupus nephritis can be complex and challenging."2.50Ten common mistakes in the management of lupus nephritis. ( Bargman, JM; Bose, B; Silverman, ED, 2014)
"Longitudinally extensive transverse myelitis (LETM) is a frequently devastating clinical syndrome which has come into focus for its association with neuromyelitis optica (NMO)."2.50Longitudinally extensive transverse myelitis. ( Lucchinetti, CF; Tobin, WO; Weinshenker, BG, 2014)
"Most reports on APF suggest systemic lupus erythematosus (SLE) as the major immunological associated disorder but the association with autoimmune hepatitis (AH) has not been previously documented."2.49Amicrobial pustulosis of the folds associated with autoimmune disorders: systemic lupus erythematosus case series and first report on the association with autoimmune hepatitis. ( Charli-Joseph, Y; Fernández Sánchez, M; Méndez-Flores, S; Orozco-Topete, R; Saeb-Lima, M, 2013)
"Azathioprine-induced aplastic anemia and fatal myelosuppression is a rare occurrence in patients with systemic lupus erythematosus (SLE)."2.49Aplastic anemia secondary to azathioprine in systemic lupus erythematosus: report of a case with normal thiopurine S-methyltransferase enzyme activity and review of the literature. ( Afkhami, M; Brynes, RK; Quismorio, FP; Yeter, KC, 2013)
"A 14-year-old girl with systemic lupus erythematosus presented with a mixed overdose of paracetamol, ibuprofen and azathioprine (1500 mg) following a deliberate self-harm attempt."2.49Intentional overdose of azathioprine in a patient with systemic lupus erythematosus. ( Khan, AM; Mahmood, K; Martin, K; Ramanan, AV, 2013)
"Arthritis in systemic lupus erythematosus (SLE) is episodic and self-limited in most patients."2.48How to treat refractory arthritis in lupus? ( Artifoni, M; Puéchal, X, 2012)
"Proliferative lupus nephritis is a strong predictor of morbidity and mortality in patients with systemic lupus erythematosus."2.48Dutch guidelines for diagnosis and therapy of proliferative lupus nephritis. ( Berden, JH; Berger, SP; Bijl, M; de Sévaux, RG; Derksen, RH; van Tellingen, A; Vervloet, MG; Voskuyl, AE, 2012)
"Adequate pregnancy care of women with systemic lupus erythematosus (SLE) rests on three pillars: a coordinated medical-obstetrical care, an agreed and well-defined management protocol and a good neonatal unit."2.47Lupus and pregnancy: integrating clues from the bench and bedside. ( Khamashta, MA; Ruiz-Irastorza, G, 2011)
" Future research will be important to more fully understand the best dosing regimen of MMF for induction versus maintenance treatment, total duration of treatment, and the utility of therapeutic monitoring of MMF levels."2.47Mycophenolate mofetil in the treatment of systemic lupus erythematosus. ( Dall'Era, M, 2011)
"Azathioprine (AZA) has immunosuppressive property and has been widely used in organ transplantation and in several autoimmune diseases including systemic lupus erythematosus."2.46Inosine triphosphate pyrophosphatase 94C>A polymorphism: clinical implications for patients with systemic lupus erythematosus treated with azathioprine. ( Hiromura, K; Nakamura, K; Nakamura, T; Nojima, Y; Okada, Y; Yamamoto, K, 2010)
"Hypoparathyroidism is rare in patients with systemic lupus erythematosus (SLE)."2.46Hypoparathyroidism in a patient with systemic lupus erythematosus coexisted with ankylosing spondylitis: a case report and review of literature. ( Dai, X; Jiang, L; Liu, J; Ma, L; Yu, F, 2010)
"Pregnancy in a woman with systemic lupus erythematosus (SLE) can be complicated by both lupus activity and pregnancy mishaps."2.44Lupus activity in pregnancy. ( Clowse, ME, 2007)
"Sensorineural hearing loss has been described in autoimmune disorders but is rare."2.44Sensorineural hearing loss in systemic lupus erythematosus: case report and literature review. ( Khalidi, NA; Rebello, R; Robertson, DD, 2008)
"Massive refractory pleural effusions are uncommon in patients with systemic lupus erythematosus."2.43Therapeutic options for refractory massive pleural effusion in systemic lupus erythematosus: a case study and review of the literature. ( Breuer, GS; Deeb, M; Fisher, D; Nesher, G, 2005)
"Optic neuropathy is a well-known ocular manifestation occurring in patients with systemic lupus erythematosus (SLE), and it remains one of the major causes of blindness in these patients."2.40Optic neuropathy in systemic lupus erythematosus and antiphospholipid syndrome (APS): clinical features, pathogenesis, review of the literature and proposed ophthalmological criteria for APS diagnosis. ( Balacco Gabrieli, C; Giorgi, D, 1999)
"Therapy in pediatric systemic lupus erythematosus (SLE) is reviewed by examining the pediatric experience, including uncontrolled retrospective observations and case reports."2.39What's new in the treatment of pediatric SLE. ( Silverman, E, 1996)
"Laryngeal involvement in systemic lupus erythematosus (SLE) can range from mild ulcerations, vocal cord paralysis, and edema to necrotizing vasculitis with airway obstruction."2.38Laryngeal involvement in systemic lupus erythematosus. ( MacKenzie, CR; Paget, SA; Stern, R; Teitel, AD, 1992)
"Prior to 1975 patients with systemic lupus erythematosus were generally not considered candidates for renal transplantation because of concern that immune complex deposition would rapidly destroy the allograft."2.38Renal transplantation for systemic lupus erythematosus and recurrent lupus nephritis. A single-center experience and a review of the literature. ( Cole, BR; Goss, JA; Hanto, DW; Jendrisak, MD; McCullough, CS; So, SK; Windus, DW, 1991)
"Azathioprine is a valuable alternative to slow-acting antirheumatic drugs in older patients with rheumatoid arthritis."2.38Azathioprine, cyclophosphamide and chlorambucil. ( Bacon, PA; Luqmani, RA; Palmer, RG, 1990)
"Children with systemic lupus erythematosus and nephritis may benefit from the addition of cytotoxic agents to their corticosteroid regime, although the indications for this are not clear, and controlled evidence is lacking."2.36Immunosuppressive agents in the treatment of the nephrotic syndrome and glomerulonephritis in children. ( Cameron, JS, 1979)
"Extensive serologic changes occur in systemic lupus erythematosus (SLE) which are probably secondary to unknow primary cause(s)."2.35Serologic abnormalities in spontaneous and drug-induced systemic lupus erythematosus. ( Dubois, EL, 1975)
"Bullous systemic lupus erythematosus (BSLE) is a rare cutaneous manifestation of SLE presenting as tense vesiculobullous eruptions in a photosensitive distribution."1.91Successful treatment of bullous lupus with corticosteroids and belimumab: A case report. ( Bansal, P; Fibeger, E; Keshavamurthy, C; Virata, A, 2023)
"A 21-year-old woman with a history of systemic lupus erythematosus presented to the emergency department with acute-onset nausea, vomiting, and fevers."1.91Azathioprine-induced hypersensitivity reaction mimicking sepsis in a patient with systemic lupus erythematosus. ( Chao, Y; Kazi, S; McKenzie, PL; Pathak, S, 2023)
"Azathioprine was switched to mycophenolate mofetil, and the patient showed significant improvement in proteinuria."1.91Fibrillar glomerulonephritis in a patient with systemic lupus erythematosus with no evidence of lupus nephritis. ( Patrick, J; Thirunavukkarasu, S; Whelband, MC; Willingham, T, 2023)
"Lupus profundus, often known as lupus panniculitis, is a rare form of persistent cutaneous lupus erythematosus."1.72Intravenous immunoglobulin in the management of refractory lupus profundus. ( Abdulla, FA; Elarabi, M; Namas, R, 2022)
"LON was not observed in minimal change disease or focal segmental glomerulosclerosis."1.62Incidence, Clinical Features, and Outcomes of Late-Onset Neutropenia From Rituximab for Autoimmune Disease. ( Cortazar, FB; Huizenga, NR; Laliberte, K; Niles, JL; Rhee, EP; Rosenthal, JM; Wallace, ZS; Zonozi, R, 2021)
"Nephritis occurs frequently in systemic lupus erythematosus (SLE) and may worsen disease morbidity and mortality."1.56Comparison of lupus patients with early and late onset nephritis: a study in 71 patients from a single referral center. ( Delfino, J; Dos Santos, TAFG; Skare, TL, 2020)
" However, these small chemical drugs suffer from poor solubility, short circulating half-life and adverse side effects."1.56A novel long-acting azathioprine polyhydroxyalkanoate nanoparticle enhances treatment efficacy for systemic lupus erythematosus with reduced side effects. ( Hu, J; Li, S; Wang, M; Wei, D; Xiao, X; Xie, Q; Xu, X; Zhang, B; Zhang, X; Zheng, Z, 2020)
"A young woman with systemic lupus erythematosus (SLE) developed recurrent enterovirus meningoencephalitis while taking prednisolone, azathioprine and rituximab."1.51Balancing immunosuppression and infection: recurrent enterovirus encephalitis in SLE. ( Bunting, E; Cheema, S; Good, C; Hajela, V; Ridha, BH; Saha, RA, 2019)
" As a conservative therapy for SLE-associated AAC, corticosteroid therapy combined with azathioprine might be beneficial."1.51Systemic Lupus Erythematosus-associated Acute Acalculous Cholecystitis Successfully Treated by a Corticosteroid Combined with Azathioprine. ( Fujiyama, S; Kudo, N; Shimomura, T; Suzushima, H; Takaoka, H, 2019)
"Background and objective Acute transverse myelitis (TM) is an infrequent neurological complication of systemic lupus erythematosus (SLE)."1.48Natural history of longitudinally extensive transverse myelitis in 35 Hispanic patients with systemic lupus erythematosus: good short-term functional outcome and paradoxical increase in long-term mortality. ( Aguirre-Villarreal, D; Cantú-Brito, C; Ceballos-Ceballos, J; Dávila-Maldonado, L; Díaz de León-Sánchez, E; Flores-Silva, FD; Fragoso-Loyo, H; González-Duarte, A; Guraieb-Chaín, P; Higuera-Calleja, J; Longoria-Lozano, O; Morales-Moreno, S; Murra-Antón, S; Quintanilla-González, L; Sentíes-Madrid, H; Treviño-Frenk, I; Valdés-Ferrer, SI; Vega-Boada, F, 2018)
"All p values were less than 0."1.48Invasive aspergillosis in patients with systemic lupus erythematosus: a retrospective study on clinical characteristics and risk factors for mortality. ( Chang, DM; Chen, MH; Chen, WS; Hung, ML; Lai, CC; Liao, HT; Tsai, CY, 2018)
"While infection burden is high among patients with systemic lupus erythematosus (SLE), there is uncertainty about whether infection rates differ by immunosuppressive drug regimens."1.46Comparative Rates of Serious Infections Among Patients With Systemic Lupus Erythematosus Receiving Immunosuppressive Medications. ( Costenbader, KH; Feldman, CH; Franklin, JM; Guan, H; Kim, SC; Marty, FM; Solomon, DH; Winkelmayer, WC, 2017)
"Juvenile systemic lupus erythematosus (JSLE) is a complex multisystemic autoimmune disorder of unknown cause."1.46Juvenile systemic lupus erythematosus in Nigeria. ( Adelowo, OO; Akintayo, RO; Animashaun, BA; Olaosebikan, BH, 2017)
"Azathioprine sodium use was observed more frequently in cases (odds ratio [OR], 7."1.46Association of Therapy for Autoimmune Disease With Myelodysplastic Syndromes and Acute Myeloid Leukemia. ( Al-Kali, A; Castro, J; Dueck, A; Ertz-Archambault, N; Finn, L; Foran, J; Gauthier, S; Kelemen, K; Kosiorek, H; Marino, R; Mesa, RA; Palmer, J; Sproat, LZ; Taylor, GE; Tibes, R, 2017)
"Psoriasis was diagnosed in 63 patients (49 females, 14 males) for a prevalence of 3."1.46Psoriasis in systemic lupus erythematosus: a single-center experience. ( Gladman, DD; Pakchotanon, R; Polachek, A; Su, J; Tselios, K; Urowitz, MB; Yap, KS, 2017)
"Hydroxychloroquine was the most common (76%), followed by azathioprine (15%) and methotrexate (13%)."1.43Drugs used in incident systemic lupus erythematosus - results from the Finnish nationwide register 2000-2007. ( Elfving, P; Kaipiainen-Seppänen, O; Kautiainen, H; Pohjolainen, T; Puolakka, K; Virta, LJ, 2016)
" Cases (1555 patients with SLE who developed HZ) and controls (3049 age- and sex-matched patients with SLE but without HZ) were analyzed for use of various immunosuppressive medications in the preceding 3-month period, and dose-response relationships were determined."1.43Immunosuppressive medication use and risk of herpes zoster (HZ) in patients with systemic lupus erythematosus (SLE): A nationwide case-control study. ( Chen, GS; Hu, SC; Lin, CL; Lin, YC; Wang, TN; Yen, FL, 2016)
"Diabetes mellitus is often severe, usually transient, and poorly responsive to exogenous insulin."1.43Diabetic Ketoacidosis Without Diabetes. ( Kim, C; Steenkamp, D; Upadhyay, J; Willard, D, 2016)
"Retrospective review of AILD [autoimmune hepatitis type 1 and 2 (AIH1, AIH2), primary sclerosing cholangitis (PSC) and autoimmune sclerosing cholangitis (ASC)] seen at two pediatric liver units in Malaysia."1.42Characteristics and outcome of autoimmune liver disease in Asian children. ( Boey, CC; Chong, SY; Khoh, KM; Lee, WS; Lim, CB; Lum, SH; Ng, RT; Pailoor, J; Teo, KM, 2015)
"Azathioprine was discontinued due to hematological toxicity and failure to control SLE."1.42First report of multi-drug resistant tuberculosis in a systemic lupus erythematosus patient. ( Dierberg, KL; Dorjee, K; Reingold, AL; Sadutshang, TD, 2015)
" This study aims to detect TPMT polymorphisms and TPMT enzyme activity in Chinese SLE patients and to describe the association between TPMT genotypes and adverse effects of AZA."1.40Association of thiopurine methyltransferase status with azathioprine side effects in Chinese patients with systemic lupus erythematosus. ( Chen, D; Lian, F; Liang, L; Qiu, Q; Wang, Y; Xu, H; Yang, X; Ye, Y; Yuan, S; Zhan, Z, 2014)
"The coexistence of systemic lupus erythematosus (SLE) and multiple sclerosis (MS) in the same individual has rarely been described."1.40Coexistence of systemic lupus erythematosus and multiple sclerosis: prevalence, clinical characteristics, and natural history. ( Amoiridis, G; Bertsias, G; Boumpas, DT; Fanouriakis, A; Mastorodemos, V; Pamfil, C; Papadaki, E; Plaitakis, A; Sidiropoulos, P, 2014)
"Treatment of thrombocytopenia in systemic lupus erythematosus (SLE) is considered in cases of current bleeding, severe bruising, or a platelet count below 50,000/µL."1.39Two cases of refractory thrombocytopenia in systemic lupus erythematosus that responded to intravenous low-dose cyclophosphamide. ( Chung, SJ; Kang, MI; Kang, Y; Lee, SK; Lee, SW; Park, HJ; Park, YB, 2013)
"A kidney biopsy showed ISN class II lupus nephritis."1.39Lupus enteritis: an uncommon manifestation of systemic lupus erythematosus. ( Petri, M; Smith, LW, 2013)
"Haematological involvement of systemic lupus erythematosus (SLE) - which ranges from the well-described haemolytic anaemia to macrophage activation syndrome - has a large impact on both morbidity and mortality."1.38Acute lymphoblastic leukaemia in a child with systemic lupus erythematosus. ( Besbas, N; Bilginer, Y; Bulus, D; Cetin, M; Gokce, M; Gumruk, F, 2012)
"The aim of our study was to investigate systemic lupus erythematosus (SLE) related protein-losing enteropathy (PLE) in the following areas: clinical features, laboratory, endoscopic and imaging characteristics, treatment and outcome."1.38The clinical characteristics of lupus related protein-losing enteropathy in Hong Kong Chinese population: 10 years of experience from a regional hospital. ( Law, ST; Li, KK; Ma, KM, 2012)
"Systemic lupus erythematosus is a chronic autoimmune disorder which affects women with child bearing potential."1.38[Successful completed pregnancies in patients with systemic lupus erythematosus]. ( Kiss, E; Szegedi, G; Tarr, T; Zeher, M, 2012)
"Chagas disease is a zoonosis caused by the protozoan Trypanosoma cruzi."1.38Reactivation of Chagas disease by immunosuppressive therapy in a patient with systemic lupus erythematosus: report of an exceptional case. ( Burgos, LG; Canese, A; Melo, M; Ojeda, A; Ortiz, BD, 2012)
"The mean SLE duration, SLEDAI score, and azathioprine dosage prescribed were 5."1.38Effect of genetic polymorphisms on effectiveness of low-dose azathioprine in Japanese patients with systemic lupus erythematosus. ( Aomori, T; Araki, T; Hiromura, K; Nagamine, A; Nakamura, T; Nojima, Y; Okada, Y; Takenaka, M; Yamamoto, K, 2012)
"Neuromyelitis optica (NMO, Devic's disease), an uncommon demyelinating neuro-immunological disease, can be associated with autoimmune diseases."1.37Devic's syndrome and SLE: challenges in diagnosis and therapeutic possibilities based on two overlapping cases. ( Kiss, EV; Matolcsi, J; Müller, V; Polgár, A; Poór, G; Rózsa, C, 2011)
"A 36-year-old woman with systemic lupus erythematosus was admitted to our hospital with malaise, myalgia, dysphagia, fever, preserved muscle strength, leukocytosis (15,600 cells), and increased creatine kinase of 1,358 IU/L that reached 75,000 IU/L in few days."1.37Fatal rhabdomyolysis in systemic lupus erythematosus. ( Bonfa, E; da Mota, LM; de Carvalho, JF, 2011)
"Lymphopenia is a common clinical manifestation in patients with systemic lupus erythematosus (SLE)."1.37Quantitative and functional profiles of CD4+ lymphocyte subsets in systemic lupus erythematosus patients with lymphopenia. ( Alcocer-Varela, J; Crispín, JC; Díaz-Zamudio, M; Gómez-Martín, D; Vanoye, G, 2011)
"Treatment with prednisolone and azathioprine led to fast and durable resolution of symptoms."1.37[Protein-losing enteropathy: a cause of hypoalbuminaemia in patients with systemic lupus erythematosus]. ( Briem, S; Fiehn, C; Mühleisen, H; Weis, D; Xanthouli, P, 2011)
"SLE patients with lupus nephritis or positive anti-dsDNA antibodies had significantly higher serum CXCL13 levels."1.36Serum BLC/CXCL13 concentrations and renal expression of CXCL13/CXCR5 in patients with systemic lupus erythematosus and lupus nephritis. ( Chen, WS; Hsu, YH; Lee, HT; Shiao, YM; Tsai, CY; Tsai, SF; Wu, TH, 2010)
"Neuroendocrine tumors are rare and localised to the stomach in only 2 - 4 %."1.36[Gastric neuroendocrine tumors in a woman with systemic lupus erythematosus]. ( Braun, B; Döcker, D; Marx, U, 2010)
"Azathioprine was given to 43."1.35Lupus nephritis among 624 cases of systemic lupus erythematosus in Riyadh, Saudi Arabia. ( Al Arfaj, AS; Al Saleh, S; Khalil, N, 2009)
"Azathioprine treatment was associated with increased CIMT."1.35Premature atherosclerosis in pediatric systemic lupus erythematosus: risk factors for increased carotid intima-media thickness in the atherosclerosis prevention in pediatric lupus erythematosus cohort. ( Ardoin, SP; Barnhart, HX; Bowyer, SL; Brunner, HI; Eberhard, A; Evans, GW; Higgins, GC; Ilowite, NT; Jung, L; Kimura, Y; Klein-Gitelman, M; Levy, DM; McCurdy, D; Mieszkalski, KL; Punaro, L; Reed, A; Sandborg, C; Schanberg, LE; Sherry, DD; Silver, R; Silverman, E; Singer, NG; Soep, JB; von Scheven, E; Wagner-Weiner, L; Wallace, C; Yow, E, 2009)
"Hypereosinophilic syndrome (HES) and systemic lupus erythematosus may be considered to have occurred concurrently in this patient."1.35Systemic lupus erythematosus and hyper-eosinophilic syndrome: an unusual association. ( Aaflaki, E; Ali Nazarinia, M; Ali Ostovan, M; Habibagahi, Z; Hadi Bagheri, M, 2009)
"Diplopia is frequently encountered in neurological practice and may occur as part of the clinical spectrum of 3rd cranial nerve palsy."1.35Third cranial nerve palsy or pseudo 3rd nerve palsy of myasthenia gravis? A challenging diagnosis in systemic lupus erythematosus. ( Appenzeller, S; Clarke, A; Veilleux, M, 2009)
"Heart failure is a rare but life-threatening manifestation of cardiac involvement in SLE."1.35Heart failure as presenting manifestation of cardiac involvement in systemic lupus erythematosus. ( Bax, JJ; Boumpas, DT; Huizinga, TW; Kritikos, H; Mollema, SA; Schoe, A; van der Laan-Baalbergen, NE; van Laar, JM, 2009)
"Maintenance therapy of severe pediatric systemic lupus erythematosus (SLE) usually consists of azathioprine and prednisone ."1.35Experience with mycophenolate mofetil as maintenance therapy in five pediatric patients with severe systemic lupus erythematosus. ( Amann, K; Benz, K; Dittrich, K; Dötsch, J; Ross, S, 2009)
"We calculated the hazard ratio (HR) for cancer after exposure to an immunosuppressive drug, in models that controlled for other medications (anti-malarial drugs, systemic glucocorticoids, non-steroidal anti-inflammatory drugs (NSAIDs), aspirin), smoking, age, sex, race/ethnicity, geographic location, calendar year, SLE duration, and lupus damage scores."1.35The relationship between cancer and medication exposures in systemic lupus erythaematosus: a case-cohort study. ( Alarcón, GS; Aranow, C; Bae, SC; Barr, S; Bernatsky, S; Boivin, JF; Clarke, AE; Dooley, MA; Edworthy, S; Fortin, PR; Ginzler, E; Gladman, D; Gordon, C; Isenberg, D; Joseph, L; Manzi, S; Petri, M; Rahman, A; Rajan, R; Ramsey-Goldman, R; Sénécal, JL; Urowitz, M; Zummer, M, 2008)
"Azathioprine (AZA) is a commonly used immunosuppressant for systemic lupus erythematosus (SLE)."1.35Azathioprine-induced fatal myelosuppression in systemic lupus erythematosus patient carrying TPMT*3C polymorphism. ( Angsuthum, S; Avihingsanon, Y; Boonsrirat, U; Hirankarn, N; Kongpunvijit, J; Tassaneeyakul, W; Vannaprasaht, S, 2008)
"However, bleeding is rare in this syndrome."1.35Bleeding and thrombosis in a patient with secondary antiphospholipid syndrome. ( Abdallah, TB; Beji, S; El Younsi, F; Ezzine, S; Guermazi, S; Hamida, FB; Kaaroud, H; Kheder, A; Moussa, FB, 2008)
"Patients who developed renal and CNS disease more than 1 year after diagnosis had higher SLEDAI scores at disease onset."1.35Clinical and laboratory characteristics and long-term outcome of pediatric systemic lupus erythematosus: a longitudinal study. ( Benseler, SM; Harvey, E; Hebert, D; Hiraki, LT; Silverman, ED; Tyrrell, PN, 2008)
"Leg ulcerations can occur in systemic lupus erythematosus (SLE) patients with antiphospholipid (aPL) antibodies and/or vasculitis, and it has been suggested that aPL antibodies may play a pathogenetic role in skin manifestations of SLE."1.34Lupus and leg ulcers--a diagnostic quandary. ( Boyce, S; Dziadzio, M; Hamdulay, S; Keat, A; Prasad, N; Reddy, V, 2007)
"Azathioprine is an immunosuppressant prescribed for the treatment of inflammatory conditions and after organ transplantation."1.34Current use of pharmacogenetic testing: a national survey of thiopurine methyltransferase testing prior to azathioprine prescription. ( Bruce, I; Elliott, R; Fargher, EA; Newman, W; Payne, K; Roberts, SA; Shaffer, JL; Tricker, K, 2007)
" A young patient presenting with toxic maculopathy after 57 g of hydroxychloroquine and a daily dosage of 2 mg/kg body weight prompted us to retrospectively look at our patients examined in this respect over about 1 year."1.34[Chloroquine/hydroxychloroquine: variability of retinotoxic cumulative doses]. ( Berndt, S; Foerster, J; Rüther, K; Schroeter, J, 2007)
"Patients with systemic lupus erythematosus (SLE) often produce autoantibodies against a large number of antigens."1.33Isaacs' syndrome (autoimmune neuromyotonia) in a patient with systemic lupus erythematosus. ( Taylor, PW, 2005)
"Azathioprine (AZA), which was used in treatment of 12 SLE patients, was invariably associated with low values of killing activity."1.33Natural killer cell activity in families of patients with systemic lupus erythematosus: demonstration of a killing defect in patients. ( Green, MR; Isenberg, DA; Kennell, AS; Larche, MJ; Salaman, MR; Seifert, MH, 2005)
"Preventive treatment during pregnancy, however, before the critical period of cardiac development, can prevent the development of CHB."1.33Successful preventive treatment of congenital heart block during pregnancy in a woman with systemic lupus erythematosus and anti-Sjögren's syndrome A/Ro antibody. ( Chen, JY; Lee, SC; Luo, SF; Yang, CH, 2005)
"Influenza vaccination in SLE patients with quiescent disease is safe but is less effective than in controls."1.33Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease. ( Benne, CA; Bijl, M; De Vries, JJ; Holvast, A; Horst, G; Huckriede, A; Kallenberg, CG; Wilschut, J, 2006)
"The authors report a case of systemic lupus erythematosus with posterior leukoencephalopathy who presented with headache, tonic-clonic seizure, loss of consciousness and bilateral loss of vision, after taking azathioprine for three weeks."1.33Reversible posterior leukoencephalopathy caused by azathioprine in systemic lupus erythematosus. ( Chamadol, N; Foocharoen, C; Sawanyawisuth, K; Srinakarin, J; Tiamkao, S, 2006)
"Lupus anticoagulant hypoprothrombinemia syndrome (LAHPS) is a rare disorder characterized by a bleeding tendency due to factor II deficiency associated with the presence of lupus anticoagulant (LAC) autoantibodies."1.33Thromboembolism complicating the treatment of lupus anticoagulant hypoprothrombinemia syndrome. ( Rich, E; Senécal, JL; Vinet, E, 2006)
"We report an unusual case of systemic lupus erythematosus presented with protein-losing enteropathy."1.33A case of systemic lupus erythematosus presenting with protein-losing enteropathy. ( Cinar, K; Duman, N; Ensari, A; Idilman, R; Küçük, O; Ozden, A; Ozyüncü, N; Türkçapar, N, 2006)
"Urticarial vasculitis is a small-vessel vasculitis, presenting clinically as persistent urticarial skin lesions and microscopically as leucocytoclastic vasculitis."1.33Hypocomplementemic urticarial vasculitis: a rare presentation of systemic lupus erythematosus. ( Adim, SB; Aydogan, K; Karadogan, SK; Tunali, S, 2006)
"The frequency of cancer-associated mortality was 11% that was 2% of the total lupus population."1.33[The occurrence of malignancies in a Hungarian lupus population]. ( Kiss, E; Szegedi, G; Szekanecz, E; Tarr, T; Zeher, M, 2006)
"The association psoriasis and systemic lupus erythematosus (SLE) is a very uncommon association."1.32[Psoriasis and systemic lupus erythematosus: a rare association with specific therapeutic problems]. ( Arlet, P; Astudillo, L; Carreiro, M; Dahan, S; Ollier, S; Sailler, L, 2003)
"To evaluate the value of genotype-based dosing by polymerase chain reaction (PCR)-based polymorphism screening in terms of cost-effectiveness for treatment with azathioprine in Korea."1.32Pharmacoeconomic analysis of thiopurine methyltransferase polymorphism screening by polymerase chain reaction for treatment with azathioprine in Korea. ( Anis, AH; Bae, SC; Oh, KT, 2004)
"Bullous systemic lupus erythematosus is a rare disease associated with subepidermal blistering and, in most cases, severe systemic manifestations."1.32[Bullous systemic lupus erythematosus]. ( Bacman, D; Kuhn, A; Megahed, M; Ostendorf, B; Ruzicka, T; Schneider, M, 2004)
"The diagnostic criteria for systemic lupus erythematosus (SLE) were not fulfilled either."1.32Late puerperal thrombohemorrhagic complications in a patient with antiphospholipid syndrome. ( Bladt, V; d'Amore, F; Laursen, B; Petersen, OB; Poulsen, LH; Steengaard-Pedersen, K, 2004)
"Zoledronic acid is a new intravenous bisphosphonate that has been approved by the US FDA for use with hypercalcemia of malignancies and might be an effective treatment for postmenopausal osteoporosis."1.32The effect of intravenous zoledronic acid on glucocorticoid-induced multiple vertebral fractures in juvenile systemic lupus erythematosus. ( Borges, CT; Jorgetti, V; Pereira, RM; Souza, SC, 2004)
"The overlapping syndrome of systemic lupus erythematosus, autoimmune hepatitis, and autoimmune hyperlipidemia is discussed."1.31Autoimmune hyperlipidemia in a child with autoimmune hepatitis. ( Betzhold, J; Merati, S; Rumbo, C; Shneider, BL, 2002)
"Individuals with systemic lupus erythematosus show evidence of a significant increase in monocyte apoptosis."1.31The apoptotic ligands TRAIL, TWEAK, and Fas ligand mediate monocyte death induced by autologous lupus T cells. ( Kaplan, MJ; Lewis, EE; McCune, WJ; Pavlic, R; Richardson, BC; Shelden, EA; Somers, E, 2002)
" Polymerase chain reaction (PCR) tests provide a sensitive, specific means of prospectively identifying these patients before AZA therapy and minimizing toxicity through dosage reduction."1.31Practical pharmacogenetics: the cost effectiveness of screening for thiopurine s-methyltransferase polymorphisms in patients with rheumatological conditions treated with azathioprine. ( Anis, AH; Esdaile, JM; Marra, CA, 2002)
"According to published reports, intracranial tuberculomas are always due to infection by Mycobacterium tuberculosis."1.31A meningioma-mimicking tumor caused by Mycobacterium avium complex in an immunocompromised patient. ( Brooks, A; Di Patre, PL; Martin, NA; Radziszewski, W; Vinters, HV, 2000)
"Azathioprine (AZA) is characterized by high interindividual differences in bioavailability and metabolization."1.31Relationship between red cell mean corpuscular volume and 6-thioguanine nucleotides in patients treated with azathioprine. ( Decaux, G; Desager, JP; Horsmans, Y; Prospert, F, 2000)
"A 26-year-old woman suffered from acute myelitis at Th 6 level associated with systemic lupus erythematosus."1.31Development of severe longitudinal atrophy of thoracic spinal cord following lupus-related myelitis. ( Kawagoe, J; Kawasaki, S; Matsukura, S; Ohi, T; Shiomi, K; Sugimoto, S; Yazawa, S, 2001)
"A diagnosis of occult systemic lupus erythematosus resulting in increased intestinal vascular permeability was made."1.31Primary protein-losing enteropathy in anti-double-stranded DNA disease: the initial and sole clinical manifestation of occult systemic lupus erythematosus? ( Northcott, KA; Steinbrecher, UP; Yoshida, EM, 2001)
"A 25-year-old Japanese woman with systemic lupus erythematosus (SLE) was admitted because of numbness of the face and left upper extremity, headache, and intermittent fever."1.31Systemic lupus erythematosus related transverse myelitis presenting longitudinal involvement of the spinal cord. ( Amano, H; Aramaki, T; Hirayama, Y; Kimura, KY; Seino, Y; Takano, T; Yamaguchi, H, 2002)
"Prednisolone was effective in improving the anemia and the serum immunoglobulin, immune complex, and antinuclear antibody levels."1.29Post-infantile giant cell hepatitis in an elderly female patient with systemic lupus erythematosus. ( Arase, K; Asayama, R; Dohmen, K; Ishibashi, H; Kuroiwa, S; Nakamura, H; Ohtsuka, S; Yokogawa, Y, 1994)
" We found three predictors of flares: renal disease, persistence of dsDNA antibodies for at least 1 year after the beginning of treatment and reduction in azathioprine dosage to below 2 mg/kg/d."1.29Predictors of flares and long-term outcome of systemic lupus erythematosus during combined treatment with azathioprine and low-dose prednisolone. ( Abendroth, K; Hein, G; Oelzner, P; Stein, G, 1996)
"We describe a case of acute nonlymphocytic leukemia with inversion of chromosome 16 in a patient with systemic lupus erythematosus treated with immunosuppressive agents including azathioprine and cyclophosphamide."1.28Acute nonlymphocytic leukemia after treatment of systemic lupus erythematosus with immunosuppressive agents. ( Kavanaugh, AF; Lipsky, PE; Schneider, NR; Vasquez, S; Wacholtz, MC, 1992)
"Two patients presented with a subacute confusional state, two with dementia, and one with depression."1.28Neuropsychiatric systemic lupus erythematosus in elderly people: a case series. ( Bendall, P; Byrne, EJ; Dennis, MS; Hopkinson, N, 1992)
"Five developed septic arthritis, including the site of a hip prosthesis in one patient."1.28Salmonella arizona arthritis and septicemia associated with rattlesnake ingestion by patients with connective tissue diseases. A dangerous complication of folk medicine. ( Alarcón-Segovia, D; Guerra-Bautista, G; Kraus, A, 1991)
"A 28 year old woman with systemic lupus erythematosus who developed chronic lupus peritonitis and ascites is described."1.28Chronic lupus peritonitis with ascites. ( Dadinas, G; Kaklamanis, P; Stamatelos, G; Tsokos, GC; Vayopoulos, G, 1991)
"Most frequent are preeclampsia, premature labour, foetal maldevelopment and flare-ups of the underlying disease."1.28[Systemic lupus erythematosus and pregnancy. Clinical aspects, serology and management]. ( DuBois, A; Hillemanns, HG; Kerl, J; Quaas, L; Röther, E; Runge, HM, 1990)
"Interstitial pneumonitis has previously been thought to be an uncommon feature in systemic lupus erythematosus (SLE)."1.28Lupus pneumonitis and anti-SSA(Ro) antibodies. ( Boulware, DW; Hedgpeth, MT, 1989)
"Treatment with thalidomide resulted in a dramatic clearing of skin lesions but failed to improve pathological laboratory tests."1.27[Treatment of subacute cutaneous lupus erythematosus with thalidomide]. ( Volc-Platzer, B; Wolff, K, 1983)
"A patient with systemic lupus erythematosus developed jaundice and biochemical evidence of hepatic dysfunction 3 wk after initiation of azathioprine therapy."1.27Azathioprine and the liver. Evidence favoring idiosyncratic, mixed cholestatic-hepatocellular injury in humans. ( DePinho, RA; Goldberg, CS; Lefkowitch, JH, 1984)
"Treatment with prednisolone alone or with a prednisolone/azathioprine combination resulted in an equal five-year survival (82%) and a similar overall preservation of renal function."1.27Renal involvement in systemic lupus erythematosus. ( Atkins, RC; Boyce, NW; Holdsworth, SR; Thomson, NM, 1984)
"Two paediatric patients with systemic lupus erythematosus were treated with immunoglobulin G (IgG)."1.27IgG therapy in systemic lupus erythematosus--two case reports. ( Dopfer, R; Gaedicke, G; Kohne, E; Niethammer, D; Teller, WM, 1984)
"The pancreatitis was first manifested by panniculitis of the lower extremities."1.27Childhood systemic lupus erythematosus. Association with pancreatitis, subcutaneous fat necrosis, and calcinosis cutis. ( Gorman, H; Penneys, N; Schachner, L; Simons-Ling, N; Strauss, J; Zillereulo, G, 1983)
" The mean dosage of azathioprin and prednisone in patients with SLE did not significantly differ from the non-SLE group."1.27[Reactivation of the alpha 1-fetoprotein synthesis in systemic lupus erythematosus]. ( Knopf, B; Schulze, M; Wollina, U, 1985)
"A 19-year old female with catatonia associated with multi-system involvement with systemic lupus erythematosus is described."1.27Lupus catatonia: a case report. ( Daradkeh, TK; Nasrallah, NS, 1987)
"In two patients with systemic lupus erythematosus, conventional therapy was considered to have failed because of persistent disease activity and unacceptable side effects."1.27Total lymphoid irradiation in refractory systemic lupus erythematosus. ( Ben-Chetrit, E; Braverman, A; Eliakim, M; Fuks, Z; Gross, DJ; Slavin, S; Weshler, Z, 1986)
"Of 66 patients with systemic lupus erythematosus (SLE), 11 (16."1.27Livedoid vasculitis and central nervous system involvement in systemic lupus erythematosus. ( Yasue, T, 1986)
"Fourteen patients with systemic lupus erythematosus had splenectomies done between 1960 and 1982 for treatment of severe thrombocytopenia."1.27Splenectomy does not cure the thrombocytopenia of systemic lupus erythematosus. ( Greipp, PR; Hall, S; McCormick, JL; McKenna, CH; Michet, CJ, 1985)
" The skin lesions responded dramatically to 100 mg of azathioprine sodium daily, flared when the drug treatment was discontinued, and again responded on reinstatement of the same dosage of azathioprine."1.27Successful treatment of generalized discoid skin lesions with azathioprine. Its use in a patient with systemic lupus erythematosus. ( Caughman, SW; Klippel, JH; Tsokos, GC, 1985)
"Pancreatitis is not a rare occurrence in SLE, and may be related in part to the vasculitis seen during periods of disease activity."1.26Acute pancreatitis in systemic lupus erythematosus: report of twenty cases and a review of the literature. ( Chuong, JH; Inman, RD; Kimberly, RP; Kovacs, JE; Reynolds, JC; Walsh, MB, 1982)
"Patients with chronic active hepatitis (CAH) (23) or systemic lupus erythematosus (SLE) (10), compared with healthy subjects (20), had a lower mean T lymphocyte count."1.26T lymphocyte subpopulations defined by two sets of monoclonal antibodies in chronic active hepatitis and systemic lupus erythematosus. ( Frazer, IH; Mackay, IR, 1982)
"Three patients had a systemic lupus erythematosus, two had primitive extracapillary glomerulonephritis, one had panarteritis nodosa, and another a Schönlein-Henoch syndrome."1.26[Plasmapheresis in the treatment of extracapillary glomerulonephritis (author's transl)]. ( Anaya, A; Barbolla, ML; Botella, J; Fernández Fernández, J; Gallego, JL; Sanz Guajardo, D, 1980)
"Of these dogs, 29 had systemic lupus erythematosus, 15 had arthritis in association with some chronic infectious disease process, and 19 had a similar type of arthritis, but without serologic evidence of systemic lupus erythematosus or any chronic infectious disease process."1.26Noninfectious canine arthritis: the inflammatory, nonerosive arthritides. ( Castles, JJ; Ling, GV; Pedersen, NC; Weiser, G; Weisner, K, 1976)
"30 of the subjects had systemic lupus erythematosus and the remaining 32 had other clinical disorders."1.26Experience of a platelet factor 3 immunoinjury technique in the detection of antiplatelet antibody in systemic lupus erythematosus and other clinical disorders. ( Kutti, J; Safai-Kutti, S, 1978)
"The development of a reticulum cell sarcoma in the lung of a patient with systemic lupus erythematosus treated with azathioprine for 18 months is described."1.26Reticulum cell sarcoma in azathioprine-treated systemic lupus erythematosus. ( Hehir, ME; Hughes, GR; Sewell, JR, 1979)
"We believe that the internal ophthalmoplegia was secondary to involvement of the accommodative and pupillary fibers of both third nerves at the base of the brain."1.26Cryptococcal meningitis and internal ophthalmoplegia. ( Leon, H; Lesser, RL; Siegel, N; Simon, RM, 1979)
"Pregnancy was best tolerated by mothers without significant nephropathy or cardiopathy who had been in clinical remission for more than three months prior to conception."1.26Systemic lupus erythematosus in pregnancy. ( Devoe, LD; Taylor, RL, 1979)
"One sister developed coombs-positive haemolytic anaemia at the age of 11 years and suffered from five haemolytic crises over a period of 8 months."1.26[Systemic lupus erythematosus in twins (author's transl)]. ( Jürgenssen, OA; Kolarz, G; Pichler, E; Scherak, O, 1978)
"Forty-nine patients with systemic lupus erythematosus (SLE) during childhood and adolescence presenting over a period of 17 years were followed during treatment with prednisone and azathioprine."1.26Systemic lupus erythematosus within the first two decades of life. ( Blau, EB; Burke, BA; Fish, AJ; Michael, AF; Vernier, RL; Westberg, NG, 1977)
"Severe acute renal failure developed in a patient with systemic lupus erythematosus which was characterized by typical skin rash, polyserositis, haemolytic anaemia and liver damage."1.25[Haemodialysis for renal failure in a case of systemic lupus erythematosus (author's transl)]. ( Kopsa, H; Schmidt, P; Zazgornik, J, 1975)
" Functional psychosis was usually preciptated by corticsoteroid therapy and respond to a reduction in steroid dosage and administration of psychotropic drugs."1.25Central nervous system disease in systemic lupus erythematosus. Therapy and prognosis. ( Klempner, MS; Lipsky, BA; Lockshin, MD; Sergent, JS, 1975)
"Neurologic complications of systemic lupus erythematosus (SLE) are common, but chorea is rare."1.25Clinical features of chorea associated with systemic lupus erythematosus. ( Lusins, JO; Szilagyi, PA, 1975)
"Acute anuric renal failure complicating systemic lupus erythematosus does not usually respond to treatment with corticosteroids and immunosuppressive agents."1.25Acute renal failure in systemic lupus erythematosus. ( Brancaccio, D; Imbasciati, E; Ponticelli, C; Rivolta, E; Tarantino, A, 1974)
"Systemic lupus erythematosus is a polysystemic disease with a high incidence of associated glomerulonephritis."1.25Systemic lupus erythematosus. ( , 1969)

Research

Studies (668)

TimeframeStudies, this research(%)All Research%
pre-1990356 (53.29)18.7374
1990's72 (10.78)18.2507
2000's102 (15.27)29.6817
2010's109 (16.32)24.3611
2020's29 (4.34)2.80

Authors

AuthorsStudies
Ntali, S1
Nikolopoulos, D1
Pantazi, L1
Emmanouilidou, E1
Papagoras, C1
Fanouriakis, A3
Dimopoulou, D1
Kallitsakis, I1
Boki, K1
Dania, V1
Sidiropoulos, PI1
Boumpas, DT4
Bertsias, G3
Keshavamurthy, C1
Fibeger, E1
Virata, A1
Bansal, P1
Namas, R1
Abdulla, FA1
Elarabi, M1
Jourde-Chiche, N1
Costedoat-Chalumeau, N2
Baumstarck, K1
Loundou, A1
Bouillet, L2
Burtey, S1
Caudwell, V1
Chiche, L1
Couzi, L1
Daniel, L1
Deligny, C1
Dussol, B1
Faguer, S1
Gobert, P1
Gondran, G1
Huart, A1
Hummel, A1
Kalbacher, E1
Karras, A1
Lambert, M1
Le Guern, V1
Lebourg, L1
Loubière, S1
Maillard-Lefebvre, H1
Maurier, F1
Pha, M1
Queyrel, V1
Remy, P1
Sarrot-Reynauld, F1
Verhelst, D1
Hachulla, E1
Amoura, Z1
Daugas, E2
Reynolds, JA1
Gayed, M1
Khamashta, MA5
Leone, F1
Toescu, V1
Bruce, IN1
Giles, I1
Teh, LS2
McHugh, N1
Akil, M2
Edwards, CJ1
Gordon, C6
Balevic, SJ1
Niu, J1
Chen, J1
Green, D1
McMahon, A1
Hornik, CP1
Schanberg, LE2
Glaser, R1
Gonzalez, D1
Burckart, GJ1
McKenzie, PL1
Chao, Y1
Pathak, S1
Kazi, S1
Dobrowolski, C1
McGinley, J1
Fazzari, M1
Su, J3
Bingham, KS1
Anderson, N1
Ruttan, L1
Beaton, DE1
Wither, JE1
Tartaglia, MC1
Kakvan, M1
Bonilla, D1
Choi, MY2
Fritzler, MJ1
Diaz Martinez, JP1
Katz, P1
Green, R1
Putterman, C1
Touma, Z1
Téllez Arévalo, AM1
Quaye, A1
Rojas-Rodríguez, LC1
Poole, BD1
Baracaldo-Santamaría, D1
Tellez Freitas, CM1
Whelband, MC1
Willingham, T1
Thirunavukkarasu, S1
Patrick, J1
Chouchana, L1
Terris, B1
Sogni, P1
Treluyer, JM1
Loriot, MA1
Birt, J1
Delbecque, L1
O'brien, D1
Wu, J1
Vasey, J1
Dean, A1
Sudaria, T1
Vadhariya, A1
Materne, E1
Choi, H1
Zhou, B1
Costenbader, KH6
Zhang, Y1
Jorge, A1
Lomanto Silva, R1
Swabe, GM1
Sattui, SE1
Magnani, JW1
Hernández-Breijo, B1
Gomez, A1
Soukka, S1
Johansson, P1
Parodis, I1
Ritter, CG1
de David Cruz, C1
Zamboni, S1
Busato, VB1
da Silveira, RG1
Provenzi, VO1
Bredemeier, M1
Zen, M1
Saccon, F1
Gatto, M1
Montesso, G1
Larosa, M1
Benvenuti, F1
Iaccarino, L1
Doria, A1
Yap, DYH1
Chan, TM2
Delfino, J1
Dos Santos, TAFG1
Skare, TL1
Kawali, A1
Bavaharan, B1
Sanjay, S1
Mohan, A1
Mahendradas, P1
Shetty, B1
Hu, J1
Wang, M1
Xiao, X1
Zhang, B1
Xie, Q1
Xu, X1
Li, S1
Zheng, Z1
Wei, D1
Zhang, X1
Bozzalla Cassione, E1
Zanframundo, G1
Biglia, A1
Codullo, V1
Montecucco, C1
Cavagna, L1
Zonozi, R1
Wallace, ZS1
Laliberte, K1
Huizenga, NR1
Rosenthal, JM1
Rhee, EP1
Cortazar, FB1
Niles, JL1
Tziolos, N1
Papachristos, DA1
Oon, S1
Hanly, JG1
Nikpour, M1
Li, D1
Feldman, CH4
Yoshida, K1
Guan, H3
Kim, SC2
Everett, BM1
Lorenzo-Vizcaya, A1
Isenberg, D4
Sun, K1
Corneli, AL1
Dombeck, C1
Swezey, T1
Rogers, JL1
Criscione-Schreiber, LG1
Sadun, RE1
Eudy, AM1
Doss, J1
Bosworth, HB1
Clowse, MEB1
Hannon, CW1
McCourt, C1
Lima, HC1
Chen, S1
Bennett, C1
Reder, AT1
Centonze, D1
Naylor, ML1
Nagpal, A1
Rajbhandari, R1
Altincatal, A1
Kim, M1
Berdofe, A1
Radhakrishnan, M1
Jung, E2
Sandrock, AW1
Smirnakis, K1
Popescu, C1
de Moor, C1
Lambert-Fliszar, F1
Bernatsky, S3
Kalache, F1
Grenier, LP1
Pineau, CA1
Vinet, E2
Davis, LS1
Reimold, AM1
Ordi-Ros, J1
Sáez-Comet, L1
Pérez-Conesa, M1
Vidal, X1
Mitjavila, F1
Castro Salomó, A1
Cuquet Pedragosa, J1
Ortiz-Santamaria, V1
Mauri Plana, M1
Cortés-Hernández, J1
Jaryal, A1
Vikrant, S1
Green, M1
Roy, D1
Frank, J1
Fett, N1
Flores-Silva, FD1
Longoria-Lozano, O1
Aguirre-Villarreal, D1
Sentíes-Madrid, H1
Vega-Boada, F1
Díaz de León-Sánchez, E1
Murra-Antón, S1
Morales-Moreno, S1
Quintanilla-González, L1
Fragoso-Loyo, H1
Guraieb-Chaín, P1
Higuera-Calleja, J1
Ceballos-Ceballos, J1
Treviño-Frenk, I1
González-Duarte, A1
Dávila-Maldonado, L1
Cantú-Brito, C1
Valdés-Ferrer, SI1
Mahmoud, GA1
Shahin, AA1
Zayed, HS1
Moghazy, A1
Eissa, BM1
Hung, ML1
Liao, HT1
Chen, WS2
Chen, MH1
Lai, CC1
Tsai, CY2
Chang, DM3
Provitera, V1
Lubrano, E1
Piscosquito, G1
Manganelli, F1
Santoro, L1
Nolano, M1
Collins, J1
Zhang, Z1
Xu, C1
Subramanian, SV1
Kawachi, I1
Solomon, DH2
Yates, M1
Castaño-González, PA1
González, LA1
Radhakrishnan, S1
Surendran, D1
Barathi, D1
Bammigatti, C1
Otsuka, M1
Koga, T1
Sumiyoshi, R1
Furukawa, K1
Okamoto, M1
Endo, Y1
Tsuji, S1
Takatani, A1
Shimizu, T1
Igawa, T1
Kawashiri, SY1
Iwamoto, N1
Ichinose, K1
Tamai, M1
Nakamura, H2
Origuchi, T1
Kawakami, A1
Giménez, AR1
Pastrana, DB1
Huaranga, MAR1
Izquierdo, JR1
Cabrera, B1
García, AN1
Rodríguez, CCR1
Chehab, G1
Krüssel, J1
Fehm, T1
Fischer-Betz, R1
Schneider, M2
Germeyer, A1
Suerdieck, MB1
Kreuzer, V1
Liebenthron, J1
Dwivedi, P1
Kumar, RR1
Dhooria, A1
Adarsh, MB1
Malhotra, S1
Kakkar, N1
Naidu, S1
Sharma, SK1
Sharma, A1
Jain, S1
Dhir, V1
Kaneko, K1
Kawai, T1
Watanabe, N1
Wada, Y1
Onodera, M1
Murashima, A1
Cheema, S1
Bunting, E1
Good, C1
Hajela, V1
Ridha, BH1
Saha, RA1
Kudo, N1
Takaoka, H1
Shimomura, T1
Suzushima, H1
Fujiyama, S1
Lim, LS1
Lefebvre, A1
Benseler, S1
Silverman, ED4
Méndez-Flores, S1
Charli-Joseph, Y1
Saeb-Lima, M1
Orozco-Topete, R1
Fernández Sánchez, M1
Park, HJ1
Kang, MI1
Kang, Y1
Chung, SJ1
Lee, SW1
Park, YB2
Lee, SK2
Yachoui, R1
Kolasinski, SL1
Han, BK1
Vinicki, JP1
Catalan Pellet, S1
Pappalardo, C1
Cruzat, VC1
Spinetto, MA1
Dubinsky, D1
Tiraboschi, IN1
Laborde, HA1
Nasswetter, G1
Ong, CS1
Cheah, TE1
Jasmin, R1
Yahya, F1
Sockalingam, S1
Ng, CT1
Yeter, KC1
Afkhami, M1
Brynes, RK1
Quismorio, FP1
Quintanilla-Flores, DL1
Hernández-Coria, MI1
Elizondo-Riojas, G1
Galarza-Delgado, DA1
González-González, J1
Tamez-Pérez, HE1
Mahmood, K1
Khan, AM1
Ramanan, AV1
Martin, K1
Chen, D1
Lian, F1
Yuan, S1
Wang, Y1
Zhan, Z1
Ye, Y1
Qiu, Q1
Xu, H1
Liang, L1
Yang, X1
Mastorodemos, V1
Pamfil, C1
Papadaki, E1
Sidiropoulos, P1
Plaitakis, A1
Amoiridis, G1
Bose, B1
Bargman, JM2
Xuan, D1
Yu, Y1
Shao, L1
Wang, J1
Zhang, W1
Zou, H1
Peart, E1
Clowse, ME3
Tobin, WO1
Weinshenker, BG1
Lucchinetti, CF1
Al Maimouni, H1
Gladman, DD4
Ibañez, D1
Urowitz, MB5
Siripaitoon, B1
Lertwises, S1
Uea-Areewongsa, P1
Khwannimit, B1
Tselios, K2
Sarantopoulos, A1
Gkougkourelas, I1
Boura, P1
Goh, KG1
Ong, SG1
Cotton, D1
Lee, WS1
Lum, SH1
Lim, CB1
Chong, SY1
Khoh, KM1
Ng, RT1
Teo, KM1
Boey, CC1
Pailoor, J1
Croyle, L1
Morand, EF2
Tedeschi, SK1
Massarotti, E1
Fine, A1
Bermas, BL1
Saavedra, MÁ1
Sánchez, A1
Morales, S1
Ángeles, U1
Jara, LJ1
Marzouk, S1
Garbaa, S1
Cherif, Y1
Jallouli, M1
Bahri, F1
Bahloul, Z1
Liu, Y1
Yu, J1
Oaks, Z1
Marchena-Mendez, I1
Francis, L1
Bonilla, E1
Aleksiejuk, P1
Patel, J1
Banki, K1
Landas, SK1
Perl, A1
Vázquez-Sanabria, IL1
Mercado-Seda, R1
Varela-Rosario, N1
Vilá, LM1
Dorjee, K1
Dierberg, KL1
Sadutshang, TD1
Reingold, AL1
Sciascia, S1
Hunt, BJ1
Talavera-Garcia, E1
Lliso, G1
Cuadrado, MJ2
Robles-Perez, A1
Molina-Molina, M1
Khan, WA1
Qureshi, JA1
González-Naranjo, LA1
Betancur, OM1
Alarcón, GS2
Ugarte-Gil, MF1
Jaramillo-Arroyave, D1
Wojdyla, D1
Pons-Estel, GJ1
Rondón-Herrera, F1
Vásquez-Duque, GM1
Quintana-López, G1
Da Silva, NA1
Tavares Brenol, JC1
Reyes-Llerena, G1
Pascual-Ramos, V1
Amigo, MC1
Massardo, L1
Alfaro-Lozano, J1
Segami, MI1
Esteva-Spinetti, MH1
Iglesias-Gamarra, A1
Pons-Estel, BA1
Elfving, P1
Puolakka, K1
Kautiainen, H1
Virta, LJ1
Pohjolainen, T1
Kaipiainen-Seppänen, O1
Glushko, T1
Marcus, VA1
Colmegna, I1
Noviani, M1
Wasserman, S1
Hu, SC1
Yen, FL1
Wang, TN1
Lin, YC1
Lin, CL1
Chen, GS1
Sarda, G1
Harvey, R1
Marty, FM1
Winkelmayer, WC1
Franklin, JM1
Willard, D1
Upadhyay, J1
Kim, C1
Steenkamp, D1
Adelowo, OO1
Olaosebikan, BH1
Animashaun, BA1
Akintayo, RO1
Staveri, C1
Karokis, D1
Liossis, SC1
Apostolopoulos, D1
Ertz-Archambault, N1
Kosiorek, H1
Taylor, GE1
Kelemen, K1
Dueck, A1
Castro, J1
Marino, R1
Gauthier, S1
Finn, L1
Sproat, LZ1
Palmer, J1
Mesa, RA1
Al-Kali, A1
Foran, J1
Tibes, R1
Yap, KS1
Pakchotanon, R1
Polachek, A1
Blaise, S1
Salameire, D1
Carpentier, PH1
Askanase, AD1
Wallace, DJ2
Weisman, MH1
Tseng, CE1
Bernstein, L1
Belmont, HM1
Seidman, E1
Ishimori, M1
Izmirly, PM1
Buyon, JP1
MacIver, H1
Hordon, L1
Okada, Y4
Nakamura, K3
Hiromura, K3
Nojima, Y4
Horiuchi, R2
Yamamoto, K4
Benseler, SM2
Feldman, BM1
Tyrrell, PN2
Harvey, E2
Hebert, D2
Korkmaz, C2
Krug, U1
Buchner, T1
Fassbinder, T1
Gaubitz, M1
Berdel, WE1
Al Arfaj, AS1
Khalil, N1
Al Saleh, S1
Sandborg, C1
Barnhart, HX1
Ardoin, SP1
Yow, E1
Evans, GW1
Mieszkalski, KL1
Ilowite, NT1
Eberhard, A2
Levy, DM1
Kimura, Y1
von Scheven, E1
Silverman, E3
Bowyer, SL1
Punaro, L1
Singer, NG2
Sherry, DD1
McCurdy, D1
Klein-Gitelman, M1
Wallace, C1
Silver, R1
Wagner-Weiner, L1
Higgins, GC1
Brunner, HI1
Jung, L1
Soep, JB1
Reed, A1
Fritsch-Stork, RD1
Leguit, RJ1
Derksen, RH2
Sahin, G1
Işiksoy, S1
Yalçin, AU1
Habibagahi, Z1
Ali Nazarinia, M1
Aaflaki, E1
Ali Ostovan, M1
Hadi Bagheri, M1
Appenzeller, S1
Veilleux, M1
Clarke, A1
Telles, RW1
Ferreira, GA1
da Silva, NP1
Sato, EI1
Lateef, A1
Tan, KB1
Lau, TC1
Aringer, M4
Houssiau, F1
Graninger, WB4
Voll, RE1
Rath, E1
Steiner, G3
Smolen, JS4
Mok, CC3
Ying, KY2
Yim, CW1
Ng, WL1
Wong, WS2
van der Laan-Baalbergen, NE1
Mollema, SA1
Kritikos, H1
Schoe, A1
Huizinga, TW2
Bax, JJ1
van Laar, JM1
Lee, HT1
Shiao, YM1
Wu, TH1
Hsu, YH1
Tsai, SF1
Dittrich, K1
Ross, S1
Benz, K1
Amann, K1
Dötsch, J1
Arce-Salinas, CA2
Pérez-Silva, E1
Griffiths, B1
Emery, P1
Ryan, V1
Thompson, R1
Maddison, P1
Griffiths, ID1
Lorenzi, A1
Miles, S1
Situnayake, D1
Plant, M1
Hallengren, C1
Nived, O2
Sturfelt, G1
Chakravarty, K1
Tait, T1
Ablin, JN1
Boguslavski, V1
Aloush, V1
Elkayam, O1
Paran, D2
Levartovski, D1
Caspi, D1
George, J1
Nakamura, T2
Kouprianoff, S1
Chiquet, C1
Romanet, JP1
Jiang, L1
Dai, X1
Liu, J1
Ma, L1
Yu, F1
Tarner, IH1
Lange, U1
Madlener, K1
Classen, K1
Kandolf, R1
Sperzel, J1
Müller-Ladner, U1
Knott, HM1
Martínez, JD1
Caltik, A1
Demircin, G1
Bülbül, M1
Erdogan, O1
Akyüz, SG1
Arda, N1
Alqanatish, JT1
Houghton, K1
Bond, M1
Senger, C1
Tucker, LB1
Döcker, D1
Marx, U1
Braun, B1
Polgár, A1
Rózsa, C1
Müller, V1
Matolcsi, J1
Poór, G2
Kiss, EV1
de Carvalho, JF1
da Mota, LM1
Bonfa, E1
Ruiz-Irastorza, G3
Gómez-Martín, D1
Díaz-Zamudio, M1
Vanoye, G1
Crispín, JC1
Alcocer-Varela, J3
Xanthouli, P1
Mühleisen, H1
Briem, S1
Weis, D1
Fiehn, C1
Efe, C1
Purnak, T1
Ozaslan, E1
Ozbalkan, Z1
Karaaslan, Y1
Altiparmak, E1
Muratori, P1
Wahlin, S1
Levine, AB1
Erkan, D1
Prado, DM1
Gualano, B1
Pinto, AL1
Sallum, AM1
Perondi, MB1
Roschel, H1
Silva, CA1
Dall'Era, M1
Kiss, E3
Kiss, CG1
Carneiro, FO1
Sampaio, LR1
Brandão, LA1
Braga, LL1
Rocha, FA1
Canese, A2
Di Martino Ortiz, B1
González Burgos, L1
Centurión, MÉ1
Ezeonyeji, AN1
Isenberg, DA3
Shu, E1
Ichiki, Y1
Moriya, C1
Iwata, H1
Kitajima, Y1
Seishima, M1
Huang, D1
Aghdassi, E1
Mosko, J1
Hirschfield, GM1
Fortin, PR3
Chizzolini, C1
Gokce, M1
Bulus, D1
Bilginer, Y1
Gumruk, F1
Besbas, N1
Cetin, M1
Artifoni, M1
Puéchal, X1
Law, ST1
Ma, KM1
Li, KK1
Tarr, T2
Szegedi, G3
Zeher, M2
Rashidi, A1
Lee, ME1
Fisher, SI1
Eickenberg, S1
Mickholz, E1
Nofer, JR1
Pavenstadt, HJ1
Jacobi, AM1
van Tellingen, A1
Voskuyl, AE1
Vervloet, MG1
Bijl, M2
de Sévaux, RG1
Berger, SP1
Berden, JH1
Burgos, LG1
Ortiz, BD1
Ojeda, A1
Melo, M1
Bassetti, M1
Nicco, E1
Giacobbe, DR1
Marchese, A1
Coppo, E1
Barbieri, R1
Viscoli, C1
Marder, W2
Ganser, MA1
Romero, V1
Hyzy, MA1
McCune, WJ7
Somers, EC2
Nagamine, A1
Takenaka, M1
Aomori, T1
Araki, T1
Ramsey-Goldman, R3
Joseph, L3
Boivin, JF2
Petri, MA1
Jacobsen, S1
Manzi, S2
Ginzler, EM2
Rahman, A3
Yelin, E1
Bae, SC3
Peschken, CA1
Dooley, MA2
Edworthy, SM1
Aranow, C2
Kamen, DL1
Romero-Diaz, J1
Askanase, A1
Witte, T1
Barr, SG1
Criswell, LA1
Sturfelt, GK1
Blanco, I1
Dreyer, L1
Patel, NM1
St Pierre, Y1
Clarke, AE2
Smith, LW1
Petri, M3
Karim, MY1
Alba, P1
Abbs, IC1
D'Cruz, DP1
Hughes, GR6
Rumbo, C1
Betzhold, J1
Merati, S1
Shneider, BL1
Kaplan, MJ1
Lewis, EE1
Shelden, EA1
Somers, E1
Pavlic, R1
Richardson, BC1
Marra, CA1
Esdaile, JM2
Anis, AH2
Aviña-Zubieta, JA1
Galindo-Rodrìguez, G1
Robledo, I1
Vela-Ojeda, J1
Vadillo-Buenfil, M1
Rosas-Cabral, A1
Salazar-Exaire, D1
Tack, DK1
Paisansinsup, T1
Amin, S1
Roy-Peaud, F1
Paccalin, M1
Le Moal, G1
Landron, C1
Juhel, L1
Roblot, P1
Becq-Giraudon, B1
Astudillo, L1
Sailler, L1
Carreiro, M1
Dahan, S1
Ollier, S1
Arlet, P1
Lau, CS2
Wong, RW1
Harten, P1
Oh, KT1
MACKAY, IR9
WEIDEN, S1
UNGAR, B1
ROENIGK, HH1
HASERICK, JR1
NAKAMOTO, S1
MCCORMACK, LJ1
Taylor, I1
Shahnaz, S1
Choksi, MT1
Tan, IJ1
Bang, S1
Kang, BS1
Park, MC1
Hwang, MH1
Kim, HK1
Nero, P1
Bacman, D1
Ostendorf, B1
Megahed, M1
Ruzicka, T1
Kuhn, A1
Ali, SS1
Rabbani, MA1
Moinuddin, SS1
Virani, S1
Farooque, F1
Salam, A1
Ahmad, A1
Ognenovski, VM1
Johnston, CM1
Farrehi, JG1
Selvaggi, SM1
Sève, P1
Ferry, T1
Charhon, A1
Calvet, A1
Broussolle, C1
Seidel, W1
Bladt, V1
Steengaard-Pedersen, K1
Poulsen, LH1
Petersen, OB1
Laursen, B1
d'Amore, F1
Souza, SC1
Borges, CT1
Jorgetti, V1
Pereira, RM1
Dancey, P1
Constantin, E1
Duffy, CM1
Scuccimarri, R1
Stummvoll, GH1
Schmaldienst, S1
Jiménez-Boj, E1
Hörl, WH1
Derfler, K1
Chen, HC1
Lai, JH1
Huang, GS1
Gao, HW1
Chen, CH1
Kuo, SY1
Mok, MY1
Lo, Y1
Taylor, PW1
Breuer, GS1
Deeb, M1
Fisher, D1
Nesher, G1
Riskalla, MM1
Nakazawa, T1
Kumagai, S1
Kogata, Y1
Green, MR1
Kennell, AS1
Larche, MJ1
Seifert, MH1
Salaman, MR1
Praprotnik, S1
Hocevar, A1
Ferlan-Marolt, V1
Tomsic, M1
Patel, P1
Moazzam, N1
Potti, A1
Mehdi, SA1
Yang, CH1
Chen, JY1
Lee, SC1
Luo, SF1
Mak, A1
To, CH1
Szeto, ML1
Kodama, T1
Ueki, K1
Tsukada, Y1
Maezawa, A1
Tsukamoto, N1
Ishizaki, T1
Holvast, A1
Huckriede, A1
Wilschut, J1
Horst, G1
De Vries, JJ1
Benne, CA1
Kallenberg, CG1
Hirose, I1
Ymamaguchi, H1
Inaguma, D1
Ono, K1
Shimada, S1
Kawada, J1
Shiraki, K1
Kimura, H1
Robak, E1
Sysa-Jedrzejowska, A2
Wozniacka, A2
Toubi, E1
Kessel, A1
Rosner, I1
Rozenbaum, M1
Shoenfeld, Y4
Reddy, V1
Dziadzio, M1
Hamdulay, S1
Boyce, S1
Prasad, N1
Keat, A1
Salamon, M1
Lesiak, A1
McCauliffe, DP1
Ng, HJ1
Crowther, MA1
Kotyla, PJ1
Sliwińska-Kotyla, B1
Lewicki, M1
Kucharz, EJ1
Foocharoen, C1
Tiamkao, S1
Srinakarin, J1
Chamadol, N1
Sawanyawisuth, K1
O'Callaghan, CA1
Rich, E1
Senécal, JL3
Lin, YJ1
Chen, DY1
Lan, JL1
Hsieh, TY1
Türkçapar, N1
Ozyüncü, N1
Cinar, K1
Ensari, A1
Küçük, O1
Idilman, R1
Duman, N1
Ozden, A1
Aydogan, K1
Karadogan, SK1
Adim, SB1
Tunali, S1
Höfler, E1
Steiner, CW1
Hrycek, A1
Kusmierz, D1
Dybała, T1
Swiatkowska, L1
Fargher, EA1
Tricker, K1
Newman, W1
Elliott, R1
Roberts, SA1
Shaffer, JL1
Bruce, I1
Payne, K1
Szekanecz, E1
Urowitz, M1
Gladman, D1
Ginzler, E3
Barr, S1
Edworthy, S1
Rajan, R1
Zummer, M1
Rüther, K1
Foerster, J1
Berndt, S1
Schroeter, J1
Biggioggero, M1
Borghi, MO1
Gerosa, M1
Trespidi, L1
Cimaz, R1
Meroni, PI1
Stratta, P2
Cremona, R1
Lazzarich, E1
Quaglia, M1
Fenoglio, R1
Canavese, C2
Boonsrirat, U1
Angsuthum, S1
Vannaprasaht, S1
Kongpunvijit, J1
Hirankarn, N1
Tassaneeyakul, W1
Avihingsanon, Y1
Khalidi, NA1
Rebello, R1
Robertson, DD1
Kaaroud, H1
Beji, S1
Guermazi, S1
Moussa, FB1
Hamida, FB1
Ezzine, S1
Abdallah, TB1
El Younsi, F1
Kheder, A1
Hiraki, LT1
Evans, SJ1
Watson, DK1
O'Sullivan, M1
Meshaka, G1
Jacquillat, C1
Sultan, Y1
Adams, DA2
Gordon, A1
Maxwell, MH1
Hollingworth, P1
de Vere Tyndall, A1
Ansell, BM1
Platts-Mills, T1
Gumpel, JM1
Mertin, J1
Smith, DS2
Denman, AM2
Kaeser, HE1
Reynolds, JC1
Inman, RD1
Kimberly, RP1
Chuong, JH1
Kovacs, JE1
Walsh, MB1
Neighbour, PA1
Grayzel, AI2
Hughes, RA1
Cameron, JS7
Hall, SM1
Heaton, J1
Payan, J1
Teoh, R1
Frazer, IH1
Krüger, KW1
Swaak, AJ2
Statius van Eps, LW1
Aarden, LA1
Feltkamp, TE1
Volc-Platzer, B1
Wolff, K1
Carette, S1
Klippel, JH8
Decker, JL8
Austin, HA3
Plotz, PH5
Steinberg, AD7
Balow, JE5
Ten Berge, RJ1
Schellekens, PT1
Syrop, CH1
Varner, MW1
Miller, ML1
Miescher, PA3
Beris, P1
Davis, BM1
Gilliam, JN1
Felson, DT1
Anderson, J1
Winter, JH1
Legge, JS1
Markenson, JA1
Lockshin, MD3
Fuzesi, L1
Warburg, M1
Joachim, C1
Morgan, JW1
Hosenpud, JD1
Montanaro, A1
Hart, MV1
Haines, JE1
Specht, HD1
Bennett, RM1
Kloster, FE1
Lee, HS2
Mujais, SK1
Kasinath, BS1
Spargo, BH3
Katz, AI1
Huskisson, EC1
McDonald, CF1
Barter, CE1
Fraser, KJ1
Hanan, JA1
Berliner, S1
Sidi, Y1
Santo, M1
Weinberger, A1
Luria, D1
Hazaz, B1
Pecht, M1
Zaizov, R1
Pinkhas, J1
Rubin, L1
Pruzanski, W1
Trautmann, F1
Krämer, G1
Poralla, T1
Eckhardt, R1
Arnold, W1
Meyer zum Büschenfelde, KH1
Cavallo, T5
Graves, K5
Granholm, NA5
Or, R1
Kleinman, Y1
Chajek-Shaul, T1
Nazarenko, PV1
Riabova, TV1
Fedorov, AA1
Stefanova, G1
Mikhaĭlova, A1
Gavrilov, G1
Naumova, E1
Bŭchvarova, E1
DePinho, RA1
Goldberg, CS1
Lefkowitch, JH1
Epstein, RJ1
Ogler, RF1
Gatenby, PA1
Ostrer, H1
Stamberg, J1
Perinchief, P1
Boyce, NW1
Holdsworth, SR1
Thomson, NM1
Atkins, RC1
Gaedicke, G1
Teller, WM1
Kohne, E1
Dopfer, R1
Niethammer, D1
Muenz, LR1
Joyce, KM1
Antonovych, TT1
Donadio, JV5
Wahn, V1
Göbel, U1
Ebell, W1
Jürgens, H1
Bokemeyer, B1
Thiele, KG1
Jones, JV2
Sussman, GL1
Rivera, VJ1
Kohler, PF1
Simons-Ling, N1
Schachner, L1
Penneys, N1
Gorman, H1
Zillereulo, G1
Strauss, J1
Taubert, M1
Döring, E1
Vismans, JJ1
Briët, E1
Meijer, K1
den Ottolander, GJ1
Tareyeva, IE1
Shilov, EM2
Gordovskaya, NB1
Robinson, MF1
Parciany, RK1
Layfer, LF1
McLeod, B1
Bollet, AJ1
Friedman, EA3
Schwartz, RS4
Ahmed, AR1
Moy, R1
Dinant, HJ1
Guérin, S1
Léveillé, M1
Kutti, J5
Bergström, AL4
Ridell, B1
Holley, KE2
Ilstrup, DM1
Coggins, CH1
Cotter, PB1
Weiter, JJ1
Małdykowa, H1
Chwalińska-Sadowska, H1
Grabowska, A1
Dratwianka, B1
Abgarowicz-Miłkowska, T1
Jedryka-Góral, A1
Swierczyńska, Z1
Rdułtowska, H1
Luft, S1
Rogozińska, E1
Belovezhdov, N1
Tsekova, D1
Dzherasi, R1
Gruev, I1
Kiperova, B1
Williamson, RA1
Karp, LE1
Nyberg, G2
Eriksson, O1
Westberg, NG2
Clark, WF1
Lindsay, RM1
Ulan, RA1
Cordy, PE1
Linton, AL1
Mulshine, J1
Lucas, FV1
Clough, JD1
Glöckner, WM1
Dienst, C1
Kindler, J1
Sieberth, HG1
Kaplan, D4
Sanz Guajardo, D1
Barbolla, ML1
Fernández Fernández, J1
Gallego, JL1
Anaya, A1
Botella, J1
Kartasheva, VI2
Tareeva, IE3
Stepanova, NS1
Solov'ev, SK1
Kaĭnova, AS1
Ivanova, MM2
Olsson, LB1
Bacon, BR1
Treuhaft, WH1
Goodman, AM1
Alarcón-Segovia, D5
Bhimma, R1
Coovadia, HM1
Adhikari, M1
Aharon, A1
Zandman-Goddard, G1
Bootsma, H1
Spronk, P1
Derksen, R1
de Boer, G1
Wolters-Dicke, H1
Hermans, J1
Limburg, P1
Gmelig-Meyling, F2
Kater, L1
Kallenberg, C1
Takeda, S1
Tatara, I1
Kono, K1
Arakawa, K1
Peral, V1
Vidau, P1
Herrera, J1
Rodriguez, C1
Tricas, L1
Tomé, R1
Arroyo, F1
Benenson, EV1
Mirrakhimova, EM1
Dohmen, K1
Ohtsuka, S1
Arase, K1
Yokogawa, Y1
Asayama, R1
Kuroiwa, S1
Ishibashi, H1
Dawisha, SM1
Türk, H1
Fox, DA2
Zanker, B1
Schirmacher, P1
Köhler, H1
TambyRaja, RL1
Fagundus, DM1
Leroy, EC1
Pincus, T2
Mientus, JM1
Kutzer, JE1
Mulvihill, JJ1
Medsger, TA1
Venables, PJ1
de Arriba, G1
Velo, M1
Barrio, V1
García Martín, F1
Hernando, L1
Lima, F1
Alves, J1
Simpson, J1
Buchanan, NM1
Rolla, G1
Brussino, L1
Bertero, MT1
Bucca, C1
Converso, M1
Caligaris-Cappio, F1
McDermott, EM1
Powell, RJ2
Martínez-Rueda, JO1
Kraus, A2
Chan, KF1
Boey, ML1
Oelzner, P1
Abendroth, K2
Hein, G1
Stein, G1
Cockwell, P1
Felchle, LM1
McPhee, LA1
Kerr, ME1
Houston, DM1
Pallis, M1
Lim, KL1
Gardner-Medwin, JM1
Robins, RA1
Little, BB1
Schiel, R2
Bambauer, R2
Latza, R1
Klinkmann, J1
Caramaschi, P1
Biasi, D1
Carletto, A1
Bambara, LM1
Jeppesen, U1
Rasmussen, JM1
Brøsen, K1
Tsakonas, E1
Choquette, D1
Cividino, A1
Danoff, D1
Osterland, CK2
Yeadon, C1
Smith, CD1
Stolk, JN1
Boerbooms, AM1
De Abreu, RA1
van de Putte, LB1
Kwong, YL1
Au, WY1
Liang, RH1
Battafarano, DF1
Battafarano, NJ1
Larsen, L1
Dyer, PD1
Older, SA1
Muehlbauer, S1
Hoyt, A1
Lima, J1
Goodman, D1
Lieberman, M1
Enzenauer, RJ1
Masago, R1
Fukuma, H1
Shteyngarts, AR1
Warner, MR1
Camisa, C1
Giorgi, D1
Balacco Gabrieli, C1
Naughton, MA1
Battaglia, E1
O'Brien, S1
Walport, MJ1
Botto, M1
Santiago, M1
Naarendorp, M1
Kerr, LD1
Khan, AS1
Ornstein, MH1
Di Patre, PL1
Radziszewski, W1
Martin, NA1
Brooks, A1
Vinters, HV1
Decaux, G1
Prospert, F1
Horsmans, Y1
Desager, JP1
Rood, MJ1
Borggreve, SE1
Jakobsen, LP1
Knudsen, TB1
Bloch, T1
Strobel, ES1
Fritschka, E1
Schmitt-Gräff, A1
Peter, HH1
Schwarze, U1
Gazzaruso, C1
Montecucco, CM1
Geroldi, D1
Garzaniti, A1
Finardi, G1
Shih, YL1
Ribeiro, JM1
Lucas, M1
Victorino, RM1
Abu-Shakra, M1
Yazawa, S1
Kawasaki, S1
Ohi, T1
Shiomi, K1
Sugimoto, S1
Kawagoe, J1
Matsukura, S1
Santi, S1
Ciccone, G1
Rosso, S1
Northcott, KA1
Yoshida, EM1
Steinbrecher, UP1
Walker, J1
Mendelson, H1
McClure, A1
Smith, MD1
Costallat, LT1
De Capitani, EM1
Zambon, L1
Kimura, KY1
Seino, Y1
Hirayama, Y1
Aramaki, T1
Yamaguchi, H1
Amano, H1
Takano, T1
Eguchi, K1
White, RP1
Abraham, S1
Singhal, S1
Manji, H1
Clarke, CR1
Pirofsky, B3
Bardana, EJ3
Alexander, M2
Kampf, D3
Mathies, H2
Dubois, EL1
Pedersen, NC1
Weisner, K1
Castles, JJ1
Ling, GV1
Weiser, G1
Canavese, JC1
Sabbour, MS1
Osman, LM1
Foucar, E1
Erickson, DG1
Tung, KS1
Matthay, RA3
Schwarz, MI1
Petty, TL3
Stanford, RE1
Gupta, RC1
Sahn, SA1
Steigerwald, JC1
Rovenský, J1
Svejcar, J1
Pekárek, J1
Zitnan, D1
Hajzok, O1
Cebecauer, L1
Morel-Maroger, L1
Méry, JP2
Droz, D1
Godin, M1
Verroust, P1
Kourilsky, O1
Richet, G1
Hayes, K1
Symington, G1
Bresnihan, B1
Grigor, RR1
Gordovskaia, NB1
Jacobs, JC1
Krupko, MI1
Gorbunov, VF1
Domaseva, TV1
Cederqvist, LL1
Merkatz, IR1
Litwin, SD1
Attman, PO1
Westberg, G1
Safai-Kutti, S2
Barnett, EV5
Dornfeld, L2
Lee, DB1
Liebling, MR1
Hehir, ME1
Sewell, JR1
Höfer, W1
Misgeld, V1
Truniger, B1
Morera Prat, J1
Capdevila Plaza, LL1
Piera Robert, LL1
Pelegri Santos, AL1
Pérez Jabaloyas, J1
Herskowitz, LJ1
Olansky, S1
Lang, PG1
Lesser, RL1
Simon, RM1
Leon, H1
Siegel, N2
Hayslett, JP3
Wallace, EZ1
Rosman, PM1
Balthazar, A1
Sacerdote, A1
Devoe, LD1
Taylor, RL1
Sessa, A1
Sirtori, CM1
Giordano, F1
Cioffi, A1
Conte, F1
Dei Poli, M1
Semenkova, EN1
Filimonova, RG1
Ianushkevich, TN1
Wysocka, K1
Kiczak, J1
Hawrlylak, E1
Jürgenssen, OA1
Kolarz, G1
Pichler, E1
Scherak, O1
Walden, PA1
Philalithis, PE1
Joekes, AM1
Bagshawe, KD1
Moloney, P1
O'Brien, E1
Appel, AE1
Sablay, LB1
Golden, RA1
Barland, P1
Bank, N1
McShane, DJ1
Porta, J1
Fries, JF1
Sergent, JS2
Lockshin, M1
Wirth, W1
Diekmann, L1
Klokenbusch, S1
Ricken, D1
Flenker, I1
Wagner, L1
Faust, G1
Zöller, B1
Brinkrolf, H1
Pollak, VE1
Fish, AJ2
Blau, EB1
Burke, BA1
Vernier, RL4
Michael, AF1
Cathcart, ES1
Horvat, Z1
Nasonova, VA1
Folomeeva, OM1
Speranskiĭ, AI2
Kozlova, VN1
Walravens, PA1
Chase, HP1
Oliver, JA1
Carreras, L1
Bernheim, J1
Beruard, M1
Zech, P2
Traeger, J2
Pelton, BK1
Kinsley, M1
Knight, S1
Partridge, C1
Walker, P1
Bannister, B1
Gumpel, M1
Loewi, E1
Bach, JF2
Dardenne, M2
Pleau, JM1
Bach, MA1
Schmidt, P1
Kopsa, H1
Zazgornik, J1
Chwal, Z1
Bennahum, DA2
Messner, RP2
Zimmerman, SW1
Jenkins, PG1
Shelf, WD1
Bloodworth, JM3
Burkholder, PM1
Hahn, BH2
Kantor, OS1
Klempner, MS1
Lipsky, BA1
Lusins, JO1
Szilagyi, PA1
Rothfield, NF1
Avioli, LV1
Szewczyk, Z1
Klinger, M1
Melcer, H1
Falkiewicz, K1
Hecht, B1
Adler, M1
Kashgarian, M2
Epstein, WV1
Shearn, MA1
Lindeman, RD1
Pederson, JA1
Matter, BJ1
Laughlin, LO1
Mandal, AK1
Bolz, M1
Schmitt, E1
Schneidwind, JM1
Teitel, AD1
MacKenzie, CR1
Stern, R1
Paget, SA1
Jardim, HM1
Leake, J1
Risdon, RA1
Barratt, TM1
Dillon, MJ1
Couper, R1
Durie, P1
Foley-Nolan, D1
Martin, MF1
Rowbotham, D1
McVerry, A1
Gooi, HC1
Lancman, ME1
Pomeraniec, C1
Norscini, J1
Vasquez, S1
Kavanaugh, AF1
Schneider, NR1
Wacholtz, MC1
Lipsky, PE1
Moens, C3
Moens, P1
Dennis, MS1
Byrne, EJ1
Hopkinson, N1
Bendall, P1
Funauchi, M1
Horiuchi, A1
Jodo, S1
Sagawa, A1
Ogura, N1
Atsumi, T1
Amasaki, Y1
Nakabayashi, T1
Watanabe, I1
Mukai, M1
Fujisaku, A1
Nakagawa, S1
Waldmann, KD1
Salim, S1
Salim, KA1
al-Rasheed, SA1
al-Fawaz, IM1
González-Gay, MA1
Fernández Camblor, B1
Agüero, JJ1
Villarino, MJ1
Eiriz, M1
Mata, I1
Guerra-Bautista, G1
Luksiene, A1
Filipaviciute, R1
Becker, H1
Potyka, P1
Weber, C1
Renelt, M1
Federlin, K1
Koehler, PJ1
Goss, JA1
Cole, BR1
Jendrisak, MD1
McCullough, CS1
So, SK1
Windus, DW1
Hanto, DW1
Kaklamanis, P1
Vayopoulos, G1
Stamatelos, G1
Dadinas, G1
Tsokos, GC3
Witt, C1
Neuhaus, K1
Winsel, K1
Brenke, A1
Hiepe, F1
Volk, HD1
Luqmani, RA1
Palmer, RG1
Bacon, PA1
Karlberg, I1
Svalander, C1
Hedman, L1
Blohmé, I1
Nossent, JC1
Rongioletti, F1
Casciaro, S1
Boccaccio, P1
Rebora, A1
Runge, HM1
Röther, E1
Kerl, J1
DuBois, A1
Quaas, L1
Hillemanns, HG1
Wollina, U1
Schulze, M1
Knopf, B1
Naert, F1
Lachapelle, JM1
Appleby, P1
Webber, DG1
Bowen, JG1
Boulware, DW1
Hedgpeth, MT1
Font, J1
Campistol, JM1
Sabouraud, O1
Clements, PJ1
Davis, J1
Ichikawa, Y1
Tanaka, H1
Hirose, S1
Yokohari, R1
Tsunematsu, T1
Espinoza, LR1
Hartmann, RC1
Sekiya, S1
Iwasaki, H1
Takeda, B1
Takamizawa, H1
Prystowsky, JH1
Finkel, L1
Tar, L1
Jegasothy, B1
Russell, AS1
Bretscher, PA1
West, SG1
Johnson, SC1
Wessel, G1
Wisheit, M1
Izui, S3
Pistor, K1
Neudorf, U1
le Riche, NG1
Meehan, RT1
Dorsey, JK1
Daradkeh, TK1
Nasrallah, NS1
Bryant, GL1
Weinblatt, ME1
Rumbaugh, C1
Coblyn, JS1
Ben-Chetrit, E1
Gross, DJ1
Braverman, A1
Weshler, Z1
Fuks, Z1
Slavin, S1
Eliakim, M1
Strober, S1
Field, E1
Hoppe, RT1
Kotzin, BL1
Shemesh, O1
Engleman, E1
Ross, JC1
Myers, BD1
Andrassy, K1
Waldherr, R1
Ritz, E1
Nashel, DJ1
Yasue, T1
Colenda, CC1
Gaston, JO1
Hall, S1
McCormick, JL1
Greipp, PR1
Michet, CJ1
McKenna, CH1
Caughman, SW1
Demin, AA1
Sentiakova, TN1
Riazantseva, TA1
Poliachenko, EA1
Boulton-Jones, M1
Robinson, R1
Ogg, C1
Sperryn, PN1
Mace, BE1
Cook, CD1
Deicher, H4
Soloway, RD2
Summerskill, WH2
Baggenstoss, AH1
Schoenfield, LJ2
Baethke, R1
Munthe, E1
Brodwall, EK1
Oyri, A1
Natvig, JB1
Götzel, L1
Gerebtzoff, A1
Abe, C1
Shiokawa, Y1
Tanaka, K1
Huber, C1
Günther, R1
Michlmayr, G1
Huber, H1
Braunsteiner, H1
Delespesse, G1
Kennes, B1
Duchateau, J1
Lorenzen, I3
Videbaek, A1
Brocteur, J1
Holmes, FF1
Stubbs, DW1
Larsen, WE1
Swanson, MA1
Cruchaud, A4
Pometta, D3
Rousso, C3
Gonyea, L1
Herdman, R1
Bridges, RA1
Chorzelski, T1
Jablońska, S1
Blaszczyk, M1
Heuckenkamp, PU1
Zöllner, N1
Robson, GS1
Schubert, JC1
Schubert, H1
Holtz, G1
Martin, H1
Gitnick, GL1
Ritman, S1
Vick, RM1
Ogg, CS1
Seymour, WM1
Chantler, C1
Turner, DR1
Houde, M1
Laplante, L1
Robitaille, P1
Jones, MB1
Gleason, TH1
Hamlin, WB1
Scheiffarth, F1
Warnatz, H1
Swannell, AJ2
Coomes, EN2
Kahn, MF2
Rambouts, C1
de Sèze, S2
Tuerk, M1
Cendrowski, W1
Riekkinen, PJ1
Rinne, UK1
Lambert, PH2
Salmon, J1
Barnikol, HU1
Vorlaender, KO2
Haustein, UF1
Ponticelli, C1
Imbasciati, E1
Brancaccio, D1
Tarantino, A1
Rivolta, E1
Klein, MB1
Pereira, FA1
Kantor, I1
Pluzańska, A1
Dmochowska, M1
Orlowski, Z1
Pawlowski, J1
Krauze-Jaworska, H1
Krykowski, E1
Zebrowski, A1
Forbes, MJ1
Sinclair, L1
Hurley, RM1
Steinberg, RH1
Patriquin, H1
Drummond, KN1
Shoop, JD1
Isaeva, LA1
Girard, JF1
Cooper, MR1
Hansen, KS1
Maynard, CD1
Elrod, IW1
Spurr, CL1
Casey, TP2
Mathews, JD2
Toh, BH1
Baker, HW1
Walker, I1
Buckley, JD1
Gledhill, VX1
Fishbein, E1
Díaz-Jouanen, E1
Richard, P1
Blanc-Brunat, N1
Labeeuw, M1
Colon, S1
Pozet, N1
Dupont, E1
Fries, D1
Klein, G3
Fellner, S1
Fellner, R1
Skinner, MD2
Yokoyama, T1
Torisu, M1
Durst, AL1
Schroter, G1
Groth, CG1
Starzl, TE1
Kardaszewicz, E2
Sharon, E3
Diamond, HS1
Wagoner, RD1
Ferguson, RH1
McDuffie, FC1
Clarkson, AR1
Robson, JS1
Wallnöfer, H1
Hanusch, M1
Baker, M2
Hadler, NM1
Whitaker, JN1
Dunner, DL1
Gerwin, RD1
Rosman, M1
Bertino, JR1
McVicar, MI1
Smithwick, EM1
Kaplan, SR1
Calabresi, P1
Silverman, NA1
Gunnells, JC1
Stickle, DL1
Michielsen, J1
Go, IH1
Sherlock, S1
Lechner, K1
Nelius, D2
Stieglitz, R2
Herreman, G1
Broquie, G1
Metzger, JP1
Godeau, P1
Levy, J1
MacDonald, NS1
Klinenberg, JR1
Pearson, CM2
Garancis, JC1
Bernhard, GC1
Hudson, LD1
Pulgram, A1
Zimprich, H1
Weippl, G1
Conde Olasagasti, J1
Ortuño Mirete, J1
Botella Garciá, J1
Cade, R1
Spooner, G1
Schlein, E1
Pickering, M1
DeQuesada, A1
Holcomb, A1
Juncos, L1
Richard, G1
Shires, D1
Levin, D1
Hackett, R1
Free, J1
Hunt, R1
Fregly, M1
Snaith, ML1
Holt, JM1
Oliver, DO1
Dunnill, MS1
Halley, W1
Stephenson, AC1
Stobbe, H4
Apostoloff, E4
Reitzig, P1
Balslov, JT2
Brun, C2
Jensen, KB2
Jorgensen, F2
Jorgensen, HE2
Larsen, M2
Thomsen, AC2
Goebel, KM1
Gassel, WD1
Goebel, FD1
Clément, F1
Kerl, H1
Sandhofer, M1
Newman, DM1
Walter, JB1
Striker, GE1
Kelly, MR1
Quadracci, LJ1
Scribner, BH1
Nanra, RS1
Kincaid-Smith, P1
Jones, J1
Diamond, H1
Ramirez-Mata, M1
Reyes, PA1
Garza, R1
Neuberg, R1
Rosenbaum, JL1
Akhtar, M1
Kramer, MS1
Raja, RM1
Manchanda, R1
Lazaro, N1
Miti, L1
Massei, V1
Sanguinetti, CM1
Ahn, YS1
Harrington, WJ1
Seelman, RC1
Eytel, CS1
Bergstein, JM1
Wiens, C1
Michael, A1
Schur, PH1
Christian, CL1
Keitel, W1
Kleine, FD1
Werner, R1
Zweiman, B1
Hildreth, EA1
Urizar, RE1
Tinglof, B1
McIntosh, R1
Litman, N1
Barnett, E1
Wilkerson, J1
Smith, F1
Heine, KM3
Klatt, R3
Dutz, W1
Ashton, H1
Beveridge, GW1
Stevenson, CJ1
Drinkard, JP1
Stanley, TM1
Austin, RC1
Latta, H1
Gonick, HC1
Fricke, R2
Krull, P1
Gewurz, H1
Pickering, RJ1
Moberg, A1
Simmons, RL1
Good, RA1
Najarian, JS1
Kruli, P1
Hopf, U1
Fateh-Moghadam, A1
Land, W1
Brendel, W1
Porter, GA2
Gourley, RT1
Bayrakci, C1
Bishko, FC1
Manny, N1
Rosenman, E1
Benbassat, J1
Kagen, LJ1
Amor, B1
Kahan, A1
Pompidou, A1
Delbarre, F1
Mey, U1
Teehan, BP1
Argy, WP1
Schreiner, GE2
Heidelmann, G1
Fleischer, J1
Schwenke, R1
Heilman, KM1
Kohler, WC1
LeMaster, PC1
Shelp, WD2
Rieselbach, RE1
Petrányi, G1
Leövey, A1
Kakuk, G1
Bobory, J1
Kostanecki, W1
Mazurkiewicz, W1
Górkiewicz, A1
Zborzil, J1
Lee, AK1
Rowley, MJ1
Yap, CY1
Zosin, C1
Mănescu, N1
Iacob, G1
Schwarzkopf, A1
Sabo, I1
Gluhovschi, G1
Purice, S1
Ghelerter, L2
Matei, I1
Brunazian, G1
Bruckner, I1
Stroescu, O1
Stroescu, V1
Gheorghiu, M1
Suţeanu, S1
Grozea, P1
Bârnaş, M1
Lynfield, YL1
Prestia, AE1
Japa, J1
Bureau, Y1
Barrière, H1
Litoux, P1
Bureau, B1
Olbing, H1
Reichenberger, M1
Kochem, HG1
Bayracki, C1
Jendrusch, C2
Maher, JF1
Matthias, JQ1
Schuppli, R1
Pavkovceková, O1
Jurkovic, I1
Tischler, V1
Mydlík, M1
Aprosina, ZG1
Mukhin, AS1
Katsuta, Y1
Matsuo, H1
Minovich, AI1
Laugier, P1
Hunziker, N1
Thivolet, J1
Perrot, H1
Golacka, K1
Tarka, Z1
Soria, C1
Soria, J1
Girard, M1
Lejeay, A1
Guérin, C1
Schwenke, H1
Helbig, W1
Müldner, J1
Pincus, D1
Tina, LU1
Bellanti, JA1
Lieberman, E1
Heuser, E1
Hanson, V1
Kornreich, H1
Donnell, GN1
Landing, BH1
Eberle, P1
Hunstein, W1
Perings, E1
Hare, WS1
Gillibrand, PN1

Clinical Trials (68)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Weaning of Immunosuppression in Nephritis of Lupus[NCT01284725]Phase 3100 participants (Actual)Interventional2011-01-31Active, not recruiting
Optimization of Glucocorticoid Taper Strategies for Maintenance Therapy of Systemic Lupus Erythematosus Associated Immune Thrombocytopenia (SLE-ITP)[NCT05506033]120 participants (Anticipated)Interventional2022-08-15Enrolling by invitation
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of R333 6% Ointment Administered Topically to Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Patients With Active Cut[NCT01597050]Phase 254 participants (Actual)Interventional2012-08-31Completed
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-220 IN SUBJECTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS[NCT03161483]Phase 2289 participants (Actual)Interventional2017-08-31Completed
A Phase III, Randomized, Double-Blind. Placebo-Controlled, Multi-Center Study of Systemic Lupus Erythematosus With Acute Severe SLE Flares Excluding Renal or Neurological Systems[NCT00111306]Phase 3510 participants Interventional2005-06-30Terminated
A Phase 2, Multi-Center, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Tolerability, and Efficacy of LymphoStat-B™ Antibody (Monoclonal Anti-BLyS Antibody) in Subjects With Systemic Lupus Erythematosus (SLE)[NCT00071487]Phase 2449 participants (Actual)Interventional2003-10-31Completed
A Randomized, Double-blind, Placebo-controlled Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Multiple Ascending Subcutaneous Doses of Efavaleukin Alfa in Subjects With Systemic Lupus Erythem[NCT03451422]Phase 135 participants (Actual)Interventional2018-04-10Completed
A Randomized, Double-Blind Phase 2b Study to Evaluate the Efficacy, Safety, and Tolerability of A 623 Administration in Subjects With Systemic Lupus Erythematosus[NCT01162681]Phase 2547 participants (Actual)Interventional2010-07-31Completed
A Phase I, Randomized, Double-Blind, Placebo Controlled, Dose-Escalation Study to Evaluate Safety and Tolerability of a Single IV Dose of MEDI-545, a Fully Human Monoclonal Antibody Directed Against Interferon Alpha Subtypes, in Patients With Systemic Lup[NCT00299819]Phase 145 participants (Actual)Interventional2006-03-31Completed
Study to Assess Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of TAB08 in Patients With Systemic Lupus Erythematosus, Not Adequately Controlled With Current Concomitant Therapy[NCT02711813]Phase 260 participants (Actual)Interventional2016-03-31Terminated (stopped due to Administrative reasons)
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of BMS-986165 in Subjects With Systemic Lupus Erythematosus[NCT03252587]Phase 2363 participants (Actual)Interventional2017-09-21Completed
Potential Effect of Anti-infection by Low-dose IL-2 in Treatment of SLE[NCT02932137]30 participants (Actual)Interventional2016-05-05Completed
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Ustekinumab in Chinese Subjects With Active Systemic Lupus Erythematosus[NCT04060888]Phase 30 participants (Actual)Interventional2020-07-14Withdrawn (stopped due to Pre-planned IA (global study) showed lack of efficacy in this indication. No new safety signals observed, findings consistent with known profile.)
Randomized Controlled Trial to Evaluate the Efficacy of Enteric-coated Mycophenolate Sodium Versus Azathioprine for the Induction and Maintenance of Remission of the Extra-renal Lupus Manifestations[NCT01112215]Phase 4240 participants (Actual)Interventional2009-12-31Completed
A Phase II Multicenter, Randomized, Double-blind, Placebo Controlled, Dose-range Finding Study to Evaluate the Safety and Efficacy of ALX-0061 Administered Subcutaneously in Subjects With Moderate to Severe Active Systemic Lupus Erythematosus[NCT02437890]Phase 2312 participants (Actual)Interventional2015-07-31Completed
A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Assess the Efficacy and Safety of Acthar Gel in Subjects With Persistently Active Systemic Lupus Erythematosus Despite Moderate Dose Corticosteroids[NCT02953821]Phase 4172 participants (Actual)Interventional2016-12-16Completed
Clarification of Abatacept Effects in SLE With Integrated Biologic and Clinical Approaches (The ABC Study)[NCT02270957]Phase 266 participants (Actual)Interventional2014-01-31Completed
A Phase1/2, Randomized, Parallel-group, Double-Blind, Placebo-Controlled, Multicenter Study of the Safety and Pharmacokinetics of One 12 Week Treatment Cycle of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE) Subjects With Moderate to Severe Di[NCT01449071]Phase 1/Phase 220 participants (Actual)Interventional2011-10-31Completed
A Phase 2b, Dose-ranging Study to Evaluate the Efficacy and Safety of Sifalimumab in Adults With Systemic Lupus Erythematosus[NCT01283139]Phase 2834 participants (Actual)Interventional2011-03-31Completed
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosu[NCT02265744]Phase 2730 participants (Actual)Interventional2014-11-13Completed
A Phase IIb Multi-Center, Open-label, Follow-up Study to Assess Safety and Efficacy of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus Patients With Active Disease Who Participated in Study SL0007[NCT00660881]Phase 2210 participants (Actual)Interventional2008-05-31Completed
Using the Cholinergic Anit-Inflammatory Pathway to Treat Systemic Lupus Musculoskeletal Pain[NCT02822989]18 participants (Anticipated)Interventional2017-11-01Enrolling by invitation
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Neutralization of the Interferon Gene Signature and the Clinical Efficacy of IFNα-Kinoid in Adult Subjects With Systemic Lupus Erythematosus[NCT02665364]Phase 2185 participants (Actual)Interventional2015-09-23Terminated (stopped due to Reorganization proceedings of the sponsor)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)[NCT01205438]Phase 31,124 participants (Actual)Interventional2011-01-31Completed
A Phase 2b Dose Ranging Study to Evaluate the Efficacy and Safety of Rozibafusp Alfa (AMG 570) in Subjects With Active Systemic Lupus Erythematosus (SLE) With Inadequate Response to Standard of Care (SOC) Therapy[NCT04058028]Phase 2244 participants (Actual)Interventional2020-02-19Completed
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Blisibimod Administration in Subjects With Systemic Lupus Erythematosus With or Without Nephritis[NCT02514967]Phase 33 participants (Actual)Interventional2016-06-30Terminated (stopped due to Study halted prematurely and will not resume. Subjects were seen until February 2017)
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 104-Week Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE)[NCT03312907]Phase 3292 participants (Actual)Interventional2018-03-01Completed
A Phase 2a, Double-blind, Placebo-Controlled Study of RSLV-132 in Subjects With Systemic Lupus Erythematosus (SLE)[NCT02660944]Phase 264 participants (Actual)Interventional2016-01-03Completed
A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study To Evaluate the Safety and Efficacy of M2951 in Subjects With SLE[NCT02975336]Phase 2469 participants (Actual)Interventional2017-01-04Terminated (stopped due to Study is completed; primary analysis completed.)
Efficacy and Safety of Twice-daily Application of Delgocitinib Cream 20 mg/g for 6 Weeks in Subjects With Active Discoid Lupus Erythematosus.[NCT03958955]Phase 227 participants (Actual)Interventional2019-07-09Terminated (stopped due to Terminated due to recruitment challenges.)
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) Administered Subcutaneously (SC) to Subjects With Systemic Lupus Erythematosus (SLE)[NCT01484496]Phase 3839 participants (Actual)Interventional2011-11-16Completed
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus[NCT03616964]Phase 3778 participants (Actual)Interventional2018-08-02Completed
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Blisibimod Administration in Subjects With Systemic Lupus Erythematosus With or Without Nephritis[NCT02074020]Phase 30 participants (Actual)Interventional2015-12-31Withdrawn
A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Two Doses of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus[NCT02446912]Phase 3460 participants (Actual)Interventional2015-06-09Completed
Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine (NAC) (SNAC)[NCT00775476]Phase 2290 participants (Anticipated)Interventional2022-03-31Recruiting
A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus[NCT02446899]Phase 3373 participants (Actual)Interventional2015-07-09Completed
A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Phase 2 Study of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)[NCT02708095]Phase 2314 participants (Actual)Interventional2016-03-24Completed
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Ustekinumab in Subjects With Active Systemic Lupus Erythematosus[NCT03517722]Phase 3516 participants (Actual)Interventional2018-04-16Terminated (stopped due to Study terminated early as a result of the outcome of the pre-planned Interim Analysis)
A Phase 2 Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination (ABBV-599 Combination) in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus[NCT03978520]Phase 2341 participants (Actual)Interventional2019-07-25Completed
A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects With Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects With Active Cutaneous Lupus Erythematosus With o[NCT02847598]Phase 2264 participants (Actual)Interventional2016-10-20Completed
A Phase IIb Randomized, Double-blind, Placebo-controlled, Dose and Dose Regimen-ranging Study of the Safety and Efficacy of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus (SLE) Patients With Active Disease[NCT00624351]Phase 2227 participants (Actual)Interventional2008-01-31Completed
A Phase III, Randomized, Double Blind, Placebo Controlled, Multi-Center Study of Epratuzumab in Patients With Active Systemic Lupus Erythematosus.[NCT00383214]Phase 354 participants (Actual)Interventional2005-05-31Terminated
A Prospective, Double-blind, Randomized, Placebo-controlled, Repeated Dose, Multicentre Phase IIa Proof-of-Concept Study With BT063 in Subjects With Systemic Lupus Erythematosus[NCT02554019]Phase 236 participants (Actual)Interventional2015-09-28Completed
A Multicenter, Randomized, Double-blind, Placebo-controlled, Proof-of-Concept Study of Ustekinumab in Subjects With Active Systemic Lupus Erythematosus[NCT02349061]Phase 2102 participants (Actual)Interventional2015-10-15Completed
A Multi-center, Randomized, Placebo-Controlled Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of Belimumab, a Human Monoclonal Anti-BLyS Antibody, Plus Standard Therapy in Pediatric Patients With Systemic Lupus Erythematosus[NCT01649765]Phase 293 participants (Actual)Interventional2012-09-07Active, not recruiting
A Pilot, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study To Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of CC-220 In Subjects With Systemic Lupus Erythematosus[NCT02185040]Phase 242 participants (Actual)Interventional2014-09-16Completed
A Two-part Study Exploring the Efficacy, Safety, and Pharmacodynamics of Acthar in Systemic Lupus Erythematosus Patients With a History of Persistently Active Disease[NCT01753401]Phase 438 participants (Actual)Interventional2013-01-31Completed
GSK1550188 A 52 Week Study of Belimumab Versus Placebo in the Treatment of Subjects With Systemic Lupus Erythematosus (SLE) Located in Northeast Asia[NCT01345253]Phase 3709 participants (Actual)Interventional2011-05-23Completed
A Randomized, Double Blind, Baseline Controlled Study Using Placebo as Reference for Assessing the Efficacy and Safety of Hydroxychloroquine Sulfate in Patients With Systemic Lupus Erythematosus or Cutaneous Lupus Erythematosus in the Presence of Active L[NCT01551069]Phase 3103 participants (Actual)Interventional2012-03-31Completed
Dipyridamole Assessment for Flare Reduction in SLE[NCT01781611]18 participants (Actual)Interventional2013-02-28Terminated (stopped due to Slow recruitment)
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus[NCT03616912]Phase 3830 participants (Actual)Interventional2018-08-02Terminated (stopped due to Study terminated due to insufficient evidence to support a positive benefit: risk profile in systemic lupus erythematosus patients.)
A Phase II Pilot-Study With Low-dose hrIL-2 for the Treatment of Systemic Lupus Erythematosus[NCT02465580]Phase 260 participants (Anticipated)Interventional2015-06-30Recruiting
A PHASE 2B, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PF-06700841 IN PARTICIPANTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)[NCT03845517]Phase 2350 participants (Actual)Interventional2019-04-18Completed
A Phase 2, Randomized Study to Evaluate the Efficacy and Safety of MEDI-546 in Subjects With Systemic Lupus Erythematosus[NCT01438489]Phase 2626 participants (Actual)Interventional2012-01-31Completed
Can Individualized Diet and Lifestyle Modifications Derived From Digital Therapeutics and Health Coaching Improve Symptoms of Systemic Lupus Erythematosus[NCT03426384]50 participants (Actual)Interventional2018-02-12Completed
A Multicenter, Double-blind, Randomized and Parallel Controlled Study of Hydroxychloroquine Sulfate in the Treatment of Recurrent Miscarriage With Antiphospholipid Syndrome[NCT04624269]Phase 4384 participants (Anticipated)Interventional2020-12-01Not yet recruiting
A Three-arm, Multicenter, Open-label Randomized Controlled Trial of Hydroxychloroquine and Low-dose Prednisone on Recurrent Spontaneous Abortion With Undifferentiated Connective Tissue Diseases: Protocol for the Immunosuppressant Regimens for Living FEtus[NCT03671174]420 participants (Anticipated)Interventional2019-08-02Recruiting
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Test the Safety and Efficacy of Lipitor (Atorvastatin) in Reducing the Progression of Carotid IMT in Early Childhood SLE[NCT00065806]Phase 3221 participants (Actual)Interventional2003-09-30Completed
Cyclophosphamide and Hydroxychloroquine for the Treatment of Severe Thrombocytopenia in Systemic Lupus Erythematosus[NCT02444728]Phase 350 participants (Actual)Interventional2015-07-31Terminated (stopped due to Because of insufficient enrollement)
Hydroxychloroquine Exposure in Systemic Lupus Erythematosus (SLE)[NCT03802188]3,700 participants (Anticipated)Observational2018-05-09Recruiting
A Randomized, Double-Blind, Placebo-Controlled, Phase II, Multi-Center Study for Treatment of Lupus Nephritis by Inhibition of Tumor Necrosis Factor-alpha Using Etanercept[NCT00447265]Phase 21 participants (Actual)Interventional2008-02-29Terminated (stopped due to The perceived risk-benefit ratio for individuals with early active RA)
A Double Blind, Randomized, Placebo Controlled, Multi-Center Trial of Anti-TNF-alpha Chimeric Monoclonal Antibody (Infliximab) and Azathioprine in Patients Suffering From Systemic Lupus Erythematosus (SLE) With WHO Class V Glomerulonephritis[NCT00368264]Phase 2/Phase 31 participants (Actual)Interventional2006-09-30Terminated (stopped due to Failure to recruit patients with membranous lupus nephritis not previously treated with azathioprine .)
Impact of Immunosuppression in Patients With Inflammatory Bowel Disease on Responsiveness to Influenza Vaccine[NCT00542776]146 participants (Actual)Observational2007-10-31Completed
Multicenter Clinical Trial Evaluating the Immunological Response of Vaccination Against Infection by Human Papillomavirus (HPV) 6, 11, 16, 18 in Girls Receiving Immunosuppressive Therapy.[NCT01687192]Phase 237 participants (Anticipated)Interventional2012-10-31Active, not recruiting
Relevance of Monitoring Blood Levels Compared to Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases: Adherence and Understanding the Possible Underlying Mechanisms Involved in Effectiveness and in Adverse Effects[NCT03122431]Phase 493 participants (Actual)Interventional2017-06-05Completed
Nature of Anifrolumab Impact on Vaccine-Emergent Immunity in Patients With Moderately to Severely Active Systemic Lupus Erythematosus: A Multi-Centre Open Label Parallel Group Trial:[NCT04726553]Early Phase 120 participants (Anticipated)Interventional2021-01-20Recruiting
Hit Hard and Early. The Effect of High Dose Methylprednisolone on Nailfold Capillary Changes and Biomarkers in Early SSc: a 12-week Randomised Explorative Double-blind Placebo-controlled Trial.[NCT03059979]Early Phase 130 participants (Anticipated)Interventional2017-01-31Recruiting
Efficacy of Lower Dose Prednisolone in the Induction of Remission of Lupus Nephritis[NCT04146220]Phase 432 participants (Actual)Interventional2018-07-16Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Decrease in the Total Combined Erythema and Scaling Score (Minimum of 0 and Maximum of 65) of All Treated Lesions.

Percentage of patients who achieved at least a 50% decrease from baseline in the total combined Erythema and Scaling score of all treated lesions at Week 4. A decrease is an improvement in measurement of erythema and scaling of the lesions. (NCT01597050)
Timeframe: Up to Week 4

Interventionpercentage of subjects (Number)
Drug: R93233322.2
Placebo27.8

Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Score

"The FACIT-Fatigue scale is a 13-item self-administered questionnaire that assesses both the physical and functional consequences of fatigue. Each question is answered on a 5-point scale, where 0 means not at all, and 4 means very much. The total FACIT-Fatigue score ranges from 0 to 52. Note: Data presented is Adjusted mean data." (NCT03161483)
Timeframe: Week 24

Interventionscores on a scale (Mean)
PBO QD3.8
0.15 mg QD2.7
0.30 mg QD3.1
0.45 mg QD5.2

Mean Change From Baseline in PGA Score

The PGA uses a visual analog scale with scores between 0 and 3 to indicate worsening of disease. The scoring is as follows: 0 = none, 1 = mild disease, 2 = moderate disease, and 3 = severe disease. (NCT03161483)
Timeframe: Week 24

Interventionscores on a scale (Mean)
PBO QD-0.803
0.15 mg QD-0.805
0.30 mg QD-0.819
0.45 mg QD-0.883

Mean Change From Baseline in Swollen Joint Count in Participants With ≥ 2 Swollen Joints at Baseline

"Joint tenderness and swelling will be noted as present or absent, with no quantitation of severity using a 28- joint count. Note: Data presented is Adjusted mean data." (NCT03161483)
Timeframe: Week 24

Interventionswollen joints (Mean)
PBO QD-6.7
0.15 mg QD-6.0
0.30 mg QD-6.0
0.45 mg QD-6.6

Mean Change From Baseline in Tender Joint Count in Participants With ≥ 2 Tender Joints at Baseline

"Joint tenderness and swelling will be noted as present or absent, with no quantitation of severity using a 28- joint count. Note: Data presented is Adjusted mean data." (NCT03161483)
Timeframe: Week 24

Interventiontender joints (Mean)
PBO QD-7.9
0.15 mg QD-6.8
0.30 mg QD-6.7
0.45 mg QD-7.6

Number of Participants Who Achieve SLE Responder Index (SRI) (4) Response

The primary objective is to evaluate the clinical efficacy of three doses of CC-220 (0.45 mg once per day [QD], 0.3 mg QD or 0.15 mg QD) compared to placebo, for the treatment of active systemic lupus erythematosus (SLE) using the SLE Responder Index at Week 24 Composite endpoint SRI(4), defined by the following criteria: - Reduction from Baseline of ≥ 4 points in the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) 2K score and - No new one or more British Isles Lupus Assessment Group (BILAG) A or new (excludes A to B) 2 or more BILAG B items compared to Baseline using BILAG 2004 Index and - No worsening from Baseline defined by an increase of < 0.30 points from Baseline on a Physician's Global Assessment (PGA) visual analog scale (VAS) from 0-3 (NCT03161483)
Timeframe: Week 24

InterventionNumber of participants (Number)
PBO QD29
0.15 mg QD20
0.30 mg QD33
0.45 mg QD44

Number of Participants With a ≥ 50% Reduction in Cutaneous Lupus Area and Severity Index (CLASI) Activity Score From Baseline, in Participants With Baseline CLASI Activity Score ≥ 10

The CLASI Activity Score ranges from 0 to 70. To generate the activity score erythema is scored on a scale of 0 (absent) to 3 (dark red; purple/violaceous/crusted/hemorrhagic) and scale/hypertrophy are scored on a scale of 0 (absent) to 2 (verrucous/hypertrophic). Both the erythema and scale/hypertrophy scores are assessed in 13 different anatomical locations. In addition, the presence of mucous membrane lesions is scored on a scale of 0 (absent) to 1 (lesion or ulceration), the occurrence of recent hair loss is captured (1=yes; 0=no) and non-scarring alopecia is scored on a scale of 0 (absent) to 3 (focal or patchy in more than one quadrant). To calculate the activity score, all scores for erythema, scale/hypertrophy, mucous membrane lesions and alopecia are added together. (NCT03161483)
Timeframe: Week 24

InterventionNumber of participants (Number)
PBO QD8
0.15 mg QD8
0.30 mg QD8
0.45 mg QD13

Number of Participants With no New Organ System Affected as Defined by 1 or More BILAG A or New (Excludes A to B) 2 or More BILAG B Items Compared to Baseline Using BILAG 2004 Index

The BILAG 2004 is a composite index that is based on the Classic BILAG index. It is a clinical measure of lupus disease activity. This tool assesses the changing severity of clinical manifestations of SLE using an ordinal scale scoring system that contain 9 systems (constitutional, mucocutaneous, neuropsychiatric, musculoskeletal, cardiorespiratory, gastrointestinal, ophthalmic, renal and hematological). Activity in each organ system is scored as: A=most active disease; B=intermediate activity; C=mild, stable disease; D=previous involvement, currently inactive; E=no previous activity. (NCT03161483)
Timeframe: Week 24

InterventionNumber of participants (Number)
PBO QD65
0.15 mg QD38
0.30 mg QD59
0.45 mg QD70

Number of Participants With SLEDAI 2K Score Improvement of ≥ 4 Points From Baseline

The SLEDAI 2K score measures disease activity through assessment of 24 lupus manifestations using a weighted score of 1 to 8 points. A manifestation is recorded if it is present over the previous 30 days regardless of severity or whether it has improved or worsened. A SLEDAI 2K score of 3 to 4 points is representative of active disease and a decrease of 1 to 2 points is considered clinically meaningful. (NCT03161483)
Timeframe: Week 24

InterventionNumber of participants (Number)
PBO QD30
0.15 mg QD20
0.30 mg QD35
0.45 mg QD45

Percent Change From Baseline in Corticosteroid Reduction

Percent change from Baseline in oral corticosteroid (OCS) dose in subjects with prednisone or equivalent ≥ 10 mg/day at Baseline Note: Data presented is Adjusted mean data. (NCT03161483)
Timeframe: Week 24

Interventionpercent change from baseline (Mean)
PBO QD-7.9
0.15 mg QD-5.1
0.30 mg QD-3.8
0.45 mg QD-1.4

Percentage of Participants With no Worsening (Increase of < 0.30 Points From Baseline) in PGA Compared to Baseline

The PGA uses a visual analog scale with scores between 0 and 3 to indicate worsening of disease. The scoring is as follows: 0 = none, 1 = mild disease, 2 = moderate disease, and 3 = severe disease. (NCT03161483)
Timeframe: Week 24

InterventionPercentage of participants (Number)
PBO QD78.3
0.15 mg QD90.5
0.30 mg QD73.2
0.45 mg QD85.2

The Total Corticosteroid Dose From Baseline Through Week 24

Standardized total oral corticosteroid (OCS) dose. (NCT03161483)
Timeframe: Through Week 24

Interventionmg (Mean)
PBO QD1139.7
0.15 mg QD1101.9
0.30 mg QD1071.8
0.45 mg QD1105.5

Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

Number of participants who experienced a TEAE during the course of the study (NCT03161483)
Timeframe: from first dose to 28 days post-last dose through Week 24 (placebo-controlled phase), approximately 28 weeks total

,,,
InterventionNumber of participants (Number)
Any TEAEAny Drug-related TEAEAny Serious TEAEAny Severe TEAEAny TEAE Leading to Drug InterruptionAny TEAE Leading to Drug WithdrawalAny TEAE Leading to Death
0.15 mg QD3114331020
0.30 mg QD64364414110
0.45 mg QD6332612340
PBO QD5424751561

Percentage of Participants With Corticosteroid Reduction

- The percentage of participants with a prednisone or equivalent dose of ≥ 10 mg/day at Baseline whose prednisone or equivalent dose has been reduced to ≤ 7.5 mg/day by Week 16 and maintained through Week 24 with no flares between Week 16 and Week 24 - The percentage of participants with a prednisone or equivalent dose of ≥ 10 mg/day at Baseline whose prednisone or equivalent dose has been reduced to < 10 mg/day by Week 16 and maintained through Week 24 with no flares between Week 16 and Week 24 (NCT03161483)
Timeframe: Week 24

,,,
InterventionPercentage of participants (Number)
Week 24, <= 7.5 mg/dayWeek 24, < 10 mg/day
0.15 mg QD0.00.0
0.30 mg QD3.33.3
0.45 mg QD0.00.0
PBO QD3.26.5

Area Under the Curve (AUC) of BILAG Score at Week 52

The BILAG index is a clinical measure of lupus disease activity. BILAG uses a single score for each of the 8 organ domains; range is from severe to no disease (A to E). The global BILAG score is the sum of the numerical scores in the 8 domains assigning A=9, B=3, C=1, D=0, E=0.The normalized AUC was created as the ratio of the area under the global BILAG score curve divided by baseline score. (NCT00071487)
Timeframe: Baseline and every 4 to 8 weeks through Week 52

Interventionratio score*days (Mean)
Placebo Plus SOC315.4
Belimumab 1 mg/kg Plus SOC310.6
Belimumab 4 mg/kg Plus SOC300.4
Belimumab 10 mg/kg Plus SOC302.7

Area Under the Curve (AUC) of SELENA SLEDAI Score at Week 52

SELENA SLEDAI is calculated from 24 individual descriptors; 0 indicates inactive disease and the maximum theoretical score is 105; scores > 20 are rare. The normalized AUC was created as the ratio of the area under the SELENA SLEDAI score curve divided by baseline score. (NCT00071487)
Timeframe: Baseline and every 4 to 8 weeks through Week 52

Interventionratio score*days (Mean)
Placebo Plus SOC317.3
Belimumab 1 mg/kg Plus SOC288.7
Belimumab 4 mg/kg Plus SOC320.3
Belimumab 10 mg/kg Plus SOC286.9

Percentage Change From Baseline in British Isles Lupus Activity Group (BILAG) Score at Week 52

The BILAG index is a clinical measure of lupus disease activity. BILAG uses a single score for each of the 8 organ domains; range is from severe to no disease (A to E). The global BILAG score is the sum of the numerical scores in the 8 domains assigning A=9, B=3, C=1, D=0, E=0. (NCT00071487)
Timeframe: Baseline, 52 weeks

Interventionpercent change (Mean)
Placebo Plus SOC-19.1
Belimumab 1 mg/kg Plus SOC-20.8
Belimumab 4 mg/kg Plus SOC-26.5
Belimumab 10 mg/kg Plus SOC-22.0

Percentage Change From Baseline in Safety of Estrogens in Lupus Erythematosus National Assessment SLE Disease Activity Index (SELENA SLEDAI) Score at Week 24.

SELENA SLEDAI is calculated from 24 individual descriptors; 0 indicates inactive disease and the maximum theoretical score is 105; scores > 20 are rare. (NCT00071487)
Timeframe: Baseline, 24 weeks

Interventionpercent change (Mean)
Placebo Plus SOC-17.2
Belimumab 1 mg/kg Plus SOC-23.3
Belimumab 4 mg/kg Plus SOC-11.3
Belimumab 10 mg/kg Plus SOC-23.7

Percentage Change From Baseline in SELENA SLEDAI Score at Week 52

SELENA SLEDAI is calculated from 24 individual descriptors; 0 indicates inactive disease and the maximum theoretical score is 105; scores > 20 are rare (NCT00071487)
Timeframe: Baseline, 52 weeks

Interventionpercent change (Mean)
Placebo Plus SOC-20.6
Belimumab 1 mg/kg Plus SOC-29.7
Belimumab 4 mg/kg Plus SOC-23.9
Belimumab 10 mg/kg Plus SOC-27.9

Percentage of Patients With a Reduction in Prednisone Dose

Percentage of patients whose average prednisone dose has been reduced by ≥ 50% and/or has been reduced to ≤ 7.5 mg/day during Weeks 40 through 52 in patients receiving greater than 7.5 mg/day at baseline. (NCT00071487)
Timeframe: Baseline, weeks 40 to 52

Interventionpercentatge of particpants (Number)
Placebo Plus SOC27.1
Belimumab 1 mg/kg Plus SOC20.0
Belimumab 4 mg/kg Plus SOC31.4
Belimumab 10 mg/kg Plus SOC44.7

Time to First Mild/Moderate or Severe SLE Flare (SLE Flare Index)

"The SLE Flare Index categorized SLE flare as mild or moderate or severe based on 5 variables: 1) change in SELENA SLEDAI score from the most recent assessment to current, 2) change in signs or symptoms of disease activity, 3) change in prednisone dosage, 4) use of new medications for disease activity or hospitalization, and 5) change in Physician's Global Assessment score, a visual analog scale scored from 0 to 3 (1=mild, 2=moderate, 3=severe)." (NCT00071487)
Timeframe: 0 to 52 weeks

Interventiondays (Median)
Placebo Plus SOC83
Belimumab 1 mg/kg Plus SOC68
Belimumab 4 mg/kg Plus SOC61
Belimumab 10 mg/kg Plus SOC70

Time to First Type A/B SLE Flare (as Defined Using BILAG) Over 52 Weeks

SLE flare indicates an increase in SLE disease activity. An SLE flare was a type A or B SLE flare (as defined using BILAG) compared with the previous visit. (NCT00071487)
Timeframe: 0 to 52 weeks

Interventiondays (Median)
Placebo Plus SOC78
Belimumab 1 mg/kg Plus SOC63
Belimumab 4 mg/kg Plus SOC84
Belimumab 10 mg/kg Plus SOC62

Adverse Events (AE) Overview

Includes AEs reported in patients from the first dose of study agent throughout the study up to the Week 76/exit visit or 8 weeks following the last dose of study agent for patients who withdrew from this study or decided not to participate in the optional continuation protocol (LBSL99/NCT00583362). (NCT00071487)
Timeframe: Up to 84 weeks

,,,,
Interventionpercentage of participants (Number)
Percent of patients with at least 1 AEPercent of patients with at least 1 SAEPercent of patients with an AE resulting in death
Belimumab 1 mg/kg Plus SOC97.418.40.9
Belimumab 10 mg/kg Plus SOC97.316.20.9
Belimumab 4 mg/kg Plus SOC96.413.50
Open-Label Extension Period: All Active96.29.60
Placebo Plus SOC97.319.50

Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE)

A TEAE was defined as any adverse event (AE) starting on or after the first dose of investigational product through to the safety follow-up visit. Any clinically significant changes in physical examinations, vital signs, and clinical laboratory test results were recorded as AEs. (NCT03451422)
Timeframe: Day 1 up to end of study, maximum of 18 weeks (12-week double-blind treatment, 6-week safety follow-up)

InterventionParticipants (Count of Participants)
Placebo7
AMG 592 Cohort 15
AMG 592 Cohort 25
AMG 592 Cohort 37
AMG 592 Cohort 43
AMG 592 Cohort 54

Area Under the Concentration-time Curve Over a Dosing Interval (AUCtau) for AMG 592

(NCT03451422)
Timeframe: Day 1 (pre-dose) and 6 to 72 hours post-dose, and Days 8, 11, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, Day 85 (pre-dose) and 6 to 72 hours post-dose, and Days 92, 99, 113 and 127

,,,,
Interventionhour*ng/mL (Mean)
First dose (Day 1)Last dose (Day 85)
AMG 592 Cohort 1538773
AMG 592 Cohort 29151120
AMG 592 Cohort 31560542
AMG 592 Cohort 419603260
AMG 592 Cohort 537703010

Maximum Observed Concentration (Cmax) for AMG 592

(NCT03451422)
Timeframe: Day 1 (pre-dose) and 6 to 72 hours post-dose, and Days 8, 11, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, Day 85 (pre-dose) and 6 to 72 hours post-dose, and Days 92, 99, 113 and 127

,,,,
Interventionng/mL (Mean)
First dose (Day 1)Last dose (Day 85)
AMG 592 Cohort 17.929.24
AMG 592 Cohort 213.018.9
AMG 592 Cohort 325.710.0
AMG 592 Cohort 430.756.5
AMG 592 Cohort 544.351.6

Number of Participants With Anti-AMG 592 Binding Antibodies and Anti-Interleukin (IL-2) Binding Antibodies

Number of participants who tested positive for developing anti-AMG 592 or anti-IL-2 binding antibodies at 1 or more post-baseline time points, with a negative or no result at baseline, are reported. (NCT03451422)
Timeframe: Day 1 up to end of study, maximum of 18 weeks (12-week double-blind treatment, 6-week safety follow-up)

InterventionParticipants (Count of Participants)
Binding anti-AMG 592 antibody
Placebo0

Number of Participants With Anti-AMG 592 Binding Antibodies and Anti-Interleukin (IL-2) Binding Antibodies

Number of participants who tested positive for developing anti-AMG 592 or anti-IL-2 binding antibodies at 1 or more post-baseline time points, with a negative or no result at baseline, are reported. (NCT03451422)
Timeframe: Day 1 up to end of study, maximum of 18 weeks (12-week double-blind treatment, 6-week safety follow-up)

,,,,
InterventionParticipants (Count of Participants)
Binding anti-AMG 592 antibodyBinding anti-IL-2 antibody
AMG 592 Cohort 232
AMG 592 Cohort 360
AMG 592 Cohort 421
AMG 592 Cohort 540
AMG 592 Cohort 131

Number of Participants With Anti-AMG 592 Neutralizing Antibodies and Anti-IL-2 Neutralizing Antibodies

Number of participants who tested positive for developing anti-AMG 592 or anti-IL-2 neutralizing antibodies at 1 or more post-baseline time points, with a negative or no result at baseline, are reported. (NCT03451422)
Timeframe: Day 1 up to end of study, maximum of 18 weeks (12-week double-blind treatment, 6-week safety follow-up)

InterventionParticipants (Count of Participants)
Neutralizing anti-AMG 592 antibody
Placebo0

Number of Participants With Anti-AMG 592 Neutralizing Antibodies and Anti-IL-2 Neutralizing Antibodies

Number of participants who tested positive for developing anti-AMG 592 or anti-IL-2 neutralizing antibodies at 1 or more post-baseline time points, with a negative or no result at baseline, are reported. (NCT03451422)
Timeframe: Day 1 up to end of study, maximum of 18 weeks (12-week double-blind treatment, 6-week safety follow-up)

,,,,
InterventionParticipants (Count of Participants)
Neutralizing anti-AMG 592 antibodyNeutralizing anti-IL-2 antibody
AMG 592 Cohort 100
AMG 592 Cohort 220
AMG 592 Cohort 310
AMG 592 Cohort 400
AMG 592 Cohort 520

Time of Cmax (Tmax) for AMG 592

(NCT03451422)
Timeframe: Day 1 (pre-dose) and 6 to 72 hours post-dose, and Days 8, 11, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, Day 85 (pre-dose) and 6 to 72 hours post-dose, and Days 92, 99, 113 and 127

,,,,
Interventionhours (Median)
First dose (Day 1)Last dose (Day 85)
AMG 592 Cohort 124.025.2
AMG 592 Cohort 247.626.2
AMG 592 Cohort 324.118.0
AMG 592 Cohort 424.624.1
AMG 592 Cohort 517.816.7

Number of Participants Who Achieve British Isles Lupus Assessment Group-Based Composite Lupus Assessment (BICLA) Response

"BICLA responder is defined as a patient whose disease course fulfills all of the following:~Improvement in all organ systems with activity graded as BILAG-2004 A (severe disease activity) or B (moderate disease activity) at baseline~No new organ system with activity graded as BILAG A; no more than 1 new organ system with activity graded as BILAG B~No increase from baseline in Systemic Lupus Erythematosus SLEDAI-2K score (≤ 0 points for change from baseline score)~No increase ≥ 10% in the Physician's Global Assessment of Disease Activity on a 3-point visual analog scale from no disease activity to severe disease activity~No discontinuation of investigational product or use of restricted medications beyond the protocol allowed threshold before assessment" (NCT03252587)
Timeframe: At week 48

InterventionParticipants (Count of Participants)
Placebo23
BMS-986165 3 mg43
BMS-986165 6 mg33
BMS-986165 12 mg32

Number of Participants Who Achieve Lupus Low Disease Activity State (LLDAS)

"LLDAS is defined as follows:~SLEDAI-2K ≤ 4, with no activity in major organ systems (renal, central nervous system, cardiopulmonary, vasculitis, fever) and no hemolytic anemia or gastrointestinal activity measured as maintaining a D (no disease activity but suggests the system had previously been affected) or E (no current or previous disease activity) score in BILAG Gastrointestinal Body System~No new lupus disease activity compared with the previous assessment measured as no new or worsening individual BILAG parameters~Physician's Global Assessment of Disease Activity ≤ 1 on a 3-point visual analog scale from no disease activity to severe disease activity~A current prednisolone (or equivalent) dose ≤ 7.5 mg daily~Well-tolerated standard maintenance doses of immunosuppressive drugs and approved biological agents" (NCT03252587)
Timeframe: At Week 48

InterventionParticipants (Count of Participants)
Placebo12
BMS-986165 3 mg33
BMS-986165 6 mg22
BMS-986165 12 mg23

Number of Participants Who Meet Response Criteria for Systemic Lupus Erythematosus (SLE) Responder Index [SRI(4)] at Week 32

"SRI(4) responder is defined as a patient whose disease course fulfills all of the following:~A 4-point or greater reduction from baseline in SLEDAI-2K score~No new British Isles Lupus Assessment Group (BILAG) A (severe disease activity) and not more than 1 new BILAG B (moderate disease activity) organ domain grade~No worsening from baseline in the Physician's Global Assessment of Disease Activity Scale by more than 0.3 points on a 3-point visual analog scale from no disease activity to severe disease activity" (NCT03252587)
Timeframe: At week 32

InterventionParticipants (Count of Participants)
Placebo31
BMS-986165 3 mg53
BMS-986165 6 mg46
BMS-986165 12 mg40

Number of Participants Who Meet Response Criteria for Systemic Lupus Erythematosus (SLE) Responder Index [SRI(4)] at Week 48

"SRI(4) responder is defined as a patient whose disease course fulfills all of the following:~A 4-point or greater reduction from baseline in SLEDAI-2K score~No new British Isles Lupus Assessment Group (BILAG) A (severe disease activity) or not more than 1 new BILAG B (moderate disease activity) organ domain grade~No worsening from baseline in the Physician's Global Assessment of Disease Activity Scale by more than 0.3 points on a 3-point visual analog scale from no disease activity to severe disease activity" (NCT03252587)
Timeframe: At week 48

InterventionParticipants (Count of Participants)
Placebo31
BMS-986165 3 mg52
BMS-986165 6 mg44
BMS-986165 12 mg42

Number of Participants With a ≥50% Reduction in CLASI Activity Score in the Sub-group With Baseline CLASI Activity Score ≥10

Number of participants with a Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) activity score ≥ 10 at baseline who achieve a CLASI response, defined as a decrease of ≥ 50% from baseline CLASI activity score (ranges from 0-70, where a higher score is associated with high disease activity). CLASI assesses by body surface area; points are given for presence of erythema, scale, hypertrophy, mucous membrane lesions, recent hair loss, and physician-observed alopecia (NCT03252587)
Timeframe: At week 48

InterventionParticipants (Count of Participants)
Placebo4
BMS-986165 3 mg16
BMS-986165 6 mg14
BMS-986165 12 mg18

Percent Change From Baseline in Anti-Double-Stranded DNA (dsDNA) Antibody Levels

Percent change from baseline in anti-double-stranded DNA (dsDNA) levels. Baseline values are defined as the last measurement before the first dose. (NCT03252587)
Timeframe: From baseline to week 52

InterventionPercent Change from Baseline (Mean)
Placebo276.26
BMS-986165 3 mg16.51
BMS-986165 6 mg-31.79
BMS-986165 12 mg-19.32

Percent Change From Baseline in Anti-Double-Stranded DNA (dsDNA) Antibody Levels at Week 32

Percent change from baseline in anti-double-stranded DNA (dsDNA) levels. Baseline values are defined as the last measurement before the first dose. (NCT03252587)
Timeframe: From baseline to week 32

InterventionPercent Change from Baseline (Mean)
Placebo21.36
BMS-986165 3 mg-15.24
BMS-986165 6 mg-11.31
BMS-986165 12 mg-24.17

BMS-986165 and Its Active Metabolite BMT-153261 Maximum Observed Plasma Concentration (Cmax)

Maximum observed plasma concentration (Cmax) for the following treatments: BMS-986165 and its active metabolite BMT-153261. Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. (NCT03252587)
Timeframe: Pre-dose, 0.5, 2, 4, and 6 hours post dose on week 12

,,
InterventionNG/ML (Geometric Mean)
BMS-986165Metabolite BMT-153261
BMS-986165 12 mg96.24911.748
BMS-986165 3 mg38.0336.358
BMS-986165 6 mg76.40012.133

BMS-986165 and Its Active Metabolite BMT-153261 Time of Maximum Observed Plasma Concentration (Tmax)

Time of maximum observed plasma concentration (Tmax) for the following treatments: BMS-986165 and its active metabolite BMT-153261. (NCT03252587)
Timeframe: Pre-dose, 0.5, 2, 4, 6, and 10 hours post dose on week 12

,,
InterventionHours (Median)
BMS-986165Metabolite BMT-153261
BMS-986165 12 mg2.00003.7330
BMS-986165 3 mg2.00004.0000
BMS-986165 6 mg2.00004.0000

BMS-986165 and Its Active Metabolite BMT-153261 Trough Observed Plasma Concentration (Ctrough)

Trough observed plasma concentration (Ctrough) for the following treatments: BMS-986165 and its active metabolite BMT-153261. Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. (NCT03252587)
Timeframe: Pre-dose, 0.5, 2, 4, and 6 hours post dose on week 2, 4, 8, 12, 24, 32, and 48

,,
InterventionNG/ML (Geometric Mean)
BMS-986165 week 2BMS-986165 week 4BMS-986165 week 8BMS-986165 week 12BMS-986165 week 24BMS-986165 week 32BMS-986165 week 48Metabolite BMT-153261 week 2Metabolite BMT-153261 week 4Metabolite BMT-153261 week 8Metabolite BMT-153261 week 12Metabolite BMT-153261 week 24Metabolite BMT-153261 week 32Metabolite BMT-153261 week 48
BMS-986165 12 mg30.813520.118226.796122.123721.872024.506015.95768.79207.27038.14517.40716.66086.87345.8602
BMS-986165 3 mg14.373714.609513.032810.751710.25468.52936.84934.26675.08864.12933.73253.36692.97592.8708
BMS-986165 6 mg29.290922.917012.958728.775113.927315.528521.78908.48417.78035.22909.32815.22295.29256.8838

Change From Baseline in the 40-Joint Count

"Change from baseline in the following 40-joint count: phalangeal joints of the hand, second through fifth metacarpophalangeal joints of the hand, and individual metatarsophalangeal joints of the feet, Bilateral first metacarpophalangeal joints and shoulders. Each of 40 joints count is evaluated based upon the presence or absence of:~Tender joint count (0 to 40)~Swollen joint count (0 to 40)~Tender and swollen joint count (0 to 40) A larger joint count indicates more severe disease." (NCT03252587)
Timeframe: Baseline and week 48

,,,
InterventionUnits on a scale (Mean)
TenderSwollenTender + Swollen
BMS-986165 12 mg-12.3-9.9-9.7
BMS-986165 3 mg-12.2-8.5-8.2
BMS-986165 6 mg-11.7-8.8-8.5
Placebo-11.2-8.3-8.2

Number of Participants With Abnormalities in Electrocardiograms (ECGs)

Number of participants with abnormalities in electrocardiograms (ECGs) assessed by QTcF, PR interval, and QRS interval (NCT03252587)
Timeframe: From baseline to up to week 48

,,,
InterventionParticipants (Count of Participants)
Baseline: QTcF 450 to < 480Baseline: QTcF 480 to < 500Baseline: QTcF >= 500Baseline: PR Interval >= 200Baseline: QRS Interval >=200Week 4: QTcF 450 to < 480Week 4: QTcF 480 to < 500Week4: QTcF >= 500Week 4: PR Interval >= 200Week 4: QRS Interval: >= 200Week 8: QTcF 450 to < 480Week 8: QTcF 480 to < 500Week 8: QTcF >=500Week 8: PR Interval >= 200Week 8 QRS Interval >=200Week 12: QTcF 450 to < 480Week 12: QTcF 480 to < 500Week 12: QTcF >= 500Week 12: PR Interval >= 200Week 12: QRS Interval >=200Week 32: QTcF 450 to < 480Week 32: QTcF 480 to < 500Week 32: QTcF >=500Week 32: PR Interval >= 200Week 32: QRS Interval >= 200Week 48: QTcF: 450 to < 480Week 48: QTcF 480 to < 500Week 48: QTcF >=500Week 48: PR Interval: >= 200Week 48: QRS Interval: >= 200
BMS-986165 12 mg500606015012060801405005050030
BMS-986165 3 mg310406207050060400805007020070
BMS-986165 6 mg601605104061050600402205080060
Placebo910505007070050300605005070040

Number of Participants With Abnormalities in Vital Signs

Number of participants with abnormalities in vital signs including heart rate, systolic blood pressure, and diastolic blood pressure (NCT03252587)
Timeframe: From first dose to 30 days post last dose (Up to 52 weeks)

,,,
InterventionParticipants (Count of Participants)
Week 2: Heart Rate: Value > 100 and change from baseline > 30Week 2: Heart Rate: Value < 55 and change from baseline < -15Week 2: Systolic Blood Pressure: Value > 140 and change from baseline > 20Week 2: Systolic Blood Pressure: Value < 90 and change from baseline < -20Week 2: Diastolic Blood Pressure: Value > 90 and change from baseline > 10Week 2: Diastolic Blood Pressure: Value < 55 and change from baseline < -10Week 4: Heart Rate: Value > 100 and change from baseline > 30Week 4: Heart Rate: Value < 55 and change from baseline < -15Week 4: Systolic Blood Pressure: Value > 140 and change from baseline > 20Week 4: Systolic Blood Pressure: Value < 90 and change from baseline < -20Week 4: Diastolic Blood Pressure: Value > 90 and change from baseline > 10Week 4: Diastolic Blood Pressure: Value < 55 and change from baseline < -10Week 8: Heart Rate: Value > 100 and change from baseline > 30Week 8: Heart Rate: Value < 55 and change from baseline < -15Week 8: Systolic Blood Pressure: Value > 140 and change from baseline > 20Week 8: Systolic Blood Pressure: Value < 90 and change from baseline < -20Week 8: Diastolic Blood Pressure: Value > 90 and change from baseline > 10Week 8: Diastolic Blood Pressure: Value < 55 and change from baseline < -10Week 12: Heart Rate: Value > 100 and change from baseline > 30Week 12: Heart Rate: Value < 55 and change from baseline < -15Week 12: Systolic Blood Pressure: Value > 140 and change from baseline > 20Week 12: Systolic Blood Pressure: Value < 90 and change from baseline < -20Week 12: Diastolic Blood Pressure: Value > 90 and change from baseline > 10Week 12: Diastolic Blood Pressure: Value < 55 and change from baseline < -10Week 16: Heart Rate: Value > 100 and change from baseline > 30Week 16: Heart Rate: Value < 55 and change from baseline < -15Week 16: Systolic Blood Pressure: Value > 140 and change from baseline > 20Week 16: Systolic Blood Pressure: Value < 90 and change from baseline < -20Week 16: Diastolic Blood Pressure: Value > 90 and change from baseline > 10Week 16: Diastolic Blood Pressure: Value < 55 and change from baseline < -10Week 20: Heart Rate: Value > 100 and change from baseline > 30Week 20: Heart Rate: Value < 55 and change from baseline < -15Week 20: Systolic Blood Pressure: Value > 140 and change from baseline > 20Week 20: Systolic Blood Pressure: Value < 90 and change from baseline < -20Week 20: Diastolic Blood Pressure: Value > 90 and change from baseline > 10Week 20: Diastolic Blood Pressure: Value < 55 and change from baseline < -10Week 24: Heart Rate: Value > 100 and change from baseline > 30Week 24: Heart Rate: Value < 55 and change from baseline < -15Week 24: Systolic Blood Pressure: Value > 140 and change from baseline > 20Week 24: Systolic Blood Pressure: Value < 90 and change from baseline < -20Week 24: Diastolic Blood Pressure: Value > 90 and change from baseline > 10Week 24: Diastolic Blood Pressure: Value < 55 and change from baseline < -10Week 28: Heart Rate: Value > 100 and change from baseline > 30Week 28: Heart Rate: Value < 55 and change from baseline < -15Week 28: Systolic Blood Pressure: Value > 140 and change from baseline > 20Week 28: Systolic Blood Pressure: Value < 90 and change from baseline < -20Week 28: Diastolic Blood Pressure: Value > 90 and change from baseline > 10Week 28: Diastolic Blood Pressure: Value < 55 and change from baseline < -10Week 32: Heart Rate: Value > 100 and change from baseline > 30Week 32: Heart Rate: Value < 55 and change from baseline < -15Week 32: Systolic Blood Pressure: Value > 140 and change from baseline > 20Week 32: Systolic Blood Pressure: Value < 90 and change from baseline < -20Week 32: Diastolic Blood Pressure: Value > 90 and change from baseline > 10Week 32: Diastolic Blood Pressure: Value < 55 and change from baseline < -10Week 36: Heart Rate: Value > 100 and change from baseline > 30Week 36: Heart Rate: Value < 55 and change from baseline < -15Week 36: Systolic Blood Pressure: Value > 140 and change from baseline > 20Week 36: Systolic Blood Pressure: Value < 90 and change from baseline < -20Week 36: Diastolic Blood Pressure: Value > 90 and change from baseline > 10Week 36: Diastolic Blood Pressure: Value < 55 and change from baseline < -10Week 40: Heart Rate: Value > 100 and change from baseline > 30Week 40: Heart Rate: Value < 55 and change from baseline < -15Week 40: Systolic Blood Pressure: Value > 140 and change from baseline > 20Week 40: Systolic Blood Pressure: Value < 90 and change from baseline < -20Week 40: Diastolic Blood Pressure: Value > 90 and change from baseline > 10Week 40: Diastolic Blood Pressure: Value < 55 and change from baseline < -10Week 44: Heart Rate: Value > 100 and change from baseline > 30Week 44: Heart Rate: Value < 55 and change from baseline < -15Week 44: Systolic Blood Pressure: Value > 140 and change from baseline > 20Week 44: Systolic Blood Pressure: Value < 90 and change from baseline < -20Week 44: Diastolic Blood Pressure: Value > 90 and change from baseline > 10Week 44: Diastolic Blood Pressure: Value < 55 and change from baseline < -10Week 48: Heart Rate: Value > 100 and change from baseline > 30Week 48: Heart Rate: Value < 55 and change from baseline < -15Week 48: Systolic Blood Pressure: Value > 140 and change from baseline > 20Week 48: Systolic Blood Pressure: Value < 90 and change from baseline < -20Week 48: Diastolic Blood Pressure: Value > 90 and change from baseline > 10Week 48: Diastolic Blood Pressure: Value < 55 and change from baseline < -10Week 52: Heart Rate: Value > 100 and change from baseline > 30Week 52: Heart Rate: Value < 55 and change from baseline < -15Week 52: Systolic Blood Pressure: Value > 140 and change from baseline > 20Week 52: Systolic Blood Pressure: Value < 90 and change from baseline < -20Week 52: Diastolic Blood Pressure: Value > 90 and change from baseline > 10Week 52: Diastolic Blood Pressure: Value < 55 and change from baseline < -10
BMS-986165 12 mg001010001010000010000010001020001020001020003020003030001020002010000020000000000010
BMS-986165 3 mg001002010000201011001031000010001020001111003041201011100010000020000001000110010000
BMS-986165 6 mg000011100000001030000021000000000000000000001100100020000010000010010010000000000000
Placebo001000000020101000001001000100001020100000001010001010000010011000000001002020000000

Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

Number of participants with any grade adverse events (AEs) and any grade serious adverse events (SAEs). An adverse event (AE) including SAEs is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in participants that do not necessarily have causal relationship with treatment (NCT03252587)
Timeframe: From first dose to 30 days post last dose (Up to 52 weeks)

,,,
InterventionParticipants (Count of Participants)
AEsSAEs
BMS-986165 12 mg757
BMS-986165 3 mg857
BMS-986165 6 mg818
Placebo7911

Number of Participants With Global Systemic Lupus Erythematosus (SLE) Clinical Response Based on Interferon-Regulated Gene (IRG) Status

"Global systemic lupus erythematosus (SLE) clinical response in participants based on interferon-regulated gene (IRG) status (high versus low IRG signature). IRG-high vs. IRG-low was determined using a 5-interferon (IFN) gene set during the sample collected at screening period. SRI(4) responder is defined as a patient whose disease course fulfills all of the following:~A 4-point or greater reduction from baseline in SLEDAI-2K score~No new British Isles Lupus Assessment Group (BILAG) A (severe disease activity) or not more than 1 new BILAG B (moderate disease activity) organ domain grade~No worsening from baseline in the Physician's Global Assessment of Disease Activity Scale by more than 0.3 points on a 3-point visual analog scale from no disease activity to severe disease activity" (NCT03252587)
Timeframe: At week 32

,,,
InterventionParticipants (Count of Participants)
IFN LowIFN High
BMS-986165 12 mg535
BMS-986165 3 mg746
BMS-986165 6 mg1135
Placebo1021

Number of Participants With Laboratory Abnormalities in Specific Liver Tests

"Number of participants with laboratory abnormalities in specific liver tests based on US conventional units. The potential drug-induced liver injury is defined by the presence of all of the following:~Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) elevation > 3× Upper Limit of Normal (ULN)~Total bilirubin > 2× ULN, without initial findings of cholestasis (elevated serum alkaline phosphatase)~No other immediately apparent possible causes of AST or AST elevation and hyperbilirubinemia, including, but not limited to, viral hepatitis, preexisting chronic or acute liver disease, or the administration of other drug(s) known to be hepatotoxic" (NCT03252587)
Timeframe: From first dose to 30 days post last dose (Up to 52 weeks)

,,,
InterventionParticipants (Count of Participants)
ALT or AST > 3XULNALT or AST > 5XULNTotal Bilirubin > 2XULNALT or AST > 3XULN and Total Bilirubin > 2XULN on the same day
BMS-986165 12 mg2100
BMS-986165 3 mg5100
BMS-986165 6 mg3100
Placebo2200

Percent Change From Baseline in Complement (C3, C4) Levels at Week 32

Percent change from baseline in complement proteins C3 and C4 levels. Baseline values are defined as the last measurement before the first dose. (NCT03252587)
Timeframe: From baseline to week 32

,,,
InterventionPercent Change from Baseline (Mean)
C3C4
BMS-986165 12 mg10.8425.13
BMS-986165 3 mg5.7812.32
BMS-986165 6 mg12.4216.71
Placebo-0.58-3.27

Percent Change From Baseline in Complement Proteins C3 and C4 Levels

Percent change from baseline in complement proteins C3 and C4 levels. Baseline values are defined as the last measurement before the first dose. (NCT03252587)
Timeframe: From baseline to week 52

,,,
InterventionPercent Change from Baseline (Mean)
C3C4
BMS-986165 12 mg14.7420.43
BMS-986165 3 mg5.333.57
BMS-986165 6 mg7.6024.96
Placebo3.5784.52

Percent Change From Baseline in Interferon-Regulated Gene (IRG) Expression Levels

Percent change from baseline in interferon-regulated gene (IRG) expression levels. IRG-high vs. IRG-low was determined using a 5-interferon (IFN) gene set during the sample collected at screening period. Baseline values are defined as the last measurement before the first dose. (NCT03252587)
Timeframe: From baseline to week 44

,,,
InterventionPercent Change from Baseline (Mean)
IFN HighIFN Low
BMS-986165 12 mg-47.5561-41.7645
BMS-986165 3 mg-39.7478-18.0641
BMS-986165 6 mg-55.5691-36.4510
Placebo-0.81304.7381

Percent Change From Baseline in Interferon-Regulated Gene (IRG) Expression Levels at Week 32

Percent change from baseline in interferon-regulated gene (IRG) expression levels. IRG-high vs. IRG-low was determined using a 5-interferon (IFN) gene set during the sample collected at screening period. Baseline values are defined as the last measurement before the first dose. (NCT03252587)
Timeframe: From baseline to week 32

,,,
InterventionPercent Change from Baseline (Mean)
IFN HighIFN Low
BMS-986165 12 mg-61.0515-42.9701
BMS-986165 3 mg-40.7944-27.4897
BMS-986165 6 mg-54.6988-42.8107
Placebo-4.3993-2.6555

Number and Percentage of Subjects Who Achieved a Response at Week 24 According to the Modified British Isles Lupus Assessment Group (BILAG)-Based Composite Lupus Assessment (mBICLA) Score

"The primary endpoint was evaluated by determining if there was a dose-response relationship between the mBICLA response rate at Week 24 and the dose administered, using the Multiple Comparison Procedure - Modelling (MCP-Mod) methodology. The existence of several candidate parametric models was assumed and multiple comparison techniques were used to choose the model(s) most likely to represent the true underlying dose-response curve. The selected model could further be used to guide the choice of adequate doses.~mBICLA responders were defined as subjects who met all of the following criteria:~BILAG-2004 normal improvement: all A scores at Baseline improved to B, C or D, and all B scores improved to C or D.~No worsening in disease activity: no new BILAG-2004 A scores and ≤ 1 new increase to B.~No worsening of total mSLEDAI-2K score from Baseline.~No significant deterioration (< 10% worsening from Baseline) in PGA.~No treatment failure (including the premature" (NCT02437890)
Timeframe: At Week 24 visit

InterventionParticipants (Count of Participants)
Placebo29
ALX-0061 75 mg q4w28
ALX-0061 150 mg q4w24
ALX-0061 150 mg q2w24
ALX-0061 225 mg q2w23

Number and Percentage of Subjects Who Were Treatment-emergent (TE) Anti-drug Antibody (ADA) Positive

(NCT02437890)
Timeframe: From first administration of ALX-0061 up to and including follow-up

InterventionParticipants (Count of Participants)
Placebo32
ALX-0061 75 mg q4w16
ALX-0061 150 mg q4w18
ALX-0061 150 mg q2w31
ALX-0061 225 mg q2w38

Actual Values for Hemolytic Complement Component 50 (CH50) at Baseline, Week 24, and Week 48

(NCT02437890)
Timeframe: At Baseline, Week 24, and Week 48

,,,,
Interventionunit(s) (Mean)
BaselineWeek 24Week 48
ALX-0061 150 mg q2w103.056.768.4
ALX-0061 150 mg q4w98.973.673.5
ALX-0061 225 mg q2w82.441.141.9
ALX-0061 75 mg q4w109.6107.0113.1
Placebo101.195.8102.2

Actual Values of Anti-double-stranded (ds) DNA Concentrations at Baseline, Week 24, and Week 48

(NCT02437890)
Timeframe: at Baseline, Week 24, and Week 48

,,,,
InterventionIU/mL (Mean)
BaselineWeek 24Week 48
ALX-0061 150 mg q2w68.9214.989.13
ALX-0061 150 mg q4w52.8846.9974.21
ALX-0061 225 mg q2w73.3423.2515.53
ALX-0061 75 mg q4w145.8768.2759.48
Placebo132.9081.3681.80

Actual Values of C-reactive Protein (CRP) Concentrations at Baseline, Week 24, and Week 48

(NCT02437890)
Timeframe: At Baseline, Week 24, and Week 48

,,,,
Interventionnmol/L (Mean)
BaselineWeek 24Week 48
ALX-0061 150 mg q2w66.323.834.41
ALX-0061 150 mg q4w38.8926.0823.20
ALX-0061 225 mg q2w32.233.204.02
ALX-0061 75 mg q4w49.0547.2237.65
Placebo43.5859.4330.70

Actual Values of Complement C3 Concentrations at Baseline, Week 24, and Week 48

(NCT02437890)
Timeframe: At Baseline, Week 24, and Week 48

,,,,
Interventionmg/dL (Mean)
BaselineWeek 24Week 48
ALX-0061 150 mg q2w105.875.383.2
ALX-0061 150 mg q4w101.982.079.0
ALX-0061 225 mg q2w98.671.872.3
ALX-0061 75 mg q4w100.295.793.2
Placebo102.3101.795.8

Actual Values of Complement C4 Concentrations at Baseline, Week 24, and Week 48

(NCT02437890)
Timeframe: At Baseline, Week 24, and Week 48

,,,,
Interventionmg/dL (Mean)
BaselineWeek 24Week 48
ALX-0061 150 mg q2w18.78.79.8
ALX-0061 150 mg q4w15.910.610.5
ALX-0061 225 mg q2w16.37.98.1
ALX-0061 75 mg q4w17.817.417.3
Placebo17.317.516.3

Actual Values of Fibrinogen Concentrations at Baseline, Week 24, and Week 48

(NCT02437890)
Timeframe: At Baseline, Week 24, and Week 48

,,,,
Interventiong/L (Mean)
BaselineWeek 24Week 48
ALX-0061 150 mg q2w3.21.91.9
ALX-0061 150 mg q4w3.22.32.3
ALX-0061 225 mg q2w3.11.91.9
ALX-0061 75 mg q4w3.23.33.3
Placebo3.23.33.3

Actual Values of Soluble Interleukin 6 Receptor (sIL-6R) Concentrations at Baseline, Week 24, and Week 48

(NCT02437890)
Timeframe: At Baseline, Week 24, and Week 48

,,,,
Interventionng/mL (Mean)
BaselineWeek 24Week 48
ALX-0061 150 mg q2w42.14668.57650.73
ALX-0061 150 mg q4w38.10603.51610.86
ALX-0061 225 mg q2w36.92634.49659.79
ALX-0061 75 mg q4w37.63198.26224.66
Placebo42.2239.7039.41

ALX-0061 Serum Concentrations at Week 24 and Week 48

(NCT02437890)
Timeframe: At Week 24 and Week 48

,,,
Interventionµg/mL (Geometric Mean)
Week 24Week 48
ALX-0061 150 mg q2w18.117.9
ALX-0061 150 mg q4w2.052.17
ALX-0061 225 mg q2w30.736.1
ALX-0061 75 mg 4qw0.1180.155

BILAG-2004 Total Score at Baseline, Week 24 and Week 48

"The British Isles Lupus Assessment Group 2004 (BILAG-2004) is a comprehensive composite clinical index that has been developed based on the principle of a physician's intention to treat using a nominal consensus approach. In the index, the nine systems (not organs) considered are: constitutional, mucocutaneous, neuropsychiatric, musculoskeletal, cardiorespiratory, gastrointestinal, renal, ophthalmic and hematological. Disease activity in each of the nine systems is categorized into five levels: grades A (= severe disease activity requiring systemic high dose oral corticosteroids, i.v. pulse corticosteroids, etc.) to E (= system never involved).~BILAG total score is derived by assigning the following value to each grade and summing the sores over all organ systems:~A = 12, B = 8, C = 1, D/E = 0. The total score ranges from 0-108, with 108 representing high disease activity in all 9 systems requiring high doses of corticosteroids, starting/increasing immunosuppressive drugs, etc." (NCT02437890)
Timeframe: At Baseline, Week 24 and Week 48

,,,,
Interventionscore (Mean)
BaselineWeek 24Week 48
ALX-0061 150 mg q2w17.47.26.0
ALX-0061 150 mg q4w15.27.05.2
ALX-0061 225 mg q2w17.37.46.2
ALX-0061 75 mg q4w17.95.74.0
Placebo17.46.86.0

Change From Baseline in 28 Joint Count Swollenness (SJC28) Score at Week 24 and Week 48

Twenty-eight joints are assessed for swollenness (a score of 1 for a joint denotes a presence of swollenness). The sum is derived to create a total score (ranging from 0 to 28; where the highest score indicate all 28 joints are swollen). Mean changes from baseline were derived from an analysis of covariance (ANCOVA) model with treatment as factor and baseline SJC28 Score and geographic region as covariates. A negative change denotes an improvement. (NCT02437890)
Timeframe: At Week 24 and Week 48

,,,,
Interventionscore (Mean)
Week 24Week 48
ALX-0061 150 mg q2w-4.8-5.1
ALX-0061 150 mg q4w-4.9-4.7
ALX-0061 225 mg q2w-4.5-4.5
ALX-0061 75 mg q4w-5.0-5.4
Placebo-4.8-5.0

Change From Baseline in 28 Joint Count Tenderness (TJC28) Score at Week 24 and Week 48

Twenty-eight joints are assessed for tenderness (a score of 1 for a joint denotes a presence of tenderness). The sum is derived to create a total score (ranging from 0 to 28; where the highest score indicate all 28 joints are tender). Mean changes from baseline were derived from an analysis of covariance (ANCOVA) model with treatment as factor and baseline TJC28 Score and geographic region as covariates. A negative change denotes and improvement. (NCT02437890)
Timeframe: At Week 24 and Week 48

,,,,
Interventionscore (Mean)
Week 24Week 48
ALX-0061 150 mg q2w-5.8-6.6
ALX-0061 150 mg q4w-6.4-6.4
ALX-0061 225 mg q2w-5.5-6.5
ALX-0061 75 mg q4w-6.8-7.4
Placebo-6.8-6.6

Change From Baseline in CLASI Damage Score at Week 12, Week 24 and Week 48

"CLASI Damage is scored based on dyspigmentation and scarring. Evaluation of dyspigmentation and scarring is based on a table: rows represent anatomical areas and columns represent major clinical symptoms. The extent of involvement for each of the skin symptoms is documented for each anatomic area (dyspigmentation: 0=absent, 1=present; scarring: 0=absent, 1=scarring, 2=severely atrophic scarring or panniculitis). Subjects are also asked whether dyspigmentation due to SLE lesions usually remains visible for >12 months, which is considered permanent and results in doubling of the dyspigmentation score. Scarring alopecia is scored as follows: 0=absent, 3=1 quadrant, 4=2 quadrants, 5=3 quadrants, 6=affects the whole skull. Total score ranges from 0-56, with higher scores indicating more damaged skin.~Mean changes from baseline were derived from an ANCOVA model with treatment as factor and baseline CLASI Damage Score and geographic region as covariates. Negative change = improvement." (NCT02437890)
Timeframe: At Week 12, Week 24 and Week 48

,,,,
Interventionscore (Mean)
Week 12Week 24Week 48
ALX-0061 150 mg q2w-0.30.30.4
ALX-0061 150 mg q4w-0.1-0.4-0.3
ALX-0061 225 mg q2w-0.4-0.1-0.7
ALX-0061 75 mg q4w0.1-0.4-0.1
Placebo0.10.40.0

Change From Baseline in Creatinine Clearance Estimation (eGFR) at Week 24 and Week 48

Mean changes from baseline were derived from an analysis of covariance (ANCOVA) model with treatment as factor and baseline eGFR and geographic region as covariates (NCT02437890)
Timeframe: At Week 24 and Week 48

,,,,
InterventionmL/min/1.73m2 (Mean)
Week 24Week 48
ALX-0061 150 mg q2w-0.90-1.47
ALX-0061 150 mg q4w-1.724.66
ALX-0061 225 mg q2w-8.91-8.08
ALX-0061 75 mg q4w4.832.47
Placebo-1.63-6.00

Change From Baseline in Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Activity Score at Week 12, Week 24 and Week 48

"CLASI Activity is scored based on erythema, scale/hyperkeratosis, mucous membrane involvement, acute hair loss and nonscarring alopecia. Evaluation of erythema and scale/hyperkeratosis is based on a table: rows represent anatomical areas and columns represent major clinical symptoms. The extent of involvement for each of the skin symptoms is documented for each anatomic area (erythema: 0=absent, 1=pink, 2=red, 3=dark red; scale: 0=absent, 1=scale, 2=verrucous/hypertrophic). Mucous membrane involvement and acute hair loss are scored based on the presence (=1) or absence (=0).~Nonscarring alopecia is scored as 0=absent, 1=diffuse/non-inflammatory, 2=focal or patchy in 1 quadrant, 3=focal or patchy in >1 quadrant. The total score ranges from 0-70, with higher scores indicating more severe skin disease.~Mean changes from baseline were derived from an ANCOVA model with treatment as factor and baseline CLASI Activity Score and geographic region as covariates. Negative change = improvement" (NCT02437890)
Timeframe: At Week 12, Week 24 and Week 48

,,,,
Interventionscore (Mean)
Week 12Week 24Week 48
ALX-0061 150 mg q2w-1.6-1.3-2.1
ALX-0061 150 mg q4w-1.4-1.6-2.5
ALX-0061 225 mg q2w-1.3-1.8-3.0
ALX-0061 75 mg q4w-1.9-2.1-3.0
Placebo-2.4-1.1-1.3

Change From Baseline in Mental Component Scores of SF-36 at Week 24 and Week 48

"The Short Form (36) Health Survey (SF-36) consists of 36 items that can be summarized into 8 domains: physical functioning, role limitations due to physical health problems (role-physical), bodily pain, general health, vitality, social functioning, role limitations due to emotional problems (role-emotional), and mental health. Two summary measures, the physical component summary and the mental component summary, can be derived based on these domain scores. Each score is directly transformed into a 0-100 score on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability.~Mean changes from baseline were derived from an analysis of covariance (ANCOVA) model with treatment as factor and baseline SF-36 Score and geographic region as covariates. A positive change denotes an improvement." (NCT02437890)
Timeframe: At Week 24 and Week 48

,,,,
Interventionscore (Mean)
Week 24Week 48
ALX-0061 150 mg q2w0.45-1.07
ALX-0061 150 mg q4w-0.56-0.07
ALX-0061 225 mg q2w-1.18-2.02
ALX-0061 75 mg q4w-0.99-0.58
Placebo0.081.50

Change From Baseline in Modified Systemic Lupus Erythematosus Disease Activity Index 2000 (mSLEDAI-2K) Score at Week 24 and Week 48

The Systemic Lupus Erythematosus Disease Activity Index 2000 is a 1-page weighted score for 24 items (seizure, psychosis, organic brain syndrome, visual disturbance, cranial nerve disorder, lupus headache, cerebrovascular accident, vasculitis, arthritis, myositis, urinary casts, hematuria, proteinuria, pyuria, rash, alopecia, mucosal ulcers, pleurisy, pericarditis, low complement, etc). The manifestations felt to be most commonly contributing to disease activity are included and scored based on the presence (= 1 multiplied by weight) or absence (= 0) within 30 days prior to the evaluation. The total score ranges from 0-105 (= sum of individual scores), with 105 being higher disease activity. mSLEDAI-2K derives from the standard index by omitting low complement. Mean changes from baseline were derived from an ANCOVA model with treatment as factor and baseline mSLEDAI-2K Score and geographic region as covariates. A negative change from baseline reflects an improvement. (NCT02437890)
Timeframe: At Week 24 and Week 48

,,,,
Interventionscore (Mean)
Week 24Week 48
ALX-0061 150 mg q2w-4.3-4.9
ALX-0061 150 mg q4w-3.8-4.3
ALX-0061 225 mg q2w-3.6-4.9
ALX-0061 75 mg q4w-4.6-5.2
Placebo-4.0-4.5

Change From Baseline in Patient's Global Assessment at Week 24 and Week 48

"The subject makes a mark between 0 (very good) and 100 mm (very bad) on the VAS to indicate how the subject is doing, while considering all the ways SLE affects him/her.~Mean changes from baseline were derived from an analysis of covariance (ANCOVA) model with treatment as factor and baseline Patient's Global Assessment and geographic region as covariates.~A negative change from baseline reflects an improvement." (NCT02437890)
Timeframe: At Week 24 and Week 48

,,,,
Interventionscore on a scale (Mean)
Week 24Week 48
ALX-0061 150 mg q2w-20.1-27.2
ALX-0061 150 mg q4w-14.9-22.1
ALX-0061 225 mg q2w-16.0-25.9
ALX-0061 75 mg q4w-13.5-21.5
Placebo-12.4-15.1

Change From Baseline in Physical Component Scores of Short Form (36) Health Survey (SF-36) at Week 24 and Week 48

"The Short Form (36) Health Survey (SF-36) consists of 36 items that can be summarized into 8 domains: physical functioning, role limitations due to physical health problems (role-physical), bodily pain, general health, vitality, social functioning, role limitations due to emotional problems (role-emotional), and mental health. Two summary measures, the physical component summary and the mental component summary, can be derived based on these domain scores. Each score is directly transformed into a 0-100 score on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability.~Mean changes from baseline were derived from an analysis of covariance (ANCOVA) model with treatment as factor and baseline SF-36 Score and geographic region as covariates. A positive change denotes an improvement." (NCT02437890)
Timeframe: At Week 24 and Week 48

,,,,
Interventionscore (Mean)
Week 24Week 48
ALX-0061 150 mg q2w4.678.62
ALX-0061 150 mg q4w6.778.67
ALX-0061 225 mg q2w5.018.85
ALX-0061 75 mg q4w4.566.97
Placebo4.713.73

Change From Baseline in Physician's Global Assessment (PGA) at Week 24 and Week 48

"The physician makes a mark between 0 (no disease) and 100 mm (severe disease) on the visual analogue scale (VAS) to indicate disease activity (independent of the subject's self-assessment).~Mean changes from baseline were derived from an analysis of covariance (ANCOVA) model with treatment as factor and baseline PGA score and geographic region as covariates.~A negative change from baseline reflects an improvement." (NCT02437890)
Timeframe: At Week 24 and Week 48

,,,,
Interventionscore on a scale (Mean)
Week 24Week 48
ALX-0061 150 mg q2w-23.5-30.1
ALX-0061 150 mg q4w-26.2-30.2
ALX-0061 225 mg q2w-22.7-30.5
ALX-0061 75 mg q4w-28.4-32.9
Placebo-25.2-28.3

Change From Baseline in Proteinuria at Week 24 and Week 48

Mean changes from baseline were derived from an analysis of covariance (ANCOVA) model with treatment as factor and baseline proteinuria and geographic region as covariates (NCT02437890)
Timeframe: At Week 24 and Week 48

,,,,
Interventiong/mol (Mean)
Week 24Week 48
ALX-0061 150 mg q2w-3.02-0.49
ALX-0061 150 mg q4w1.03-1.62
ALX-0061 225 mg q2w0.16-1.21
ALX-0061 75 mg q4w1.773.83
Placebo6.174.89

Change From Baseline in Serum Creatinine at Week 24 and Week 48

Mean changes from baseline were derived from an analysis of covariance (ANCOVA) model with treatment as factor and baseline serum creatinine and geographic region as covariates (NCT02437890)
Timeframe: At Week 24 and Week 48

,,,,
Interventionumol/L (Mean)
Week 24Week 48
ALX-0061 150 mg q2w-3.98-4.04
ALX-0061 150 mg q4w-1.50-6.26
ALX-0061 225 mg q2w-0.86-1.24
ALX-0061 75 mg q4w-3.29-1.87
Placebo-1.251.19

Number and Percentage of Subjects Experiencing Severe Flares According to BILAG-2004 Flare Index From Baseline to Week 24 and Week 48

(NCT02437890)
Timeframe: From Baseline to Week 24 and Week 48

,,,,
InterventionParticipants (Count of Participants)
Baseline to Week 24Baseline to Week 48
ALX-0061 150 mg q2w79
ALX-0061 150 mg q4w610
ALX-0061 225 mg q2w69
ALX-0061 75 mg q4w66
Placebo88

Number and Percentage of Subjects Experiencing Severe Flares According to mSLEDAI-2K Flare Index (mSFI) From Baseline to Week 24 and Week 48

(NCT02437890)
Timeframe: From Baseline to Week 24 and Week 48

,,,,
InterventionParticipants (Count of Participants)
Baseline to Week 24Baseline to Week 48
ALX-0061 150 mg q2w24
ALX-0061 150 mg q4w24
ALX-0061 225 mg q2w12
ALX-0061 75 mg q4w00
Placebo14

Number and Percentage of Subjects Who Discontinued Prednisone (or Equivalent) by Week 48 Without Experiencing a Severe Flare

Number and percentage of subjects who discontinued Prednisone (or equivalent) by Week 48 without experiencing a BILAG-2004-defined or mSFI-defined severe flare (NCT02437890)
Timeframe: Up to and including Week 48

,,,,
InterventionParticipants (Count of Participants)
BILAG-2004-defined FlaremSFI-defined Flare
ALX-0061 150 mg q2w11
ALX-0061 150 mg q4w12
ALX-0061 225 mg q2w00
ALX-0061 75 mg q4w00
Placebo00

Number and Percentage of Subjects Whose Daily Dose of Steroids Was Reduced Without Severe Flares During Weeks 40-48

Number and percentage of subjects whose prednisone equivalent dose was >7.5 mg/day at baseline and reduced to ≤7.5 mg/day during Weeks 40-48 without experiencing a BILAG-2004-defined or mSFI-defined severe flare after the first prednisone equivalent dose decrease. (NCT02437890)
Timeframe: Between Week 40 and Week 48

,,,,
InterventionParticipants (Count of Participants)
BILAG-2004-defined FlaremSFI-defined Flare
ALX-0061 150 mg q2w11
ALX-0061 150 mg q4w54
ALX-0061 225 mg q2w34
ALX-0061 75 mg q4w22
Placebo33

Number and Percentage of Subjects With BILAG-2004 Enhanced Improvement at Week 24 and Week 48

Enhanced improvement: all A scores at baseline improved to B/C/D, and all B scores improved to C or D and no worsening between consecutive visits from baseline up to the considered visit Only subjects with non-missing BILAG-2004 who had at least one A or B score at Baseline were assessed for this endpoint (NCT02437890)
Timeframe: At Week 24 and Week 48

,,,,
InterventionParticipants (Count of Participants)
Week 24Week 48
ALX-0061 150 mg q2w66
ALX-0061 150 mg q4w117
ALX-0061 225 mg q2w137
ALX-0061 75 mg q4w1610
Placebo75

Number and Percentage of Subjects With BILAG-2004 Normal Improvement at Week 24 and Week 48

"Normal Improvement: all A scores at baseline improved to B/C/D, and all B scores improved to C or D.~Only subjects with non-missing BILAG-2004 who had at least one A or B score at Baseline were assessed for this endpoint" (NCT02437890)
Timeframe: At Week 24 and Week 48

,,,,
InterventionParticipants (Count of Participants)
Week 24Week 48
ALX-0061 150 mg q2w2522
ALX-0061 150 mg q4w2829
ALX-0061 225 mg q2w2425
ALX-0061 75 mg q4w2934
Placebo3134

Number and Percentage of Subjects With BILAG-2004 Normal Improvement in Mucocutaneous System at Week 24 and Week 48

"An improvement is defined as an A score at Baseline improved to B/C/D, or a B score improved to C or D.~Only subjects with non-missing BILAG-2004 who had at least one A or B score at Baseline were assessed for this endpoint" (NCT02437890)
Timeframe: At Week 24 and Week 48

,,,,
InterventionParticipants (Count of Participants)
Week 24Week 48
ALX-0061 150 mg q2w2118
ALX-0061 150 mg q4w1818
ALX-0061 225 mg q2w2522
ALX-0061 75 mg q4w2427
Placebo2526

Number and Percentage of Subjects With BILAG-2004 Normal Improvement in Musculoskeletal System at Week 24 and Week 48

"An improvement is defined as an A score at Baseline improved to B/C/D, or a B score improved to C or D.~Only subjects with non-missing BILAG-2004 who had at least one A or B score at Baseline were assessed for this endpoint" (NCT02437890)
Timeframe: At Week 24 and Week 48

,,,,
InterventionParticipants (Count of Participants)
Week 24Week 48
ALX-0061 150 mg q2w3633
ALX-0061 150 mg q4w3635
ALX-0061 225 mg q2w3331
ALX-0061 75 mg q4w3938
Placebo4140

Number and Percentage of Subjects With mBICLA Response at Week 24 and Week 48

Number and percentage of mBICLA responders at Week 24 and Week 48 (NCT02437890)
Timeframe: At Week 24 and Week 48

,,,,
InterventionParticipants (Count of Participants)
Week 24Week 48
ALX-0061 150 mg q2w2419
ALX-0061 150 mg q4w2222
ALX-0061 225 mg q2w2222
ALX-0061 75 mg q4w2832
Placebo2828

Number and Percentage of Subjects With Modified Systemic Lupus Erythematosus Responder Index (mSRI-4) Response at Week 24 and Week 48

"The composite index mSRI-4 enables quantification of decrease and increase in disease activity in a broad spectrum of manifestations thereby offering a comprehensive assessment of SLE disease status. mSRI combines advantages from 3 validated measurement tools. The mSRI-4 criteria for response are:~modified SLE disease activity index 2000 (mSLEDAI-2K): ≥ 4 point reduction (covers global disease improvement),~British Isles Lupus Assessment Group 2004 (BILAG-2004): no new A domain score and no more than 1 new increase to B (covers organ-specific disease improvement),~Physician's Global Assessment (PGA) (is used as validity and safety net for items that were not addressed by the other two indices): < 10% increase from Baseline (no worsening) When all 3 criteria are met, the subject is a mSRI-4 responder at that time point.~Subjects who were treatment failures or discontinued from treatment were considered non-responder after treatment failure/discontinuation." (NCT02437890)
Timeframe: At Week 24 and Week 48

,,,,
InterventionParticipants (Count of Participants)
Week 24Week 48
ALX-0061 150 mg q2w3326
ALX-0061 150 mg q4w3029
ALX-0061 225 mg q2w2933
ALX-0061 75 mg q4w3936
Placebo3734

Number and Percentage of Subjects With mSRI-5 Response at Week 24 and Week 48

"The mSRI-5 criteria for response are:~mSLEDAI-2K: ≥ 5 point reduction~BILAG-2004: no new A domain score and no more than 1 new increase to B domain score~PGA: no worsening (< 10% increase from Baseline) Only subjects with Baseline mSLEDAI-2K ≥ 5 were considered for the derivation of that endpoint.~Subjects who were treatment failures or discontinued from treatment were considered non-responder after treatment failure/discontinuation." (NCT02437890)
Timeframe: At Week 24 and Week 48

,,,,
InterventionParticipants (Count of Participants)
Week 24Week 48
ALX-0061 150 mg q2w2016
ALX-0061 150 mg q4w1918
ALX-0061 225 mg q2w1622
ALX-0061 75 mg q4w2428
Placebo1720

Number and Percentage of Subjects With mSRI-6 Response at Week 24 and Week 48

"The mSRI-6 criteria for response are:~mSLEDAI-2K: ≥ 6 point reduction~BILAG-2004: no new A domain score and no more than 1 new increase to B domain score~PGA: no worsening (< 10% increase from Baseline) Only subjects with Baseline mSLEDAI-2K ≥ 6 were considered for the derivation of that endpoint.~Subjects who were treatment failures or discontinued from treatment were considered non-responder after treatment failure/discontinuation" (NCT02437890)
Timeframe: At Week 24 and Week 48

,,,,
InterventionParticipants (Count of Participants)
Week 24Week 48
ALX-0061 150 mg q2w1916
ALX-0061 150 mg q4w1916
ALX-0061 225 mg q2w1522
ALX-0061 75 mg q4w2328
Placebo1620

Number and Percentage of Subjects With mSRI-7 Response at Week 24 and Week 48

"The mSRI-7 criteria for response are:~mSLEDAI-2K: ≥ 7 point reduction~BILAG-2004: no new A domain score and no more than 1 new increase to B domain score~PGA: no worsening (< 10% increase from Baseline) Only subjects with Baseline mSLEDAI-2K ≥ 7 were considered for the derivation of that endpoint.~Subjects who were treatment failures or discontinued from treatment were considered non-responder after treatment failure/discontinuation." (NCT02437890)
Timeframe: At Week 24 and Week 48

,,,,
InterventionParticipants (Count of Participants)
Week 24Week 48
ALX-0061 150 mg q2w128
ALX-0061 150 mg q4w87
ALX-0061 225 mg q2w79
ALX-0061 75 mg q4w814
Placebo912

Number and Percentage of Subjects With mSRI-8 Response at Week 24 and Week 48.

"The mSRI-8 criteria for response are:~mSLEDAI-2K: ≥ 8 point reduction~BILAG-2004: no new A domain score and no more than 1 new increase to B domain score~PGA: no worsening (< 10% increase from Baseline) Only subjects with Baseline mSLEDAI-2K ≥ 8 were considered for the derivation of that endpoint.~Subjects who were treatment failures or discontinued from treatment were considered non-responder after treatment failure/discontinuation." (NCT02437890)
Timeframe: At Week 24 and Week 48

,,,,
InterventionParticipants (Count of Participants)
Week 24Week 48
ALX-0061 150 mg q2w107
ALX-0061 150 mg q4w87
ALX-0061 225 mg q2w78
ALX-0061 75 mg q4w714
Placebo911

Number and Percentage of Subjects With Persistent Minimal or no Activity in 9 Organ Systems According to BILAG-2004 Systems Tally at Week 24 and Week 48

(NCT02437890)
Timeframe: At Week 24 and Week 48

,,,,
InterventionParticipants (Count of Participants)
Week 24Week 48
ALX-0061 150 mg q2w1616
ALX-0061 150 mg q4w1923
ALX-0061 225 mg q2w1619
ALX-0061 75 mg q4w2427
Placebo1520

Number of and Percentage Treatment Failures From Baseline to Week 24 and Week 48

Defined as non-protocol allowed increase in steroid dose, start i.v. or i.m. steroids, or start or increase of immunosuppressant (NCT02437890)
Timeframe: From Baseline to Week 24 and Week 48

,,,,
InterventionParticipants (Count of Participants)
Baseline to Week 24Baseline to Week 48
ALX-0061 150 mg q2w26
ALX-0061 150 mg q4w49
ALX-0061 225 mg q2w36
ALX-0061 75 mg q4w01
Placebo25

Number of Subjects Who Were Treatment-emergent Urine Sediment Positive at Week 24 and Week 48

Efficacy Laboratory Parameters (Urinalysis) - Active Urine Sediment Number of subjects who were urine sediment negative at Baseline, but positive at Week 24 and Week 48, respectively. (NCT02437890)
Timeframe: At Week 24 and Week 48

,,,,
InterventionParticipants (Count of Participants)
Week 24Week 48
ALX-0061 150 mg q2w00
ALX-0061 150 mg q4w00
ALX-0061 225 mg q2w00
ALX-0061 75 mg q4w00
Placebo10

Percent Change From Baseline in Daily Dose of Steroids at Week 24 and Week 48

Mean changes from baseline were derived from an analysis of covariance (ANCOVA) model with treatment as factor and baseline prednisone equivalent total daily dose and geographic region as covariates (NCT02437890)
Timeframe: At Week 24 and Week 48

,,,,
Interventionpercentage (Mean)
Week 24Week 48
ALX-0061 150 mg q2w-1.40-2.32
ALX-0061 150 mg q4w0.25-1.03
ALX-0061 225 mg q2w-3.46-1.73
ALX-0061 75 mg q4w-0.80-3.22
Placebo3.876.93

Number of Participants With Severe Flare, Based on the SELENA Flare Index (SFI) at Week 16

Among some adults, having a period of SLE symptoms-called flares-may happen every so often, sometimes even years apart, and go away at other times-called remission. The SFI categorizes SLE flares as mild, moderate or severe. (NCT02953821)
Timeframe: Week 16

InterventionParticipants (Count of Participants)
Placebo Gel3
Acthar Gel0

British Isles Lupus Assessment Group 2004 (BILAG 2004)

"BILAG records disease activity occurring over the past 4 weeks, and is used to determine whether different course of treatment is required. The BILAG-2004 index covers 97 signs/symptoms across 9 organ systems. Each question is answered as 0-not present, 1-improving, 2-same, 3-worse, or 4-new.~The BILAG-2004 index categorizes disease activity in each organ system into five different levels from A to E. Grade A represents very active disease, Grade B represents moderate disease activity, Grade C indicates mild stable disease, and grade D implies no disease activity, but suggests the organ system had previously been affected. Grade E indicates no current or previous disease activity. A score is applied to each grade of each organ system using coding scheme of A=12, B=8, C=1, and D/E=0 and is summarized as a total score ranging 0-108. Higher scores indicate more severe disease activity." (NCT02953821)
Timeframe: Baseline, Week 16, Week 24

,
Interventionscore on a scale (Mean)
BaselineWeek 16Week 24
Acthar Gel18.07.76.9
Placebo Gel18.29.78.0

Mean Cutaneous Lupus Erythematosus Disease Area and Severity Score- Activity (CLASI) Total Activity Score

The CLASI total activity score reflects ongoing inflammation that can be treated, with points given for the presence of erythema, scale, mucous membrane lesions, recent hair loss, and inflammatory alopecia. Mild, moderate, and severe disease correspond with CLASI activity score ranges of 0 to 9, 10 to 20, and 21 to 70, respectively. Higher scores indicate more disease activity, lower scores indicate improvement. (NCT02953821)
Timeframe: at Baseline and Weeks 4, 8, and 16

,
Interventionscore on a scale (Mean)
BaselineWeek 4Week 8Week 12Week 16
Acthar Gel7.95.65.04.03.4
Placebo Gel7.15.85.04.53.8

Mean Number of Swollen or Tender Joints on the 28-Joint Count

The 28 Joint Count includes assessment of swelling and tenderness in the shoulders, elbows, wrists, metacarpophalangeal joints, proximal interphalangeal joints and knees. The investigator counts how many of the 28 joints are swollen or tender at the given week. (NCT02953821)
Timeframe: at Baseline and at Weeks 4, 8, 12 and 16

,
InterventionJoints (Mean)
BaselineWeek 4Week 8Week 12Week 16
Acthar Gel8.24.22.92.31.9
Placebo Gel7.24.93.82.92.8

Number of Participants With at Least a 4 Point Change From Baseline in Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K)

The SLEDAI-2K is a modified version of a composite score based on the presence or absence of clinical signs, clinical symptoms, and immunologic laboratory results taken within 10 days of the evaluations. Each of the descriptors has a weighted score and the total score of SLEDAI-2K is the sum of all 24 descriptor scores. The total SLEDAI-2K score falls between 0 and 105, with higher scores representing higher disease activity. Decrease from baseline indicates improvement. (NCT02953821)
Timeframe: Week 16, Week 24

,
InterventionParticipants (Count of Participants)
Week 16Week 24
Acthar Gel4144
Placebo Gel4046

Number of Participants With Decrease in Prednisone Dose to < 7.5 mg/Day at Week 20 and Week 24

(NCT02953821)
Timeframe: Week 20, Week 24

,
InterventionParticipants (Count of Participants)
Week 20Week 24
Acthar Gel34
Placebo Gel56

Physician's Global Assessment (PGA)

PGA is a 100 mm visual analogue scale where higher scores indicate more severe disease activity. Lower scores indicate improvement. (NCT02953821)
Timeframe: Baseline, Week 16, Week 24

,
Interventionscore on a scale (Mean)
BaselineWeek 16Week 24
Acthar Gel60.630.225.5
Placebo Gel58.833.226.9

4 Point Improvement in the SLE Disease Activity Index (SLEDAI)

The SLEDAI is a discontinuous scoring system that weights disease activity not by severity of individual symptoms but by the weighting of organs. This makes it less robust for comparing one group of patients to another, but it is quite useful to gave numbers of patients with improvement, since to lower the score a rigorous improvement must be documented (NCT02270957)
Timeframe: Comparison of Baseline to 6 months

InterventionParticipants (Count of Participants)
Abatacept9
Placebo8

British Isles Lupus Assessment Group Index-based Combined Lupus Assessment (BICLA)

"The British Isles Lupus Assessment Group Index is a scoring system for progress of disease activity over the prior month with a scoring system that rates each organ system as A or severe, B or moderate, C or mild vs no activity in the past month. To meet the BICLA endpoint requires all baseline severe features (BILAG A) improving to moderate (BILAG B), mild or resolved, and all baseline BILAG B features improving to mild or resolved without increase in any other feature on either the BILAG or a different measure called the SLEDAI (SLE Disease Activity Index). Furthermore there must be no increase in Physician's Global Assessment or any rescue medications after the month 2 visit. Only those meeting all of these criteria meet the primary endpoint." (NCT02270957)
Timeframe: 6 months

InterventionParticipants (Count of Participants)
Abatacept8
Placebo8

SLE Responder Index-4 (SRI-4)

Comparing the endpoint date at six months to Baseline, there must be a 4 point decreased in SLEDAI score (SLEDAI is defined as the SLE Disease Activity Index). The SLEDAI is a discontinuous scale in which each type of sign or symptom of active SLE is assigned a fixed number of points. Although the scale includes possible signs or symptoms adding up to more than 100 points it is rare for any (even very severe) patient to ever have a total score > 20. To meet the SLE Responder Index endpoint, There must also be no worsening of BILAG (British Isles Lupus Assessment Group Index (described in the primary endpoint section) and no worsening of PGA (a visual analogue scale reflecting physicians global assessment) by more than 10% of the scale. To meet this endpoint there must also be no new or increased medication initiated after Baseline other than the steroid rescues up to Month 2. (NCT02270957)
Timeframe: 6 months

InterventionParticipants (Count of Participants)
Abatacept9
Placebo8

Number of Participants With Abnormal Electrocardiogram (ECG) Findings Reported as TEAEs

The 12-lead ECG data were summarized and evaluated. Number of participants with clinically significant abnormal ECG findings as assessed by cardiologist were recorded and reported as TEAEs. (NCT01283139)
Timeframe: Day 1 up to Week 56

Interventionparticipants (Number)
Placebo2
Sifalimumab 200 Milligram (mg)0
Sifalimumab 600 mg1
Sifalimumab 1,200 mg0

Percentage of Participants Achieving a Positive Response in SRI (4) in 4-Gene Interferon Test High Participants

SRI (4) responder is defined as: 1) a reduction in baseline SLEDAI-2K disease activity score of >=4 points (with increased DNA binding item of SLEDAI-2K score based on the ANA Multi-Lyte® ANA-II Plus Test System); 2) no worsening in Physician Global Assessment (MDGA) (worsening is defined as an increase of >=0.3 from baseline on a 0-3 visual analogue scale) and 3) no worsening in BILAG-2004 (worsening is defined as at least 1 new 'A' score or 2 new 'B' scores on the BILAG-2004 compared with baseline). (NCT01283139)
Timeframe: Day 365

Interventionpercentage of participants (Number)
Placebo42.0
Sifalimumab 200 Milligram (mg)57.5
Sifalimumab 600 mg50.0
Sifalimumab 1,200 mg57.5

Percentage of Participants Achieving a Response in Systemic Lupus Erythematosus Responder Index 4 (SRI [4])

SRI (4) responder is defined as: 1) a reduction in baseline Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) disease activity score of greater than or equal to (>=) 4 points (with increased deoxyribonucleic acid [DNA] binding item of SLEDAI-2K score based on the ANA Multi-Lyte® ANA-II Plus Test System); 2) no worsening in Physician Global Assessment (MDGA) (worsening is defined as an increase of >=0.3 from baseline on a 0-3 visual analogue scale) and 3) no worsening in British Isles Lupus Assessment Group (BILAG-2004) (worsening is defined as at least 1 new 'A' score or 2 new 'B' scores on the BILAG-2004 compared with baseline). (NCT01283139)
Timeframe: Day 365

Interventionpercentage of participants (Number)
Placebo45.4
Sifalimumab 200 Milligram (mg)58.3
Sifalimumab 600 mg56.5
Sifalimumab 1,200 mg59.8

Number of Participants With Abnormal Clinical Laboratory Parameters Reported as Treatment-Emergent Adverse Events (TEAEs)

Laboratory investigations included hematology, serum chemistries and urinalysis parameters. Participants with clinically significant abnormalities in these laboratory investigations recorded as TEAEs were reported. (NCT01283139)
Timeframe: Day 1 up to Week 61

,,,
Interventionparticipants (Number)
AnaemiaWhite blood cell count increasedNeutrophil count increasedIron deficiency anaemiaHaemoglobin decreasedLymphocyte count decreasedWhite blood cell count decreasedAutoimmune haemolytic anaemiaEosinophiliaHaematocrit increasedHaemoglobin increasedLeukopeniaLymphopeniaNeutropeniaNeutrophil count decreasedPlatelet count increasedRed blood cell count decreasedThrombocytopeniaPlatelet count decreasedMonocyte count increasedHypokalaemiaAlanine aminotransferase increasedGamma-glutamyltransferase increasedHypertriglyceridaemiaDyslipidaemiaHepatic enzyme increasedAspartate aminotransferase increasedBlood creatine phosphokinase increasedBlood creatinine increasedBlood glucose increasedHyperglycaemiaTransaminases increasedBlood potassium decreasedLow density lipoprotein increasedBlood albumin decreasedBlood alkaline phosphatase decreasedBlood calcium increasedBlood cholesterol increasedBlood homocysteine increasedLiver function test abnormalHyperlipidaemiaHypoalbuminaemiaHypoglycaemiaBlood bilirubin increasedHypocalcaemiaBlood triglycerides increasedHyperbilirubinaemiaHypertransaminasaemia
Placebo133102110000131000214552222201110001100102011100
Sifalimumab 1,200 mg232210101000011010005343202012210001000010100000
Sifalimumab 200 Milligram (mg)411211010001100001001101021010001100000000000000
Sifalimumab 600 mg422001100110000100004111220200011110111101000111

Number of Participants With Abnormal Vital Signs Reported as Treatment-Emergent Adverse Events (TEAEs)

Vital sign assessments included blood pressure, pulse rate, temperature, weight and respiratory rate. Vital signs abnormalities recorded as TEAEs were reported. (NCT01283139)
Timeframe: Day 1 up to Week 61

,,,
Interventionparticipants (Number)
PyrexiaHypertensionWeight increasedBlood pressure increasedChillsHypertensive crisisOrthostatic hypotensionWeight decreasedHypotension
Placebo370110111
Sifalimumab 1,200 mg742011110
Sifalimumab 200 Milligram (mg)241220000
Sifalimumab 600 mg652100000

Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (TESAEs)

An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent defined as events present at baseline that worsened in intensity after administration of investigational product or events absent at baseline that emerged after administration of investigational product, for the period extending until the end of participant participation in the study. (NCT01283139)
Timeframe: Day 1 up to Week 74

,,,
Interventionparticipants (Number)
TEAETESAE
Placebo9419
Sifalimumab 1,200 mg9321
Sifalimumab 200 Milligram (mg)9716
Sifalimumab 600 mg9722

Percentage of Participants on Greater Than or Equal to 10 mg/Day Oral Prednisone (or Equivalent) at Baseline Who Were Able to Reduce to Less Than or Equal to (<=) 7.5 mg/Day

Percentage of participants on >=10 mg/day oral corticosteroids (OCS) at baseline who were able to taper it to <=7.5 mg/day by Day 365 were recorded. (NCT01283139)
Timeframe: Day 365

,,,
Interventionpercentage of participants (Number)
Reduce OCS to <=7.5 mg/day: YesReduce OCS to <=7.5 mg/day: No
Placebo6.593.5
Sifalimumab 1,200 mg6.293.8
Sifalimumab 200 Milligram (mg)8.291.8
Sifalimumab 600 mg9.490.6

Percentage of Participants Who Achieved a Greater Than 3-Point Improvement in the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale

FACIT-F is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (not at all) to 4 (very much). Larger the participant's response to the questions (with the exception of 2 negatively stated), greater was the participant's fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the participant's response). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). (NCT01283139)
Timeframe: Day 365

,,,
Interventionpercentage of participants (Number)
Achieved > 3-point improvement: YesAchieved > 3-point improvement: No
Placebo30.569.5
Sifalimumab 1,200 mg35.664.4
Sifalimumab 200 Milligram (mg)38.161.9
Sifalimumab 600 mg42.257.8

Percentage of Participants With a Cutaneous Lupus Erythematosus Disease Activity and Severity Index (CLASI) Activity Score Greater Than or Equal to (>=) 10 at Baseline Who Achieved a >= 4-point Reduction

The CLASI consists of two scores, the first summarizes the activity of the disease while the second is a measure of the damage done by the disease. Activity is scored on the basis of erythema, scale/hyperkeratosis, mucous membrane involvement, acute hair loss and non-scarring alopecia. Damage is scored in terms of dyspigmentation and scarring, including scarring alopecia. The percentage of participants with a CLASI activity score >=10 at baseline who achieved a clinically significant (>=4-point) reduction at Day 365 were reported. (NCT01283139)
Timeframe: Day 365

,,,
Interventionpercentage of participants (Number)
Achieved >=4-point reduction: YesAchieved >=4-point reduction: No
Placebo48.651.4
Sifalimumab 1,200 mg73.126.9
Sifalimumab 200 Milligram (mg)72.727.3
Sifalimumab 600 mg57.642.4

Change From Baseline in Arthritis, as Assessed by American College of Rheumatology (ACR) 28-joint Count of Tender and Swollen Joints on Day 85 and Day 169

Mean Change from Baseline Over Time; Measured by Disease Activity Score 28: A single score on a continuous scale (0-9.4). The level of RA disease activity can be interpreted as low (DAS28 <=3.2),moderate (3.2 < DAS28 <=5.1), or as high disease activity (DAS28 > 5.1) (NCT02265744)
Timeframe: At baseline, Day 85 and Day 169

InterventionScores on a scale (Mean)
Experimental: 12.5mg SC BMS-931699 Weekly-4.63
Experimental: 12.5mg SC BMS-931699 Every Other Week-4.63
Experimental: 5mg SC Injection BMS-931699 Every Other Week-4.75
Experimental: 1.25mg SCBMS-931699 Every Other Week-4.42
Placebo Comparator: 0mg SC Weekly BMS-931699-3.84

Ctrough: Trough Level Serum Concentration of BMS-931699 at Time Point Specified

Pharmacokinetics of BMS-931699 derived from serum concentration versus time data; Ctrough = Trough level serum concentration of BMS-931699 at time point specified Pharmacokinetic Population: defined as all subjects who receive any study medication and have any available concentration-time data. (NCT02265744)
Timeframe: Day 169

Interventionng/mL (Mean)
Experimental: 12.5mg SC BMS-931699 Weekly2040
Experimental: 12.5mg SC BMS-931699 Every Other Week640.8
Experimental: 5mg SC Injection BMS-931699 Every Other Week207.1
Experimental: 1.25mg SCBMS-931699 Every Other Week62.2
Placebo Comparator: 0mg SC Weekly BMS-9316990

Percentage of Participants Who Achieve a BICLA Response (BICLA Response Rate) at Day 169

"The British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) is a measure of systemic lupus erythematosus (SLE) response. BICLA is defined as: British Isle Lupus Assessment Group improvement, defined as BILAG As at Baseline improved to B/C/D, and BILAG Bs at baseline improved to C/D, and no BILAG worsening in other BILAG organ systems such that there are no new BILAG As or greater than 1 new BILAG B; and no worsening in the SLEDAI-2K total score compared to Baseline (defined as no increase in SLEDAI total score); and no worsening in the physician's global assessment (MDGA) of disease activity (no worsening is defined as less than 10% worsening, equivalent to a 10mm increase on a 100mm visual analog scale [VAS]) compared to Baseline." (NCT02265744)
Timeframe: At Day 169

InterventionPercentage of participants (Number)
Experimental: 12.5mg SC BMS-931699 Weekly59.4
Experimental: 12.5mg SC BMS-931699 Every Other Week63.2
Experimental: 5mg SC Injection BMS-931699 Every Other Week57.4
Experimental: 1.25mg SCBMS-931699 Every Other Week58.6
Placebo Comparator: 0mg SC Weekly BMS-93169959.2

Percentage of Participants With an Improvement of >4 or a Decrease of >50% From Baseline in Their Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Score

Mean change from baseline, CLASI = Cutaneous Lupus Erythematosus Disease Area and Severity Index. Scores can range from 0 to 70 with higher scores denoting greater disease activity or damage. (NCT02265744)
Timeframe: At Day 85 and Day 169

InterventionPercentage of participants (Number)
Experimental: 12.5mg SC BMS-931699 Weekly39.3
Experimental: 12.5mg SC BMS-931699 Every Other Week46.9
Experimental: 5mg SC Injection BMS-931699 Every Other Week34.5
Experimental: 1.25mg SCBMS-931699 Every Other Week36.1
Placebo Comparator: 0mg SC Weekly BMS-93169942.4

Percentage of Participants With BICLA Response (BICLA Response Rate) at Day 85

"BICLA is defined as: British Isle Lupus Assessment Group improvement, defined as BILAG As at Baseline improved to B/C/D, and BILAG Bs at baseline improved to C/D, and no BILAG worsening in other BILAG organ systems such that there are no new BILAG As or greater than 1 new BILAG B; and no worsening in the SLEDAI-2K total score compared to Baseline (defined as no increase in SLEDAI total score); and no worsening in the physician's global assessment (MDGA) of disease activity (no worsening is defined as less than 10% worsening, equivalent to a 10mm increase on a 100mm visual analog scale [VAS]) compared to Baseline; No changes in concomitant medications according to the following criteria: No increase of or addition of a new immunosuppressant agent (azathioprine,mycophenolic acid/mycophenolate mofetil, methotrexate, anti-malarial, leflunomide) over baseline levels; No increase in corticosteroid dose above baseline level outside of those allowed per protocol." (NCT02265744)
Timeframe: At Day 85

InterventionPercentage of participants (Number)
Experimental: 12.5mg SC BMS-931699 Weekly69.6
Experimental: 12.5mg SC BMS-931699 Every Other Week64.7
Experimental: 5mg SC Injection BMS-931699 Every Other Week57.4
Experimental: 1.25mg SCBMS-931699 Every Other Week57.1
Placebo Comparator: 0mg SC Weekly BMS-93169954.9

Percentage of Participants With Clinically Significant Changes in Vital Signs: Respiration Rate

RESPIRATION RATE (RESP) (PER MIN) RESP > 16 OR RESP CHANGE FROM BASELINE > 10 (NCT02265744)
Timeframe: At Day 85 and Day 169

InterventionPercentage of participants (Number)
Experimental: 12.5mg SC BMS-931699 Weekly82.4
Experimental: 12.5mg SC BMS-931699 Every Other Week85.5
Experimental: 5mg SC Injection BMS-931699 Every Other Week75.0
Experimental: 1.25mg SCBMS-931699 Every Other Week70.0
Placebo Comparator: 0mg SC Weekly BMS-93169981.7

Percentage of Participants With Clinically Significant Changes in Vital Signs: Temperature

TEMPERATURE (TEMP) (C) TEMP > 38.3 OR TEMP CHANGE FROM BASELINE > 1.6 (NCT02265744)
Timeframe: At Day 85 and Day 169

InterventionPercentage of participants (Number)
Experimental: 12.5mg SC BMS-931699 Weekly0
Experimental: 12.5mg SC BMS-931699 Every Other Week0
Experimental: 5mg SC Injection BMS-931699 Every Other Week1.5
Experimental: 1.25mg SCBMS-931699 Every Other Week1.4
Placebo Comparator: 0mg SC Weekly BMS-9316991.4

Change From Baseline in BILAG-2004 Score of Systemic Lupus Erythematosus (SLE) Activity on Day 85 and Day 169

Overall British Isles Lupus Assessment Group-2004 score, BILAG Scores: A=Severe disease activity, B=Moderate disease activity, C=Mild disease, D=Inactive disease but previously affected, E=System never involved.The categories are converted to a numeric score (A=9, B=3, C=1, D=0, E=0) and treated as a continuous variable. Higher score= more severe disease activity. (NCT02265744)
Timeframe: At baseline, Day 85 and Day 169

,,,,
InterventionScore (Mean)
BILAG-2004 Score Day 85BILAG-2004 Score Day 169
Experimental: 1.25mg SCBMS-931699 Every Other Week-8.66-9.73
Experimental: 12.5mg SC BMS-931699 Every Other Week-8.83-10.46
Experimental: 12.5mg SC BMS-931699 Weekly-10.31-11.50
Experimental: 5mg SC Injection BMS-931699 Every Other Week-7.07-8.98
Placebo Comparator: 0mg SC Weekly BMS-931699-7.94-9.78

Change From Baseline in Physician Global Assessment of Disease Activity (MDGA) on Day 85 and Day 169

Physician Global Assessment of Arthritis was measured by asking the physician to assess the participant's current arthritis disease activity by placing a vertical line on a 0 to 100 millimeter (mm) visual analog scale (VAS), where 0 mm = very good and 100 mm = very bad. (NCT02265744)
Timeframe: At baseline, Day 85 and Day 169

,,,,
InterventionScore (Mean)
MDGA score Day 85MDGA score Day 169
Experimental: 1.25mg SCBMS-931699 Every Other Week-20.55-26.71
Experimental: 12.5mg SC BMS-931699 Every Other Week-23.87-26.87
Experimental: 12.5mg SC BMS-931699 Weekly-28.77-29.30
Experimental: 5mg SC Injection BMS-931699 Every Other Week-21.00-28.68
Placebo Comparator: 0mg SC Weekly BMS-931699-23.83-25.28

Change From Baseline in the SLEDAI-2K Score of SLE Activity on Day 85 and Day 169

Systemic Lupus Erythematosus Disease Activity Index, SLEDAI; Version 2000, also known as SLEDAI-2K. The SLEDAI-2K score is a weighted, cumulative index of lupus disease activity. SLEDAI-2K is calculated from 24 individual descriptors across 9 organ systems; 0 indicates inactive disease and the maximum theoretical score is 105. (NCT02265744)
Timeframe: At baseline, Day 85 and Day 169

,,,,
InterventionScore (Mean)
SLEDAI-2K Score Day 85SLEDAI-2K Score Day 169
Experimental: 1.25mg SCBMS-931699 Every Other Week-4.02-4.82
Experimental: 12.5mg SC BMS-931699 Every Other Week-3.24-4.17
Experimental: 12.5mg SC BMS-931699 Weekly-3.61-4.88
Experimental: 5mg SC Injection BMS-931699 Every Other Week-3.17-3.98
Placebo Comparator: 0mg SC Weekly BMS-931699-3.29-4.15

Cumulative Corticosteroid and Immunosuppressant Use

Percent of participants requiring use of corticosteroids and mmunosuppressants use over time (NCT02265744)
Timeframe: Up to one day prior to the first dose of long-term extension period or up to 42 days post last short-term dose date, which ever is earlier

,,,,
InterventionPercentage of participants (Number)
Corticosteroids: OralCorticosteroids: Oral inhalationImmunosuppressantImmunosuppressant AzathioprineImmunosuppressant Methotrexate
Experimental: 1.25mg SCBMS-931699 Every Other Week84.3051.428.624.3
Experimental: 12.5mg SC BMS-931699 Every Other Week82.4063.229.435.3
Experimental: 12.5mg SC BMS-931699 Weekly89.9046.423.226.1
Experimental: 5mg SC Injection BMS-931699 Every Other Week86.81.538.214.725.0
Placebo Comparator: 0mg SC Weekly BMS-93169994.4059.233.826.8

Mean Change From Baseline in CLASI Score at Day 85 and Day 169

Mean change from baseline, CLASI = Cutaneous Lupus Erythematosus Disease Area and Severity Index. Scores can range from 0 to 70 with higher scores denoting greater disease activity or damage. (NCT02265744)
Timeframe: At Day 85 and Day 169

,,,,
InterventionScores on a scale (Mean)
Day 85Day 169
Experimental: 1.25mg SCBMS-931699 Every Other Week-1.82-2.94
Experimental: 12.5mg SC BMS-931699 Every Other Week-3.20-3.78
Experimental: 12.5mg SC BMS-931699 Weekly-2.31-3.17
Experimental: 5mg SC Injection BMS-931699 Every Other Week-1.69-2.47
Placebo Comparator: 0mg SC Weekly BMS-931699-3.11-3.57

Number of Participants Clinically Significant Abnormalities in General Laboratory Tests : IMMUNOLOGY

IMMUNE ACTIVATION MARKERS:C-REACTIVE PROTEIN (CRP) CRP MG/L H > 1.5×ULN; CRP, HIGH SENSITIVITY MG/L H > 1.5×ULN; (NCT02265744)
Timeframe: Up to 42 days post last dose of study medication in short-term or long-term extension period

,,
InterventionParticipants (Number)
C-Reactive Protein (CRP) LowC-Reactive Protein (CRP) High
Experimental: 12.5mg SC BMS-931699 Every Other WeekNA18
Experimental: 12.5mg SC BMS-931699 WeeklyNA19
Placebo Comparator: 0mg SC Weekly BMS-931699NA22

Number of Participants Clinically Significant Abnormalities in General Laboratory Tests : IMMUNOLOGY

IMMUNE ACTIVATION MARKERS:C-REACTIVE PROTEIN (CRP) CRP MG/L H > 1.5×ULN; CRP, HIGH SENSITIVITY MG/L H > 1.5×ULN; (NCT02265744)
Timeframe: Up to 42 days post last dose of study medication in short-term or long-term extension period

,
InterventionParticipants (Number)
C-Reactive Protein (CRP) LowC-Reactive Protein (CRP) HighCRP, High Sensitivity LowCRP, High Senstivity High
Experimental: 1.25mg SCBMS-931699 Every Other WeekNA18NA0
Experimental: 5mg SC Injection BMS-931699 Every Other WeekNA22NA1

Number of Participants Clinically Significant Abnormalities in General Laboratory Tests : OTHER CHEMISTRY TESTING 1

GLUCOSE TESTS:GLUCOSE, FASTING SERUM MMOL/L H > 1.3×ULN IF PRE-RX IS MISSING OR > 1.3×ULN IF PRE-RX <= ULN OR > 2×PRE-RX IF PRE-RX > ULN OR > ULN IF PRE-RX < LLN GLUCOSE, FASTING SERUM MMOL/L L < 0.8×LLN IF PRE-RX IS MISSING OR < 0.8×LLN IF PRE-RX >= LLN OR < 0.8×PRE-RX IF PRE-RX < LLN OR < LLN IF PRE-RX > ULN; PROTEIN TESTS:ALBUMIN G/L L < 0.9×LLN IF PRE-RX IS MISSING OR < 0.9×LLN IF PRE-RX >= LLN OR < 0.9×PRE-RX IF PRE-RX < LLN PROTEIN, TOTAL G/L H > 1.1×ULN IF PRE-RX IS MISSING OR > 1.1×ULN IF PRE-RX <= ULN OR > 1.1×PRE-RX IF PRE-RX > ULN OR > ULN IF PRE-RX < LLN PROTEIN, TOTAL G/L L < 0.9×LLN IF PRE-RX IS MISSING OR < 0.9×LLN IF PRE-RX >= LLN OR < 0.9×PRE-RX IF PRE-RX < LLN OR < LLN IF PRE-RX > ULN (NCT02265744)
Timeframe: Up to 42 days post last dose of study medication in short-term or long-term extension period

,,,,
InterventionParticipants (Number)
Glucose, Fasting serum, LowGlucose, Fasting Serum, HighAlbumin, LowAlbumin, HighProtein, Total, LowProtein, Total, High
Experimental: 1.25mg SCBMS-931699 Every Other Week402011
Experimental: 12.5mg SC BMS-931699 Every Other Week332000
Experimental: 12.5mg SC BMS-931699 Weekly131000
Experimental: 5mg SC Injection BMS-931699 Every Other Week002011
Placebo Comparator: 0mg SC Weekly BMS-931699541000

Number of Participants Clinically Significant Abnormalities in General Laboratory Tests : OTHER CHEMISTRY TESTING 2

OTHER CHEMISTRY TESTING LIPID TESTS: CHOLESTEROL, TOTAL (TC) MMOL/L H > 1.2×ULN IF PRE-RX IS MISSING OR > 1.2×ULN IF PRE-RX <= ULN OR > 1.2×PRE-RX IF PRE-RX > ULN TRIGLYCERIDES, FASTING MMOL/L H > 1.25×ULN IF PRE-RX IS MISSING OR > 1.25×ULN IF PRE-RX <= ULN OR > 1.5×PRE-RX IF PRE-RX > ULN PANCREATIC TESTS: AMYLASE, TOTAL U/L H > 1.5×ULN; LIPASE, TOTAL (TURBIDIMETRIC ASSAY) U/L H > 1.5×ULN; LIPASE, TOTAL (COLORIMETRIC ASSAY) U/L H > 1.5×ULN; ENDOCRINE TESTS:CORTISOL, AM NMOL/L L < 138 THYROID STIMULATING HORMONE (TSH) TSH MU/L H > 1.5×ULN IF PRE-RX IS MISSING OR > 1.5×ULN IF PRE-RX <= ULN OR > 2×PRE-RX IF PRE-RX > ULN (NCT02265744)
Timeframe: Up to 42 days post last dose of study medication in short-term or long-term extension period

InterventionParticipants (Number)
Cholesterol, Total (TC) LowCholesterol, Total (TC) HighTriglycerides, Fasting LowTriglycerides, Fasting HighAmylase, Total LowAmylase, Total HighLipase, Total (Colorimetric Assay) LowLipase, Total (Colorimetric Assay) HighLipase, Total (Turbidimetric Assay) LowLipase, Total (Turbidimetric Assay) HighThyroid Stimulating Hormone, LowThyroid Stimulating Hormone, High
Experimental: 5mg SC Injection BMS-931699 Every Other WeekNA12NA12NA0NA1NA1NA0

Number of Participants Clinically Significant Abnormalities in General Laboratory Tests : OTHER CHEMISTRY TESTING 2

OTHER CHEMISTRY TESTING LIPID TESTS: CHOLESTEROL, TOTAL (TC) MMOL/L H > 1.2×ULN IF PRE-RX IS MISSING OR > 1.2×ULN IF PRE-RX <= ULN OR > 1.2×PRE-RX IF PRE-RX > ULN TRIGLYCERIDES, FASTING MMOL/L H > 1.25×ULN IF PRE-RX IS MISSING OR > 1.25×ULN IF PRE-RX <= ULN OR > 1.5×PRE-RX IF PRE-RX > ULN PANCREATIC TESTS: AMYLASE, TOTAL U/L H > 1.5×ULN; LIPASE, TOTAL (TURBIDIMETRIC ASSAY) U/L H > 1.5×ULN; LIPASE, TOTAL (COLORIMETRIC ASSAY) U/L H > 1.5×ULN; ENDOCRINE TESTS:CORTISOL, AM NMOL/L L < 138 THYROID STIMULATING HORMONE (TSH) TSH MU/L H > 1.5×ULN IF PRE-RX IS MISSING OR > 1.5×ULN IF PRE-RX <= ULN OR > 2×PRE-RX IF PRE-RX > ULN (NCT02265744)
Timeframe: Up to 42 days post last dose of study medication in short-term or long-term extension period

,,,
InterventionParticipants (Number)
Cholesterol, Total (TC) LowCholesterol, Total (TC) HighTriglycerides, Fasting LowTriglycerides, Fasting High
Experimental: 1.25mg SCBMS-931699 Every Other WeekNA10NA10
Experimental: 12.5mg SC BMS-931699 Every Other WeekNA4NA13
Experimental: 12.5mg SC BMS-931699 WeeklyNA5NA12
Placebo Comparator: 0mg SC Weekly BMS-931699NA8NA8

Number of Participants Clinically Significant Abnormalities in General Laboratory Tests : OTHER CHEMISTRY TESTING 3

OTHER CHEMISTRY TESTING CARDIAC TESTS: CREATINE KINASE (CK) CK U/L H > 1.5×ULN IF PRE-RX IS MISSING OR > 1.5×ULN IF PRE-RX <= ULN OR > 1.5×PRE-RX IF PRE-RX > ULN; TROPONIN-I, CARDIAC SPECIFIC UG/L H > ULN; METABOLITE TESTS:URIC ACID URIC MMOL/L H > 1.2×ULN IF PRE-RX IS MISSING OR > 1.2×ULN IF PRE-RX <= ULN OR > 1.25×PRE-RX IF PRE-RX > ULN; CHEM TEST, MULTI INDICATIONS : LACTATE DEHYDROGENASE (LD) LD U/L H > 1.25×ULN IF PRE-RX IS MISSING OR > 1.25×ULN IF PRE-RX <= ULN OR > 1.5×PRE-RX IF PRE-RX > ULN (NCT02265744)
Timeframe: Up to 42 days post last dose of study medication in short-term or long-term extension period

,,,
InterventionParticipants (Number)
Creatine Kinase LowCreatine Kinase High
Experimental: 1.25mg SCBMS-931699 Every Other WeekNA3
Experimental: 12.5mg SC BMS-931699 Every Other WeekNA5
Experimental: 12.5mg SC BMS-931699 WeeklyNA5
Placebo Comparator: 0mg SC Weekly BMS-931699NA1

Number of Participants Clinically Significant Abnormalities in General Laboratory Tests : OTHER CHEMISTRY TESTING 3

OTHER CHEMISTRY TESTING CARDIAC TESTS: CREATINE KINASE (CK) CK U/L H > 1.5×ULN IF PRE-RX IS MISSING OR > 1.5×ULN IF PRE-RX <= ULN OR > 1.5×PRE-RX IF PRE-RX > ULN; TROPONIN-I, CARDIAC SPECIFIC UG/L H > ULN; METABOLITE TESTS:URIC ACID URIC MMOL/L H > 1.2×ULN IF PRE-RX IS MISSING OR > 1.2×ULN IF PRE-RX <= ULN OR > 1.25×PRE-RX IF PRE-RX > ULN; CHEM TEST, MULTI INDICATIONS : LACTATE DEHYDROGENASE (LD) LD U/L H > 1.25×ULN IF PRE-RX IS MISSING OR > 1.25×ULN IF PRE-RX <= ULN OR > 1.5×PRE-RX IF PRE-RX > ULN (NCT02265744)
Timeframe: Up to 42 days post last dose of study medication in short-term or long-term extension period

InterventionParticipants (Number)
Creatine Kinase LowCreatine Kinase HighTROPONIN-I, CARDIAC SPECIFIC LowTROPONIN-I, CARDIAC SPECIFIC HighUric Acid, LowUric Acid, HighLactate dehydrogenase (LD) lowLactate dehydrogenase (LD) high
Experimental: 5mg SC Injection BMS-931699 Every Other WeekNA3NA0NA0NA0

Number of Participants Clinically Significant Abnormalities in General Laboratory Tests : URINALYSIS

QUALITATIVE URINE CHEMISTRY: BLOOD, URINE N/A H >= 2 IF PRE-RX IS MISSING OR >= 2 IF PRE-RX < 1 OR >= 2×PRE-RX IF PRE-RX >= 1 GLUCOSE, URINE N/A H >= 1 IF PRE-RX IS MISSING OR >= 1 IF PRE-RX < 1 OR >= 2×PRE-RX IF PRE-RX >= 1 PROTEIN, URINE UNKNOWN H >= 2 IF PRE-RX IS MISSING OR >= 2 IF PRE-RX < 1 OR >= 2×PRE-RX IF PRE-RX >= 1 URINALYSIS II URINE WBC + RBC ; RBC, URINE HPF H >= 2 IF PRE-RX IS MISSING OR >= 2 IF PRE-RX < 2 OR >= 4 IF PRE-RX >= 2 WBC, URINE HPF H >= 2 IF PRE-RX IS MISSING OR >= 2 IF PRE-RX < 2 OR >= 4 IF PRE-RX >= 2 (NCT02265744)
Timeframe: Up to 42 days post last dose of study medication in short-term or long-term extension period

,,,,
InterventionParticipants (Number)
Blood, Urine, LowBlood, Urine, HighGlucose, Urine, LowGlucose, Urine, HighProtein, Urine, LowProtein, Urine, HighRBC, Urine, LowRBC, Urine, HighWBC, Urine, LowWBC, Urine, High
Experimental: 1.25mg SCBMS-931699 Every Other WeekNA21NA0NA7NA17NA31
Experimental: 12.5mg SC BMS-931699 Every Other WeekNA21NA2NA7NA19NA29
Experimental: 12.5mg SC BMS-931699 WeeklyNA18NA2NA7NA18NA28
Experimental: 5mg SC Injection BMS-931699 Every Other WeekNA20NA0NA13NA13NA31
Placebo Comparator: 0mg SC Weekly BMS-931699NA20NA1NA10NA18NA25

Number of Participants Clinically Significant Abnormalities in General Laboratory Tests ELECTROLYTES 1

CALCIUM, TOTAL MMOL/L H > 1.1×ULN IF PRE-RX IS MISSING OR > 1.1×ULN IF PRE-RX <= ULN OR > 1.1×PRE-RX IF PRE-RX > ULN OR > ULN IF PRE-RX < LLN; CALCIUM, TOTAL MMOL/L L < 0.9×LLN IF PRE-RX IS MISSING OR < 0.9×LLN IF PRE-RX >= LLN OR < 0.9×PRE-RX IF PRE-RX < LLN OR < LLN IF PRE-RX > ULN; CHLORIDE, SERUM MMOL/L H > 1.1×ULN IF PRE-RX IS MISSING OR > 1.1×ULN IF PRE-RX <= ULN OR > 1.1×PRE-RX IF PRE-RX > ULN OR > ULN IF PRE-RX < LLN; CHLORIDE, SERUM MMOL/L L < 0.9×LLN IF PRE-RX IS MISSING OR < 0.9×LLN IF PRE-RX >= LLN OR < 0.9×PRE-RX IF PRE-RX < LLN OR < LLN IF PRE-RX > ULN; (NCT02265744)
Timeframe: Up to 42 days post last dose of study medication in short-term or long-term extension period

,,,,
InterventionParticipants (Number)
Calcium, Total, LowCalcium, Total, HighChloride, Serum, LowChloride, Serum, High
Experimental: 1.25mg SCBMS-931699 Every Other Week0000
Experimental: 12.5mg SC BMS-931699 Every Other Week0000
Experimental: 12.5mg SC BMS-931699 Weekly0000
Experimental: 5mg SC Injection BMS-931699 Every Other Week1000
Placebo Comparator: 0mg SC Weekly BMS-9316990000

Number of Participants Clinically Significant Abnormalities in General Laboratory Tests: ELECTROLYTES 2

BICARBONATE MMOL/L H > 1.2×ULN IF PRE-RX IS MISSING OR > 1.2×ULN IF PRE-RX <= ULN OR > 1.2×PRE-RX IF PRE-RX > ULN OR > ULN IF PRE-RX < LLN; BICARBONATE MMOL/L L < 0.8×LLN IF PRE-RX IS MISSING OR < 0.8×LLN IF PRE-RX >= LLN OR < 0.8×PRE-RX IF PRE-RX < LLN OR < LLN IF PRE-RX > ULN; POTASSIUM, SERUM MMOL/L H > 1.1×ULN IF PRE-RX IS MISSING OR > 1.1×ULN IF PRE-RX <= ULN OR > 1.1×PRE-RX IF PRE-RX > ULN OR > ULN IF PRE-RX < LLN; POTASSIUM, SERUM MMOL/L L < 0.9×LLN IF PRE-RX IS MISSING OR < 0.9×LLN IF PRE-RX >= LLN OR < 0.9×PRE-RX IF PRE-RX < LLN OR < LLN IF PRE-RX > ULN; MAGNESIUM, SERUM MMOL/L H > 1.1×ULN IF PRE-RX IS MISSING OR > 1.1×ULN IF PRE-RX <= ULN OR > 1.1×PRE-RX IF PRE-RX > ULN OR > ULN IF PRE-RX < LLN MAGNESIUM, SERUM MMOL/L L < 0.9×LLN IF PRE-RX IS MISSING OR < 0.9×LLN IF PRE-RX >= LLN OR < 0.9×PRE-RX IF PRE-RX < LLN OR < LLN IF PRE-RX > ULN (NCT02265744)
Timeframe: Up to 42 days post last dose of study medication in short-term or long-term extension period

,,,
InterventionParticipants (Number)
Potassium, Serum, LowPotassium, Serum, High
Experimental: 1.25mg SCBMS-931699 Every Other Week11
Experimental: 12.5mg SC BMS-931699 Every Other Week00
Experimental: 12.5mg SC BMS-931699 Weekly10
Placebo Comparator: 0mg SC Weekly BMS-93169910

Number of Participants Clinically Significant Abnormalities in General Laboratory Tests: ELECTROLYTES 2

BICARBONATE MMOL/L H > 1.2×ULN IF PRE-RX IS MISSING OR > 1.2×ULN IF PRE-RX <= ULN OR > 1.2×PRE-RX IF PRE-RX > ULN OR > ULN IF PRE-RX < LLN; BICARBONATE MMOL/L L < 0.8×LLN IF PRE-RX IS MISSING OR < 0.8×LLN IF PRE-RX >= LLN OR < 0.8×PRE-RX IF PRE-RX < LLN OR < LLN IF PRE-RX > ULN; POTASSIUM, SERUM MMOL/L H > 1.1×ULN IF PRE-RX IS MISSING OR > 1.1×ULN IF PRE-RX <= ULN OR > 1.1×PRE-RX IF PRE-RX > ULN OR > ULN IF PRE-RX < LLN; POTASSIUM, SERUM MMOL/L L < 0.9×LLN IF PRE-RX IS MISSING OR < 0.9×LLN IF PRE-RX >= LLN OR < 0.9×PRE-RX IF PRE-RX < LLN OR < LLN IF PRE-RX > ULN; MAGNESIUM, SERUM MMOL/L H > 1.1×ULN IF PRE-RX IS MISSING OR > 1.1×ULN IF PRE-RX <= ULN OR > 1.1×PRE-RX IF PRE-RX > ULN OR > ULN IF PRE-RX < LLN MAGNESIUM, SERUM MMOL/L L < 0.9×LLN IF PRE-RX IS MISSING OR < 0.9×LLN IF PRE-RX >= LLN OR < 0.9×PRE-RX IF PRE-RX < LLN OR < LLN IF PRE-RX > ULN (NCT02265744)
Timeframe: Up to 42 days post last dose of study medication in short-term or long-term extension period

InterventionParticipants (Number)
Bicarbonate, LowBicarbonate, HighMagnesium, Serum, LowMagnesium, Serum, HighPotassium, Serum, LowPotassium, Serum, High
Experimental: 5mg SC Injection BMS-931699 Every Other Week000011

Number of Participants Clinically Significant Abnormalities in General Laboratory Tests: ELECTROLYTES 3

SODIUM, SERUM MMOL/L H > 1.05×ULN IF PRE-RX IS MISSING OR > 1.05×ULN IF PRE-RX <= ULN OR > 1.05×PRE-RX IF PRE-RX > ULN OR > ULN IF PRE-RX < LLN SODIUM, SERUM MMOL/L L < 0.95×LLN IF PRE-RX IS MISSING OR < 0.95×LLN IF PRE-RX >= LLN OR < 0.95×PRE-RX IF PRE-RX < LLN OR < LLN IF PRE-RX > ULN PHOSPHORUS, INORGANIC PHOS MMOL/L H > 1.25×ULN IF PRE-RX IS MISSING OR > 1.25×ULN IF PRE-RX <= ULN OR > 1.25×PRE-RX IF PRE-RX > ULN OR > ULN IF PRE-RX < LLN PHOSPHORUS, INORGANIC PHOS MMOL/L L < 0.85×LLN IF PRE-RX IS MISSING OR < 0.85×LLN IF PRE-RX >=LLN OR < 0.85×PRE-RX IF PRE-RX < LLN OR < LLN IF PRE-RX > ULN (NCT02265744)
Timeframe: Up to 42 days post last dose of study medication in short-term or long-term extension period

,,,,
InterventionParticipants (Number)
Sodium, Serum LowSodium, Serum HighPhosphorus, Inorganic, LowPhosphorus, Inorganic, High
Experimental: 1.25mg SCBMS-931699 Every Other Week0011
Experimental: 12.5mg SC BMS-931699 Every Other Week0020
Experimental: 12.5mg SC BMS-931699 Weekly0000
Experimental: 5mg SC Injection BMS-931699 Every Other Week0040
Placebo Comparator: 0mg SC Weekly BMS-9316990000

Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and Pre-established Events of Special Interest

Although there are no identified risks for BMS-931699, BMS has developed a list of events of special interest for the BMS-931699 program based on the known biologic class effects, the mechanism of action of BMS-931699, overall potential consequences of mmunosuppression, and preliminary data from unblinded clinical trials. Event categories of special interest for this study may include, but are not limited to: Infections, Autoimmunity, Malignancies, Injection-related reactions (NCT02265744)
Timeframe: On or after the first dose date of short-term study medication and up to 42 days post last short-term dose date or up to the day prior to the first dose of long-term extension period, whichever is earlier

,,,,
InterventionParticipants (Count of Participants)
Serious Adverse EventsRelated SAEsRelated Adverse EventsAEs of MalignanciesAEs of Infections and InfestationsAEs Leading to DiscontinuationAdverse Events of AutoimmunityMost Common Adverse EventsAdverse Events of Local Injection Reactions
Experimental: 1.25mg SCBMS-931699 Every Other Week801903990593
Experimental: 12.5mg SC BMS-931699 Every Other Week533004150568
Experimental: 12.5mg SC BMS-931699 Weekly5333038845910
Experimental: 5mg SC Injection BMS-931699 Every Other Week9529035906010
Placebo Comparator: 0mg SC Weekly BMS-931699611903031624

Number of Participants With Clinically Significant Abnormalities in General Laboratory Tests : LIVER FUNCTION TESTS

LIVER FUNCTION TESTS:ALKALINE PHOSPHATASE (ALP) ALP U/L H > 1.25×ULN IF PRE-RX IS MISSING OR > 1.25×ULN IF PRE-RX <= ULN OR > 1.25×PRE-RX IF PRE-RX > ULN; ALANINE AMINOTRANSFERASE (ALT) ALT U/L H > 1.25×ULN IF PRE-RX IS MISSING OR > 1.25×ULN IF PRE-RX <= ULN OR > 1.25×PRE-RX IF PRE-RX > ULN; ASPARTATE AMINOTRANSFERASE (AST) AST U/L H > 1.25×ULN IF PRE-RX IS MISSING OR > 1.25×ULN IF PRE-RX <= ULN OR > 1.25×PRE-RX IF PRE-RX > ULN; BILIRUBIN, DIRECT UMOL/L H > 1.1×ULN IF PRE-RX IS MISSING OR > 1.1×ULN IF PRE-RX <= ULN OR > 1.25×PRE-RX IF PRE-RX > ULN G-GLUTAMYL TRANSFERASE (GGT) GGT U/L H > 1.15×ULN IF PRE-RX IS MISSING OR > 1.15×ULN IF PRE-RX <= ULN OR > 1.2×PRE-RX IF PRE-RX > ULN BILIRUBIN, TOTAL UMOL/L H > 1.1×ULN IF PRE-RX IS MISSING OR > 1.1×ULN IF PRE-RX <= ULN OR > 1.25×PRE-RX IF PRE-RX > ULN (NCT02265744)
Timeframe: Up to 42 days post last dose of study medication in short-term or long-term extension period

,,,,
InterventionParticipants (Number)
Alanine Aminotransferase LowAlanine Aminotransferase HighAlkaline Phosphatase LowAlkaline Phosphatase HighAspartate Aminotransferase LowAspartate Aminotransferase HighBilirubin, Direct LowBilirubin Direct, HighBilirubin Total, LowBilirubin Total, HighG-Glutamyl Transferase, LowG-Glutamyl Transferase, High
Experimental: 1.25mg SCBMS-931699 Every Other WeekNA9NA5NA8NA1NA1NA15
Experimental: 12.5mg SC BMS-931699 Every Other WeekNA17NA3NA13NA13NA0NA14
Experimental: 12.5mg SC BMS-931699 WeeklyNA12NA2NA10NA0NA0NA18
Experimental: 5mg SC Injection BMS-931699 Every Other WeekNA6NA2NA11NA0NA0NA16
Placebo Comparator: 0mg SC Weekly BMS-931699NA8NA8NA10NA0NA1NA13

Number of Participants With Clinically Significant Abnormalities in General Laboratory Tests: HEMATOLOGY I

HEMATOLOGY I: ERYTHROCYTE/PLATELET ATTRIBUTES HEMOGLOBIN G/L L < 0.85×PRE-RX; HEMATOCRIT VOL L < 0.85×PRE-RX; PLATELET COUNT X10*9 C/L H > 1.5×ULN (ULN = Upper Limit of Normal) IF PRE-RX IS MISSING OR > 1.5×ULN PLATELET COUNT X10*9 C/L L < 0.85×LLN (LLN = Lower Limit of Normal) IF PRE-RX IS MISSING OR < 0.85×LLN IF PRE-RX >= LLN OR < 0.85×PRE-RX IF PRE-RX < LLN; ERYTHROCYTES RBC X10*12 C/L L < 0.85×PRE-RX HEMATOLOGY II QUANTITATIVE WBC : LEUKOCYTES X10*9 C/L H > 1.2×ULN IF PRE-RX IS MISSING OR > 1.2×ULN IF LLN <= PRE-RX <= ULN OR > 1.5×PRE-RX IF PRE-RX > ULN OR > ULN IF PRE-RX < LLN; LEUKOCYTES WBC X10*9 C/L L < 0.9×LLN IF PRE-RX IS MISSING OR < 0.9×LLN IF LLN <= PRE-RX <= ULN OR < 0.85×PRE-RX IF PRE-RX < LLN OR < LLN IF PRE-RX > ULN (NCT02265744)
Timeframe: Up to 42 days post last dose of study medication in short-term or long-term extension period

,,,,
InterventionParticipants (Number)
Erythrocytes LowErythrocytes HighHematocrit LowHematocrit HighHemoglobin LowHemoglobin HighPlatelet count lowPlatelet count highQuantitative WBC: Leukocytes lowQuantitative WBC: Leukocytes high
Experimental: 1.25mg SCBMS-931699 Every Other Week3NA5NA4NA11163
Experimental: 12.5mg SC BMS-931699 Every Other Week4NA10NA4NA10181
Experimental: 12.5mg SC BMS-931699 Weekly4NA6NA4NA10121
Experimental: 5mg SC Injection BMS-931699 Every Other Week6NA5NA5NA10120
Placebo Comparator: 0mg SC Weekly BMS-9316995NA8NA5NA20161

Number of Participants With Clinically Significant Abnormalities in General Laboratory Tests: HEMATOLOGY II

WBC DIFFERENTIAL COUNT: BASOPHILS (ABSOLUTE) X10*9 C/L H > 0.4; BLASTS (ABSOLUTE) X10*9 C/L H > 0; EOSINOPHILS (ABSOLUTE) EOSA X10*9 C/L H > 0.75; LYMPHOCYTES (ABSOLUTE) X10*9 C/L H > 7.5; LYMPHOCYTES (ABSOLUTE) X10*9 C/L L < 0.75; MONOCYTES (ABSOLUTE) X10*9 C/L H > 2; NEUTROPHILS (ABSOLUTE) X10*9 C/L L < 1.5 IF PRE-RX IS MISSING OR < 1.5 IF PRE-RX >= 1.5 OR < 0.85×PRE-RX IF PRE-RX < 1.5; COAGULATION activated Partial thromboplastin time (APTT) SEC H > 1.5×ULN; INTL NORMALIZED RATIO (INR) INR FRACTION H > 1.5×ULN PROTHROMBIN TIME (PT) PT SEC H > 1.5×ULN (NCT02265744)
Timeframe: Up to 42 days post last dose of study medication in short-term or long-term extension period

,,,
InterventionParticipants (Number)
Basophils (Absolute) LowBasophils (Absolute) HighEosinophils (Absolute) LowEosinophils (Absolute) HighLymphocytes (Absolute) LowLymphocytes (Absolute) HighMonocytes (Absolute) HighMonocytes (Absolute) LowNeutrophils (Absolute) LowNeutrophils (Absolute) High
Experimental: 1.25mg SCBMS-931699 Every Other WeekNA0NA2250NA07NA
Experimental: 12.5mg SC BMS-931699 WeeklyNA0NA3210NA010NA
Experimental: 5mg SC Injection BMS-931699 Every Other WeekNA0NA0240NA05NA
Placebo Comparator: 0mg SC Weekly BMS-931699NA0NA1250NA04NA

Number of Participants With Clinically Significant Abnormalities in General Laboratory Tests: HEMATOLOGY II

WBC DIFFERENTIAL COUNT: BASOPHILS (ABSOLUTE) X10*9 C/L H > 0.4; BLASTS (ABSOLUTE) X10*9 C/L H > 0; EOSINOPHILS (ABSOLUTE) EOSA X10*9 C/L H > 0.75; LYMPHOCYTES (ABSOLUTE) X10*9 C/L H > 7.5; LYMPHOCYTES (ABSOLUTE) X10*9 C/L L < 0.75; MONOCYTES (ABSOLUTE) X10*9 C/L H > 2; NEUTROPHILS (ABSOLUTE) X10*9 C/L L < 1.5 IF PRE-RX IS MISSING OR < 1.5 IF PRE-RX >= 1.5 OR < 0.85×PRE-RX IF PRE-RX < 1.5; COAGULATION activated Partial thromboplastin time (APTT) SEC H > 1.5×ULN; INTL NORMALIZED RATIO (INR) INR FRACTION H > 1.5×ULN PROTHROMBIN TIME (PT) PT SEC H > 1.5×ULN (NCT02265744)
Timeframe: Up to 42 days post last dose of study medication in short-term or long-term extension period

InterventionParticipants (Number)
Basophils (Absolute) LowBasophils (Absolute) HighBlasts (Absolute) LowBlasts (Absolute) HighEosinophils (Absolute) LowEosinophils (Absolute) HighLymphocytes (Absolute) LowLymphocytes (Absolute) HighMonocytes (Absolute) HighMonocytes (Absolute) LowNeutrophils (Absolute) LowNeutrophils (Absolute) High
Experimental: 12.5mg SC BMS-931699 Every Other WeekNA0NA0NA0290NA08NA

Number of Participants With Clinically Significant Abnormalities in General Laboratory Tests: KIDNEY FUNCTION TESTS

KIDNEY FUNCTION TESTS:BLOOD UREA NITROGEN MMOL/L H > 1.1×ULN IF PRE-RX IS MISSING OR > 1.1×ULN IF PRE-RX <= ULN OR > 1.2×PRE-RX IF PRE-RX > ULN CREATININE UMOL/L H > 1.5×ULN IF PRE-RX IS MISSING OR > 1.5×ULN IF PRE-RX <= ULN OR > 1.33×PRE-RX IF PRE-RX > ULN GLOMERULAR FILTRATION RATE, CALC. ML/S/M*2 L < 0.8×PRE-RX; UREA UREA MMOL/L H > 1.1×ULN IF PRE-RX IS MISSING OR > 1.1×ULN IF PRE-RX <= ULN OR > 1.2×PRE-RX IF PRE-RX > ULN (NCT02265744)
Timeframe: Up to 42 days post last dose of study medication in short-term or long-term extension period

InterventionParticipants (Number)
Blood Urea Nitrogen, LowBlood Urea Nitrogen, HighCreatinine, LowCreatinine, High
Placebo Comparator: 0mg SC Weekly BMS-931699NA10NA1

Number of Participants With Clinically Significant Abnormalities in General Laboratory Tests: KIDNEY FUNCTION TESTS

KIDNEY FUNCTION TESTS:BLOOD UREA NITROGEN MMOL/L H > 1.1×ULN IF PRE-RX IS MISSING OR > 1.1×ULN IF PRE-RX <= ULN OR > 1.2×PRE-RX IF PRE-RX > ULN CREATININE UMOL/L H > 1.5×ULN IF PRE-RX IS MISSING OR > 1.5×ULN IF PRE-RX <= ULN OR > 1.33×PRE-RX IF PRE-RX > ULN GLOMERULAR FILTRATION RATE, CALC. ML/S/M*2 L < 0.8×PRE-RX; UREA UREA MMOL/L H > 1.1×ULN IF PRE-RX IS MISSING OR > 1.1×ULN IF PRE-RX <= ULN OR > 1.2×PRE-RX IF PRE-RX > ULN (NCT02265744)
Timeframe: Up to 42 days post last dose of study medication in short-term or long-term extension period

,,
InterventionParticipants (Number)
Blood Urea Nitrogen, LowBlood Urea Nitrogen, HighCreatinine, LowCreatinine, HighUrea, LowUrea, High
Experimental: 1.25mg SCBMS-931699 Every Other WeekNA14NA2NA0
Experimental: 12.5mg SC BMS-931699 Every Other WeekNA11NA0NA0
Experimental: 12.5mg SC BMS-931699 WeeklyNA9NA2NA0

Number of Participants With Clinically Significant Abnormalities in General Laboratory Tests: KIDNEY FUNCTION TESTS

KIDNEY FUNCTION TESTS:BLOOD UREA NITROGEN MMOL/L H > 1.1×ULN IF PRE-RX IS MISSING OR > 1.1×ULN IF PRE-RX <= ULN OR > 1.2×PRE-RX IF PRE-RX > ULN CREATININE UMOL/L H > 1.5×ULN IF PRE-RX IS MISSING OR > 1.5×ULN IF PRE-RX <= ULN OR > 1.33×PRE-RX IF PRE-RX > ULN GLOMERULAR FILTRATION RATE, CALC. ML/S/M*2 L < 0.8×PRE-RX; UREA UREA MMOL/L H > 1.1×ULN IF PRE-RX IS MISSING OR > 1.1×ULN IF PRE-RX <= ULN OR > 1.2×PRE-RX IF PRE-RX > ULN (NCT02265744)
Timeframe: Up to 42 days post last dose of study medication in short-term or long-term extension period

InterventionParticipants (Number)
Blood Urea Nitrogen, LowBlood Urea Nitrogen, HighCreatinine, LowCreatinine, HighGLOMERULAR FILTRATION RATE, CALC. LowGLOMERULAR FILTRATION RATE, CALC. HighUrea, LowUrea, High
Experimental: 5mg SC Injection BMS-931699 Every Other WeekNA3NA00NANA0

Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities

QTc (corrected QT) Fridericia, PR Interval, QRS Interval and Change from baseline in QTCF (NCT02265744)
Timeframe: Up to 42 days post last dose of short-term double-blind study medication or up to the day prior to the start of long-term extension period, whichever is earlier.

,,,,
InterventionParticipants (Count of Participants)
QTC Fredericia (msec) <= 450QTC Fredericia (msec) 450< To <= 480QTC Fredericia (msec) 480 < to <= 500QTC Fredericia (msec) > 500PR Interval (msec) <= 200PR Interval (msec) > 200QRS Interval (msec) <= 120QRS Interval (msec) > 120Change from baseline in QTCF (msec) <= 30Change from baseline in QTCF (msec) 30 To <= 60Change from baseline in QTCF (msec) > 60
Experimental: 1.25mg SCBMS-931699 Every Other Week5611036646735523
Experimental: 12.5mg SC BMS-931699 Every Other Week588116806715972
Experimental: 12.5mg SC BMS-931699 Weekly5612016906816620
Experimental: 5mg SC Injection BMS-931699 Every Other Week585236446625473
Placebo Comparator: 0mg SC Weekly BMS-931699655106837016250

Percentage of Participants Who Meet Response Criteria for the SLE Responder Index : SRI(4), SRI(5) and SRI(6) at Day 169

"SRI is the Systemic Lupus Erythematosus Responder Index. An SRI(4) Response is defined as a reduction in Day 1 SLEDAI-2K disease activity score of ≥ 4 points AND (a)no worsening in the physician's global assessment (MDGA) of disease activity (no worsening is defined as less than 10% worsening, equivalent to a 10mm increase on a 100mm visual analog scale [VAS]) compared to Baseline) AND (b) no new BILAG-2004 Index A organ system score AND (c)no more than one new or worsening BILAG-2004 Index B organ system scores.~An SRI(5) Response is defined as a reduction in Day 1 SLEDAI-2K disease activity score of ≥ 5 points AND (a) AND (b) AND (c).~An SRI(6) Response is defined as a reduction in Day 1 SLEDAI-2K disease activity score of ≥ 6 points AND (a) AND (b) AND (c) The outcomes are better in increasing order from SRI(4) to SRI(5) to SRI(6)" (NCT02265744)
Timeframe: At Day 169

,,,,
InterventionPercentage of participants (Number)
SRI (4)SRI (5)SRI (6)
Experimental: 1.25mg SCBMS-931699 Every Other Week44.331.431.4
Experimental: 12.5mg SC BMS-931699 Every Other Week48.529.426.5
Experimental: 12.5mg SC BMS-931699 Weekly55.137.737.7
Experimental: 5mg SC Injection BMS-931699 Every Other Week39.727.927.9
Placebo Comparator: 0mg SC Weekly BMS-93169949.333.833.8

Percentage of Participants Who Meet Response Criteria for the SLE Responder Index: SRI(4), SRI(5) and SRI(6) at Day 85

"SRI is the Systemic Lupus Erythematosus Responder Index. An SRI(4) Response is defined as a reduction in Day 1 SLEDAI-2K disease activity score of ≥ 4 points AND (a)no worsening in the physician's global assessment (MDGA) of disease activity (no worsening is defined as less than 10% worsening, equivalent to a 10mm increase on a 100mm visual analog scale [VAS]) compared to Baseline) AND (b) no new BILAG-2004 Index A organ system score AND (c)no more than one new or worsening BILAG-2004 Index B organ system scores.~An SRI(5) Response is defined as a reduction in Day 1 SLEDAI-2K disease activity score of ≥ 5 points AND (a) AND (b) AND (c).~An SRI(6) Response is defined as a reduction in Day 1 SLEDAI-2K disease activity score of ≥ 6 points AND (a) AND (b) AND (c) The outcomes are better in increasing order from SRI(4) to SRI(5) to SRI(6)" (NCT02265744)
Timeframe: At Day 85

,,,,
InterventionPercentage of participants (Number)
SRI (4)SRI (5)SRI (6)
Experimental: 1.25mg SCBMS-931699 Every Other Week47.131.431.4
Experimental: 12.5mg SC BMS-931699 Every Other Week48.532.430.9
Experimental: 12.5mg SC BMS-931699 Weekly49.329.029.0
Experimental: 5mg SC Injection BMS-931699 Every Other Week41.225.025.0
Placebo Comparator: 0mg SC Weekly BMS-93169943.728.226.8

Percentage of Participants With BMS-931699 Induced Antibody Response Over Time Point Specified

Immunogenicity defined as positive for anti-drug antibodies post-baseline measurement if baseline missing or negative. If baseline is positive, then immunogenicity is defined as a positive post-baseline measurement with titer value 4 times greater than baseline. (A) all subjects with a laboratory reported positive antibody responses to BMS-931699 during the short-term double-blind treatment period are included. Overall: At least one positive sample relative to baseline during short-term double-blind and follow-up period. (NCT02265744)
Timeframe: Day 169

,,,
InterventionPercentage of participants (Number)
% with Neutralizing activity% with Neutralizing activity (Baseline)% with Neutralizing activity (Overall)
Experimental: 1.25mg SCBMS-931699 Every Other Week34.1034.1
Experimental: 12.5mg SC BMS-931699 Every Other Week41.25.935.3
Experimental: 12.5mg SC BMS-931699 Weekly23.1023.1
Experimental: 5mg SC Injection BMS-931699 Every Other Week64.7064.7

Percentage of Participants With Clinically Significant Changes in Vital Signs: Systolic and Diastolic Blood Pressure

SYSTOLIC BLOOD PRESSURE (SYSBP) (MMHG); SYSBP > 140 AND CHANGE FROM BASELINE > 20 OR SYSBP < 90 AND CHANGE FROM BASELINE < -20; DIASTOLIC BLOOD PRESSURE (DIABP) > 90 AND CHANGE FROM BASELINE > 10 OR DIABP < 55 AND CHANGE FROM BASELINE < -10; (NCT02265744)
Timeframe: At Day 85 and Day 169

,,,,
InterventionPercentage of participants (Number)
SYSTOLIC BLOOD PRESSURE (MMHG) SITTINGSYSTOLIC BLOOD PRESSURE (MMHG) STANDINGSYSTOLIC BLOOD PRESSURE (MMHG) SUPINEDIASTOLIC BLOOD PRESSURE (MM HG) SITTINGDIASTOLIC BLOOD PRESSURE (MM HG) STANDINGDIASTOLIC BLOOD PRESSURE (MM HG) SUPINE
Experimental: 1.25mg SCBMS-931699 Every Other Week10.011.4017.121.40
Experimental: 12.5mg SC BMS-931699 Every Other Week11.614.5026.118.80
Experimental: 12.5mg SC BMS-931699 Weekly17.614.7017.627.90
Experimental: 5mg SC Injection BMS-931699 Every Other Week10.38.8111.825.00
Placebo Comparator: 0mg SC Weekly BMS-93169915.520.009.920.00

Percentage of Participants With Clinically Significant Changes in Vital Signs:Heart Rate

HEART RATE (HR) Beats per min (BPM): HR > 100 AND CHANGE FROM BASELINE > 30 OR HR < 55 AND CHANGE FROM BASELINE < -15 (NCT02265744)
Timeframe: At Day 85 and Day 169

,,,,
InterventionPercentage of participants (Number)
HEART RATE (BPM) SITTINGHEART RATE (BPM) STANDINGHEART RATE (BPM) SUPINE
Experimental: 1.25mg SCBMS-931699 Every Other Week2.97.10
Experimental: 12.5mg SC BMS-931699 Every Other Week2.94.30
Experimental: 12.5mg SC BMS-931699 Weekly5.95.90
Experimental: 5mg SC Injection BMS-931699 Every Other Week2.97.40
Placebo Comparator: 0mg SC Weekly BMS-9316995.65.70

Serum Biomarkers C3, C4

Serum biomarkers C3, C4, anti-double-stranded deoxyribonucleic acid (anti-dsDNA), anti-nuclear antibody (ANA) and other autoantibodies were measured from blood serum samples collected on Day 85 and Day 169 (NCT02265744)
Timeframe: At Day 85 and Day 169

,,,,
Interventiong/L (Mean)
C3, BaselineC3, Day 85C3, Day 169C4, BaselineC4, Day 85C4, Day 169
Experimental: 1.25mg SCBMS-931699 Every Other Week1.0281.0831.0770.2020.2150.207
Experimental: 12.5mg SC BMS-931699 Every Other Week1.0291.0141.0100.1850.1950.185
Experimental: 12.5mg SC BMS-931699 Weekly1.0681.0371.0450.2010.2060.212
Experimental: 5mg SC Injection BMS-931699 Every Other Week0.9901.0301.0270.1770.1900.187
Placebo Comparator: 0mg SC Weekly BMS-9316990.9910.9860.9920.1830.1790.184

Serum Biomarkers: Anti-Nuclear Antibodies (ANA)

Serum biomarkers C3, C4, anti-double-stranded deoxyribonucleic acid (anti-dsDNA), anti-nuclear antibody (ANA) and other autoantibodies were measured from blood serum samples collected on Day 85 and Day 169. No anti-dsDNA data was available for this report (NCT02265744)
Timeframe: At Day 85 and Day 169

,,,,
InterventionPercentage (Number)
Baseline Negative Day 85 NegativeBaseline Negative Day 85 PositiveBaseline Positive Day 85 NegativeBaseline Positive Day 85 PositiveBaseline Negative Day 169 NegativeBaseline Negative Day 169 PositiveBaseline Positive Day 169 NegativeBaseline Positive Day 169 Positive
Experimental: 1.25mg SCBMS-931699 Every Other Week50.050.02.098.057.142.94.395.7
Experimental: 12.5mg SC BMS-931699 Every Other Week57.142.93.496.633.366.72.098.0
Experimental: 12.5mg SC BMS-931699 Weekly62.537.511.388.771.428.69.390.7
Experimental: 5mg SC Injection BMS-931699 Every Other Week100.001.898.2100.005.894.2
Placebo Comparator: 0mg SC Weekly BMS-93169960.040.00100.040.060.01.898.2

Short Term: Receptor Occupancy Over Time

Percent CD4+ Receptor Occupancy and percent CD8+ Receptor Occupancy (NCT02265744)
Timeframe: At Day 85 and Day 169

,,,,
InterventionPercentage (Mean)
%CD4+ RO Baseline%CD4+ RO Day 85%CD4+ RO Day 169%CD8+ RO Baseline%CD8+ RO Day 85%CD8+ RO Day 169
Experimental: 1.25mg SCBMS-931699 Every Other Week037.15544.115032.51640.989
Experimental: 12.5mg SC BMS-931699 Every Other Week083.24477.210081.73074.726
Experimental: 12.5mg SC BMS-931699 Weekly095.72292.390095.83192.043
Experimental: 5mg SC Injection BMS-931699 Every Other Week070.52074.286068.96069.850
Placebo Comparator: 0mg SC Weekly BMS-93169900.3500.33400.1600.235

BILAG Global Score Change From Baseline to Last Available Value (LVA) Between Week 24 and Week 36

"British Isles Lupus Assessment Group (BILAG)-2004 index, it categorizes disease activity into 5 different levels from A to E, with Grade A representing very active disease and Grade E indicating no current or previous disease activity. Scoring was based on a total of 101 items, grouped into 9 organ/systems and the summation of the numerical values for the nine-system scores was given by the following formula: Numerical global score = A*12 + B*8 + C*1, where A, B and C represent the number of Grades A, B and C respectively at each assessment. Grades D and E are considered as 0 (Chee-Seng Yee et al, 2010). The minimum score is 0 with no predefined maximum. The higher scores mean a worse outcome.~The BILAG global score change from baseline to Last Available Value (LVA) week 24 and week 36 were presented analyzed." (NCT02665364)
Timeframe: Last Available Value (LVA) between week 24 and week 36

Interventionscores on a scale (Mean)
IFN-K-11.43
Placebo-10.76

CLASI Total Activity Change From Baseline at Week 36

Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) was specifically developed to assess the cutaneous manifestations of SLE. It measures both disease activity and permanent damage (e.g. dyspigmentation and scarring) over the entire body surface. CLASI total activity score ranges from 0 to 70, with higher scores indicating more severe skin disease. (NCT02665364)
Timeframe: Baseline and Week 36

Interventionscores on a scale (Mean)
IFN-K-3.22
Placebo-2.85

CS Mean Daily Dose at W36

mean daily dose of corticosteroid (CS) (prednisone equivalent) (NCT02665364)
Timeframe: At W36

Interventionmg/day (Mean)
IFN-K5.42
Placebo7.06

Number of Participants Who Achieved a British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) With Superimposed CS Tapering at Week 36

"British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) responder was defined as a subject who had the following criteria at week 36:~All BILAG A scores at baseline improve to B/C/D and all BILAG B scores improve to C/D at W36, and~No BILAG worsening in other body systems: no new BILAG A or ≥ 2 new BILAG B scores at W36, and~No worsening in SLEDAI-2K total score at W36 compared with baseline, and~No deterioration in Physician Global Assessment (PGA) (< 10% worsening) on Visual Analog Scale (VAS) 100 mm at W36 compared with baseline, and~No addition or increased dose level of anti-malarial drugs or immunosuppressive drugs or CS* between W24 and W36 (*≤5 mg prednisolone or equivalent /day at W24 and no increase until W36)." (NCT02665364)
Timeframe: At Week 36

InterventionParticipants (Count of Participants)
IFN-K35
Placebo29

Number of Participants Who Achieved a Composite SRI-4 (CS ≤5mg/Day) Excluding IFN-K Subjects Without Positive Anti-IFNalpha Neutralizing Antibodies at Week 36

Subjects who had the following criteria defined as : SRI-4 plus CS ≤5mg/day -excluding IFN-K subjects without positive anti-IFN-alpha neutralizing antibodies (NCT02665364)
Timeframe: At week 36

InterventionParticipants (Count of Participants)
IFN-K40
Placebo30

Number of Participants Who Achieved a Composite SRI-4 (CS ≤7.5mg/Day) Excluding IFN-K Subjects Without Positive Anti-IFNalpha Neutralizing Antibodies at Week 36

participant who had the following criteria defined as : SRI-4 plus CS ≤7.5mg/day -excluding IFN-K Patients without positive anti-IFN-alpha neutralizing antibodies (NCT02665364)
Timeframe: At week 36

InterventionParticipants (Count of Participants)
IFN-K43
Placebo33

Number of Participants Who Achieved a Composite SRI-4 Including CS ≤5mg/Day at Week 36

"SRI-4 plus CS ≤ 5mg/day responder was defined as a participant who had the following criteria at Week 36:~reduction ≥4 points in SELENA-SLEDAI at week 36 compared with baseline, and~no new BILAG A at week 36, and~no more than 1 new BILAG B at week 36, and~no deterioration in PGA (<10% worsening) on 100-mm VAS compared with baseline plus corticosteroids (CS) ≤5mg equivalent prednisolone per day at week 36" (NCT02665364)
Timeframe: At Week 36

InterventionParticipants (Count of Participants)
IFN-K43
Placebo30

Number of Participants Who Achieved a Composite SRI-4 Including CS ≤7,5mg/Day at Week 36

"SRI (4) plus CS ≤ 7.5 mg/day responder was defined as a participant who had the following criteria at week 36:~reduction ≥4 points in SELENA-SLEDAI at week 36 compared with baseline, and~no new BILAG A at week 36, and~no more than 1 new BILAG B at week 36, and~no deterioration in PGA (<10% worsening) on 100-mm VAS compared with baseline plus CS ≤7.5mg equivalent prednisolone per day at week 36" (NCT02665364)
Timeframe: At Week 36

InterventionParticipants (Count of Participants)
IFN-K46
Placebo33

Number of Participants Who Achieved a Lupus Low Disease Activity State (LLDAS) at Week 36

"Lupus low disease activity state (LLDAS) was conceptually defined as 'a state which, if sustained, is associated with a low likelihood of adverse outcome, considering disease activity and medication safety'. Subsequently defined using consensus methodology, LLDAS is attained if all the following items are met:~SLEDAI-2K ≤4, with no activity in major organ systems (renal, central nervous system (CNS), cardiopulmonary, vasculitis, fever) and no hemolytic anemia or gastrointestinal activity~No new features of lupus disease activity compared with the previous assessment~SELENA-SLEDAI physician global assessment (PGA, scale 0-3) ≤1~Current prednisolone (or equivalent) dose ≤7.5 mg daily~Well tolerated standard maintenance doses of immunosuppressive drugs and approved biological agents, excluding investigational drugs" (NCT02665364)
Timeframe: At Week 36

InterventionParticipants (Count of Participants)
IFN-K45
Placebo25

Number of Participants Who Achieved a Systematic Lupus Erythematosus (SLE) Responder Index (SRI)-4 at Week 36

"SLE Responder Index (SRI); SRI-4 responder was defined as a subject who had the following criteria at week 36:~reduction ≥4 points in SELENA-SLEDAI at week 36 compared with baseline, and~no new BILAG A at week 36, and~no more than 1 new BILAG B at week 36, and~no deterioration in PGA (<10% worsening) on 100-mm VAS compared with baseline" (NCT02665364)
Timeframe: W36 (9 months)

InterventionParticipants (Count of Participants)
IFN-K57
Placebo54

Number of Participants With Neutralizing Anti-IFN-alpha Antibodies at W36

Individual serum antibody neutralizing capacity against recombinant IFN-alpha2b was measured by reporter gene assay using Interferon Sensitive Response Element (ISRE) reporter. (NCT02665364)
Timeframe: At week 36

InterventionParticipants (Count of Participants)
IFN-K72
Placebo0

Number of Participants With Treatment-related Adverse Events

Number of participants who reported any treatment-related adverse events until month 9 (NCT02665364)
Timeframe: 9 months

InterventionParticipants (Count of Participants)
IFN-K75
Placebo71

Percent Change From Baseline in IFN Gene Signature at W36

The biological endpoint aimed at evaluating the neutralization of the IFN gene signature following treatment with IFN-K compared to placebo, as measured by the % change from baseline of the expression of IFN-induced genes. (NCT02665364)
Timeframe: Baseline and Last Available Value (LVA) between week 24 and week 36

Interventionpercent change (Mean)
IFN-K-31.04
Placebo-0.44

SELENA-SLEDAI - Change From Baseline to Week 36

Safety of Estrogens in Systemic Lupus Erythematosus National Assessment (SELENA)-SLEDAI, is a slightly modified version of the SLEDAI. This is a weighted index in which signs and symptoms, laboratory tests, and Physician's Global Assessment (PGA) for each of nine organ systems are given a weighted score and summed up if present at the time of the visit or in the preceding 10 days. The maximum theoretical score for the SELENA SLEDAI is 105 (all 24 descriptors present simultaneously) with 0 indicating inactive disease. (NCT02665364)
Timeframe: Baseline and Week 36

InterventionSELENA SLEDAI Score (Mean)
IFN-K-5.48
Placebo-5.54

SLICC/ACR-DI Change From Baseline at Week 36

Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index for systemic lupus erythematosus (SLICC/ACR-DI) captures permanent changes which have occurred in patients with SLE, regardless of causality. The questionnaire contains 41 items covering 12 different organ systems. The score of items ranges from 1 to 3 and the total score from 0 to 47. By definition score 0 corresponds to diagnostics and damage over time can only be stable or increase, theoretically to a maximum of 47 points. (NCT02665364)
Timeframe: Baseline and Week 36

Interventionscores on a scale (Mean)
IFN-K-0.09
Placebo-0.17

Change From Baseline to 52 Week Endpoint in Brief Fatigue Inventory (BFI) Scores

A participants-reported scale that measures the severity of fatigue based on the worst fatigue experienced during the past 24-hours. The severity scores ranged from 0 (no fatigue) to 10 (fatigue as severe as you can imagine). (NCT01205438)
Timeframe: Baseline, 52 weeks

Interventionunits on a scale (Mean)
LY2127399 Every 2 Weeks-0.7
LY2127399 Every 4 Weeks-0.5
Placebo-0.5

Change From Baseline to 52 Week Endpoint in Physician's Global Assessment (PGA)

PGA is a single-item clinician rated assessment of the participant's current level of disease activity measured on a continuous 100-millimeter (mm) visual analytic scale with benchmarks of 0, 1, 2, and 3 from left to right corresponding to no, mild, moderate, and severe SLE disease activity. Scores are presented from 0 to 100. No worsening defined as increase of ≤ 0.30 points from Baseline. (NCT01205438)
Timeframe: Baseline, 52 weeks

Interventionunits on a scale (Mean)
LY2127399 Every 2 Weeks-21.2
LY2127399 Every 4 Weeks-19.2
Placebo-15.1

Change From Baseline to 52 Weeks Endpoint in SELENA-SLEDAI Disease Activity Score

Safety of Estrogens in Lupus Erythematosus National Assessment - SLE Disease Activity Index (SELENA-SLEDAI) score is a weighted, cumulative index of lupus disease activity. SELENA-SLEDAI is calculated from 24 individual descriptors across 9 organ systems; 0 indicates inactive disease and the maximum theoretical score is 105. (NCT01205438)
Timeframe: Baseline, 52 weeks

Interventionunits on a scale (Mean)
LY2127399 Every 2 Weeks-5.1
LY2127399 Every 4 Weeks-4.8
Placebo-3.7

Change From Baseline to 52 Weeks in Anti-double Stranded Deoxyribonucleic Acid (Anti-dsDNA) Level

Anti-double stranded deoxyribonucleic acid (anti-dsDNA) is a lab analyte used to assist in the diagnosis of SLE. (NCT01205438)
Timeframe: Baseline, 52 weeks

InterventionInternational Units (IU) (Mean)
LY2127399 Every 2 Weeks-27.7
LY2127399 Every 4 Weeks-26.4
Placebo-7.0

Number of Participants With No New BILAG A and No More Than One New BILAG B Disease Activity Scores Compared to Baseline

The British Isles Lupus Assessment Group (BILAG) instrument assesses global disease activity across 9 organ system domains. BILAG flare is assessed for each of the 9 organ domains using BILAG2004 index flare rules; A is a severe flare and B is a moderate flare. (NCT01205438)
Timeframe: Baseline through 52 weeks

InterventionParticipants (Count of Participants)
LY2127399 Every 2 Weeks134
LY2127399 Every 4 Weeks144
Placebo160

Percentage of Participants Able to Decrease Dose of Prednisone or Equivalent With No Increase in Disease Activity at Week 52

A participant achieves corticosteroid sparing effects (quiescent disease) if they have met the following criteria during Weeks 24 through 52; able to decrease their dose of prednisone or equivalent to 7.5 mg/day or less, have quiescent disease (BILAG C score or better in all nine systems), and no BILAG A or B flares in the previous three months, without an increase in either antimalarials or immunosuppressants on or prior to the visit. (NCT01205438)
Timeframe: 52 weeks

Interventionpercentage of participants (Number)
LY2127399 Every 2 Weeks21.2
LY2127399 Every 4 Weeks14.7
Placebo11.5

Percentage of Participants Achieving a Response as Measured by Modified SRI With No BILAG A or No More Than 1 BILAG B Organ Domain Flares at 52 Weeks

"Percentage of participants with a ≥ 5 point reduction from baseline in SELENA SLEDAI score, and no worsening (increase of < 0.30 points from baseline) in PGA, and no new BILAG A or no more than 1 new BILAG B organ domain flare compared with baseline. (Primary outcome modified to use BILAG flare instead of BILAG disease score)~SELENA SLEDAI is calculated from 24 individual descriptors across 9 organ systems; 0 indicates inactive disease and the maximum theoretical score is 105. PGA is a visual analog scale scored from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe). BILAG flare is assessed for each of the 9 organ domains; A is a severe flare and B is a moderate flare. Participants who were unable to comply with allowed concomitant medications requirements were considered non-responders, as were participants who dropped out or were missing Week 52 data." (NCT01205438)
Timeframe: 52 weeks

Interventionpercentage of participants (Number)
LY2127399 Every 2 Weeks38.7
LY2127399 Every 4 Weeks34.8
Placebo27.7

Percentage of Participants Achieving an SLE Responder Index Response at Week 52

"Percentage of participants with a ≥ 5 point reduction from baseline in SELENA SLEDAI score, and no worsening (increase of < 0.30 points from baseline) in PGA, and no new BILAG A organ domain score or 2 new BILAG B organ domain scores compared with baseline.~SELENA SLEDAI is calculated from 24 individual descriptors across 9 organ systems; 0 indicates inactive disease and the maximum theoretical score is 105; scores > 20 are rare. PGA is a visual analog scale scored from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe). BILAG uses a single score for each of the 9 organ domains; range is from severe (A) to no disease (E). Participants who were unable to comply with allowed concomitant medications requirements were considered non-responders, as were participants who dropped out or were missing Week 52 data." (NCT01205438)
Timeframe: 52 weeks

Interventionpercentage of participants (Number)
LY2127399 Every 2 Weeks38.5
LY2127399 Every 4 Weeks34.8
Placebo27.7

Percentage of Participants With an Increase in Corticosteroids Dose at 52 Weeks

An increase in corticosteroids at a visit was defined as a change from baseline greater than 2.5 mg/day in dose or prednisone or equivalent using average daily dose of corticosteroids taken since the previous scheduled visit. (NCT01205438)
Timeframe: 52 weeks

Interventionpercentage of participants (Number)
LY2127399 Every 2 Weeks4.7
LY2127399 Every 4 Weeks6.2
Placebo5.9

Percentage of Participants With No Worsening in Physician Global Assessment (PGA) Score at 52 Weeks

Physician's Global Assessment (PGA) is a single-item clinician rated assessment of the participant's current level of disease activity measured on a continuous 100-mm visual analytic scale with benchmarks of 0, 1, 2, and 3 from left to right corresponding to no, mild, moderate, and severe SLE disease activity. Scores are presented from 0 to 100.No worsening defined as increase of ≤ 0.30 points from Baseline. (NCT01205438)
Timeframe: 52 weeks

Interventionpercentage of participants (Number)
LY2127399 Every 2 Weeks32.8
LY2127399 Every 4 Weeks37.8
Placebo42.8

Change From Baseline to 52 Week Endpoint in Systemic Lupus Erythematosus Disease Activity Index (SLEDAI2K) Score

SLE Disease Activity Index 2000 (SLEDAI-2K) score is a weighted, cumulative index of lupus disease activity. SLEDAI-2K is calculated from 24 individual descriptors across 9 organ systems; 0 indicates inactive disease and the maximum theoretical score is 105. (NCT01205438)
Timeframe: Baseline, 52 weeks

,,
Interventionunits on a scale (Mean)
Baseline52 Weeks
LY2127399 Every 2 Weeks10.3-4.9
LY2127399 Every 4 Weeks10.4-4.7
Placebo9.8-3.6

Change From Baseline to 52 Week Endpoint Lupus Quality of Life (LupusQOL) Domain Scores

The LupusQoL is a disease-specific, 34-item, self-report questionnaire designed to measure the health-related quality of life (HRQoL) of participants with SLE within 8 domains.Responses are based on a 5-point Likert scale where 0 (all of the time) to 4 (never). A LupusQoL score for each domain is reported on a 0 to 100 scale, with greater values indicating better HRQoL. (NCT01205438)
Timeframe: Baseline, 52 weeks

,,
Interventionunits on a scale (Mean)
Physical HealthEmotional HealthBody ImagePainPlanningFatigueIntimate RelationshipsBurden to Others
LY2127399 Every 2 Weeks69.072.773.668.571.065.568.462.6
LY2127399 Every 4 Weeks66.272.372.867.570.762.466.163.7
Placebo70.774.073.171.473.269.372.469.2

Duration of Clinical Remission

Clinical remission was defined as clinical SLEDAI-2K score =0 (does not include anti-dsDNA and complement activity scores), achieved without immunosuppressants and with corticosteroids at a prednisone equivalent dose of 0 mg/day. The duration of clinical remission (PI assessed) was the longest period between 2 visits that the participant was a clinical remission responder at all visits and was calculated as the first visit of clinical remission minus last visit of clinical remission plus 1. SLEDAI-2K consisted of 24 individual items within each of 9 organ systems. Each item was given a weighted score (1 to 8, higher score indicates increased activity) and summed if present at the time of visit or in preceding 10 days. The clinical SLEDAI-2K score was sum of 22 out of all 24 individual items from the SLEDAI-2K and ranges from 0 (no symptoms) to 101 (presence of all defined symptoms) with higher scores representing increased disease activity. (NCT03312907)
Timeframe: Up to Week 104

InterventionDays (Median)
Belimumab + Placebo31.0
Belimumab + Rituximab73.0
Belimumab + Standard Therapy176.0

Duration of Disease Control

Duration of disease control was defined as SLEDAI-2K score <=2, achieved without immunosuppressants and with corticosteroids at a prednisone equivalent dose of <=5 mg/day. The duration of disease control (PI assessed) was the longest period between 2 visits that the participant was a disease control responder at all visits and calculated as the first visit of disease control minus last visit of disease control plus 1. SLEDAI-2K consisted of 24 individual items within each of 9 organ systems. Each item was given a weighted score (1 to 8, higher score indicates increased activity) and summed if present at the time of visit or in preceding 10 days. SLEDAI-2K score was the sum of all 24 individual items from SLEDAI-2K, ranges from 0(no symptoms) to 105 (presence of all defined symptoms),higher scores representing increased disease activity (NCT03312907)
Timeframe: Up to Week 104

InterventionDays (Median)
Belimumab + Placebo49.5
Belimumab + Rituximab116.0
Belimumab + Standard Therapy116.0

Percentage of Participants With a State of Clinical Remission (CLR) Sustained for at Least 24 Weeks From Week 80 to Week 104

Percentage of participants with a state of CLR (PI assessed) at Week 104 was defined as percentage of participants with a clinical SLEDAI-2K score=0 (does not include anti-dsDNA and complement activity scores) achieved without immunosuppressants and with corticosteroids at a prednisone equivalent dose of 0 mg/day, sustained for at least 24 weeks(from Week 80 to Week 104). Sustained CLR is longest period a participant maintains CLR without a break, calculated as last consecutive CLR date minus first consecutive CLR date plus 1. SLEDAI-2K consisted of 24 individual items within each of 9 organ systems. Each item was given a weighted score(1 to 8 with higher score indicating increased activity) and summed if present at the time of visit or in preceding 10 days. The clinical SLEDAI-2K score was sum of 22 out of all 24 individual items from the SLEDAI-2K and ranges from 0 (no symptoms) to 101 (presence of all defined symptoms) with higher scores representing increased disease activity. (NCT03312907)
Timeframe: From Week 80 to Week 104

InterventionPercentage of participants (Number)
Belimumab + Placebo2.8
Belimumab + Rituximab2.1
Belimumab + Standard Therapy4.3

Percentage of Participants With a State of Clinical Remission at Week 64

Percentage of participants with a state of clinical remission (IBA) was defined as percentage of participants with a clinical SLEDAI-2K score =0 (does not include anti-double stranded deoxyribonucleic [dsDNA] and complement activity scores), achieved without immunosuppressants and with corticosteroids at a prednisone equivalent dose of 0 mg/day at Week 64. SLEDAI-2K was a weighted, cumulative index for measuring SLE disease activity in previous 10 days, consisting 24 individual items in which signs and symptoms, laboratory tests, and physician's assessment for each item within each of 9 organ systems were given a weighted score (1 to 8 with higher score indicating increased activity) and summed if present at the time of the visit or in the preceding 10 days. The clinical SLEDAI-2K score was sum of 22 out of all 24 individual items from the SLEDAI-2K and ranges from 0 (no symptoms) to 101 (presence of all defined symptoms) with higher scores representing increased disease activity. (NCT03312907)
Timeframe: Week 64

InterventionPercentage of participants (Number)
Belimumab + Placebo5.6
Belimumab + Rituximab6.3
Belimumab + Standard Therapy10.6

Percentage of Participants With a State of Complete Remission (CR) Sustained for at Least 24 Weeks During Week 52 to Week 104

Percentage of participants with a state of CR (Principal Investigator [PI] assessed) was defined as percentage of participants with a SLEDAI-2K=0 achieved without immunosuppressants and with corticosteroids at prednisone equivalent dose of 0 mg/day,sustained for at least 24 weeks. Sustained CR was longest period a participant maintains CR without break calculated as last consecutive CR date minus first consecutive CR date plus 1. SLEDAI-2K consisted of 24 individual items within each 9 organ systems. Each item was given a weighted score (1 to 8, higher score indicates increased activity) and summed if present at time of visit or in preceding 10 days. SLEDAI-2K score was sum of all 24 individual items from SLEDAI-2K, ranges from 0(no symptoms) to 105(presence of all defined symptoms),higher scores indicates increased disease activity. Percentage of participants with a state of CR sustained for at least 24 weeks at any visit during Week 52 to Week 104 were reported. (NCT03312907)
Timeframe: Week 52 to Week 104

InterventionPercentage of participants (Number)
Belimumab + Placebo2.8
Belimumab + Rituximab0
Belimumab + Standard Therapy6.4

Percentage of Participants With a State of Disease Control at Week 104

Percentage of participants with a state of disease control (IBA) was defined as the percentage of participants with a SLEDAI-2K score <=2, achieved without immunosuppressants and with corticosteroids at a prednisone equivalent dose of <=5 mg/day at Week 104. SLEDAI-2K was a weighted, cumulative index for measuring SLE disease activity in previous 10 days which consisted of 24 individual items in which signs and symptoms, laboratory tests, and physician's assessment for each item within each of 9 organ systems were given a weighted score (1 to 8 with higher score indicating increased activity) and summed if present at the time of the visit or in the preceding 10 days. The SLEDAI-2K score was the sum of all 24 individual items from the SLEDAI-2K which ranges from 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. (NCT03312907)
Timeframe: Week 104

InterventionPercentage of participants (Number)
Belimumab + Placebo6.9
Belimumab + Rituximab11.1
Belimumab + Standard Therapy21.3

Percentage of Participants With a State of Disease Control at Week 52

Percentage of participants with a state of disease control (Independent blinded assessor [IBA]) was defined as the percentage of participants with a Systemic Lupus Erythematosus Disease Activity Index 2000(SLEDAI-2K)score less than or equal to(<=)2 achieved without immunosuppressants and with corticosteroids at a prednisone equivalent dose of <=5 mg/day at Week 52. SLEDAI-2K was a weighted, cumulative index for measuring systemic lupus erythematosus (SLE) disease activity in previous 10 days,consisting 24 individual items in which signs and symptoms, laboratory tests and physician's assessment for each item within each of 9 organ systems were given a weighted score(1 to 8 with higher score indicating increased activity)and summed if present at the time of visit or in preceding 10 days. The SLEDAI-2K score was sum of all 24 individual items from the SLEDAI-2K, ranges from 0(no symptoms) to 105(presence of all defined symptoms) with higher scores representing increased disease activity. (NCT03312907)
Timeframe: Week 52

InterventionPercentage of participants (Number)
Belimumab + Placebo16.7
Belimumab + Rituximab19.4
Belimumab + Standard Therapy25.5

Time to Clinical Remission Sustained for at Least 24 Weeks and Maintained Through Week 104

Clinical remission sustained for at least 24 weeks and maintained through Week 104 was defined as clinical SLEDAI-2K score=0 (does not include anti-dsDNA and complement activity scores), achieved without immunosuppressants and with corticosteroids at a prednisone equivalent dose of 0 mg/day. Time to CLR (PI assessed) was defined as first visit of sustained CLR until Week 104 on or before Week 80 minus treatment start date (Day 1) plus 1. Sustained CLR was longest period a participant maintained clinical remission without a break. SLEDAI-2K consisted of 24 individual items within each of 9 organ systems. Each item was given a weighted score (1 to 8, higher score indicates increased activity) and summed if present at the time of visit or in preceding 10 days. The clinical SLEDAI-2K score was sum of 22 out of all 24 individual items from the SLEDAI-2K and ranges from 0 (no symptoms) to 101 (presence of all defined symptoms) with higher scores representing increased disease activity. (NCT03312907)
Timeframe: Up to Week 104

InterventionDays (Median)
Belimumab + PlaceboNA
Belimumab + RituximabNA
Belimumab + Standard TherapyNA

Time to Disease Control Sustained for at Least 24 Weeks and Maintained Through Week 104

Disease control sustained for at least 24 weeks and maintained through Week 104 was defined as SLEDAI-2K score <=2, achieved without immunosuppressants and with corticosteroids at a prednisone equivalent dose of <=5 mg/day. Time to disease control (PI assessed) was defined as the first visit of sustained disease control until Week 104 on or before Week 80 minus treatment start date (Day 1) plus 1. Sustained disease control was longest period a participant maintained disease control without a break. SLEDAI-2K consisted of 24 individual items within each of 9 organ systems. Each item was given a weighted score (1 to 8, higher score indicates increased activity) and summed if present at the time of visit or in preceding 10 days. SLEDAI-2K score was the sum of all 24 individual items from SLEDAI-2K , ranges from 0 (no symptoms) to 105 (presence of all defined symptoms),higher scores representing increased disease activity. (NCT03312907)
Timeframe: Up to Week 104

InterventionDays (Median)
Belimumab + PlaceboNA
Belimumab + RituximabNA
Belimumab + Standard TherapyNA

Time to First Flare

Time to first SLE flare was the number of days from treatment start date until the participant met an event. Time to first flare was defined as event date minus treatment start date plus 1. Time to first flare was measured by modified SLE flare index which identifies whether a participant had experienced a mild/moderate or severe flare. (NCT03312907)
Timeframe: Up to Week 104

InterventionDays (Median)
Belimumab + Placebo168.0
Belimumab + Rituximab170.0
Belimumab + Standard Therapy168.0

Time to First Severe Flare

Time to first severe SLE flare was the number of days from treatment start date until the participant met an event. Time to first severe flare was defined as event date minus treatment start date plus 1. Time to first severe flare was measured by Modified SLE flare index which identifies whether a participant had experienced a mild/moderate or severe flare. Analysis of first severe flare was performed on the modified SLE Flare index that excludes severe flares that were triggered only by an increase is SLEDAI-2K score to greater than 12. (NCT03312907)
Timeframe: Up to Week 104

InterventionDays (Median)
Belimumab + Placebo372.0
Belimumab + Rituximab379.0
Belimumab + Standard Therapy730.0

Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score by Visit

The FACIT-Fatigue scale was a 13-item questionnaire completed by the participant, which provides a measure of fatigue/quality of life, with a 7-day recall period. The participant scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The higher score for the questions, the greater the fatigue. The total score was the sum of the responses from all questions (inverted for reversed items) multiplied by 13, then divided by the number of questions answered, ranging from 0 (worse fatigue) to 52 (no fatigue) where a higher score indicates an improvement in the participant's health status and decrease in the score indicates worse fatigue/quality of life. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was defined as the post-dose visit value minus Baseline value. (NCT03312907)
Timeframe: Baseline (Day 1) and Weeks 8, 12, 26, 40, 52, 64, 72 and 104

,,
InterventionScores on a scale (Mean)
Week 8; n=66, 132, 44Week 12; n=66, 133, 44Week 26; n=61, 115, 40Week 40; n=63, 122, 43Week 52; n=64, 120, 41Week 64;n=62, 117, 36Week 72; n=59, 107, 33Week 104; n=55, 111, 36
Belimumab + Placebo4.24.73.16.06.54.95.65.7
Belimumab + Rituximab4.64.05.45.26.16.25.27.1
Belimumab + Standard Therapy4.83.84.15.25.14.62.93.1

Change From Baseline in Lupus Quality of Life (LupusQoL) Domain Scores by Visit

LupusQoL is a SLE-specific health related qualify of life (HRQOL) instrument with 34 questions across 8 domains:Physical health(8 items),Pain(3 items),Planning(3 items),Intimate relationship(2 items),Burden to others(3 items),Emotional health(6 items),Body image(5 items),Fatigue(4 items). Questions were related to participants experience in prior 4 weeks.A 5-point Likert response format was used, ranging from 0(all of the time) to 4(never) for each question. Individual domain scores were reported which were calculated by taking sum of responses to all items within each domain. Individual domain scores range:Physical health(0-32),Pain(0-12),Planning(0-12),Intimate relationship(0-8),Burden to others(0-12),Emotional health(0-24),Body image(0-20),Fatigue(0-16). Higher score indicates better HRQOL. Baseline value was latest pre-dose assessment with a non-missing value including those from unscheduled visits. Change from Baseline was defined as post-dose visit value minus Baseline value. (NCT03312907)
Timeframe: Baseline (Day 1) and Weeks 8, 12, 26, 40, 52, 64, 72 and 104

,,
InterventionScores on a scale (Mean)
Physical health; Week 8; n=66, 132, 44Physical health; Week 12; n=66, 133, 44Physical health; Week 26; n=61, 115, 40Physical health; Week 40; n=63, 122, 43Physical health; Week 52; n=64, 120, 41Physical health; Week 64; n=62, 117, 36Physical health; Week 72; n=59, 107, 33Physical health; Week 104; n=55, 111, 36Pain; Week 8; n=66, 132, 44Pain; Week 12; n=66, 133, 44Pain; Week 26; n=61, 115, 40Pain; Week 40; n=63, 122, 43Pain; Week 52; n=64, 120, 41Pain; Week 64; n=62, 117, 36Pain; Week 72; n=59, 107, 33Pain; Week 104; n=55, 111, 36Planning; Week 8; n=66, 132, 44Planning; Week 12; n=66, 133, 44Planning; Week 26; n=61, 115, 40Planning; Week 40; n=63, 122, 43Planning; Week 52; n=64, 120, 41Planning; Week 64; n=62, 117, 36Planning; Week 72; n=59, 107, 33Planning; Week 104; n=55, 111, 36Intimate relationship; Week 8; n=51, 110, 36Intimate relationship; Week 12; n=52, 106, 36Intimate relationship; Week 26; n=48, 86, 30Intimate relationship; Week 40; n=50, 94, 30Intimate relationship; Week 52; n=51, 91, 30Intimate relationship; Week 64; n=47, 90, 25Intimate relationship; Week 72; n=42, 83, 21Intimate relationship; Week 104; n=40, 85,27Burden to others; Week 8; n=66, 132, 44Burden to others; Week 12; n=66, 133, 44Burden to others; Week 26; n=61, 115, 40Burden to others; Week 40; n=63, 122, 43Burden to others; Week 52; n=64, 120, 41Burden to others; Week 64; n=62, 117, 36Burden to others; Week 72; n=59, 107, 33Burden to others; Week 104; n=55, 111, 36Emotional health; Week 8; n=66, 132, 44Emotional health; Week 12; n=66, 133, 44Emotional health; Week 26; n=61,115, 40Emotional health; Week 40; n=63, 122, 43Emotional health; Week 52; n=64, 120, 41Emotional health; Week 64; n=62, 117, 36Emotional health; Week 72; n=59, 107, 33Emotional health; Week 104; n=55, 111, 36Body image; Week 8; n=60, 114, 37Body image; Week 12; n=58, 118, 39Body image; Week 26; n=56, 96, 33Body image; Week 40; n=54, 103, 35Body image; Week 52; n=55, 101, 33Body image; Week 64; n=52, 98, 27Body image; Week 72; n=44, 93, 25Body image; Week 104; n=48, 94, 28Fatigue; Week 8; n=66,132, 44Fatigue; Week 12; n=66, 133, 44Fatigue; Week 26; n=61, 115, 40Fatigue; Week 40; n=63, 122, 43Fatigue; Week 52; n=64, 120, 41Fatigue; Week 64; n=62, 117, 36Fatigue; Week 72; n=59, 107, 33Fatigue; Week 104; n=55, 111, 36
Belimumab + Placebo3.03.53.38.58.15.87.06.25.87.57.012.313.910.213.113.83.44.53.411.611.67.89.212.1-1.2-2.6-1.34.34.7-4.50.0-0.37.311.48.713.916.514.417.118.95.28.17.79.710.28.18.86.85.71.95.88.97.96.07.84.49.88.28.611.914.210.512.19.4
Belimumab + Rituximab6.05.810.59.510.010.29.110.611.413.017.218.017.617.417.019.08.07.69.912.212.614.511.414.25.24.68.97.76.611.08.611.26.88.410.512.614.917.014.415.06.44.56.76.77.89.36.29.38.910.19.08.29.111.38.711.49.27.011.410.312.014.013.114.3
Belimumab + Standard Therapy6.36.411.68.211.69.58.57.210.46.113.112.615.713.211.912.510.07.812.110.714.07.26.68.87.67.614.215.815.812.55.44.610.66.47.512.015.012.311.112.711.69.110.19.411.48.16.610.55.75.95.75.110.37.72.53.58.510.411.911.316.610.811.69.7

Change From Baseline in Patient Global Assessment (PtGA) by Visits

The Patient's Global Assessment (PtGA) of Disease Activity is a single-item, participant reported scale developed for the assessment of the participant's overall rating of their disease activity due to SLE. The scale measures disease activity ranging from 0 (Very Well) to 10 (Very Poor) and the higher score indicates severe disease activity. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was defined as the post-dose visit value minus Baseline value. (NCT03312907)
Timeframe: Baseline (Day 1) and Weeks 8, 12, 26, 40, 52, 64, 72 and 104

,,
InterventionScores on a scale (Mean)
Week 8; n=66, 132, 44Week 12; n=66, 133, 44Week 26; n=61, 115, 40Week 40; n=63, 123, 43Week 52; n=64, 120, 41Week 64; n=62, 117, 36Week 72; n=59, 107, 33Week 104; n=55, 111, 36
Belimumab + Placebo-0.96-0.69-0.95-1.77-1.74-1.41-1.46-1.61
Belimumab + Rituximab-1.06-1.07-1.50-1.60-1.82-1.96-1.81-2.00
Belimumab + Standard Therapy-0.91-1.57-1.57-1.67-1.84-1.96-1.43-1.98

Change From Baseline in Physician Global Assessment (PGA) by Visits

The Physician's Global Assessment (PGA) was a physician-reported visual analogue scale that provides an overall measure of the participant's current disease activity. Physician's Global Assessment was collected on a 10 centimeter (cm) visual analogue scale (VAS) by placing a mark on the scale between 0 (no disease activity) to 10 (maximum disease activity). The PGA score was then rescaled for reporting by multiplying the collected score by 3 divided by 10. Hence, the PGA score ranges from 0 to 3 with higher scores indicating greater disease activity. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was defined as the post-dose visit value minus Baseline value. (NCT03312907)
Timeframe: Baseline (Day 1) and Weeks 4, 8, 12, 16, 20, 24, 26, 28, 32, 36, 40, 44, 48, 52, 60, 64, 72, 80, 88, 96, 104

,,
InterventionScores on a scale (Mean)
Week 4; n=72, 142, 45Week 8; n=66, 135, 44Week 12; n=66, 137, 44Week 16; n=68, 132, 44Week 20; n=66, 130, 44Week 24; n=62, 130, 43Week 26; n=62, 120, 40Week 28; n=63, 127, 43Week 32; n=62, 124, 43Week 36; n=64, 126, 43Week 40; n=63, 126, 43Week 44; n=63, 124, 43Week 48; n=59, 121, 40Week 52; n=64, 122, 41Week 60; n=61, 120, 37Week 64; n=62, 120, 36Week 72; n=58, 110, 33Week 80; n=57, 112, 37Week 88; n=59, 109, 36Week 96; n=54, 109, 35Week 104; n=55, 114, 36
Belimumab + Placebo-0.285-0.535-0.592-0.619-0.697-0.770-0.786-0.781-0.851-0.916-0.893-0.800-0.885-0.947-0.836-0.876-0.928-0.949-1.060-1.016-1.052
Belimumab + Rituximab-0.247-0.520-0.660-0.717-0.787-0.766-0.811-0.817-0.864-0.927-0.925-0.905-0.928-0.938-0.848-0.943-0.944-0.954-0.993-0.994-1.074
Belimumab + Standard Therapy-0.303-0.585-0.654-0.759-0.786-0.965-0.929-0.980-1.005-0.917-0.993-0.970-0.956-1.004-1.206-1.095-1.047-1.138-1.140-1.214-1.085

Change From Baseline in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) Score by Visit (PI Assessed)

The SLEDAI-2K consisted of 24 individual items within 9 organ systems. Each item was given a weighted score (1 to 8 with higher score indicating increased activity) and summed if present at the time of visit or in the preceding 10 days. Weighted scores for central nervous system (CNS) (7 items) was 8; for vascular (1 item) was 8; for Musculoskeletal (2 items) was 4; for Renal (4 items) was 4; for Mucocutaneous (3 items) was 2; for Cardiovascular and Respiratory (2 items) was 2; for Immunologic (2 items) was 2;for Constitutional (1 item) was 1 and for Hematologic (2 items) was 1. SLEDAI-2K score was the sum of all 24 individual items from the SLEDAI-2K which ranges from 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. Baseline value was latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was defined as post-dose visit value minus Baseline value. (NCT03312907)
Timeframe: Baseline (Day 1) and Weeks 4, 8, 12, 16, 20, 24, 26, 28, 32, 36, 40, 44, 48, 52, 60, 64, 72, 80, 88, 96, 104

,,
InterventionScores on a scale (Mean)
Week 4; n=69, 137, 43Week 8; n=63, 132, 43Week 12; n=63, 131, 43Week 16; n=65, 129, 43Week 20; n=63, 127, 44Week 24; n=61, 128, 43Week 26; n=61, 118, 40Week 28; n=62, 125, 43Week 32; n=61, 125, 43Week 36; n=61, 125, 43Week 40; n=62, 125, 43Week 44; n=62, 122, 43Week 48; n=59, 122, 40Week 52; n=62, 119, 39Week 60; n=57, 114, 37Week 64; n=60, 117, 36Week 72; n=49, 103, 30Week 80; n=46, 102, 36Week 88; n=49, 101, 34Week 96; n=49, 100, 34Week 104; n=50, 104, 34
Belimumab + Placebo-1.4-3.2-2.8-3.4-3.8-4.0-4.1-3.7-4.7-5.0-4.6-4.7-4.5-5.3-5.0-5.1-5.2-5.4-5.3-5.6-5.1
Belimumab + Rituximab-0.8-2.9-3.6-4.4-5.0-5.0-5.4-5.1-5.7-5.6-5.8-6.1-6.2-6.1-5.8-6.2-6.6-6.5-6.5-7.0-7.2
Belimumab + Standard Therapy-1.3-2.9-2.9-4.1-3.8-5.0-5.0-5.2-5.3-5.0-5.0-5.2-5.3-5.6-6.0-5.5-5.3-6.0-6.1-6.1-6.3

Number of Participants With Adverse Events of Special Interest (AESIs)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. AESIs were Malignant Neoplasms, Post-Injection Systemic Reactions (PISR), All Infections of Special Interest (Opportunistic Infections (OI), Herpes Zoster (HZ), Tuberculosis (TB), and Sepsis), Depression (including mood disorders and anxiety)/suicide/self-injury and Deaths. Data for number of participants with AESIs has been summarized. (NCT03312907)
Timeframe: Up to Week 104

,,
InterventionParticipants (Count of Participants)
Malignant NeoplasmsPISRAll Infections of Special InterestDepression/suicide/self-injuryDeaths
Belimumab + Placebo17591
Belimumab + Rituximab11912162
Belimumab + Standard Therapy14550

Number of Participants With Serious Adverse Events (SAE) and Non-serious AE (Non-SAE)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or any other situations as per medical or scientific judgment. Data for number of participants with SAE and non-SAE (>=5 %) has been summarized. (NCT03312907)
Timeframe: Up to Week 111 (including 8 weeks of safety follow-up)

,,
InterventionParticipants (Count of Participants)
SAEnon-SAE
Belimumab + Placebo1048
Belimumab + Rituximab32109
Belimumab + Standard Therapy1553

Percentage of Participants That Met the Lupus Low Disease Activity State (LLDAS) Response Criteria by Visits (PI Assessed)

Lupus low disease activity state (LLDAS) was defined as a state which, if sustained, was associated with a low likelihood of adverse outcome, considering disease activity and medication safety. The LLDAS response criteria were: (1) SLEDAI-2K <=4, with no activity in major organ systems (renal, CNS, cardiopulmonary, vasculitis, fever) and no hemolytic anemia or gastrointestinal activity; (2) no new features of lupus disease activity compared with the previous assessment; (3) PGA (scale 0-3), <=1; (4) current prednisolone (or equivalent) dose <=7.5 mg daily; and (5) well tolerated standard maintenance doses of immunosuppressive drugs and approved biological agents, excluding investigational drugs. Percentage of participants that met the LLDAS response criteria were reported. (NCT03312907)
Timeframe: Weeks 4, 8, 12, 16, 20, 24, 26, 28, 32, 36, 40, 44, 48, 52, 60, 64, 72, 80, 88, 96 and 104

,,
InterventionPercentage of participants (Number)
Week 4Week 8Week 12Week 16Week 20Week 24Week 26Week 28Week 32Week 36Week 40Week 44Week 48Week 52Week 60Week 64Week 72Week 80Week 88Week 96Week 104
Belimumab + Placebo09.78.311.111.112.522.220.829.230.622.230.626.427.826.420.822.218.123.620.820.8
Belimumab + Rituximab2.11.49.716.725.722.225.725.031.934.033.337.537.534.023.630.631.326.424.330.632.6
Belimumab + Standard Therapy2.110.66.419.119.136.234.034.036.229.838.331.931.929.836.231.931.934.029.836.238.3

Percentage of Participants With a State of Clinical Remission by Visits

Percentage of participants with a state of clinical remission (IBA) was defined as percentage of participants with a clinical SLEDAI-2K score =0 (does not include anti-dsDNA and complement activity scores), achieved without immunosuppressants and with corticosteroids at a prednisone equivalent dose of 0 mg/day. SLEDAI-2K was a weighted, cumulative index for measuring SLE disease activity in previous 10 days, consisting 24 individual items in which signs and symptoms, laboratory tests, and physician's assessment for each item within each of 9 organ systems were given a weighted score (1 to 8 with higher score indicating increased activity) and summed if present at the time of the visit or in the preceding 10 days. The clinical SLEDAI-2K score was sum of 22 out of all 24 individual items from the SLEDAI-2K and ranges from 0 (no symptoms) to 101 (presence of all defined symptoms) with higher scores representing increased disease activity (NCT03312907)
Timeframe: Weeks 64, 80 and 104

,,
InterventionPercentage of participants (Number)
Week 64Week 80Week 104
Belimumab + Placebo5.64.21.4
Belimumab + Rituximab6.34.24.2
Belimumab + Standard Therapy10.612.86.4

Percentage of Participants With a State of Clinical Remission Using the PI Assessment of SLEDAI-2K by Visit

Percentage of participants with a state of clinical remission was defined as the percentage of participants with a clinical SLEDAI-2K score =0 (does not include anti-dsDNA and complement activity scores), achieved without immunosuppressants (which was allowed in Belimumab+ Standard therapy arm only) and with corticosteroids at a prednisone equivalent dose of 0 mg/day using the PI assessment of SLEDAI-2K. SLEDAI-2K consisted of 24 individual items within each of 9 organ systems. Each item was given a weighted score (1 to 8, higher score indicates increased activity) and summed if present at the time of visit or in preceding 10 days. The clinical SLEDAI-2K score was sum of 22 out of all 24 individual items from the SLEDAI-2K and ranges from 0 (no symptoms) to 101 (presence of all defined symptoms) with higher scores representing increased disease activity. Percentage of participants with a state of clinical remission using the PI assessment of SLEDAI-2K were summarized. (NCT03312907)
Timeframe: Weeks 60, 64, 72, 80, 88, 96 and 104

,,
InterventionPercentage of participants (Number)
Week 60Week 64Week 72Week 80Week 88Week 96Week 104
Belimumab + Placebo6.96.96.96.96.94.22.8
Belimumab + Rituximab3.55.63.54.22.14.23.5
Belimumab + Standard Therapy10.610.614.914.914.912.86.4

Percentage of Participants With a State of Complete Remission by Visits

Percentage of participants with a state of complete remission (PI assessed) was defined as the percentage of participants with a SLEDAI-2K score =0, achieved without immunosuppressants and with corticosteroids at a prednisone equivalent dose of 0 mg/day. SLEDAI-2K was a weighted, cumulative index for measuring systemic lupus erythematosus (SLE) disease activity in the previous 10 days which consisted of 24 individual items in which signs and symptoms, laboratory tests, and physician's assessment for each item within for each of 9 organ systems were given a weighted score (1 to 8 with higher score indicating increased activity) and summed if present at the time of the visit or in the preceding 10 days. The SLEDAI-2K score was the sum of all 24 individual items from the SLEDAI-2K which ranges from 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. (NCT03312907)
Timeframe: Weeks 60, 64, 72, 80, 88, 96 and 104

,,
InterventionPercentage of participants (Number)
Week 60Week 64Week 72Week 80Week 88Week 96Week 104
Belimumab + Placebo5.65.64.22.82.81.41.4
Belimumab + Rituximab0.70.70.71.400.70.7
Belimumab + Standard Therapy6.46.46.48.54.36.44.3

Percentage of Participants With a State of Disease Control by Visits

Percentage of participants with a state of disease control (IBA) was defined as the percentage of participants with a SLEDAI-2K score <=2, achieved without immunosuppressants and with corticosteroids at a prednisone equivalent dose of <=5 mg/day. SLEDAI-2K was a weighted, cumulative index for measuring SLE disease activity in previous 10 days which consisted of 24 individual items in which signs and symptoms, laboratory tests, and physician's assessment for each item within each of 9 organ systems were given a weighted score (1 to 8 with higher score indicating increased activity) and summed if present at the time of the visit or in the preceding 10 days. The SLEDAI-2K score was the sum of all 24 individual items from the SLEDAI-2K which ranges from 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. (NCT03312907)
Timeframe: Weeks 12, 26, 40, 52, 64, 80 and 104

,,
InterventionPercentage of participants (Number)
Week 12Week 26Week 40Week 52Week 64Week 80Week 104
Belimumab + Placebo8.316.713.916.711.16.96.9
Belimumab + Rituximab12.521.520.819.418.113.211.1
Belimumab + Standard Therapy21.325.523.425.525.527.721.3

Percentage of Participants With a State of Disease Control Using the PI Assessment of SLEDAI-2K by Visit

Percentage of participants with a state of disease control was defined as the percentage of participants with a SLEDAI-2K score <=2, achieved without immunosuppressants and with corticosteroids at a prednisone equivalent dose of <=5 mg/day, using the PI assessment of SLEDAI-2K. SLEDAI-2K consisted of 24 individual items within each of 9 organ systems. Each item was given a weighted score (1 to 8, higher score indicates increased activity) and summed if present at the time of visit or in preceding 10 days. SLEDAI-2K score was the sum of all 24 individual items from SLEDAI-2K, ranges from 0 (no symptoms) to 105 (presence of all defined symptoms), higher scores representing increased disease activity. Percentage of participants with a state of disease control using the PI assessment of SLEDAI-2K were summarized. (NCT03312907)
Timeframe: Weeks 4, 8, 12, 16, 20, 24, 26, 28, 32, 36, 40, 44, 48, 52, 60, 64, 72, 80, 88, 96, 104

,,
InterventionPercentage of participants (Number)
Week 4Week 8Week 12Week 16Week 20Week 24Week 26Week 28Week 32Week 36Week 40Week 44Week 48Week 52Week 60Week 64Week 72Week 80Week 88Week 96Week 104
Belimumab + Placebo2.813.911.115.313.918.115.311.115.319.416.718.118.119.418.111.19.78.311.18.38.3
Belimumab + Rituximab3.59.012.522.224.325.025.725.728.527.824.326.426.420.120.818.112.513.29.712.511.8
Belimumab + Standard Therapy8.521.319.129.831.934.025.536.231.927.723.427.727.727.723.427.723.431.921.331.923.4

Percentage of Participants With Improvement in FACIT-Fatigue Score Exceeding the Minimal Clinically Important Difference (MCID, Greater Than or Equal to [>=]4)

The FACIT-Fatigue scale was a 13-item questionnaire completed by the participant, which provides a measure of fatigue/quality of life, with a 7-day recall period. The participant scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions, the greater the fatigue. The total score was the sum of the responses (inverted for reversed items) multiplied by 13, then divided by the number of questions answered, ranging from 0 (worse fatigue) to 52 (no fatigue) where a higher score indicates an improvement in the participant's health status and decrease in the score indicates worse fatigue/quality of life. A participant was considered to had an improvement exceeding the minimal clinically important difference if they had >=4 points improvement in their FACIT-Fatigue Scale score from Baseline. Percentage of participants with improvement in FACIT-Fatigue scale score exceeding the MCID (>=4 points) were summarized. (NCT03312907)
Timeframe: Weeks 8, 12, 26, 40, 52, 64, 72 and 104

,,
InterventionPercentage of participants (Number)
Week 8; n=66, 132, 44Week 12; n=66, 133, 44Week 26; n=61, 115, 40Week 40; n=63, 122, 43Week 52; n=64, 120, 41Week 64; n=62, 117, 36Week 72; n=59, 107, 33Week 104; n=55, 111, 36
Belimumab + Placebo47.056.147.554.060.951.657.656.4
Belimumab + Rituximab51.550.456.554.158.359.857.062.2
Belimumab + Standard Therapy59.152.345.053.556.152.842.444.4

Percentage of Participants With SLEDAI-2K Organ Improvement Compared to Baseline by Visits (PI Assessed)

SLEDAI-2K assessments consisted of 24 individual items with 9 organ systems. Each item was given a weighted score(1 to 8 with higher score indicating increased activity)and summed if present at the time of analysis. SLEDAI-2K score was sum of all 24 individual items from SLEDAI-2K ranges from 0(no symptoms) to 105(presence of all defined symptoms). Higher scores indicates increased disease activity. An improvement was defined as a decrease(compared to Baseline) in SLEDAI-2K score within same organ system at a post-Baseline visit. Baseline value was latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Data for following organ systems was reported: CNS total, Vascular total, Musculoskeletal total, Renal total, Mucocutaneous total, Cardiovascular (Cardio) and Respiratory (Resp) total, Immunologic total and Hematologic total. Constitutional organ system was removed from analysis and its one item (fever)moved to hematologic organ system. (NCT03312907)
Timeframe: Baseline (Day 1) and Weeks 4, 8, 12, 16, 20, 24, 26, 28, 32, 36, 40, 44, 48, 52, 60, 64, 72, 80, 88, 96, 104

InterventionPercentage of participants (Number)
CNS Total; Week 4; n= 2,3,2CNS Total; Week 8; n= 2,3,2CNS Total; Week 12; n= 2,3,2CNS Total; Week 16; n= 2,3,2CNS Total; Week 20; n= 2,3,2CNS Total; Week 24; n= 2,3,2CNS Total; Week 26; n= 2,3,2CNS Total; Week 28; n= 2,3,2CNS Total; Week 32; n= 2,3,2CNS Total; Week 36; n= 2,3,2CNS Total; Week 40; n= 2,3,2CNS Total; Week 44; n= 2,3,2CNS Total; Week 48; n= 2,3,2CNS Total; Week 52; n= 2,3,2CNS Total; Week 60; n= 2,3,2CNS Total; Week 64; n= 2,3,2CNS Total; Week 72; n= 2,3,2CNS Total; Week 80; n= 2,3,2CNS Total; Week 88; n= 2,3,2CNS Total; Week 96; n= 2,3,2CNS Total; Week 104; n=2,3,2Musculoskeletal Total; Week 4; n= 57, 110, 34Musculoskeletal Total; Week 8; n=57,110, 34Musculoskeletal Total; Week 12; n= 57,110,34Musculoskeletal Total; Week 16; n= 57,110,34Musculoskeletal Total; Week 20; n= 57,110,34Musculoskeletal Total; Week 24; n= 57,110,34Musculoskeletal Total;; Week 26; n=57,110,34Musculoskeletal Total; Week 28; n= 57,110,34Musculoskeletal Total; Week 32; n= 57,110,34Musculoskeletal Total; Week 36; n= 57,110,34Musculoskeletal Total; Week 40; n= 57,110,34Musculoskeletal Total; Week 44; n= 57,110,34Musculoskeletal Total; Week 48; n= 57,110,34Musculoskeletal Total; Week 52; n= 57,110,34Musculoskeletal Total; Week 60; n= 57,110,34Musculoskeletal Total; Week 64; n= 57,110,34Musculoskeletal Total; Week 72; n= 57,110,34Musculoskeletal Total; Week 80; n= 57,110,34Musculoskeletal Total; Week 88; n= 57,110,34Musculoskeletal Total; Week 96; n= 57,110,34Musculoskeletal Total; Week 104; n= 57,110,34Renal Total; Week 4; n= 14,23,8Renal Total; Week 8; n= 14, 23, 8Renal Total; Week 12; n= 14, 23, 8Renal Total; Week 16; n= 14, 23, 8Renal Total; Week 20; n= 14, 23, 8Renal Total; Week 24; n= 14, 23, 8Renal Total; Week 26; n= 14, 23, 8Renal Total; Week 28; n= 14, 23, 8Renal Total; Week 32; n= 14, 23, 8Renal Total; Week 36; n= 14, 23, 8Renal Total; Week 40; n=14, 23, 8Renal Total; Week 44; n= 14, 23, 8Renal Total; Week 48; n=14, 23, 8Renal Total; Week 52; n= 14, 23, 8Renal Total; Week 60; n= 14, 23, 8Renal Total; Week 64; n= 14, 23, 8Renal Total; Week 72; n= 14, 23, 8Renal Total; Week 80; n= 14, 23, 8Renal Total; Week 88; n= 14, 23, 8Renal Total; Week 96; n= 14, 23, 8Renal Total; Week 104; n= 14, 23, 8Mucocutaneous Total; Week 4; n= 59, 126,43Mucocutaneous Total; Week 8; n= 59,126,43Mucocutaneous Total; Week 12; n= 59, 126, 43Mucocutaneous Total; Week 16; n= 59, 126, 43Mucocutaneous Total; Week 20; n= 59, 126, 43Mucocutaneous Total; Week 24; n= 59, 126, 43Mucocutaneous Total; Week 26; n=59, 126, 43Mucocutaneous Total; Week 28; n= 59, 126, 43Mucocutaneous Total; Week 32; n= 59, 126, 43Mucocutaneous Total; Week 36; n= 59, 126, 43Mucocutaneous Total; Week 40; n= 59, 126, 43Mucocutaneous Total; Week 44; n= 59, 126, 43Mucocutaneous Total; Week 48; n= 59, 126, 43Mucocutaneous Total; Week 52; n=59, 126, 43Mucocutaneous Total; Week 60; n=59, 126, 43Mucocutaneous Total; Week 64; n=59, 126, 43Mucocutaneous Total; Week 72; n=59, 126, 43Mucocutaneous Total; Week 80; n= 59, 126, 43Mucocutaneous Total; Week 88; n= 59, 126, 43Mucocutaneous Total; Week 96; n= 59, 126, 43Mucocutaneous Total; Week 104; n= 59, 126, 43Immunologic Total; Week 4; n=48, 104, 34Immunologic Total; Week 8; n= 48, 104, 34Immunologic Total; Week 12; n= 48, 104, 34Immunologic Total; Week 16; n= 48, 104, 34Immunologic Total; Week 20; n= 48, 104, 34Immunologic Total; Week 24; n= 48, 104, 34Immunologic Total; Week 26; n= 48, 104, 34Immunologic Total; Week 28; n= 48, 104, 34Immunologic Total; Week 32; n= 48, 104, 34Immunologic Total; Week 36; n= 48, 104, 34Immunologic Total; Week 40; n= 48, 104, 34Immunologic Total; Week 44; n= 48, 104, 34Immunologic Total; Week 48; n= 48, 104, 34Immunologic Total; Week 52; n= 48, 104, 34Immunologic Total; Week 60; n= 48, 104, 34Immunologic Total; Week 64; n= 48, 104, 34Immunologic Total; Week 72; n=48, 104, 34Immunologic Total; Week 80; n=48, 104, 34Immunologic Total; Week 88; n=48, 104, 34Immunologic Total; Week 96; n=48, 104, 34Immunologic Total; Week 104; n=48, 104, 34Hematologic Total; Week 4; n= 8, 19, 3Hematologic Total; Week 8; n= 8, 19, 3Hematologic Total; Week 12; n= 8, 19, 3Hematologic Total; Week 16; n= 8, 19, 3Hematologic Total; Week 20; n= 8, 19, 3Hematologic Total; Week 24; n= 8, 19, 3Hematologic Total; Week 26; n= 8, 19, 3Hematologic Total; Week 28; n= 8, 19, 3Hematologic Total; Week 32; n= 8, 19, 3Hematologic Total; Week 36; n= 8, 19, 3Hematologic Total; Week 40; n= 8, 19, 3Hematologic Total; Week 44; n= 8, 19, 3Hematologic Total; Week 48; n= 8, 19, 3Hematologic Total; Week 52; n= 8, 19, 3Hematologic Total; Week 60; n= 8, 19, 3Hematologic Total; Week 64; n= 8, 19, 3Hematologic Total; Week 72; n= 8, 19, 3Hematologic Total; Week 80; n= 8, 19, 3Hematologic Total; Week 88; n= 8, 19, 3Hematologic Total; Week 96; n= 8, 19, 3Hematologic Total; Week 104; n= 8, 19, 3
Belimumab + Standard Therapy0050.000100010010050.010010050.010010010050.050.010010010023.550.047.167.664.770.673.576.576.576.573.576.573.573.567.667.658.876.567.670.667.612.512.512.512.512.512.525.037.525.050.025.012.550.025.025.012.512.550.025.037.550.032.651.255.867.469.869.865.169.874.469.867.469.869.869.867.462.858.162.867.462.760.517.617.617.611.823.520.611.820.623.517.623.538.229.426.520.626.517.623.514.720.620.6066.733.366.710010010066.766.766.766.766.766.733.333.333.3033.333.333.333.3

Percentage of Participants With SLEDAI-2K Organ Improvement Compared to Baseline by Visits (PI Assessed)

SLEDAI-2K assessments consisted of 24 individual items with 9 organ systems. Each item was given a weighted score(1 to 8 with higher score indicating increased activity)and summed if present at the time of analysis. SLEDAI-2K score was sum of all 24 individual items from SLEDAI-2K ranges from 0(no symptoms) to 105(presence of all defined symptoms). Higher scores indicates increased disease activity. An improvement was defined as a decrease(compared to Baseline) in SLEDAI-2K score within same organ system at a post-Baseline visit. Baseline value was latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Data for following organ systems was reported: CNS total, Vascular total, Musculoskeletal total, Renal total, Mucocutaneous total, Cardiovascular (Cardio) and Respiratory (Resp) total, Immunologic total and Hematologic total. Constitutional organ system was removed from analysis and its one item (fever)moved to hematologic organ system. (NCT03312907)
Timeframe: Baseline (Day 1) and Weeks 4, 8, 12, 16, 20, 24, 26, 28, 32, 36, 40, 44, 48, 52, 60, 64, 72, 80, 88, 96, 104

,
InterventionPercentage of participants (Number)
CNS Total; Week 4; n= 2,3,2CNS Total; Week 8; n= 2,3,2CNS Total; Week 12; n= 2,3,2CNS Total; Week 16; n= 2,3,2CNS Total; Week 20; n= 2,3,2CNS Total; Week 24; n= 2,3,2CNS Total; Week 26; n= 2,3,2CNS Total; Week 28; n= 2,3,2CNS Total; Week 32; n= 2,3,2CNS Total; Week 36; n= 2,3,2CNS Total; Week 40; n= 2,3,2CNS Total; Week 44; n= 2,3,2CNS Total; Week 48; n= 2,3,2CNS Total; Week 52; n= 2,3,2CNS Total; Week 60; n= 2,3,2CNS Total; Week 64; n= 2,3,2CNS Total; Week 72; n= 2,3,2CNS Total; Week 80; n= 2,3,2CNS Total; Week 88; n= 2,3,2CNS Total; Week 96; n= 2,3,2CNS Total; Week 104; n=2,3,2Vascular Total; Week 4; n= 6,11,0Vascular Total; Week 8; n= 6,11,0Vascular Total; Week 12; n= 6,11,0Vascular Total; Week 16; n= 6,11,0Vascular Total; Week 20; n=6,11,0Vascular Total; Week 24; n= 6,11,0Vascular Total; Week 26; n= 6, 11, 0Vascular Total; Week 28; n= 6, 11,0Vascular Total; Week 32; n= 6,11, 0Vascular Total; Week 36; n= 6, 11,0Vascular Total; Week 40; n= 6, 11,0Vascular Total; Week 44; n= 6, 11, 0Vascular Total; Week 48; n= 6, 11, 0Vascular Total; Week 52; n= 6, 11, 0Vascular Total; Week 60; n= 6, 11, 0Vascular Total; Week 64; n= 6, 11, 0Vascular Total; Week 72; n= 6, 11, 0Vascular Total; Week 80; n= 6, 11, 0Vascular Total; Week 88; n= 6, 11, 0Vascular Total; Week 96; n= 6, 11, 0Vascular Total; Week 104; n= 6, 11, 0Musculoskeletal Total; Week 4; n= 57, 110, 34Musculoskeletal Total; Week 8; n=57,110, 34Musculoskeletal Total; Week 12; n= 57,110,34Musculoskeletal Total; Week 16; n= 57,110,34Musculoskeletal Total; Week 20; n= 57,110,34Musculoskeletal Total; Week 24; n= 57,110,34Musculoskeletal Total;; Week 26; n=57,110,34Musculoskeletal Total; Week 28; n= 57,110,34Musculoskeletal Total; Week 32; n= 57,110,34Musculoskeletal Total; Week 36; n= 57,110,34Musculoskeletal Total; Week 40; n= 57,110,34Musculoskeletal Total; Week 44; n= 57,110,34Musculoskeletal Total; Week 48; n= 57,110,34Musculoskeletal Total; Week 52; n= 57,110,34Musculoskeletal Total; Week 60; n= 57,110,34Musculoskeletal Total; Week 64; n= 57,110,34Musculoskeletal Total; Week 72; n= 57,110,34Musculoskeletal Total; Week 80; n= 57,110,34Musculoskeletal Total; Week 88; n= 57,110,34Musculoskeletal Total; Week 96; n= 57,110,34Musculoskeletal Total; Week 104; n= 57,110,34Renal Total; Week 4; n= 14,23,8Renal Total; Week 8; n= 14, 23, 8Renal Total; Week 12; n= 14, 23, 8Renal Total; Week 16; n= 14, 23, 8Renal Total; Week 20; n= 14, 23, 8Renal Total; Week 24; n= 14, 23, 8Renal Total; Week 26; n= 14, 23, 8Renal Total; Week 28; n= 14, 23, 8Renal Total; Week 32; n= 14, 23, 8Renal Total; Week 36; n= 14, 23, 8Renal Total; Week 40; n=14, 23, 8Renal Total; Week 44; n= 14, 23, 8Renal Total; Week 48; n=14, 23, 8Renal Total; Week 52; n= 14, 23, 8Renal Total; Week 60; n= 14, 23, 8Renal Total; Week 64; n= 14, 23, 8Renal Total; Week 72; n= 14, 23, 8Renal Total; Week 80; n= 14, 23, 8Renal Total; Week 88; n= 14, 23, 8Renal Total; Week 96; n= 14, 23, 8Renal Total; Week 104; n= 14, 23, 8Mucocutaneous Total; Week 4; n= 59, 126,43Mucocutaneous Total; Week 8; n= 59,126,43Mucocutaneous Total; Week 12; n= 59, 126, 43Mucocutaneous Total; Week 16; n= 59, 126, 43Mucocutaneous Total; Week 20; n= 59, 126, 43Mucocutaneous Total; Week 24; n= 59, 126, 43Mucocutaneous Total; Week 26; n=59, 126, 43Mucocutaneous Total; Week 28; n= 59, 126, 43Mucocutaneous Total; Week 32; n= 59, 126, 43Mucocutaneous Total; Week 36; n= 59, 126, 43Mucocutaneous Total; Week 40; n= 59, 126, 43Mucocutaneous Total; Week 44; n= 59, 126, 43Mucocutaneous Total; Week 48; n= 59, 126, 43Mucocutaneous Total; Week 52; n=59, 126, 43Mucocutaneous Total; Week 60; n=59, 126, 43Mucocutaneous Total; Week 64; n=59, 126, 43Mucocutaneous Total; Week 72; n=59, 126, 43Mucocutaneous Total; Week 80; n= 59, 126, 43Mucocutaneous Total; Week 88; n= 59, 126, 43Mucocutaneous Total; Week 96; n= 59, 126, 43Mucocutaneous Total; Week 104; n= 59, 126, 43Cardio and Resp Total; Week 4; n= 3, 7, 0Cardio and Resp Total; Week 8; n= 3, 7, 0Cardio and Resp Total; Week 12; n= 3, 7, 0Cardio and Resp Total; Week 16; n= 3, 7, 0Cardio and Resp Total; Week 20; n= 3,7, 0Cardio and Resp Total; Week 24; n= 3, 7, 0Cardio and Resp Total; Week 26; n=3, 7, 0Cardio and Resp Total; Week 28; n= 3,7, 0Cardio and Resp Total; Week 32; n= 3, 7, 0Cardio and Resp Total; Week 36; n= 3, 7, 0Cardio and Resp Total; Week 40; n=3,7, 0Cardio and Resp Total; Week 44; n= 3,7, 0Cardio and Resp Total; Week 48; n= 3, 7, 0Cardio and Resp Total; Week 52; n= 3, 7, 0Cardio and Resp Total; Week 60; n= 3,7,0Cardio and Resp Total; Week 64; n=3,7,0Cardio and Resp Total; Week 72; n= 3,7,0Cardio and Resp Total; Week 80; n=3,7,0Cardio and Resp Total; Week 88; n= 3,7,0Cardio and Resp Total; Week 96; n= 3,7,0Cardio and Resp Total; Week 104; n= 3,7,0Immunologic Total; Week 4; n=48, 104, 34Immunologic Total; Week 8; n= 48, 104, 34Immunologic Total; Week 12; n= 48, 104, 34Immunologic Total; Week 16; n= 48, 104, 34Immunologic Total; Week 20; n= 48, 104, 34Immunologic Total; Week 24; n= 48, 104, 34Immunologic Total; Week 26; n= 48, 104, 34Immunologic Total; Week 28; n= 48, 104, 34Immunologic Total; Week 32; n= 48, 104, 34Immunologic Total; Week 36; n= 48, 104, 34Immunologic Total; Week 40; n= 48, 104, 34Immunologic Total; Week 44; n= 48, 104, 34Immunologic Total; Week 48; n= 48, 104, 34Immunologic Total; Week 52; n= 48, 104, 34Immunologic Total; Week 60; n= 48, 104, 34Immunologic Total; Week 64; n= 48, 104, 34Immunologic Total; Week 72; n=48, 104, 34Immunologic Total; Week 80; n=48, 104, 34Immunologic Total; Week 88; n=48, 104, 34Immunologic Total; Week 96; n=48, 104, 34Immunologic Total; Week 104; n=48, 104, 34Hematologic Total; Week 4; n= 8, 19, 3Hematologic Total; Week 8; n= 8, 19, 3Hematologic Total; Week 12; n= 8, 19, 3Hematologic Total; Week 16; n= 8, 19, 3Hematologic Total; Week 20; n= 8, 19, 3Hematologic Total; Week 24; n= 8, 19, 3Hematologic Total; Week 26; n= 8, 19, 3Hematologic Total; Week 28; n= 8, 19, 3Hematologic Total; Week 32; n= 8, 19, 3Hematologic Total; Week 36; n= 8, 19, 3Hematologic Total; Week 40; n= 8, 19, 3Hematologic Total; Week 44; n= 8, 19, 3Hematologic Total; Week 48; n= 8, 19, 3Hematologic Total; Week 52; n= 8, 19, 3Hematologic Total; Week 60; n= 8, 19, 3Hematologic Total; Week 64; n= 8, 19, 3Hematologic Total; Week 72; n= 8, 19, 3Hematologic Total; Week 80; n= 8, 19, 3Hematologic Total; Week 88; n= 8, 19, 3Hematologic Total; Week 96; n= 8, 19, 3Hematologic Total; Week 104; n= 8, 19, 3
Belimumab + Placebo050.050.050.010010050.010010010010010010010010010010010010010010050.033.350.050.050.050.050.033.350.050.033.333.333.366.750.050.033.350.050.050.033.322.840.436.842.147.442.143.949.154.461.454.450.957.959.654.456.147.447.457.950.947.421.450.028.635.757.135.728.621.435.742.942.950.042.964.350.050.050.042.950.035.735.730.554.255.957.650.859.359.362.762.766.162.761.050.864.455.964.457.662.759.352.561.0000033.366.70033.366.733.366.733.366.710010066.766.766.766.766.712.516.722.920.820.822.918.818.825.020.814.625.020.820.825.020.829.222.931.320.827.150.062.562.575.087.562.575.062.562.587.562.587.537.575.050.062.562.550.037.550.050.0
Belimumab + Rituximab33.366.766.766.766.766.766.766.766.766.766.766.766.766.766.766.733.333.333.333.333.39.136.454.554.572.772.763.672.772.763.672.772.763.663.663.690.981.872.745.563.672.713.640.044.556.458.254.546.453.663.661.858.260.060.959.154.555.558.258.259.160.964.530.443.552.252.260.960.965.256.565.265.269.669.669.669.665.269.665.265.273.978.369.628.645.257.158.762.761.960.362.765.165.966.761.166.764.365.165.960.361.962.762.769.042.971.471.485.771.410085.785.710085.771.457.185.785.771.485.771.485.771.471.471.410.617.324.030.836.534.639.434.640.441.344.239.441.337.545.243.336.531.729.833.740.442.163.252.663.257.952.636.857.957.963.252.657.963.252.657.968.447.452.657.952.663.2

Percentage of Participants With SLEDAI-2K Organ Worsening Compared to Baseline by Visits (PI Assessed)

SLEDAI-2K assessments consisted of 24 individual items with 9 organ systems. Each item was given a weighted score(1 to 8 with higher score indicating increased activity)and summed if present at time of analysis. SLEDAI-2K score was sum of all 24 individual items from SLEDAI-2K, ranges from 0(no symptoms) to 105(presence of all defined symptoms). Higher scores indicates increased disease activity. A worsening was defined as an increase(compared to Baseline) in SLEDAI-2K score within same organ system at a post-Baseline visit. Baseline value was latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Percentage of participants with SLEDAI-2K organ worsening for following organ systems were reported;CNS total,Vascular total,Musculoskeletal total,Renal total,Mucocutaneous total,Cardio and Resp total,Immunologic total and Hematologic total. Constitutional organ system was removed from analysis and its one item (fever)moved to hematologic organ system. (NCT03312907)
Timeframe: Baseline (Day 1) and Weeks 4, 8, 12, 16, 20, 24, 26, 28, 32, 36, 40, 44, 48, 52, 60, 64, 72, 80, 88, 96, 104

,,
InterventionPercentage of participants (Number)
CNS Total; Week 4; n= 69, 136, 43CNS Total; Week 8; n= 64,132, 42CNS Total; Week 12; n= 65, 134, 42CNS Total; Week 16; n= 65, 130, 42CNS Total; Week 20; n= 63, 128, 42CNS Total; Week 24; n= 61, 127, 41CNS Total; Week 26; n=61, 116, 38CNS Total; Week 28; n=62, 124, 41CNS Total; Week 32; n= 61, 124, 41CNS Total; Week 36; n=61, 124, 41CNS Total; Week 40; n=61, 123, 41CNS Total; Week 44; n= 61, 121, 41CNS Total; Week 48; n= 58, 120,39CNS Total; Week 52; n= 62, 120, 38CNS Total; Week 60; n=59, 117, 35CNS Total; Week 64; n=60, 117, 34CNS Total; Week 72; n= 56, 109, 31CNS Total; Week 80; n=55, 111, 35CNS Total; Week 88; n= 57, 107, 34CNS Total; Week 96; n=52, 107, 33CNS Total; Week 104; n= 53, 112, 34Vascular Total;Week 4; n= 65, 128, 45Vascular Total;Week 8; n= 61, 124, 44Vascular Total; Week 12; n= 62, 126, 44Vascular Total; Week 16; n=62, 122, 44Vascular Total; Week 20; n=60, 120, 44Vascular Total; Week 24; n= 59, 119, 43Vascular Total; Week 26; n=58, 109, 40Vascular Total;Week 28; n= 61, 116, 43Vascular Total;Week 32; n=59, 116, 43Vascular Total;Week 36; n= 59, 116, 43Vascular Total;Week 40; n=59, 115, 43Vascular Total;Week 44; n= 59, 113, 43Vascular Total;Week 48; n= 57, 112, 40Vascular Total;Week 52; n=60, 112, 40Vascular Total;Week 60; n= 58, 109, 37Vascular Total;Week 64; n=59, 109, 36Vascular Total;Week 72; n=55, 101, 33Vascular Total;Week 80; n= 54, 104, 37Vascular Total;Week 88; n=56, 102, 36Vascular Total;Week 96; n=51, 101, 35Vascular Total;Week 104; n=53, 105, 36Musculoskeletal Total; Week 4; n=15, 33, 12Musculoskeletal Total; Week 8; n= 15, 33, 12Musculoskeletal Total; Week 12; n= 15, 33, 12Musculoskeletal Total; Week 16; n= 15, 32, 12Musculoskeletal Total; Week 20; n= 15, 32, 12Musculoskeletal Total; Week 24; n= 15, 31, 11Musculoskeletal Total; Week 26; n= 15, 31, 11Musculoskeletal Total; Week 28; n= 14, 31, 11Musculoskeletal Total; Week 32; n= 15, 30, 11Musculoskeletal Total; Week 36; n= 14, 30, 11Musculoskeletal Total; Week 40; n=15, 30, 11Musculoskeletal Total; Week 44; n=15, 29, 11Musculoskeletal Total; Week 48; n= 14, 30, 10Musculoskeletal Total; Week 52; n= 15, 30, 11Musculoskeletal Total; Week 60; n= 14, 28, 11Musculoskeletal Total; Week 64; n=14, 29, 10Musculoskeletal Total; Week 72; n= 14, 27, 10Musculoskeletal Total; Week 80; n= 13, 26, 9Musculoskeletal Total; Week 88; n= 13, 25, 9Musculoskeletal Total; Week 96; n= 12, 26, 9Musculoskeletal Total; Week 104; n= 13, 27, 9Renal Total; Week 4; n= 57, 117, 36Renal Total; Week 8; n=51, 110, 36Renal Total; Week 12; n=53, 115, 35Renal Total; Week 16; n=53, 112, 35Renal Total; Week 20; n= 49, 108, 36Renal Total; Week 24; n= 49, 111, 35Renal Total; Week 26; n= 49, 99, 33Renal Total; Week 28; n= 50, 106, 36Renal Total; Week 32; n= 50,107, 36Renal Total; Week 36; n= 50, 107, 36Renal Total; Week 40; n= 47, 106, 34Renal Total; Week 44; n= 49, 103, 35Renal Total; Week 48; n= 47, 101, 32Renal Total; Week 52; n= 49, 103, 32Renal Total; Week 60; n=47, 96, 30Renal Total; Week 64; n= 50, 99, 29Renal Total; Week 72; n= 40, 89, 26Renal Total; Week 80; n= 41, 90, 29Renal Total; Week 88; n= 44, 85, 29Renal Total; Week 96; n= 43, 85, 29Renal Total; Week 104; n= 44, 90, 30Mucocutaneous Total; Week 4; n= 13, 18, 4Mucocutaneous Total; Week 8; n= 12, 18, 4Mucocutaneous Total; Week 12; n= 12, 18, 4Mucocutaneous Total; Week 16; n= 12, 18, 4Mucocutaneous Total; Week 20; n= 12, 18, 4Mucocutaneous Total; Week 24; n= 11, 17, 4Mucocutaneous Total; Week 26; n= 10, 17, 4Mucocutaneous Total; Week 28; n= 10, 17, 4Mucocutaneous Total; Week 32; n= 10, 17, 4Mucocutaneous Total; Week 36; n= 10, 17, 4Mucocutaneous Total; Week 40; n= 10, 17, 4Mucocutaneous Total; Week 44; n= 10, 17, 4Mucocutaneous Total; Week 48; n=10, 16, 3Mucocutaneous Total; Week 52; n= 10, 17, 4Mucocutaneous Total; Week 60; n= 9, 17, 4Mucocutaneous Total; Week 64; n= 10, 16, 4Mucocutaneous Total; Week 72; n=10, 16, 4Mucocutaneous Total; Week 80; n= 9, 17, 4Mucocutaneous Total; Week 88; n= 9, 16, 4Mucocutaneous Total; Week 96; n= 9, 15, 4Mucocutaneous Total; Week 104; n= 9, 17, 4Cardio and Resp Total; Week 4; n= 68, 132, 45Cardio and Resp Total; Week 8; n= 63, 128, 44Cardio and Resp Total; Week 12; n= 64, 130, 44Cardio and Resp Total; Week 16; n= 64, 126, 44Cardio and Resp Total; Week 20; n= 63, 124, 44Cardio and Resp Total; Week 24; n= 60, 123, 43Cardio and Resp Total; Week 26; n=59, 112, 40Cardio and Resp Total; Week 28; n= 61, 120, 43Cardio and Resp Total; Week 32; n= 60, 120, 43Cardio and Resp Total; Week 36; n= 60, 120, 43Cardio and Resp Total; Week 40; n=60, 119, 43Cardio and Resp Total; Week 44; n= 60, 117, 43Cardio and Resp Total; Week 48; n= 57, 116, 40Cardio and Resp Total; Week 52; n=61, 116, 40Cardio and Resp Total; Week 60; n= 58, 114, 37Cardio and Resp Total; Week 64; n= 59, 114, 36Cardio and Resp Total; Week 72; n= 55, 106, 33Cardio and Resp Total; Week 80; n= 54, 107, 37Cardio and Resp Total; Week 88; n= 56, 104, 36Cardio and Resp Total; Week 96; n=51, 104, 35Cardio and Resp Total; Week 104; n= 52, 109, 36Immunologic Total; Week 4; n=23, 37, 13Immunologic Total; Week 8; n=20, 37, 12Immunologic Total; Week 12; n=21, 37,12Immunologic Total; Week 16; n= 21, 35, 12Immunologic Total; Week 20; n= 19, 35, 12Immunologic Total; Week 24; n= 18, 35, 12Immunologic Total; Week 26; n= 18, 30, 12Immunologic Total; Week 28; n= 19, 35, 12Immunologic Total; Week 32; n= 19, 33, 12Immunologic Total; Week 36; n= 19, 34, 12Immunologic Total; Week 40; n= 19, 33, 12Immunologic Total; Week 44; n= 18, 33, 12Immunologic Total; Week 48; n= 18, 33, 11Immunologic Total; Week 52; n= 19, 32, 12Immunologic Total; Week 60; n= 18, 32, 10Immunologic Total; Week 64; n= 19, 33, 10Immunologic Total; Week 72; n= 17, 28, 9Immunologic Total; Week 80; n= 18, 29, 11Immunologic Total; Week 88; n= 19, 29, 11Immunologic Total; Week 96; n= 16, 30, 11Immunologic Total; Week 104; n= 17, 28, 12Hematologic Total; Week 4; n= 59, 115, 40Hematologic Total; Week 8; n= 52, 109, 38Hematologic Total; Week 12; n= 55, 110, 38Hematologic Total; Week 16; n=54, 107, 34Hematologic Total; Week 20; n= 54, 108, 40Hematologic Total; Week 24; n= 53, 111, 37Hematologic Total; Week 26; n= 53, 101, 37Hematologic Total; Week 28; n= 52, 106, 39Hematologic Total; Week 32; n=52, 110, 38Hematologic Total; Week 36; n= 53, 109, 40Hematologic Total; Week 40; n= 51, 108, 37Hematologic Total; Week 44; n=53, 107, 38Hematologic Total; Week 48; n=51, 105, 35Hematologic Total; Week 52; n= 53, 103, 37Hematologic Total; Week 60; n=53, 101, 35Hematologic Total; Week 64; n=54, 98, 32Hematologic Total; Week 72; n= 47,96, 29Hematologic Total; Week 80; n= 45, 94, 35Hematologic Total; Week 88; n= 46, 88, 32Hematologic Total; Week 96; n= 45, 90, 32Hematologic Total; Week 104; n= 46, 94, 32
Belimumab + Placebo000000000000000000000001.600000000000000000006.713.36.76.700007.1007.16.7000015.4005.32.01.97.58.210.26.110.06.08.06.46.110.68.26.42.05.014.613.64.76.815.48.38.3025.018.220.0010.0020.010.00011.10200011.111.12.9003.11.6003.31.71.701.7000001.91.80017.420.023.89.515.85.65.615.810.515.821.122.222.221.116.721.123.55.610.512.511.85.13.81.81.95.63.89.47.705.707.55.93.89.411.110.6010.94.44.3
Belimumab + Rituximab0000.800.80.900.81.6000000000003.92.41.61.60.800.91.72.61.71.7000.901.801.000012.16.16.13.16.36.53.23.26.73.33.36.93.36.703.411.104.03.806.03.63.54.53.73.601.92.82.84.71.05.93.94.22.04.53.31.21.22.25.611.116.75.65.65.911.811.85.95.911.806.35.911.86.36.306.305.90.80.80.800.8000.800000000.90001.00010.88.111.411.45.76.78.612.18.86.103.03.16.36.17.16.96.913.317.93.55.54.52.85.62.75.03.84.56.410.26.54.83.95.05.15.24.39.14.46.4
Belimumab + Standard Therapy0000000000000000000000000000000000000000000008.30009.19.19.19.19.110.09.19.110.010.011.100011.15.68.62.98.32.902.82.85.602.96.33.10006.9000000000000000025.0025.025.025.025.025.000000000000002.5000000007.7016.70008.316.78.316.78.3027.38.3020.011.118.218.218.216.75.0010.52.95.02.710.85.17.92.55.45.302.75.76.33.45.73.13.16.3

Percentage of Participants With Systemic Lupus International Collaborating Clinics (SLICC) -American College of Rheumatology (ACR) Damage Index Worsening Compared With Baseline at Week 52 and Week 104

The SLICC-ACR Damage Index measures irreversible (not related to active inflammation) changes occurring since the diagnosis of SLE ascertained by clinical assessment and present for at least 6 months. The questionnaire contains 39 items covering 12 different organ systems which were scored on a numerical scale between 0 (no damage) to 7 (increasing disease damage). Individual ranges for organ systems were; ocular: 0-2, neuropsychiatric: 0-6, renal: 0-3, pulmonary: 0-5, cardiovascular:0-6, peripheral vascular: 0-5, gastrointestinal:0-5, musculoskeletal: 0-6, skin: 0-3, endocrine (diabetes): 0-1, gonadal:0-1 and malignancies: 0-2. The SLICC-ACR score was calculated by taking sum of the individual scores for 12 organ systems which ranges from 0 (no damage) to 45 (increasing disease damage) where higher score indicates increasing disease damage severity. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. (NCT03312907)
Timeframe: Baseline (Day 1), Week 52 and Week 104

,,
InterventionPercentage of participants (Number)
Week 52Week 104
Belimumab + Placebo1.45.6
Belimumab + Rituximab2.15.6
Belimumab + Standard Therapy2.16.4

Mean Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Improvement Compared to Placebo.

"Mean change from baseline (from baseline to Day 85; or baseline to Day 169) in CLASI activity scores (Last Observation Carried Forward [LOCF] post censoring values).~The CLASI is a single-page tool that separately quantifies disease activity and damage. For the activity score, points are given for the presence of erythema, scale, mucous membrane lesions, recent hair loss, and inflammatory alopecia. The total score represents the sum of the individual scores and ranges from 0 to 70. Higher scores are awarded for more severe manifestations." (NCT02660944)
Timeframe: Baseline and Days 29, 57, 85, 99, 113, 127, 141, 155, 169

,
InterventionScores on a scale (Mean)
Day 85Day 169
Placebo-6.5-5.7
RSLV-132-6.2-6.2

Percentage of Participants Achieving a 50% Improvement in CLASI Activity Score

Percentage of participants achieving a 50% improvement in CLASI activity score at Day 85 and Day 169 (LOCF post censoring due to use of exclusionary medications) (NCT02660944)
Timeframe: Baseline and Days 29, 57, 85, 99, 113, 127, 141, 155, 169

,
InterventionParticipants (Count of Participants)
Day 85Day 169 All ParticipantsDay 169 Participants with Severe CLASI >/=21Day 169 Participants with Severe SLEDAI >/=9
Placebo2531
RSLV-132111474

Percentage of Participants With a British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) Response

Percentage of participants with a BICLA response on Day 169. This is a composite responder index incorporating the BILAG-2004, SLEDAI-2K and PGA responses. The BILAG-2004 index, an organ-based transitional activity instrument, provides disease activity scorings across nine organ systems (constitutional, mucocutaneous, neuropsychiatry, musculoskeletal, cardiorespiratory, gastrointestinal, ophthalmic, renal and hematological) on an ordinal scale (A to E) based on the physician's intention-to-treat premise. Grade A represents the most active and Grade E the least active disease. The PGA is measured on a 0 to 100 mm scale with score 0 to be No Disease Activity and score 100 to be the most Severe Disease Activity. (NCT02660944)
Timeframe: Baseline and Day 169

,
InterventionParticipants (Count of Participants)
Day 169 All ParticipantsDay 169 Participants with Severe CLASI >/=21Day 169 Participants with Severe SLEDAI >/=9
Placebo411
RSLV-1321054

Percentage of Participants With SRI-4 Response

Percentage of participants with an Systemic Lupus Erythematous Responder Index (SRI) 4 response on Day 169. This is a composite responder index incorporating the British Isles Lupus Assessment Group (BILAG) 2004, SLEDAI-2K and Physician Global Assessment (PGA) responses. The BILAG-2004 index, an organ-based transitional activity instrument, provides disease activity scorings across nine organ systems (constitutional, mucocutaneous, neuropsychiatry, musculoskeletal, cardiorespiratory, gastrointestinal, ophthalmic, renal and hematological) on an ordinal scale (A to E) based on the physician's intention-to-treat premise. Grade A represents the most active and Grade E the least active disease. The Physician's Global Assessment is measured on a 0 to 100 mm scale with score 0 to be No Disease Activity and score 100 to be the most Severe Disease Activity. (NCT02660944)
Timeframe: Baseline and Day 169

,
InterventionParticipants (Count of Participants)
Day 169 All participantsDay 169 Participants with Severe CLASI >/=21Day 169 Participants with Severe SLEDAI >/=9
Placebo714
RSLV-1321178

DBPC Period: Annualized Flare Rate

A flare was defined as either 1 or more new BILAG-2004 A (severe disease activity) or 2 or more new BILAG-2004 B (moderate disease activity) items compared to the previous visit. The occurrence of a new flare was checked for each available visit versus the previous available visit up to Week 52. If no new flares occurred, the number of flares was set to 0. Otherwise all flares were counted leading to the maximum number of flares of 13. The annualized flare rate was calculated as the number of flares divided by the flare exposure time in days multiplied with 365.25 (1 year). The flare exposure time is the time up to Week 52 (date of BILAG-2004 assessment at Week 52) or up to the date of last available BILAG 2004 assessment. (NCT02975336)
Timeframe: Baseline up to Week 52

InterventionAnnualized flare rate ratio (Number)
DBPC Period: Placebo0.15
DBPC Period: M2951 25 mg QD0.23
DBPC Period: M2951 75 mg QD0.13
DBPC Period: M2951 50 mg BID0.19

DBPC Period: Change From Baseline in Total B Cell Count at Week 24

Change from baseline in Total B cell count were assessed. Flow cytometry analysis of lymphocyte populations using four-color fluorescence-activated cell sorting was performed for the analysis of B cell counts. (NCT02975336)
Timeframe: Baseline and Week 24

InterventionCells per microliter (Mean)
DBPC Period: Placebo2
DBPC Period: M2951 25 mg QD5
DBPC Period: M2951 75 mg QD3
DBPC Period: M2951 50 mg BID-7

DBPC Period: Change From Baseline in Total B Cell Count at Week 4

Change from baseline in Total B cell count were assessed. Flow cytometry analysis of lymphocyte populations using four-color fluorescence-activated cell sorting was performed for the analysis of B cell counts. (NCT02975336)
Timeframe: Baseline and Week 4

InterventionCells per microliter (Mean)
DBPC Period: Placebo-5
DBPC Period: M2951 25 mg QD65
DBPC Period: M2951 75 mg QD87
DBPC Period: M2951 50 mg BID67

DBPC Period: Change From Baseline in Total B Cell Count at Week 52

Change from baseline in Total B cell count were assessed. Flow cytometry analysis of lymphocyte populations using four-color fluorescence-activated cell sorting was performed for the analysis of B cell counts. (NCT02975336)
Timeframe: Baseline and Week 52

InterventionCells per microliter (Mean)
DBPC Period: Placebo-14
DBPC Period: M2951 25 mg QD-19
DBPC Period: M2951 75 mg QD-14
DBPC Period: M2951 50 mg BID-52

DBPC Period: Change From Baseline in Total B Cell Count at Week 56

Change from baseline in Total B cell count were assessed. Flow cytometry analysis of lymphocyte populations using four-color fluorescence-activated cell sorting was performed for the analysis of B cell counts. (NCT02975336)
Timeframe: Baseline and Week 56

InterventionCells per microliter (Mean)
DBPC Period: Placebo7
DBPC Period: M2951 25 mg QD-70
DBPC Period: M2951 75 mg QD-75
DBPC Period: M2951 50 mg BID-48

DBPC Period: Cumulative Prednisone Equivalent Corticosteroid (CS) Dose at Week 52

Cumulative Prednisone-equivalent Corticosteroid (CS) Dose was calculated at Week 52. (NCT02975336)
Timeframe: Week 52

InterventionMilligrams (Mean)
DBPC Period: Placebo2267.66
DBPC Period: M2951 25 mg QD2209.46
DBPC Period: M2951 75 mg QD2137.70
DBPC Period: M2951 50 mg BID2205.56

DBPC Period: Mean Absolute Total B Cell Count at Week 24

Mean absolute total B cell count were assessed. Flow cytometry analysis of lymphocyte populations using four-color fluorescence activated cell sorting was performed for the analysis of B cell counts. (NCT02975336)
Timeframe: Week 24

InterventionCells per microliter (Mean)
DBPC Period: Placebo161
DBPC Period: M2951 25 mg QD184
DBPC Period: M2951 75 mg QD204
DBPC Period: M2951 50 mg BID151

DBPC Period: Mean Absolute Total B Cell Count at Week 4

Mean total B cell count were assessed. Flow cytometry analysis of lymphocyte populations using four-color fluorescence activated cell sorting was performed for the analysis of B cell counts. (NCT02975336)
Timeframe: Week 4

InterventionCells per microliter (Mean)
DBPC Period: Placebo150
DBPC Period: M2951 25 mg QD236
DBPC Period: M2951 75 mg QD296
DBPC Period: M2951 50 mg BID229

DBPC Period: Mean Absolute Total B Cell Count at Week 52

Mean absolute total B cell count were assessed. Flow cytometry analysis of lymphocyte populations using four-color fluorescence activated cell sorting was performed for the analysis of B cell counts. (NCT02975336)
Timeframe: Week 52

InterventionCells per microliter (Mean)
DBPC Period: Placebo169
DBPC Period: M2951 25 mg QD167
DBPC Period: M2951 75 mg QD180
DBPC Period: M2951 50 mg BID119

DBPC Period: Mean Absolute Total B Cell Count at Week 56

Mean absolute total B cell count were assessed. Flow cytometry analysis of lymphocyte populations using four-color fluorescence activated cell sorting was performed for the analysis of B cell counts. (NCT02975336)
Timeframe: Week 56

InterventionCells per microliter (Mean)
DBPC Period: Placebo164
DBPC Period: M2951 25 mg QD129
DBPC Period: M2951 75 mg QD156
DBPC Period: M2951 50 mg BID104

DBPC Period: Number of Participants With a Sustained Reduction of Oral Corticosteroids (OCS) Dose to 7.5 mg Prednisone Equivalent Per Day or Less With Response Based on SRI-4 at Week 52 in Serologically Active Subgroup

SRI-4 response was defined as greater than or equal to (>=) 4-point reduction in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) total score, no new British Isles Lupus Assessment Group (BILAG) A and no more than 1 new BILAG B domain score, no worsening (less than 10 percent increase) from baseline in Physician's Global Assessment of Disease Activity (PGA) and no treatment failure. SLEDAI-2K assessment consists of 24 items with total score of 0(no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to Systemic Lupus Erythematosus (SLE), divided into 9 organ systems. For each organ system A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. The PGA assess disease activity on a visual analogue scale = from very well(0)-very poor(100). (NCT02975336)
Timeframe: Week 52

InterventionParticipants (Count of Participants)
DBPC Period: Placebo21
DBPC Period: M2951 25 mg QD25
DBPC Period: M2951 75 mg QD22
DBPC Period: M2951 50 mg BID25

DBPC Period: Number of Participants With a Sustained Reduction of Oral Corticosteroids (OCS) Dose to 7.5 mg Prednisone Equivalent Per Day or Less With Response Based on Systemic Lupus Erythematosus Responder Index 4 (SRI-4) at Week 52

SRI-4 response was defined as greater than or equal to (>=) 4-point reduction in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) total score, no new British Isles Lupus Assessment Group (BILAG) A and no more than 1 new BILAG B domain score, no worsening (less than 10 percent increase) from baseline in Physician's Global Assessment of Disease Activity (PGA) and no treatment failure. SLEDAI-2K assessment consists of 24 items with total score of 0(no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to Systemic Lupus Erythematosus (SLE), divided into 9 organ systems. For each organ system A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. The PGA assess disease activity on a visual analogue scale =from 0(very well) to 100(very poor). (NCT02975336)
Timeframe: Week 52

InterventionParticipants (Count of Participants)
DBPC Period: Placebo43
DBPC Period: M2951 25 mg QD45
DBPC Period: M2951 75 mg QD43
DBPC Period: M2951 50 mg BID41

DBPC Period: Number of Participants With a Sustained Reduction of Oral Corticosteroids (OCS) Dose to 7.5 mg Prednisone Equivalent Per Day or Less With Response Based on Systemic Lupus Erythematosus Responder Index 6 (SRI-6) at Week 52

SRI-6 response was defined as >= 6-point reduction in SLEDAI-2K total score, no new BILAG A and no more than 1 new BILAG B domain score and no worsening (less than 10 percent increase) from baseline in Physician's Global Assessment of Disease Activity (PGA) and treatment failure. SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system :A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. The PGA assess disease activity on a visual analogue scale =from 0(very well) to 100(very poor). (NCT02975336)
Timeframe: Week 52

InterventionParticipants (Count of Participants)
DBPC Period: Placebo18
DBPC Period: M2951 25 mg QD19
DBPC Period: M2951 75 mg QD23
DBPC Period: M2951 50 mg BID15

DBPC Period: Number of Participants With British Isles Lupus Assessment Group (BILAG) 2004 Flare-Free Status During the 52-Week Treatment Period

A participant has a flare-free status if no flare has been reported during the 52-week treatment period. Participants who discontinued treatment prior to Week 52, without having a flare are counted as not being flare free at Week 52. A flare was defined as either 1 or more new BILAG-2004 A (severe disease activity) or 2 or more new BILAG-2004 B (moderate disease activity) items compared to the previous visit. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system based on alphabetic score: A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. (NCT02975336)
Timeframe: up to Week 52

InterventionParticipants (Count of Participants)
DBPC Period: Placebo41
DBPC Period: M2951 25 mg QD35
DBPC Period: M2951 75 mg QD37
DBPC Period: M2951 50 mg BID33

DBPC Period: Number of Participants With Change From Baseline in Prednisone Equivalent Corticosteroid (CS) Dose by >=25% to a Dose of <=7.5 Milligram Per Day (mg/Day), With no BILAG A or 2B Flare in Disease Activity at Week 52

BILAG A or 2B flare is defined as at least one BILAG A grade or two BILAG B grade in any organ system due to items that are new or worse, compared to the BILAG evaluation at the previous visit, during the 52 week treatment period. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to systemic lupus erythematosus (SLE), divided into 9 organ systems. For each organ system based on alphabetic score: A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. (NCT02975336)
Timeframe: Baseline and Week 52

InterventionParticipants (Count of Participants)
DBPC Period: Placebo19
DBPC Period: M2951 25 mg QD23
DBPC Period: M2951 75 mg QD20
DBPC Period: M2951 50 mg BID21

DBPC Period: Number of Participants With Clinically Significant Change From Baseline in Vital Signs

Vital signs included body temperature, systolic and diastolic blood pressure, pulse rate, respiratory rate, weight and height. Clinical significance was determined by the investigator. The number of participants with clinically significant changes from baseline in vital signs were reported. (NCT02975336)
Timeframe: Baseline up to Week 56

InterventionParticipants (Count of Participants)
DBPC Period: Placebo0
DBPC Period: M2951 25 mg QD0
DBPC Period: M2951 75 mg QD0
DBPC Period: M2951 50 mg BID0

DBPC Period: Number of Participants With Clinically Significant Changes From Baseline in 12-Lead Electrocardiogram (ECG) Findings

12-lead ECG recordings included rhythm, heart rate (as measured by RR interval), PR interval, QRS duration, and QT interval. The corrected QT interval (QTcF) was calculated using Fridericia's formula. 12-lead ECG recordings were obtained after the participants have rested for at least 10 minutes in semisupine position. Clinical significance was determined by the investigator. The number of participants with clinically significant changes from baseline in 12-lead ECG findings were reported. (NCT02975336)
Timeframe: Baseline up to Week 56

InterventionParticipants (Count of Participants)
DBPC Period: Placebo0
DBPC Period: M2951 25 mg QD0
DBPC Period: M2951 75 mg QD0
DBPC Period: M2951 50 mg BID0

DBPC Period: Number of Participants With Clinically Significant Changes From Baseline in Laboratory Parameters

Laboratory investigation included hematology, biochemistry, urinalysis and coagulation. Clinical significance was determined by the investigator. The number of participants with clinically significant changes from baseline in laboratory parameters were reported. (NCT02975336)
Timeframe: Baseline up to Week 56

InterventionParticipants (Count of Participants)
DBPC Period: Placebo0
DBPC Period: M2951 25 mg QD0
DBPC Period: M2951 75 mg QD0
DBPC Period: M2951 50 mg BID0

DBPC Period: Number of Participants With Low Disease Activity Status, Defined by Clinical Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K) Score of Less Than or Equal (<= ) 2 at Week 52

Low disease activity is defined as SLEDAI-2K score <=2. SLEDAI-2K is an activity index that measures disease activity and records feature of active lupus as present or not present. SLEDAI-2K uses a weighted checklist to assign a numerical score based on the presence or absence of 24 symptoms at the time of assessment or during the previous 30 days. Each symptom present is assigned between 1 and 8 points based on its usual clinical importance, yielding a total score that ranges from 0 points (no symptoms) to 105 points (presence of all defined symptoms). Clinical SLEDAI-2K score is equal to the SLEDAI-2K score from electronic case report form (eCRF) excluding the components 'Increased Deoxyribonucleic acid (DNA) Binding' and 'Low Complement'. (NCT02975336)
Timeframe: Week 52

InterventionParticipants (Count of Participants)
DBPC Period: Placebo42
DBPC Period: M2951 25 mg QD50
DBPC Period: M2951 75 mg QD52
DBPC Period: M2951 50 mg BID41

DBPC Period: Number of Participants With Low Disease Activity Status, Defined by Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K) Score of Less Than or Equal (<= ) 2 at Week 52

Low disease activity is defined as SLEDAI-2K score <=2. SLEDAI-2K is an activity index that measures disease activity and records feature of active lupus as present or not present. SLEDAI-2K uses a weighted checklist to assign a numerical score based on the presence or absence of 24 symptoms at the time of assessment or during the previous 30 days. Each symptom present is assigned between 1 and 8 points based on its usual clinical importance, yielding a total score that ranges from 0 points (no symptoms) to 105 points (presence of all defined symptoms). (NCT02975336)
Timeframe: Week 52

InterventionParticipants (Count of Participants)
DBPC Period: Placebo26
DBPC Period: M2951 25 mg QD32
DBPC Period: M2951 75 mg QD39
DBPC Period: M2951 50 mg BID28

DBPC Period: Number of Participants With Lupus Low Disease Activity State (LLDAS) at Week 52

Lupus low disease activity state will be measured as: SLEDAI-2K <= 4; No activity in any major organ systems (renal, central nervous system, cardiopulmonary, vasculitis, fever); No new features of disease activity compared with the previous assessment; Prednisone-equivalent <= 7.5 milligram per day; Unchanged background immunosuppressive therapy. (NCT02975336)
Timeframe: Week 52

InterventionParticipants (Count of Participants)
DBPC Period: Placebo29
DBPC Period: M2951 25 mg QD32
DBPC Period: M2951 75 mg QD35
DBPC Period: M2951 50 mg BID29

DBPC Period: Number of Participants With Response Based on BILAG-Based Composite Lupus Assessment (BICLA) at Week 52

BICLA response defined as participants meeting following criteria: [1] At least one gradation of improvement in baseline BILAG scores in all body systems with moderate or severe disease activity at entry (example: all A (severe disease) scores falling to B (moderate), C (mild), or D (no activity) and all B scores falling to C or D; [2] No new BILAG A or more than one new BILAG B scores; [3] No worsening of total SLEDAI-2K score from baseline; [4] No significant deterioration (=<10%) in physician's global assessment and [5] No treatment failure (initiation of non-protocol treatment). (NCT02975336)
Timeframe: Week 52

InterventionParticipants (Count of Participants)
DBPC Period: Placebo30
DBPC Period: M2951 25 mg QD29
DBPC Period: M2951 75 mg QD33
DBPC Period: M2951 50 mg BID24

DBPC Period: Number of Participants With Response Based on Systemic Lupus Erythematosus Responder Index 4 (SRI-4) at Week 52

SRI-4 response was defined as greater than or equal to (>=) 4-point reduction in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) total score, no new British Isles Lupus Assessment Group (BILAG) A and no more than 1 new BILAG B domain score, no worsening (less than 10 percent increase) from baseline in Physician's Global Assessment of Disease Activity (PGA) and no treatment failure. SLEDAI-2K assessment consists of 24 items with total score of 0(no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to Systemic Lupus Erythematosus (SLE) divided into 9 organ systems. For each organ system A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. The PGA assess disease activity on a visual analogue scale =from 0(very well) to 100(very poor). (NCT02975336)
Timeframe: Week 52

InterventionParticipants (Count of Participants)
DBPC Period: Placebo52
DBPC Period: M2951 25 mg QD64
DBPC Period: M2951 75 mg QD60
DBPC Period: M2951 50 mg BID55

DBPC Period: Number of Participants With Response Based on Systemic Lupus Erythematosus Responder Index 4 (SRI-4) at Week 52 in Serologically Active (SA) Subgroup

SRI-4 response was defined as greater than or equal to (>=) 4-point reduction in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) total score, no new British Isles Lupus Assessment Group (BILAG) A and no more than 1 new BILAG B domain score, no worsening (less than 10 percent increase) from baseline in Physician's Global Assessment of Disease Activity (PGA) and no treatment failure. SLEDAI-2K assessment consists of 24 items with total score of 0(no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to Systemic Lupus Erythematosus (SLE), divided into 9 organ systems. For each organ system A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. The PGA assess disease activity on a visual analogue scale =from 0(very well) to 100(very poor). (NCT02975336)
Timeframe: Week 52

InterventionParticipants (Count of Participants)
DBPC Period: Placebo28
DBPC Period: M2951 25 mg QD38
DBPC Period: M2951 75 mg QD29
DBPC Period: M2951 50 mg BID34

DBPC Period: Number of Participants With Response Based on Systemic Lupus Erythematosus Responder Index 6 (SRI-6) at Week 52

SRI-6 response was defined as >= 6-point reduction in SLEDAI-2K total score, no new BILAG A and no more than 1 new BILAG B domain score and no worsening (less than 10 percent increase) from baseline in Physician's Global Assessment of Disease Activity (PGA) and treatment failure. SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system :A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. The PGA assess disease activity on a visual analogue scale =from 0(very well) to 100(very poor). (NCT02975336)
Timeframe: Week 52

InterventionParticipants (Count of Participants)
DBPC Period: Placebo22
DBPC Period: M2951 25 mg QD27
DBPC Period: M2951 75 mg QD30
DBPC Period: M2951 50 mg BID24

DBPC Period: Number of Participants With Response Based on Systemic Lupus Erythematosus Responder Index 6 (SRI-6) at Week 52 in Serologically Active Subgroup

SRI-6 response was defined as >= 6-point reduction in SLEDAI-2K total score, no new BILAG A and no more than 1 new BILAG B domain score and no worsening (less than 10 percent increase) from baseline in Physician's Global Assessment of Disease Activity (PGA) and treatment failure. SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system :A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. The PGA assess disease activity on a visual analogue scale = from 0(very well) to 100(very poor). (NCT02975336)
Timeframe: Week 52

InterventionParticipants (Count of Participants)
DBPC Period: Placebo17
DBPC Period: M2951 25 mg QD25
DBPC Period: M2951 75 mg QD23
DBPC Period: M2951 50 mg BID23

DBPC Period: Time to First British Isles Lupus Assessment Group (BILAG) A or 2B Moderate to Severe Flare

BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system based on alphabetic score: A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. BILAG evaluated by scoring each of a list of signs and symptoms as: improving (1); same (2); worse (3); new (4); not present (0); not done (ND). Total BILAG score is sum of scores of 9 domains where A=12, B=8, C=1, D=0, and E=0. Total score ranges from 0 to 108 with a higher score indicating greater lupus activity. A Moderate to Severe (BILAG A or 2B) flare is defined as at least one BILAG A (severe disease activity) grade or two BILAG B (moderate disease activity) grade in any organ system due to items that are new or worse, compared to the BILAG evaluation at the previous visit, during the 52 week treatment. It was measured using Kaplan-Meier (KM) estimates. (NCT02975336)
Timeframe: Baseline up to Week 56

InterventionDays (Median)
DBPC Period: PlaceboNA
DBPC Period: M2951 25 mg QDNA
DBPC Period: M2951 75 mg QDNA
DBPC Period: M2951 50 mg BIDNA

DBPC Period: Time to First Severe British Isles Lupus Assessment Group (BILAG) A Flare

BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system based on alphabetic score: A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. BILAG evaluated by scoring each of a list of signs and symptoms as: improving (1); same (2); worse (3); new (4); not present (0); not done (ND). Total BILAG score is sum of scores of 9 domains where A=12, B=8, C=1, D=0, and E=0. Total score ranges from 0 to 108 with a higher score indicating greater lupus activity. Time to first severe flare, where a severe flare is defined as at least one BILAG A (Severe disease activity) score in any organ system due to items that are new or worse, compared to the BILAG evaluation at the previous visit, during the 52-Week Treatment. It was measured using Kaplan-Meier (KM) estimates. (NCT02975336)
Timeframe: Baseline up to Week 56

InterventionDays (Median)
DBPC Period: PlaceboNA
DBPC Period: M2951 25 mg QDNA
DBPC Period: M2951 75 mg QDNA
DBPC Period: M2951 50 mg BIDNA

DBPC Period: Change From Baseline in British Isles Lupus Assessment Group (BILAG)-2004 Score at Week 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

BILAG 2004 disease activity Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system based on alphabetic score: A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. BILAG evaluated by scoring each of a list of signs and symptoms as: improving (1); same (2); worse (3); new (4); not present (0); not done (ND). Total BILAG score is sum of scores of 9 domains where A=12, B=8, C=1, D=0, and E=0. Total score ranges from 0 to 108 with a higher score indicating greater lupus activity. (NCT02975336)
Timeframe: Baseline, Week 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

,,,
InterventionUnits on a Scale (Mean)
Week 4Week 8Week 12Week 16Week 20Week 24Week 28Week 32Week 36Week 40Week 44Week 48Week 52
DBPC Period: M2951 25 mg QD-4-5-7-7-7-7-8-8-8-8-9-8-9
DBPC Period: M2951 50 mg BID-4-6-6-6-6-6-7-7-7-7-7-7-7
DBPC Period: M2951 75 mg QD-3-6-6-6-7-8-8-8-8-9-9-9-9
DBPC Period: Placebo-4-6-7-7-7-8-8-9-8-9-9-8-8

DBPC Period: Change From Baseline in Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) Score at Week 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

CLASI is an validated measurement instrument for lupus erythematosus developed for use in clinical studies that consists of separate scores for the activity of the disease (CLASI-A). The CLASI activity score is calculated on the basis of erythema, scale/hyperkeratosis, mucous membrane involvement, acute hair loss and non-scarring alopecia. The CLASI activity score ranges from 0-70, with higher scores indicating more severe skin disease. Severity categories based on the CLASI activity score are as follows: mild (0-9), moderate (10-20), and severe (21-70). (NCT02975336)
Timeframe: Baseline, Week 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

,,,
InterventionUnits on a Scale (Mean)
Week 2Week 4Week 8Week 12Week 16Week 20Week 24Week 28Week 32Week 36Week 40Week 44Week 48Week 52
DBPC Period: M2951 25 mg QD-1-1-1-2-2-3-3-3-3-3-3-3-3-4
DBPC Period: M2951 50 mg BID0-1-1-2-2-2-2-2-3-3-3-3-3-3
DBPC Period: M2951 75 mg QD0-1-1-2-2-3-3-3-3-3-3-3-3-3
DBPC Period: Placebo-1-1-2-2-2-3-3-3-3-3-3-3-3-3

DBPC Period: Change From Baseline in European Quality of Life 5-dimensions (EQ-5D-5L) Health Outcome Questionnaire at Week 4, 8, 12, 16, 24, 32, 40 and 52

The EQ-5D-5L questionnaire is a generic measure of health status that provides a simple descriptive profile and a single index value. The EQ-5D-5L profile defines health in terms of mobility, self-care, usual activities, pain or discomfort, and anxiety or depression. Each dimension has five levels: 1: no problems, 2: slight problems, 3: moderate problems, 4: severe problems, and 5: extreme problems. Responses were used to generate a weighted summary index (EQ-5D index), which ranges from 0 (dead) to 1.00 (perfect health). A higher score indicates better health and positive changes from baseline indicate improvement of health. (NCT02975336)
Timeframe: Baseline, Week 4, 8, 12, 16, 24, 32, 40, and 52

,,,
InterventionUnits on a Scale (Mean)
Week 4Week 8Week 12Week 16Week 24Week 32Week 40Week 52
DBPC Period: M2951 25 mg QD0.0450.0640.0700.0720.0670.0670.0610.078
DBPC Period: M2951 50 mg BID0.0380.0610.0650.0560.0550.0710.0840.096
DBPC Period: M2951 75 mg QD0.0360.0460.0550.0670.0860.0750.0900.102
DBPC Period: Placebo0.0360.0340.0610.0830.0800.0830.0930.096

DBPC Period: Change From Baseline in European Quality of Life 5-dimensions (EQ-5D-5L) Visual Analog Scale (VAS) at Week 4, 8, 12, 16, 24, 32, 40 and 52

The EQ-5D-5L questionnaire is a generic measure of health status that provides a simple descriptive profile and a single index value. The EQ-5D-5L profile defines health in terms of mobility, self-care, usual activities, pain or discomfort, and anxiety or depression. Each dimension has five levels: 1: no problems, 2: slight problems, 3: moderate problems, 4: severe problems, and 5: extreme problems. The responses were used to derive overall score using a visual analog scale (VAS) that ranged from 0 to 100 millimeter (mm), where 0 was the worst health you can imagine and 100 was the best health you can imagine. (NCT02975336)
Timeframe: Baseline, Week 4, 8, 12, 16, 24, 32, 40, and 52

,,,
InterventionMillimeter (Mean)
Week 4Week 8Week 12Week 16Week 24Week 32Week 40Week 52
DBPC Period: M2951 25 mg QD26655468
DBPC Period: M2951 50 mg BID464447810
DBPC Period: M2951 75 mg QD4456971010
DBPC Period: Placebo33577888

DBPC Period: Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score at Week 4, 8, 12, 16, 24, 32, 40 and 52

The FACIT-Fatigue score was calculated according to a 13-item questionnaire that assess self reported fatigue and its impact upon daily activities and function. It uses a 5-point Likert-type scale (0 = not at all; 1 = a little bit; 2 = somewhat; 3 = quite a bit; 4 = very much). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse possible score) to 52 (best score). A higher score reflected an improvement in the participant's health status. (NCT02975336)
Timeframe: Baseline, Week 4, 8, 12, 16, 24, 32, 40, and 52

,,,
InterventionUnits on a scale (Mean)
Week 4Week 8Week 12Week 16Week 24Week 32Week 40Week 52
DBPC Period: M2951 25 mg QD23434434
DBPC Period: M2951 50 mg BID35433445
DBPC Period: M2951 75 mg QD43345565
DBPC Period: Placebo33343444

DBPC Period: Change From Baseline in Lupus Quality of Life (LupusQoL) Questionnaire Score at Week 4, 8, 12, 16, 24, 32, 40 and 52

The Lupus QoL assessment is a 34 item questionnaire across 8 domains that is designed to find out how systemic lupus erythematosus (SLE) affects a participant's life. Domains include physical health, pain, planning, intimate relationships, burden to others, emotional health, body image, and fatigue. Participants indicate their responses on a 5-point Likert response format, where 4=never, 3=occasionally, 2= a good bit of the time, 1=most of the time, and 0=worst of the time. Summary scores can be calculated for all 8 domains. A LupusQoL score for each domain was reported on a 0 to 100 scale, with greater values indicating better health related QoL. (NCT02975336)
Timeframe: Baseline, Week 4, 8, 12, 16, 24, 32, 40, and 52

,,,
InterventionUnits on a scale (Mean)
Physical Health Week 4Physical Health Week 8Physical Health Week 12Physical Health Week 16Physical Health Week 24Physical Health Week 32Physical Health Week 40Physical Health Week 52Pain Week 4Pain Week 8Pain Week 12Pain Week 16Pain Week 24Pain Week 32Pain Week 40Pain Week 52Planning Week 4Planning Week 8Planning Week 12Planning Week 16Planning Week 24Planning Week 32Planning Week 40Planning Week 52Intimate Relationship Week 4Intimate Relationship Week 8Intimate Relationship Week 12Intimate Relationship Week 16Intimate Relationship Week 24Intimate Relationship Week 32Intimate Relationship Week 40Intimate Relationship Week 52Burden to Others Week 4Burden to Others Week 8Burden to Others Week 12Burden to Others Week 16Burden to Others Week 24Burden to Others Week 32Burden to Others Week 40Burden to Others Week 52Emotional Health Week 4Emotional Health Week 8Emotional Health Week 12Emotional Health Week 16Emotional Health Week 24Emotional Health Week 32Emotional Health Week 40Emotional Health Week 52Body Image Week 4Body Image Week 8Body Image Week 12Body Image Week 16Body Image Week 24Body Image Week 32Body Image Week 40Body Image Week 52Fatigue Week 4Fatigue Week 8Fatigue Week 12Fatigue Week 16Fatigue Week 24Fatigue Week 32Fatigue Week 40Fatigue Week 52
DBPC Period: M2951 25 mg QD4.76.36.76.17.26.78.29.06.79.98.88.39.39.210.912.94.98.45.85.38.17.67.87.01.64.24.71.62.11.36.64.45.29.36.78.19.06.812.410.74.77.07.67.55.64.38.36.48.47.57.17.610.28.18.29.84.37.15.86.64.83.76.14.5
DBPC Period: M2951 50 mg BID3.54.65.76.26.17.07.17.95.76.75.56.96.28.79.69.64.63.95.16.35.66.98.010.53.23.76.44.25.31.47.88.92.28.07.37.45.88.412.110.51.85.34.76.24.36.06.77.64.06.56.65.76.75.89.07.83.94.55.04.13.64.15.36.7
DBPC Period: M2951 75 mg QD4.03.85.67.48.49.49.611.69.07.39.810.513.012.815.314.95.45.86.86.511.59.911.69.94.79.72.33.86.76.56.48.46.85.77.46.711.89.612.413.04.22.34.97.48.99.07.68.22.5-1.32.3-0.45.83.34.65.16.24.97.37.19.08.511.011.2
DBPC Period: Placebo1.92.84.86.66.95.77.67.13.64.87.59.49.46.711.010.24.85.57.88.37.96.59.09.93.48.25.58.86.42.512.07.45.85.68.611.810.310.616.115.36.44.56.38.37.16.38.48.53.15.76.56.76.75.17.76.64.45.06.77.77.57.011.38.9

DBPC Period: Change From Baseline in Physician's Global Assessment (PGA) Score at Week 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

The Physician's Global Assessment of Disease Activity was recorded using the 100 millimeter horizontal Visual Analog Scale (VAS). Physician rated participant's disease activity on a scale ranged from 0-100 millimeter (mm), where 0 indicated no disease activity and 100 represented maximum disease activity. (NCT02975336)
Timeframe: Baseline, Week 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

,,,
InterventionMillimeter (Mean)
Week 4Week 8Week 12Week 16Week 20Week 24Week 28Week 32Week 36Week 40Week 44Week 48Week 52
DBPC Period: M2951 25 mg QD-8-14-18-20-21-24-26-26-26-27-28-29-31
DBPC Period: M2951 50 mg BID-9-14-18-19-20-21-24-26-26-25-26-28-27
DBPC Period: M2951 75 mg QD-9-13-19-21-24-25-26-26-29-30-30-32-33
DBPC Period: Placebo-8-13-18-21-23-24-26-26-26-27-28-29-29

DBPC Period: Change From Baseline in Serum Immunoglobulin (Ig) Levels (IgG, IgA, IgM) at Week 12

Change from baseline in the serum levels of IgG, IgA, IgM were assessed. (NCT02975336)
Timeframe: Baseline and Week 12

,,,
Interventiongram per liter (g/L) (Mean)
IgGIgAIgM
DBPC Period: M2951 25 mg QD-0.62-0.02-0.20
DBPC Period: M2951 50 mg BID-0.93-0.03-0.20
DBPC Period: M2951 75 mg QD-0.720.06-0.18
DBPC Period: Placebo-0.360.00-0.01

DBPC Period: Change From Baseline in Serum Immunoglobulin (Ig) Levels (IgG, IgA, IgM) at Week 2

Change from baseline in the serum levels of IgG, IgA, IgM were assessed. (NCT02975336)
Timeframe: Baseline and Week 2

,,,
Interventiongram per liter (g/L) (Mean)
IgGIgAIgM
DBPC Period: M2951 25 mg QD-0.06-0.04-0.05
DBPC Period: M2951 50 mg BID-0.40-0.03-0.07
DBPC Period: M2951 75 mg QD-0.15-0.01-0.04
DBPC Period: Placebo-0.51-0.110.00

DBPC Period: Change From Baseline in Serum Immunoglobulin (Ig) Levels (IgG, IgA, IgM) at Week 24

Change from baseline in the serum levels of IgG, IgA, IgM were assessed. (NCT02975336)
Timeframe: Baseline and Week 24

,,,
Interventiongram per liter (g/L) (Mean)
IgGIgAIgM
DBPC Period: M2951 25 mg QD0.110.14-0.23
DBPC Period: M2951 50 mg BID-0.570.04-0.25
DBPC Period: M2951 75 mg QD-0.460.19-0.23
DBPC Period: Placebo-0.210.06-0.01

DBPC Period: Change From Baseline in Serum Immunoglobulin (Ig) Levels (IgG, IgA, IgM) at Week 36

Change from baseline in the serum levels of IgG, IgA, IgM were assessed. (NCT02975336)
Timeframe: Baseline and Week 36

,,,
Interventiongram per liter (g/L) (Mean)
IgGIgAIgM
DBPC Period: M2951 25 mg QD0.020.22-0.25
DBPC Period: M2951 50 mg BID-0.690.08-0.28
DBPC Period: M2951 75 mg QD-0.430.24-0.25
DBPC Period: Placebo-0.15-0.02-0.04

DBPC Period: Change From Baseline in Serum Immunoglobulin (Ig) Levels (IgG, IgA, IgM) at Week 4

Change from baseline in the serum levels of IgG, IgA, IgM were assessed. (NCT02975336)
Timeframe: Baseline and Week 4

,,,
Interventiongram per liter (g/L) (Mean)
IgGIgAIgM
DBPC Period: M2951 25 mg QD-0.16-0.04-0.09
DBPC Period: M2951 50 mg BID-0.45-0.03-0.08
DBPC Period: M2951 75 mg QD-0.240.03-0.07
DBPC Period: Placebo-0.26-0.010.01

DBPC Period: Change From Baseline in Serum Immunoglobulin (Ig) Levels (IgG, IgA, IgM) at Week 52

Change from baseline in the serum levels of IgG, IgA, IgM were assessed. (NCT02975336)
Timeframe: Baseline and Week 52

,,,
Interventiongram per liter (g/L) (Mean)
IgGIgAIgM
DBPC Period: M2951 25 mg QD0.290.32-0.25
DBPC Period: M2951 50 mg BID-0.310.18-0.33
DBPC Period: M2951 75 mg QD0.350.39-0.21
DBPC Period: Placebo0.410.19-0.02

DBPC Period: Change From Baseline in Serum Immunoglobulin (Ig) Levels (IgG, IgA, IgM) at Week 56

Change from baseline in the serum levels of IgG, IgA, IgM were assessed. (NCT02975336)
Timeframe: Baseline and Week 56

,,,
Interventiongram per liter (g/L) (Mean)
IgGIgAIgM
DBPC Period: M2951 25 mg QD1.060.48-0.15
DBPC Period: M2951 50 mg BID-0.400.26-0.21
DBPC Period: M2951 75 mg QD0.740.35-0.11
DBPC Period: Placebo0.740.230.01

DBPC Period: Change From Baseline in Study 36-Item Short Form Health Survey Version 2 (SF-36v2) Physical Component Summary Score and Mental Component Summary Scores at Week 4, 8, 12, 16, 24, 32, 40 and 52

The 36-Item Short-Form Health Survey (SF-36) was a standardized survey evaluating 8 aspects of functional health and well-being. These eight subscales were summarized as relating to either physical health or mental health. Physical component summary (PCS) was based primarily on physical functioning, role-physical, bodily pain, and general health scales and mental component summary (MCS) encompasses vitality, social functioning, role-emotional, and mental health scales. Score from mental health, role emotional, social functioning, and vitality domains were averaged to calculate MCS. Total score range for MCS was 0 - 100 (100 = highest level of mental functioning). Score from physical function, role physical, bodily pain, and general health domains were averaged to calculate PCS. Total score range for PCS was 0-100 (100 = highest level of physical functioning). (NCT02975336)
Timeframe: Baseline, Week 4, 8, 12, 16, 24, 32, 40 and 52

,,,
InterventionUnits on a Scale (Mean)
Physical Component Summary Score at Week 4Physical Component Summary Score at Week 8Physical Component Summary Score at Week 12Physical Component Summary Score at Week 16Physical Component Summary Score at Week 24Physical Component Summary Score at Week 32Physical Component Summary Score at Week 40Physical Component Summary Score at Week 52Mental Component Summary Score at Week 4Mental Component Summary Score at Week 8Mental Component Summary Score at Week 12Mental Component Summary Score at Week 16Mental Component Summary Score at Week 24Mental Component Summary Score at Week 32Mental Component Summary Score at Week 40Mental Component Summary Score at Week 52
DBPC Period: M2951 25 mg QD2.53.53.74.04.63.84.65.41.72.23.12.52.41.81.51.7
DBPC Period: M2951 50 mg BID2.22.23.03.42.83.84.14.82.43.62.92.92.74.34.04.6
DBPC Period: M2951 75 mg QD3.53.04.24.45.45.45.76.51.91.60.82.83.42.83.23.9
DBPC Period: Placebo1.21.82.43.33.43.54.23.73.92.53.13.62.93.54.53.8

DBPC Period: Change From Baseline in Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K) Score at Week 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

SLEDAI-2K is an activity index that measures disease activity and records feature of active lupus as present or not present. SLEDAI-2K uses a weighted checklist to assign a numerical score based on the presence or absence of 24 symptoms at the time of assessment or during the previous 30 days. Each symptom present is assigned between 1 and 8 points based on its usual clinical importance, yielding a total score that ranges from 0 points (no symptoms) to 105 points (presence of all defined symptoms). (NCT02975336)
Timeframe: Baseline, Week 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

,,,
InterventionUnits on a Scale (Mean)
Week 4Week 8Week 12Week 16Week 20Week 24Week 28Week 32Week 36Week 40Week 44Week 48Week 52
DBPC Period: M2951 25 mg QD-1-2-3-3-4-4-4-4-5-5-5-5-5
DBPC Period: M2951 50 mg BID-1-2-3-3-4-3-4-4-4-4-4-5-5
DBPC Period: M2951 75 mg QD0-2-3-3-4-4-4-4-5-5-5-5-5
DBPC Period: Placebo-1-2-3-4-4-4-4-4-4-5-4-4-5

DBPC Period: Change From Baseline to Week 52 in Prednisone Equivalent Corticosteroid (CS) Daily Dose at at Week 1, 2, 4, 6, 8, 10, 12, 14, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

Change From Baseline in Prednisone-equivalent CS Daily Dose at Week 1, 2, 4, 6, 8, 10, 12, 14, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52 were reported. (NCT02975336)
Timeframe: Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

,,,
InterventionMilligram (mg) (Mean)
Week 1Week 2Week 4Week 6Week 8Week 10Week 12Week 14Week 16Week 20Week 24Week 28Week 32Week 36Week 40Week 44Week 48Week 52
DBPC Period: M2951 25 mg QD0.00-0.07-0.45-0.64-1.24-2.04-1.85-2.70-2.70-2.82-2.64-2.97-3.13-3.31-3.21-3.21-3.22-2.94
DBPC Period: M2951 50 mg BID0.00-0.13-0.15-0.70-1.02-2.50-1.97-2.76-2.40-2.53-2.34-2.46-2.44-2.37-2.67-2.56-2.62-2.63
DBPC Period: M2951 75 mg QD0.000.00-0.04-0.59-1.09-1.56-1.73-1.87-2.47-2.64-2.61-3.07-3.18-3.18-3.24-3.27-3.37-3.09
DBPC Period: Placebo0.210.100.01-1.07-0.57-1.43-1.26-2.00-1.67-1.94-1.99-2.23-2.45-2.42-2.08-2.42-2.38-1.70

DBPC Period: Mean Absolute Value of Serum Immunoglobulin (Ig) Levels (IgG, IgA, IgM) at Week 12

Mean absolute value of serum levels of IgG, IgA, IgM were assessed at Week 12. (NCT02975336)
Timeframe: Week 12

,,,
Interventiongram per liter (g/L) (Mean)
IgG:IgAIgM
DBPC Period: M2951 25 mg QD12.922.731.05
DBPC Period: M2951 50 mg BID12.382.681.02
DBPC Period: M2951 75 mg QD13.642.880.95
DBPC Period: Placebo14.912.721.11

DBPC Period: Mean Absolute Value of Serum Immunoglobulin (Ig) Levels (IgG, IgA, IgM) at Week 2

Mean absolute value of serum levels of IgG, IgA, IgM were assessed at Week 2. (NCT02975336)
Timeframe: Week 2

,,,
Interventiongram per liter (g/L) (Mean)
IgGIgAIgM
DBPC Period: M2951 25 mg QD13.752.751.22
DBPC Period: M2951 50 mg BID12.812.661.18
DBPC Period: M2951 75 mg QD14.372.781.09
DBPC Period: Placebo14.562.621.12

DBPC Period: Mean Absolute Value of Serum Immunoglobulin (Ig) Levels (IgG, IgA, IgM) at Week 24

Mean absolute value of serum levels of IgG, IgA, IgM were assessed at Week 24. (NCT02975336)
Timeframe: Week 24

,,,
Interventiongram per liter (g/L) (Mean)
IgGIgAIgM
DBPC Period: M2951 25 mg QD13.752.891.01
DBPC Period: M2951 50 mg BID12.862.780.98
DBPC Period: M2951 75 mg QD13.792.980.89
DBPC Period: Placebo15.012.791.07

DBPC Period: Mean Absolute Value of Serum Immunoglobulin (Ig) Levels (IgG, IgA, IgM) at Week 36

Mean absolute value of serum levels of IgG, IgA, IgM were assessed at Week 36. (NCT02975336)
Timeframe: Week 36

,,,
Interventiongram per liter (g/L) (Mean)
IgGIgAIgM
DBPC Period: M2951 25 mg QD13.542.891.01
DBPC Period: M2951 50 mg BID12.652.860.95
DBPC Period: M2951 75 mg QD13.673.010.85
DBPC Period: Placebo14.812.721.06

DBPC Period: Mean Absolute Value of Serum Immunoglobulin (Ig) Levels (IgG, IgA, IgM) at Week 4

Mean absolute value of serum levels of IgG, IgA, IgM were assessed at Week 4. (NCT02975336)
Timeframe: Week 4

,,,
Interventiongram per liter (g/L) (Mean)
IgGIgAIgM
DBPC Period: M2951 25 mg QD13.602.731.18
DBPC Period: M2951 50 mg BID12.732.641.16
DBPC Period: M2951 75 mg QD14.212.821.06
DBPC Period: Placebo14.922.711.12

DBPC Period: Mean Absolute Value of Serum Immunoglobulin (Ig) Levels (IgG, IgA, IgM) at Week 52

Mean absolute value of serum levels of IgG, IgA, IgM were assessed at Week 52 (NCT02975336)
Timeframe: Week 52

,,,
Interventiongram per liter (g/L) (Mean)
IgGIgAIgM
DBPC Period: M2951 25 mg QD13.902.950.94
DBPC Period: M2951 50 mg BID13.012.950.96
DBPC Period: M2951 75 mg QD14.323.170.82
DBPC Period: Placebo15.212.821.08

DBPC Period: Mean Absolute Value of Serum Immunoglobulin (Ig) Levels (IgG, IgA, IgM) at Week 56

Mean absolute value of serum levels of IgG, IgA, IgM were assessed at Week 56 (NCT02975336)
Timeframe: Week 56

,,,
Interventiongram per liter (g/L) (Mean)
IgGIgAIgM
DBPC Period: M2951 25 mg QD14.253.011.01
DBPC Period: M2951 50 mg BID13.123.031.31
DBPC Period: M2951 75 mg QD14.252.890.95
DBPC Period: Placebo14.822.951.11

DBPC Period: Number of Participants With Reduction From Baseline in Prednisone Equivalent Corticosteroid (CS) Daily Dose by > 0 to 25%, >25% to 50%, >50% to 100% or an Increase at Week 1, 2, 4, 6, 8, 10, 12, 14, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

Number of Participants With Reduction From Baseline in Prednisone-equivalent Corticosteroid (CS) Daily Dose by > 0 to 25%, >25% to 50%, >50% to 100% or an Increase at Week 1, 2, 4, 6, 8, 10, 12, 14, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52 were reported. (NCT02975336)
Timeframe: Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52

,,,
InterventionParticipants (Count of Participants)
Reduction of dose by >0-25% Week 1Reduction of dose by >0-25% Week 2Reduction of dose by >0-25% Week 4Reduction of dose by >0-25% Week 6Reduction of dose by >0-25% Week 8Reduction of dose by >0-25% Week 10Reduction of dose by >0-25% Week 12Reduction of dose by >0-25% Week 14Reduction of dose by >0-25% Week 16Reduction of dose by >0-25% Week 20Reduction of dose by >0-25% Week 24Reduction of dose by >0-25% Week 28Reduction of dose by >0-25% Week 32Reduction of dose by >0-25% Week 36Reduction of dose by >0-25% Week 40Reduction of dose by >0-25% Week 44Reduction of dose by >0-25% Week 48Reduction of dose by >0-25% Week 52Reduction of dose by >25- 50% Week 1Reduction of dose by >25- 50% Week 2Reduction of dose by >25- 50% Week 4Reduction of dose by >25- 50% Week 6Reduction of dose by >25- 50% Week 8Reduction of dose by >25- 50% Week 10Reduction of dose by >25- 50% Week 12Reduction of dose by >25- 50% Week 14Reduction of dose by >25- 50% Week 16Reduction of dose by >25- 50% Week 20Reduction of dose by >25- 50% Week 24Reduction of dose by >25- 50% Week 28Reduction of dose by >25- 50% Week 32Reduction of dose by >25- 50% Week 36Reduction of dose by >25- 50% Week 40Reduction of dose by >25- 50% Week 44Reduction of dose by >25- 50% Week 48Reduction of dose by >25- 50% Week 52Reduction of dose by >50-100% Week 1Reduction of dose by >50-100% Week 2Reduction of dose by >50-100% Week 4Reduction of dose by >50-100% Week 6Reduction of dose by >50-100% Week 8Reduction of dose by >50-100% Week 10Reduction of dose by >50-100% Week 12Reduction of dose by >50-100% Week 14Reduction of dose by >50-100% Week 16Reduction of dose by >50-100% Week 20Reduction of dose by >50-100% Week 24Reduction of dose by >50-100% Week 28Reduction of dose by >50-100% Week 32Reduction of dose by >50-100% Week 36Reduction of dose by >50-100% Week 40Reduction of dose by >50-100% Week 44Reduction of dose by >50-100% Week 48Reduction of dose by >50-100% Week 52Increased from Baseline Week 1Increased from Baseline Week 2Increased from Baseline Week 4Increased from Baseline Week 6Increased from Baseline Week 8Increased from Baseline Week 10Increased from Baseline Week 12Increased from Baseline Week 14Increased from Baseline Week 16Increased from Baseline Week 20Increased from Baseline Week 24Increased from Baseline Week 28Increased from Baseline Week 32Increased from Baseline Week 36Increased from Baseline Week 40Increased from Baseline Week 44Increased from Baseline Week 48Increased from Baseline Week 52
DBPC Period: M2951 25 mg QD02546311210101087555550021969612119121113151514120011336613131414161715151517001111101000000000
DBPC Period: M2951 50 mg BID001465656554333334000051015816141316161516161717011134679111111121111101012000000000001111112
DBPC Period: M2951 75 mg QD00235484555544334400126410298898666670000436713141315161818181919001010101000000000
DBPC Period: Placebo011360525542111101001457147161312141515151515160001121557791110101099122121111000001002

DBPC Period: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs According to National Cancer Institute-Common Terminology Criteria for Adverse Events Version 4.03 (NCI-CTCAE v4.03)

Adverse event (AE) was defined as any untoward medical occurrence in a participant, which does not necessarily have causal relationship with treatment. A serious AE was defined as an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged in participant hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs: events between first dose of study drug that were absent before treatment/that worsened relative to pre-treatment state up to 56 weeks. TEAEs included both serious TEAEs and non-serious TEAEs. Number of participants with TEAEs and serious TEAEs were reported. (NCT02975336)
Timeframe: Baseline up to Week 56

,,,
InterventionParticipants (Count of Participants)
Any TEAEsAny serious TEAE
DBPC Period: M2951 25 mg QD10313
DBPC Period: M2951 50 mg BID999
DBPC Period: M2951 75 mg QD10011
DBPC Period: Placebo9610

DBPC Period: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) by Severity According to National Cancer Institute-Common Terminology Criteria for Adverse Events Version 4.03 (NCI-CTCAE v4.03)

Severity of TEAEs were graded using NCI-CTCAE v4.03 toxicity grades, as follows: Grade 1= Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Life-threatening and Grade 5 = Death. Number of participants with TEAEs by severity were reported. (NCT02975336)
Timeframe: Baseline up to Week 56

,,,
InterventionParticipants (Count of Participants)
Grade 1Grade 2Grade 3Grade 4Grade 5
DBPC Period: M2951 25 mg QD80772911
DBPC Period: M2951 50 mg BID76782120
DBPC Period: M2951 75 mg QD79722401
DBPC Period: Placebo76632410

DBPC Period: Number of Participants With Patient Global Impression of Change (PGIC) Scale Score of Any Improvement, no Change and Any Worsening

The PGIC is a self-rated scale that asks the participant to describe the change in activity limitations, symptoms, emotions, and overall quality of life (QoL) related to the participants painful condition on the following scale: 1 (very much improved), 2 (much improved), 3 (minimally improved), 4 (no change), 5 (minimally worse), 6 (much worse) and 7 (very much worse). Number of participants in the PGIC categories of any improvement (that is PGIC scale score 1, 2 or 3), no change (that is PGIC scale score 4) and any worsening (that is PGIC scale score 5, 6 or 7) are reported. (NCT02975336)
Timeframe: Week 4, 8, 12, 16, 24, 32, 40, and 52

InterventionParticipants (Count of Participants)
Week 472538922Week 472538923Week 472538925Week 472538924Week 872538923Week 872538924Week 872538922Week 872538925Week 1272538922Week 1272538923Week 1272538924Week 1272538925Week 1672538922Week 1672538923Week 1672538925Week 1672538924Week 2472538922Week 2472538923Week 2472538924Week 2472538925Week 3272538922Week 3272538923Week 3272538925Week 3272538924Week 4072538922Week 4072538923Week 4072538925Week 4072538924Week 5272538922Week 5272538923Week 5272538924Week 5272538925
MissingAny ImprovementNo ChangeAny Worsening
DBPC Period: Placebo69
DBPC Period: M2951 25 mg QD78
DBPC Period: M2951 50 mg BID71
DBPC Period: Placebo33
DBPC Period: M2951 25 mg QD27
DBPC Period: M2951 75 mg QD23
DBPC Period: M2951 50 mg BID34
DBPC Period: Placebo8
DBPC Period: M2951 25 mg QD9
DBPC Period: M2951 75 mg QD8
DBPC Period: M2951 50 mg BID8
DBPC Period: Placebo80
DBPC Period: M2951 75 mg QD85
DBPC Period: M2951 50 mg BID75
DBPC Period: Placebo22
DBPC Period: M2951 75 mg QD19
DBPC Period: M2951 50 mg BID28
DBPC Period: M2951 25 mg QD2
DBPC Period: M2951 75 mg QD1
DBPC Period: Placebo78
DBPC Period: M2951 25 mg QD82
DBPC Period: M2951 75 mg QD81
DBPC Period: M2951 50 mg BID77
DBPC Period: Placebo23
DBPC Period: M2951 25 mg QD13
DBPC Period: M2951 75 mg QD15
DBPC Period: M2951 50 mg BID20
DBPC Period: Placebo5
DBPC Period: M2951 25 mg QD7
DBPC Period: M2951 75 mg QD7
DBPC Period: M2951 50 mg BID4
DBPC Period: Placebo2
DBPC Period: M2951 25 mg QD3
DBPC Period: M2951 75 mg QD4
DBPC Period: M2951 50 mg BID3
DBPC Period: Placebo75
DBPC Period: M2951 25 mg QD81
DBPC Period: M2951 75 mg QD87
DBPC Period: M2951 50 mg BID79
DBPC Period: M2951 75 mg QD16
DBPC Period: M2951 50 mg BID15
DBPC Period: Placebo3
DBPC Period: M2951 50 mg BID2
DBPC Period: M2951 25 mg QD0
DBPC Period: M2951 75 mg QD0
DBPC Period: Placebo67
DBPC Period: M2951 25 mg QD77
DBPC Period: M2951 50 mg BID73
DBPC Period: M2951 25 mg QD12
DBPC Period: M2951 50 mg BID17
DBPC Period: Placebo6
DBPC Period: M2951 25 mg QD6
DBPC Period: M2951 50 mg BID5
DBPC Period: M2951 50 mg BID0
DBPC Period: Placebo70
DBPC Period: M2951 25 mg QD70
DBPC Period: M2951 75 mg QD80
DBPC Period: M2951 50 mg BID72
DBPC Period: Placebo16
DBPC Period: M2951 25 mg QD15
DBPC Period: M2951 50 mg BID13
DBPC Period: Placebo4
DBPC Period: Placebo1
DBPC Period: M2951 50 mg BID1
DBPC Period: M2951 25 mg QD69
DBPC Period: Placebo19
DBPC Period: M2951 50 mg BID9
DBPC Period: M2951 25 mg QD8
DBPC Period: M2951 75 mg QD2
DBPC Period: Placebo66
DBPC Period: M2951 25 mg QD64
DBPC Period: M2951 75 mg QD76
DBPC Period: M2951 50 mg BID64
DBPC Period: Placebo14
DBPC Period: M2951 25 mg QD18
DBPC Period: M2951 75 mg QD6
DBPC Period: M2951 25 mg QD1
DBPC Period: M2951 75 mg QD5
DBPC Period: M2951 75 mg QD3

Erythema Score at Week 6.

The erythema score is lesion-specific and based on the CLASI and the RCLASI which are validated scoring systems to assess disease activity and damage in patients with cutaneous lupus erythematosus. The severity of the erythema is scored on a 4-point scale ranging from 0 to 3. The severity is scored from low to high with 0=absent and 3=dark red, purple/violaceous/crusted/haemorrhagic. (NCT03958955)
Timeframe: Week 6

Interventionscores on a scale (Median)
Delgocitinib Cream 20 mg/g1.5
Delgocitinib Cream Vehicle1.5

Number of Adverse Events (AEs) up to Week 6.

Number of AEs from baseline to Week 6 (NCT03958955)
Timeframe: Week 0 to Week 6

InterventionAEs (Number)
All Subjects8

Number of Lesion-specific, Treatment-related AEs up to Week 6.

The number of lesion-specific, treatment-related AEs per target lesion will be compared for active and vehicle treatment. Lesion-specific AEs are defined as lesional/perilesional AEs (i.e. AE location within the treatment area and/or ≤2 cm from the border of a target lesion). (NCT03958955)
Timeframe: Week 0 to Week 6

InterventionAEs (Number)
Delgocitinib Cream 20 mg/g2
Delgocitinib Cream Vehicle0

Number of Lesions With ≥2-point Reduction in Erythema Score at Week 6 Compared to Baseline.

The erythema score is lesion-specific and based on the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) and the Revised CLASI (RCLASI) which are validated scoring systems to assess disease activity and damage in patients with cutaneous lupus erythematosus. The severity of the erythema is scored on a 4-point scale ranging from 0 to 3. The severity is scored from low to high with 0=absent and 3=dark red, purple/violaceous/crusted/haemorrhagic. (NCT03958955)
Timeframe: Week 0 to Week 6

Interventionlesions (Number)
Delgocitinib Cream 20 mg/g5
Delgocitinib Cream Vehicle5

Number of Lesions With ≥2-point Reduction in IGA Score at Week 6 Compared to Baseline.

The IGA is an instrument used in clinical trials to rate the severity of the subject's global disease and is based on a 5-point scale ranging from 0 (clear) to 4 (severe). In this trial, the IGA was a lesion-specific assessment and was evaluated separately for each of the 2 target lesions. (NCT03958955)
Timeframe: Week 0 to Week 6

Interventionlesions (Number)
Delgocitinib Cream 20 mg/g3
Delgocitinib Cream Vehicle6

Number of Subjects With AEs up to Week 6.

Number of subjects with AEs from baseline to Week 6 (NCT03958955)
Timeframe: Week 0 to Week 6

InterventionParticipants (Count of Participants)
All Subjects8

Target Lesions With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 6.

The IGA is an instrument used in clinical trials to rate the severity of the subject's global disease and is based on a 5-point scale ranging from 0 (clear) to 4 (severe). In this trial, the IGA was a lesion-specific assessment and was evaluated separately for each of the 2 target lesions. (NCT03958955)
Timeframe: Week 6

Interventionlesions (Number)
Delgocitinib Cream 20 mg/g3
Delgocitinib Cream Vehicle6

Total Skin Disease Activity Score (Sum of Scores for Erythema, Scaling/Hyperkeratosis, and Oedema/Infiltration) at Week 6.

The skin disease activity scores are based on the CLASI and the RCLASI which are validated scoring systems to assess disease activity and damage in patients with cutaneous lupus erythematosus. The total skin disease activity score is defined as the sum of the scores for 3 clinical signs (erythema, scaling/hyperkeratosis, oedema/infiltration) for each target lesion. For the total score and the individual clinical signs, higher scores indicate more severe symptoms. Erythema is scored on a 4-point scale ranging from 0 (absent) to 3 (dark red, purple/violaceous/crusted/haemorrhagic). Hyperkeratosis/scaling is scored on a 3-point scale from 0 (absent) to 2 (verrucous hyperkeratosis). Oedema/infiltration is scored on a 3-point scale from 0 (absent) to 2 (palpable and visible). The total skin disease activity score can therefore range from 0 to 7. (NCT03958955)
Timeframe: Week 6

Interventionscores on a scale (Median)
Delgocitinib Cream 20 mg/g2.5
Delgocitinib Cream Vehicle2.5

Percentage of Par. Achieving a SLE Responder Index (SRI) Response Rate at Week 52

SRI response is defined as >=4 point reduction, from Baseline in safety of estrogen in lupus national assessment (SELENA) systemic lupus erythematosus disease activity index (SLEDAI) score, no worsening (increase of <0.30 points from Baseline) in physician's global assessment (PGA) and no new British Isles Lupus Assessment Group of SLE clinics (BILAG) A organ domain score or 2 new BILAG B organ domain scores compared with Baseline. Analysis was performed using a logistic regression model for the comparison between belimumab and placebo with covariates treatment group, Baseline SELENA SLEDAI score (<=9 vs. >=10), Baseline complement levels (low C3 and/or C4 vs. no low C3 or C4) and race (black vs. other). (NCT01484496)
Timeframe: Week 52

InterventionPercentage of par. (Number)
Placebo SC48.4
Belimumab 200 mg SC61.4

Percentage of Par. Whose Average Prednisone Dose Had Been Reduced by >=25% From Baseline to <=7.5 mg/Day During Weeks 40 Through 52 in Par. Receiving Greater Than 7.5 mg/Day at Baseline

For the analysis of steroid use, all steroid dosages were converted to a prednisone equivalent in mg. The average daily prednisone dose was calculated taking into account all steroids taken intravenously, intramuscularly, SC, intradermally and orally for both SLE and non-SLE reasons. A responder was defined as having a prednisone reduction by >=25% from Baseline to <=7.5 mg/day during Weeks 40 through 52. At Baseline, the average daily prednisone dose was the sum of all prednisone doses over 7 consecutive days up to, but not including Day 0, divided by 7. For this analysis, the average prednisone dose was the total prednisone dose during weeks 40 through 52 divided by the number of days during Weeks 40 through 52. Analysis was performed using a logistic regression model with covariates treatment group, Baseline prednisone dose, Baseline SELENA SLEDAI score, (<=9 vs >=10), Baseline complement levels (low C3 and/or C4 vs. no low C3 or C4) and race (black vs. other). (NCT01484496)
Timeframe: Baseline (Day 0, prior to dosing), Weeks 40 through Week 52

InterventionPercentage of par. (Number)
Placebo SC11.9
Belimumab 200 mg SC18.2

Time to First Severe Flare (as Measured by the Modified SLE Flare Index)

Time to first severe SLE flare is defined as the number of days from treatment start date until the participant met an event (event date - treatment start date +1). Analyses of severe SLE flare was performed on modified SELENA SLEDAI SLE flare index that excludes severe flares that were triggered only by an increase in SELENA SLEDAI score to >12 (since this may only represent a modest increase in disease activity). Only post-baseline severe flares were considered. (NCT01484496)
Timeframe: Baseline (Day 0, prior to dosing) to Week 52

InterventionDays (Median)
Placebo SC118
Belimumab 200 mg SC171

Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Total Score

FACIT-Fatigue score calculated according to a 13-item questionnaire that assess self reported fatigue and its impact upon daily activities and function. It uses a 5-point Likert-type scale (0 = not at all; 1 = a little bit; 2 = somewhat; 3 = quite a bit; 4 = very much). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse possible score) to 52 (best score). A higher score reflected an improvement in the participant's health status. Least Squares (LS) mean was calculated using Mixed Model Repeated Measures (MMRM) analysis with treatment, baseline disease activity (total SLEDAI-2K <10; >=10), baseline corticosteroid dose (<10 mg/day; >= 10 mg/day prednisone or equivalent), region (North America, Central/South, America/Mexico, Europe, Asia Rest of World), visit (as categorical variable), baseline value, treatment-by-visit interaction, and baseline value-by-visit interaction. (NCT03616964)
Timeframe: Baseline, Week 52

Interventionscore on a scale (Least Squares Mean)
Placebo7.26
2 mg Baricitinib6.90
4 mg Baricitinib6.96

Change From Baseline in Swollen Joint Count

The number of swollen joints is determined by examination of 28 joints (14 on each side) which include: the 2 shoulders, the 2 elbows, the 2 wrists, the 10 metacarpophalangeal joints, the 2 interphalangeal joints of the thumb, the 8 proximal interphalangeal joints, and the 2 knees. The joints are assessed and classified as swollen or not swollen. LS mean was calculated using MMRM analysis with treatment, baseline disease activity (total SLEDAI-2K <10; >=10), baseline corticosteroid dose (<10 mg/day; >=10 mg/day prednisone or equivalent), region (North America, Central/South America/Mexico, Europe, Asia and Rest of World), visit (as categorical variable), baseline value, treatment-by-visit interaction, and baseline value-by-visit interaction. (NCT03616964)
Timeframe: Baseline, Week 52

Interventionswollen joint count (Least Squares Mean)
Placebo-4.79
2 mg Baricitinib-5.10
4 mg Baricitinib-5.31

Change From Baseline in Tender Joint Count

The number of tender and painful joints is determined by examination of 28 joints (14 on each side) which include: the 2 shoulders, the 2 elbows, the 2 wrists, the 10 metacarpophalangeal joints, the 2 interphalangeal joints of the thumb, the 8 proximal interphalangeal joints, and the 2 knees. The joints are assessed and classified as tender or not tender. LS mean was calculated using Mixed Model Repeated Measures (MMRM) analysis with treatment, baseline disease activity (total SLEDAI-2K <10; >=10), baseline corticosteroid dose (<10 mg/day; >=10 mg/day prednisone or equivalent), region (North America, Central/South America/Mexico, Europe, Asia and Rest of World), visit (as categorical variable), baseline value, treatment-by-visit interaction, and baseline value-by-visit interaction. (NCT03616964)
Timeframe: Baseline, Week 52

Interventiontender joint count (Least Squares Mean)
Placebo-6.92
2 mg Baricitinib-7.40
4 mg Baricitinib-7.83

Change From Baseline in Worst Pain Numeric Rating Scale (NRS)

Participants assessed the worst pain in the last 24 hours on an 11-point numeric rating scale (NRS) ranging from 0 (no pain) to 10 (pain as bad as you can imagine). The average worst daily pain score was calculated as the mean of the scores over the last 7 days prior to each assessment time point. Higher score indicated severe pain. Least Squares (LS) mean was calculated using Mixed Model Repeated Measures (MMRM) analysis with treatment, baseline disease activity (total SLEDAI-2K <10; >=10), baseline corticosteroid dose (<10 mg/day; >= 10 mg/day prednisone or equivalent), region (North America, Central/South, America/Mexico, Europe, Asia Rest of World), visit (as categorical variable), baseline value, treatment-by-visit interaction, and baseline value-by-visit interaction. (NCT03616964)
Timeframe: Baseline, Week 52

Interventionscore on a scale (Least Squares Mean)
Placebo-1.37
2 mg Baricitinib-1.45
4 mg Baricitinib-1.44

Percentage of Participants Achieving a Lupus Low Disease Activity State (LLDAS)

"The LLDAS is a composite measure designed to identify patients achieving a state of low disease activity. The LLDAS response criteria were: (1) SLEDAI-2K <=4, with no activity in major organ systems (CNS, vascular, renal, cardiorespiratory and constitutional); where no activity is defined as all items of SLEDAI-2K within these major organ systems equal to 0. (2) no new features of lupus disease activity compared to previous occurred visit, where the new feature is defined as any of the SLEDAI-2K 24 items changed from 0 to greater than 0; (3) PGA (scale 0-3), <=1; (4) current prednisolone (or equivalent) dose <=7.5 mg daily." (NCT03616964)
Timeframe: Week 52

Interventionpercentage of participants (Number)
Placebo23.2
2 mg Baricitinib24.0
4 mg Baricitinib25.4

Percentage of Participants Achieving a Systemic Lupus Erythematosus Responder Index 4 (SRI-4) Response (4 mg Baricitinib)

"SRI-4 response defined as 1)greater than or equal to (>=) 4-point reduction in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) total score 2)no new British Isles Lupus Assessment Group (BILAG) A and no more than 1 new BILAG B domain score and 3)no worsening in Physician Global Assessment (PGA) of Disease Activity (worsening defined as an increase of >=0.3 from baseline on a 0-3 visual analogue scale).~SLEDAI-2K assessment consists of 24 items with total score of 0(no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms,or laboratory parameters related to Systemic Lupus Erythematosus (SLE),divided into 9 organ systems. For each organ system A=severe disease,B=moderate disease,C=mild stable disease,D=inactive,but previously active,E=inactive and never affected. PGA assess disease activity on a visual analogue scale from 0 to 3 (1=mild, 2=moderate, 3=severe)." (NCT03616964)
Timeframe: Week 52

Interventionpercentage of participants (Number)
Placebo45.6
4 mg Baricitinib47.1

Percentage of Participants Achieving SRI-4 Response (2 mg Baricitinib)

"SRI-4 response defined as 1)greater than or equal to (>=) 4-point reduction in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) total score 2)no new British Isles Lupus Assessment Group (BILAG) A and no more than 1 new BILAG B domain score and 3)no worsening in Physician Global Assessment (PGA) of Disease Activity (worsening defined as an increase of >=0.3 from baseline on a 0-3 visual analogue scale).~SLEDAI-2K assessment consists of 24 items with total score of 0(no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms,or laboratory parameters related to Systemic Lupus Erythematosus (SLE),divided into 9 organ systems. For each organ system A=severe disease,B=moderate disease,C=mild stable disease,D=inactive,but previously active,E=inactive and never affected. PGA assess disease activity on a visual analogue scale from 0 to 3 (1=mild, 2=moderate, 3=severe)." (NCT03616964)
Timeframe: Week 52

Interventionpercentage of participants (Number)
Placebo45.6
2 mg Baricitinib46.3

Percentage of Participants Whose Average Prednisone Dose Had Been Reduced by >=25% From Baseline to <=7.5 mg/Day During Weeks 40 Through 52 in Participants Receiving Greater Than 7.5 mg/Day at Baseline

For the analysis of steroid use, steroid dosages were converted to a prednisone equivalent in mg. A responder was defined as having a prednisone reduction by >=25% from Baseline to <=7.5 mg/day during Weeks 40 through 52. (NCT03616964)
Timeframe: Baseline, Week 40 through Week 52

Interventionpercentage of participants (Number)
Placebo31.7
2 mg Baricitinib29.8
4 mg Baricitinib34.3

Percentage of Participants With Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Total Activity Score ≥10 at Baseline With ≥50% Reduction in CLASI Total Activity Score

The CLASI is a single-page tool that separately quantifies disease activity and damage. For the activity score, points are given for the presence of erythema, scale, mucous membrane lesions, recent hair loss, and inflammatory alopecia. The total score represents the sum of the individual scores and ranges from 0 to 70. Higher scores are awarded for more severe manifestations. (NCT03616964)
Timeframe: Week 52

Interventionpercentage of participants (Number)
Placebo66.1
2 mg Baricitinib56.9
4 mg Baricitinib58.0

Population Pharmacokinetics (PK): Area Under the Concentration-Time Curve for Dosing Interval of Baricitinib at Steady State (AUCtau,ss)

AUCtau,ss reported for participants who received multiple doses of mg baricitinib was derived by a population pharmacokinetics approach. (NCT03616964)
Timeframe: Week 0 (Baseline): 15 minutes (min) and 60 min postdose; Week 4: 2 to 4 hours (hr) postdose; Week 8: 4 to 6 hr postdose; Week 12 and Week 16 predose

Interventionnanogram*hour/milliliter (ng*h/mL) (Geometric Mean)
2 mg Baricitinib257
4 mg Baricitinib505

Population PK: Maximum Observed Drug Concentration at Steady State (Cmax,ss)

PK: Maximum Concentration of Baricitinib at steady-state (Cmax,ss) was derived by a population pharmacokinetics approach. (NCT03616964)
Timeframe: Week 0 (Baseline): 15 minutes (min) and 60 min postdose; Week 4: 2 to 4 hours (hr) postdose; Week 8: 4 to 6 hr postdose; Week 12 and Week 16 predose

Interventionnanograms per milliliter (ng/mL) (Geometric Mean)
2 mg Baricitinib27.0
4 mg Baricitinib54.1

Time to First Severe Flare

Time to first severe flare analyzed using a Cox proportional hazards model with treatment group, baseline disease activity [Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) <10; SLEDAI-2K ≥10], baseline corticosteroid dose (<10 mg/day; ≥10 mg/day prednisone or equivalent), and region fitted as explanatory variables. Participants who did not have severe flare during the flare exposure time period were censored at the end of the flare exposure time. (NCT03616964)
Timeframe: Baseline to Week 52

Interventionweeks (Median)
PlaceboNA
2 mg BaricitinibNA
4 mg BaricitinibNA

Annualized Flare Rate

A flare was defined as either 1 or more new British Isle Lupus Assessment Group (BILAG-2004) A or 2 or more new BILAG-2004 B items compared to the previous visit. The occurrence of a new flare was checked for each available visit versus the previous available visit up to Week 52. If no new flares occurred, the number of flares was set to 0. Otherwise all flares were counted leading to the maximum number of flares of 13. The annualized flare rate was calculated as the number of flares divided by the flare exposure time in days multiplied with 365.25 (1 year). The flare exposure time is the time up to Week 52 (date of BILAG-2004 assessment at Week 52) or up to the date of last available BILAG-2004 assessment. (NCT02446912)
Timeframe: Baseline to Week 52

InterventionAnnualized flare rate ratio (Number)
Anifrolumab 150 mg0.62
Anifrolumab 300 mg0.60
Placebo0.72

Change From Baseline in Personal Health Questionnaire Depression Scale-8 (PHQ-8) Score

PHQ-8 is a 8-item self-report scale, all items are rated on a score of 0-3, for a total range of 0-24. PHQ-8 assesses symptoms of depression over the previous 2 weeks. Higher scores indicate more depressive symptoms. A negative change from baseline score indicates improvement in symptoms. (NCT02446912)
Timeframe: Baseline to Week 52

InterventionScore on a Scale (Mean)
Anifrolumab 150 mg-2.1
Anifrolumab 300 mg-2.7
Placebo-1.7

Number of Participants Reporting One or More Adverse Events (AE)

An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. AEs were collected throughout the duration of the study, from baseline until end of follow-up (a maximum of 12 weeks post last dose [Week 48]), or until Week 52 for participants who enrolled onto the long term extension (LTE). The reported value is inclusive of serious and non-serious AEs. (NCT02446912)
Timeframe: Baseline to End of Trial (Maximum of 60 weeks)

InterventionParticipants (Count of Participants)
Anifrolumab 150 mg80
Anifrolumab 300 mg161
Placebo145

Number of Participants Reporting One or More Adverse Events of Special Interest (AESI)

"An AESI is an AE of scientific and medical concern specific to understanding biologics and requires close monitoring and rapid communication by the Investigator to the Sponsor/Sponsor's delegate. An AESI may be serious or nonserious. The events of interest are serious infections, including non opportunistic serious infections, opportunistic infections, anaphylaxis, malignancy, herpes zoster, TB (including latent TB), influenza, vasculitis (non-SLE), and MACE (including stroke, MI, or cardiovascular death).~AEs were collected throughout the duration of the study, from baseline until end of follow-up (a maximum of 12 weeks post last dose [Week 48]), or until Week 52 for participants who enrolled onto the long term extension (LTE)." (NCT02446912)
Timeframe: Baseline to End of Trial (Maximum of 60 weeks)

InterventionParticipants (Count of Participants)
Anifrolumab 150 mg11
Anifrolumab 300 mg23
Placebo18

Number of Participants Who Achieved a Systemic Lupus Erythematosus (SLE) Responder Index ≥4 (SRI[4]) at Week 52 (Original Analysis With Restricted Medication Rules)

"SRI(4) was defined as meeting all of the following criteria:~Reduction from baseline of ≥4 points in the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) No new organ systems affected, defined by 1 or more British Isles Lupus Assessment Group (BILAG-2004) A or 2 or more BILAG-2004 B items No worsening from baseline in participants lupus disease activity. Worsening was defined as an increase of ≥0.30 points on a 3-point Physician's Global Assessment (PGA) visual analogue scale (VAS) No discontinuation of investigational product and no use of restricted medications beyond the pre-specified analysis threshold." (NCT02446912)
Timeframe: Week 52

InterventionParticipants (Count of Participants)
Anifrolumab 150 mg35
Anifrolumab 300 mg65
Placebo74

Number of Participants Who Achieved a Systemic Lupus Erythematosus (SLE) Responder Index ≥4 (SRI[4]) at Week 52 (Post-Hoc Analysis With Revised Restricted Medication Rules)

"SRI(4) was defined as meeting all of the following criteria:~Reduction from baseline of ≥4 points in the SLEDAI-2K No new organ systems affected, defined by 1 or more BILAG-2004 A or 2 or more BILAG-2004 B items No worsening from baseline in lupus disease activity. Worsening defined as an increase of ≥0.30 points on a 3-point PGA VAS No discontinuation of investigational product and no use of restricted medications beyond the revised post-hoc allowed threshold.~Revised rules were designed to be more clinically appropriate, capture intent of protocol, minimize the risk of restricted medications confounding efficacy, and to allow appropriate quantification and interpretation of the relevant endpoints." (NCT02446912)
Timeframe: Week 52

InterventionParticipants (Count of Participants)
Anifrolumab 150 mg45
Anifrolumab 300 mg84
Placebo79

Number of Participants Who Achieved a Systemic Lupus Erythematosus (SLE) Responder Index of ≥4 (SRI[4]) at Week 24 (Original Analysis With Restricted Medication Rules)

"SRI(4) was defined as meeting all of the following criteria:~Reduction from baseline of ≥4 points in the SLEDAI-2K No new organ systems affected as defined by 1 or more BILAG-2004 A or 2 or more BILAG-2004 B items No worsening from baseline in participants lupus disease activity. Worsening was defined as an increase of ≥0.30 points on a 3-point PGA VAS No discontinuation of investigational product and no use of restricted medications beyond the pre-specified threshold." (NCT02446912)
Timeframe: Week 24

InterventionParticipants (Count of Participants)
Anifrolumab 150 mg34
Anifrolumab 300 mg74
Placebo75

Number of Participants Who Achieved a Systemic Lupus Erythematosus (SLE) Responder Index of ≥4 (SRI[4]) at Week 24 (Post-Hoc Analysis With Revised Restricted Medication Rules)

"SRI(4) was defined as meeting all of the following criteria:~Reduction from baseline of ≥4 points in the SLEDAI-2K No new organ systems affected, defined by 1 or more BILAG-2004 A or 2 or more BILAG-2004 B items No worsening from baseline in lupus disease activity. Worsening defined as an increase of ≥0.30 points on a 3-point PGA VAS No discontinuation of investigational product and no use of restricted medications beyond the revised post-hoc allowed threshold.~Revised rules were designed to be more clinically appropriate, capture intent of protocol, minimize the risk of restricted medications confounding efficacy, and to allow appropriate quantification and interpretation of the relevant endpoints." (NCT02446912)
Timeframe: Week 24

InterventionParticipants (Count of Participants)
Anifrolumab 150 mg40
Anifrolumab 300 mg83
Placebo79

Number of Participants Who Achieved a Systemic Lupus Erythematosus (SLE) Responder Index of ≥4 at Week 52 in the Interferon (IFN) Test-High Sub-Group (Original Analysis With Restricted Medication Rules)

"SRI(4) was defined as meeting all of the following criteria:~Reduction from baseline of ≥4 points in the SLEDAI-2K No new organ systems affected, defined by 1 or more BILAG-2004 A or 2 or more BILAG-2004 B No worsening from baseline in participants lupus disease activity. Worsening was defined as an increase of ≥0.30 points on a 3-point PGA VAS No discontinuation of investigational product and no use of restricted medications beyond the pre-specified analysis threshold." (NCT02446912)
Timeframe: Week 52

InterventionParticipants (Count of Participants)
Anifrolumab 150 mg30
Anifrolumab 300 mg53
Placebo59

Number of Participants Who Achieved an Systemic Lupus Erythematosus (SLE) Responder Index of ≥4 at Week 52 in the Interferon (IFN) Test-High Sub-Group (Post-Hoc Analysis With Revised Restricted Medication Rules)

"SRI(4) was defined as meeting all of the following criteria:~Reduction from baseline of ≥4 points in the SLEDAI-2K No new organ systems affected, defined by 1 or more BILAG-2004 A or 2 or more BILAG-2004 B items No worsening from baseline in lupus disease activity. Worsening defined as an increase of ≥0.30 points on a 3-point PGA VAS No discontinuation of investigational product and no use of restricted medications beyond the revised post-hoc analysis threshold.~Revised rules were designed to be more clinically appropriate, capture intent of protocol, minimize the risk of restricted medications confounding efficacy, and to allow appropriate quantification and interpretation of the relevant endpoints." (NCT02446912)
Timeframe: Week 52

InterventionParticipants (Count of Participants)
Anifrolumab 150 mg40
Anifrolumab 300 mg71
Placebo63

Number of Participants Who Achieved and Maintained an Oral Corticosteroid (OCS) Dose of ≤7.5 mg/Day in the Sub-group of Participants With Baseline OCS ≥10 mg/Day (Original Analysis With Restricted Medication Rules)

"Maintained OCS reduction was defined by meeting all the following criteria:~Achieve an OCS dose of ≤7.5 mg/day prednisone or equivalent by Week 40 Maintain an OCS dose ≤7.5 mg/day prednisone or equivalent from Week 40 to Week 52 No discontinuation of investigational product and no use of restricted medications beyond the pre-specified analysis threshold." (NCT02446912)
Timeframe: Week 52

InterventionParticipants (Count of Participants)
Anifrolumab 150 mg17
Anifrolumab 300 mg42
Placebo33

Number of Participants Who Achieved and Maintained an Oral Corticosteroid (OCS) Dose of ≤7.5 mg/Day in the Sub-group of Participants With Baseline OCS ≥10 mg/Day (Post-Hoc Analysis With Revised Restricted Medication Rules)

"Maintained OCS reduction was defined by meeting all of the following criteria:~Achieve an OCS dose of ≤7.5 mg/day prednisone or equivalent by Week 40 Maintain an OCS dose ≤7.5 mg/day prednisone or equivalent from Week 40 to Week 52 No discontinuation of investigational product and no use of restricted medications beyond the revised post-hoc analysis threshold.~Revised rules were designed to be more clinically appropriate, capture intent of protocol, minimize the risk of restricted medication confounding efficacy, and to allow appropriate quantification and interpretation of the relevant endpoints." (NCT02446912)
Timeframe: Week 52

InterventionParticipants (Count of Participants)
Anifrolumab 150 mg24
Anifrolumab 300 mg50
Placebo33

Number of Participants Who Met the Criteria for British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) Response (Original Analysis With Restricted Medication Rules)

"A BICLA responder was achieved if all of the following criteria was met:~All criteria related to SRI(4) (please see primary endpoint) plus:~Reduction of all baseline BILAG-2004 A to B/C/D and baseline BILAG-2004 B to C/D, and no BILAG-2004 worsening in other organ systems, as defined by 1 or more BILAG-2004 A or 1 or more new BILAG-2004 B item No discontinuation of investigational product and no use of restricted medications beyond the revised post-hoc analysis threshold before assessment." (NCT02446912)
Timeframe: Week 52

InterventionParticipants (Count of Participants)
Anifrolumab 150 mg27
Anifrolumab 300 mg67
Placebo49

Number of Participants Who Met the Criteria for British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) Response (Post-Hoc Analysis With Revised Restricted Medication Rules)

"A BICLA responder was achieved if all of the following criteria was met:~All criteria related to SRI(4) (please see primary endpoint) plus:~Reduction of all baseline BILAG-2004 A to B/C/D and baseline BILAG-2004 B to C/D, and no BILAG-2004 worsening in other organ systems, as defined by 1 or more BILAG-2004 A or 1 or more new BILAG-2004 B item No discontinuation of investigational product and no use of restricted medications beyond the revised post-hoc analysis threshold before assessment.~Revised rules were designed to be more clinically appropriate, capture intent of protocol, minimize the risk of restricted medications confounding efficacy, and to allow appropriate quantification and interpretation of the relevant endpoints." (NCT02446912)
Timeframe: Week 52

InterventionParticipants (Count of Participants)
Anifrolumab 150 mg35
Anifrolumab 300 mg83
Placebo54

Number of Participants With a ≥50% Reduction in CLASI Activity Score at Week 12 in the Sub-group of Participants With Baseline CLASI Activity Score ≥10 (Original Analysis With Restricted Medication Rules)

"50% reduction in Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) activity score compared to baseline was defined by meeting all of the following criteria:~Achieve ≥50% reduction of CLASI activity score at Week 12 compared to baseline No discontinuation of investigational product and no use of restricted medications beyond the pre-specified analysis threshold before assessment." (NCT02446912)
Timeframe: Week 12

InterventionParticipants (Count of Participants)
Anifrolumab 150 mg15
Anifrolumab 300 mg24
Placebo14

Number of Participants With a ≥50% Reduction in CLASI Activity Score at Week 12 in the Sub-group of Participants With Baseline CLASI Activity Score ≥10 (Post-Hoc Analysis With Revised Restricted Medication Rules)

"50% reduction in Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) activity score compared to baseline was defined by meeting all the following criteria:~Achieve ≥50% reduction of CLASI activity score at Week 12 compared to baseline No discontinuation of investigational product and no use of restricted medications beyond the revised post-hoc analysis threshold before assessment.~Revised rules were designed to be more clinically appropriate, capture intent of protocol, minimize the risk of restricted medication confounding efficacy, and to allow appropriate quantification and interpretation of the relevant endpoints." (NCT02446912)
Timeframe: Week 12

InterventionParticipants (Count of Participants)
Anifrolumab 150 mg16
Anifrolumab 300 mg25
Placebo14

Number of Participants With Markedly Abnormal Electrocardiogram (ECG) Scores

ECGs documented the date, time, heart rate, QRS duration, PR interval, RR interval, QT, and corrected QT interval, which were calculated using the Fridericia formula. The investigator judged the overall interpretation as normal or abnormal, and if abnormal it was decided as to whether or not the abnormality was clinically significant or not clinically significant. (NCT02446912)
Timeframe: Baseline to Week 52

InterventionParticipants (Count of Participants)
Anifrolumab 150 mg0
Anifrolumab 300 mg0
Placebo0

Number of Participants With Markedly Abnormal Laboratory Tests

Laboratory tests were collected at central clinical laboratories and included hematology, serum chemistry and urinalysis tests. Laboratory values were collected throughout the duration of the study, from baseline until end of follow-up (a maximum of 12 weeks post last dose [Week 48]), or until Week 52 for participants who enrolled onto the long term extension (LTE). (NCT02446912)
Timeframe: Baseline to End of Trial (Maximum of 60 weeks)

InterventionParticipants (Count of Participants)
Anifrolumab 150 mg44
Anifrolumab 300 mg71
Placebo87

Number of Participants With Markedly Abnormal Physical Examinations

"Physical examinations included height and weight. Participants were weighed at each study visit and any medically significant changes were reported.~Physical examination values were collected throughout the duration of the study, from baseline until end of follow-up (a maximum of 12 weeks post last dose [Week 48]), or until Week 52 for participants who enrolled onto the long term extension (LTE)." (NCT02446912)
Timeframe: Baseline to End of Trial (Maximum of 60 weeks)

InterventionParticipants (Count of Participants)
Anifrolumab 150 mg3
Anifrolumab 300 mg2
Placebo2

Number of Participants With Markedly Abnormal Vital Signs

"Vital signs included oral temperature, blood pressure (BP), pulse rate, and respiratory rate.~Vital signs were collected throughout the duration of the study, from baseline until end of follow-up (a maximum of 12 weeks post last dose [Week 48]), or until Week 52 for participants who enrolled onto the long term extension (LTE)." (NCT02446912)
Timeframe: Baseline to End of Trial (Maximum of 60 weeks)

InterventionParticipants (Count of Participants)
Anifrolumab 150 mg14
Anifrolumab 300 mg36
Placebo46

Number of Participants With Mild To Moderate Lupus Flare Evaluated by Modified Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA)-SLEDAI Flare Index

"The modified SELENA flare index was completed by the Investigator or delegated/qualified physician. Assessment of flares were scored in comparison to the participant's previous visit and should only include findings which, in the opinion of the Investigator, are due to systemic lupus erythematosus (SLE) disease activity within that timeframe. Flare was defined as any 1 criterion present in either the Mild/Moderate Flare or Severe Flare categories.~Number of flares were collected throughout the duration of the study, from baseline until end of follow-up (a maximum of 12 weeks post last dose [Week 48]), or until Week 52 for participants who enrolled onto the long term extension (LTE)." (NCT02446912)
Timeframe: Baseline to End of Trial (Maximum of 60 weeks)

InterventionParticipants (Count of Participants)
Anifrolumab 150 mg38
Anifrolumab 300 mg58
Placebo67

Number of Participants With Suicidal Ideation or Behaviour Assessed Via the Columbia Suicide Severity Rating Scale (C-SSRS)

"The C-SSRS is an assessment tool that evaluates suicidal ideation and behavior. Number of participants with suicidal ideation or behavior was defined as the number of participants who answered yes at any time during the treatment period (Baseline to Week 52) to one of the 10 categories:~Category 1: Wish to be dead Category 2: Non-specific active suicidal thoughts Category 3: Active suicidal ideation with any methods (not plan) without intent to act Category 4: Active suicidal ideation with some intent to act, without specific plan Category 5: Active suicidal ideation with specific plan and intent Category 6: Preparatory acts or behavior Category 7: Aborted attempt Category 8: Interrupted attempt Category 9: Actual attempt (non-fatal) Category 10: Completed suicide" (NCT02446912)
Timeframe: Baseline to Week 52

,,
InterventionParticipants (Count of Participants)
Suicidal ideationSuicidal behaviour
Anifrolumab 150 mg10
Anifrolumab 300 mg20
Placebo21

Annualised Flare Rate Through 52 Weeks

A flare was defined as either 1 or more new British Isle Lupus Assessment Group (BILAG-2004) A or 2 or more new BILAG-2004 B items compared to the previous visit. The occurrence of a new flare was checked for each available visit versus the previous available visit up to Week 52. If no new flares occurred, the number of flares was set to 0. Otherwise all flares were counted leading to the maximum number of flares of 13. The annualized flare rate was calculated as the number of flares divided by the flare exposure time in days multiplied with 365.25 (1 year). The flare exposure time is the time up to Week 52 (date of BILAG-2004 assessment at Week 52) or up to the date of last available BILAG-2004 assessment. (NCT02446899)
Timeframe: Baseline to Week 52

InterventionAnnualized flare rate ratio (Number)
Anifrolumab 300 mg0.43
Placebo0.64

Number of Participants Who Achieved and Maintained an Oral Corticosteroids (OCS) Dose of ≤7.5 mg/Day at Week 52 in the Sub-Group of Participants With Baseline OCS ≥10 mg/Day

"Maintained OCS reduction was defined by meeting all of the following criteria:~Achieve an OCS dose of ≤7.5 mg/day prednisone or equivalent by Week 40~Maintain an OCS dose ≤7.5 mg/day prednisone or equivalent from Week 40 to Week 52~No discontinuation of investigational product~No use of restricted medications beyond the protocol allowed threshold before assessment" (NCT02446899)
Timeframe: Week 40; Week 52

InterventionParticipants (Count of Participants)
Anifrolumab 300 mg45
Placebo25

Number of Participants Who Achieved the British Isles Lupus Assessment Group Based Composite Lupus Assessment (BICLA) Response at Week 52

"Composite endpoint BICLA was defined by meeting all of the following criteria:~Reduction of all baseline British Isles Lupus Assessment Group (BILAG)-2004 A to B/C/D and baseline BILAG-2004 B to C/D, and no BILAG-2004 worsening in other organ systems, as defined by ≥1 new BILAG-2004 A or ≥2 new BILAG-2004 B~No worsening from baseline in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), where worsening is defined as an increase from baseline of >0 points in SLEDAI-2K~No worsening from baseline in participants' lupus disease activity, where worsening is defined by an increase ≥0.30 points on a 3-point Physician's Global Assessment (PGA) visual analogue scale (VAS)~No discontinuation of investigational product~No use of restricted medications beyond the protocol allowed threshold before assessment" (NCT02446899)
Timeframe: Baseline; Week 52

InterventionParticipants (Count of Participants)
Anifrolumab 300 mg86
Placebo57

Number of Participants Who Achieved the British Isles Lupus Assessment Group Based Composite Lupus Assessment (BICLA) Response at Week 52 in the IFN Test-High Sub-group

"Defined by meeting all of the following criteria:~Reduction of all baseline British Isles Lupus Assessment Group (BILAG)-2004 A to B/C/D and baseline BILAG-2004 B to C/D, and no BILAG-2004 worsening in other organ systems, as defined by ≥1 new BILAG-2004 A or ≥2 new BILAG-2004 B~No worsening from baseline in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), where worsening is defined as an increase from baseline to >0 points in SLEDAI-2K~No worsening from baseline in participants' lupus disease activity, where worsening is defined by an increase ≥0.30 points on a 3-point Physician's Global Assessment (PGA) visual analogue scale (VAS)~No discontinuation of investigational product~No use of restricted medications beyond the protocol allowed threshold before assessment" (NCT02446899)
Timeframe: Baseline; Week 52

InterventionParticipants (Count of Participants)
Anifrolumab 300 mg72
Placebo46

Number of Participants With ≥50% Reduction in Joint Counts at Week 52 in The Sub-group of Participants With ≥6 Swollen and ≥6 Tender Joints at Baseline

"50% reduction in the number of swollen and tender joints compared to baseline was defined by meeting all of the following criteria:~Achieve ≥50% reduction from baseline in the number of swollen and tender joints, separately~No discontinuation of investigational product~No use of restricted medications beyond the protocol allowed threshold before assessment" (NCT02446899)
Timeframe: Baseline; Week 52

InterventionParticipants (Count of Participants)
Anifrolumab 300 mg30
Placebo34

Number of Participants With a ≥50% Reduction in Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Activity Score at Week 12 in The Sub-Group of Participants With Baseline CLASI Activity Score of ≥10

"50% reduction in CLASI activity score compared to baseline was defined by meeting all of the following criteria:~Achieve ≥50% reduction of CLASI activity score at Week 12 compared to baseline~No discontinuation of investigational product~No use of restricted medications beyond the protocol allowed threshold before assessment" (NCT02446899)
Timeframe: Baseline; Week 12

InterventionParticipants (Count of Participants)
Anifrolumab 300 mg24
Placebo10

Number of Participants With a Potentially Clinically Important Change From Baseline in Clinical Laboratory Tests

"Clinical laboratory tests were analyzed in a central clinical laboratory and included hematology, serum chemistry and urinalysis tests.~Laboratory values were collected throughout the duration of the study, from baseline until end of follow-up (a maximum of 12 weeks post last dose [Week 48]), or until Week 52 for participants who enrolled onto the long term extension (LTE)." (NCT02446899)
Timeframe: Baseline to end of study (Maximum of 60 weeks)

InterventionParticipants (Count of Participants)
Anifrolumab 300 mg72
Placebo87

Number of Participants With a Potentially Clinically Important Change From Baseline in Vital Sign Measurements

"Vital sign measurements included oral temperature, blood pressure (BP), pulse rate, and respiratory rate.~Vital signs were collected throughout the duration of the study, from baseline until end of follow-up (a maximum of 12 weeks post last dose [Week 48]), or until Week 52 for participants who enrolled onto the long term extension (LTE)." (NCT02446899)
Timeframe: Baseline to end of study (Maximum of 60 weeks)

InterventionParticipants (Count of Participants)
Anifrolumab 300 mg45
Placebo45

Number of Participants With One or More Adverse Events (AEs)

An AE is the development of an undesirable medical condition or the deterioration of a pre-existing medical condition following or during exposure to a pharmaceutical product, whether or not considered causally related to the product. AEs were collected throughout the duration of the study, from baseline until end of follow-up (a maximum of 12 weeks post last dose [Week 48]), or until Week 52 for participants who enrolled onto the long term extension (LTE). The reported value is inclusive of serious and non-serious AEs. (NCT02446899)
Timeframe: Baseline to end of study (Maximum of 60 weeks)

InterventionParticipants (Count of Participants)
Anifrolumab 300 mg162
Placebo154

Number of Participants With One or More Adverse Events of Special Interest (AESIs)

"An AESI is an adverse event (AE) of scientific and medical concern specific to understanding biologics. An AESI may be serious or non-serious. AESI are serious infections, including non-opportunistic serious infections, opportunistic infections, anaphylaxis, malignancy, herpes zoster, tuberculosis (TB) (including latent TB), influenza, vasculitis (non-systemic lupus erythematosus [SLE]), and major adverse cardiovascular events (MACE) (including stroke, myocardial infarction [MI], or cardiovascular death).~AESIs were collected throughout the study, from baseline until end of follow-up (a maximum of 12 weeks post last dose [Week 48]), or until Week 52 for participants who enrolled onto the long term extension (LTE)." (NCT02446899)
Timeframe: Baseline to end of study (Maximum of 60 weeks)

InterventionParticipants (Count of Participants)
Anifrolumab 300 mg29
Placebo20

Change From Baseline in Patient's Global Assessment of Disease Activity

"The Patient's Global Assessment of Disease Activity is a single-item, patient reported scale developed for the assessment of the patient's overall rating of their disease activity due to SLE. The scale measures disease activity through a 5 point Likert scale ranging from 0 (No disease activity) to 4 (Severe disease activity) at its worst over the past 7 days. LS mean was determined by MMRM model with baseline of response, region, baseline disease activity (SLEDAI-2K <10, >=10), baseline anti-dsDNA status (positive, negative), treatment, time, treatment*time (type III sum of squares)." (NCT02708095)
Timeframe: Baseline, Week 24

InterventionUnits on a scale (Least Squares Mean)
Placebo-0.67
2 mg Baricitinib-0.83
4 mg Baricitinib-1.00

Change From Baseline in SLEDAI-2K Score

SLE Disease Activity Index 2000 (SLEDAI-2K) score is a weighted, cumulative index of lupus disease activity. SLEDAI-2K is calculated from 24 individual descriptors across 9 organ systems; 0 indicates inactive disease and the maximum theoretical score is 105. Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with baseline of response, region, baseline disease activity (SLEDAI-2K <10, >=10), baseline anti-dsDNA status (positive, negative), treatment, time, treatment*time (type III sum of squares). (NCT02708095)
Timeframe: Baseline, Week 24

InterventionUnits on a scale (Least Squares Mean)
Placebo-3.82
2 mg Baricitinib-4.07
4 mg Baricitinib-4.39

Percentage of Participants Who Achieve Remission of Arthritis and/or Rash Defined by the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K)

Participants were defined as responder as follows using SLEDAI-2K definitions of arthritis and rash. If only arthritis is present at baseline, then arthritis must be absent at Week 24 to meet the primary endpoint. If only rash is present at baseline, then rash must be absent at Week 24 to meet the primary endpoint. If both arthritis and rash are present at baseline, then the primary endpoint is met if either arthritis, or rash, or both arthritis and rash are absent at Week 24. (NCT02708095)
Timeframe: Week 24

InterventionPercentage of Participants (Number)
Placebo53.3
2 mg Baricitinib58.1
4 mg Baricitinib67.3

Percentage of Participants Who Achieve SLE Responder Index 4 (SRI-4) Response

SRI-4 response is defined as: 1) Reduction of ≥4 points from baseline in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score; 2) no new British Isles Lupus Assessment Group (BILAG) A or no more than 1 new BILAG B disease activity scores; and 3) no worsening (defined as an increase of ≥0.3 points [10 mm] from baseline) in Physician's Global Assessment of Disease Activity. The SRI-4 is a composite index used to assess disease activity in SLE. SLEDAI-2K assessment consists of 24 items with total score of 0 to 105, with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system: A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. PGA is a visual analog scale scored from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe). (NCT02708095)
Timeframe: Week 24

InterventionPercentage of Participants (Number)
Placebo47.6
2 mg Baricitinib51.4
4 mg Baricitinib64.4

Population Pharmacokinetics (PK): Area Under the Concentration-Time Curve of Baricitinib at Steady State (AUCτ, ss)

Plasma samples for pharmacokinetic (PK) analysis were obtained in week 0, week 4, week 8, week 16 and 24. AUC takes all time points post dose into account and one value is reported. (NCT02708095)
Timeframe: Week (Wk) 0: 15-30 minutes (min) postdose; Wk 4: Predose, 1.5 - 4 hour (hr) postdose; Wk 8: 1 - 3 hr postdose; Wk 16: Predose

Interventionnanogram*hour per milliliter (ng*h/mL) (Geometric Mean)
2 mg Baricitinib265
4 mg Baricitinib569

Population Pharmacokinetics (PK): Maximum Observed Drug Concentration at Steady State (Cmax,ss)

Plasma samples for pharmacokinetic (PK) analysis were obtained in week 0, week 4, week 8, week 16 and 24. Cmax takes all time points post dose into account and one value is reported. (NCT02708095)
Timeframe: Week (Wk) 0: 15-30 minutes (min) postdose; Wk 4: Predose, 1.5 - 4 hour (hr) postdose; Wk 8: 1 - 3 hr postdose; Wk 16: Predose

Interventionnanogram per milliliter (ng/mL) (Geometric Mean)
2 mg Baricitinib29.0
4 mg Baricitinib59.2

Percentage of Participants Achieving a Systemic Lupus Erythematosus Responder Index-4 (SRI-4) Composite Response at Week 52

SRI-4 response:>=4-point reduction in SLEDAI-2K total score, no British Isles Lupus Assessment Group (BILAG) A (severe disease) and no more than 1 new BILAG B (moderate disease) domain score and no worsening (<10 % increase)from baseline in Physician's Global Assessment(PGA).SLEDAI measures disease activity in 9 organ systems,higher scores=more severe disease activity.Each organ system measured as either absent/present within last 30 days and weighted score across systems was utilized to calculate total SLEDAI score(range:0=no symptoms to 105=presence of all defined symptoms). Improvement is defined as reduction in SLEDAI score (BILAG) Index: assessing clinical signs, symptoms,or laboratory parameters related to SLE,divided into 9 domains. Each domain can range from A=new domain activity, B=worse domain activity, C=same domain activity, D=improving domain activity to E=absence of domain activity. PGA assesses disease activity on visual analogue scale from very well(0)-very poor(10). (NCT03517722)
Timeframe: Week 52

Interventionpercentage of participants (Number)
Placebo to Ustekinumab56.0
Ustekinumab43.9

Percentage of Participants Receiving Glucocorticoid at Baseline Who Achieved Change in Glucocorticoid Dose by Week 40 and Sustain That Change Through Week 52

Reduction of glucocorticoid dose was defined as a reduction in average daily oral glucocorticoid dose by at least 50% (relative to the baseline dose) or reduction of average daily oral glucocorticoid dose by at least 25% (relative to the baseline dose) so that the average daily dose was reduced to less than or equal to (<=) 7.5 milligram (mg) (prednisone or equivalent). Sustained reduction of glucocorticoid dose was defined as achieving an average daily oral glucocorticoid dose reduction between Weeks 24 and 40, and sustaining that reduction through Week 52, in those participants who, at baseline, were receiving oral glucocorticoids. (NCT03517722)
Timeframe: Up to Week 52

Interventionpercentage of participants (Number)
Placebo to Ustekinumab29.3
Ustekinumab44.3

Percentage of Participants Receiving Glucocorticoid at Baseline Who Achieved Change in Glucocorticoid Dose by Week 40, Sustained That Change Through Week 52, and Achieved an SRI-4 Composite Response at Week 52

Percentage of participants with reduction in glucocorticoid dose by Week 40, its sustenance through Week 52, and SRI 4 composite response at Week 52 were reported. Reduction of glucocorticoid dose was defined as reduction in average daily oral glucocorticoid dose by at least 50% (relative to baseline dose) or reduction of average daily oral glucocorticoid dose by at least 25% (relative to baseline dose) so that average daily dose is reduced to <=7.5 mg (prednisone or equivalent). Sustained reduction of glucocorticoid dose was defined as achieving an average daily oral glucocorticoid dose reduction between Weeks 24 and 40, and sustaining that reduction through Week 52, in those participants who,at baseline,were receiving oral glucocorticoids. SRI-4 was defined as composite of at least 4-point improvement in SLEDAI-2K score of 0=no symptoms to 105=presence of all defined symptoms with higher scores representing increased disease activity),no worsening in BILAG and no worsening in PGA. (NCT03517722)
Timeframe: Up to Week 52

Interventionpercentage of participants (Number)
Placebo to Ustekinumab23.9
Ustekinumab30.0

Percentage of Participants With 50 Percent (%) Improvement in Joints With Pain and Signs of Inflammation (Active Joints) at Week 52

The percentage of participants who achieved at least 50% improvement from baseline in number of joints with pain and signs of inflammation at Week 52 for participants with at least 4 joints with pain and signs of inflammation at baseline were reported. (NCT03517722)
Timeframe: Week 52

Interventionpercentage of participants (Number)
Placebo to Ustekinumab66.3
Ustekinumab64.7

Percentage of Participants With an SRI-4 Composite Response at Week 24

SRI-4 response:>=4-point reduction in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) total score, no BILAG A (severe disease) and no more than 1 new BILAG B (moderate disease) domain score and no worsening (<10 % increase)from baseline in PGA.SLEDAI measures disease activity in 9 organ systems, higher scores=more severe disease activity. Each organ system measured as either absent/present within last 30 days and weighted score across systems was utilized to calculate total SLEDAI score(range:0=no symptoms to 105=presence of all defined symptoms). Improvement is defined as reduction in SLEDAI score (BILAG) Index: assessing clinical signs, symptoms,or laboratory parameters related to SLE,divided into 9 domains. Each domain can range from A=new domain activity, B=worse domain activity, C=same domain activity, D=improving domain activity to E=absence of domain activity. PGA assesses disease activity on visual analogue scale from very well(0)-very poor(10). (NCT03517722)
Timeframe: Week 24

Interventionpercentage of participants (Number)
Placebo to Ustekinumab56
Ustekinumab45.7

Percentage of Participants With at Least a 50% Improvement in the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Activity Score at Week 52

Percentage of participants achieving at least 50% improvement in CLASI activity score at Week 52 reported in participants with a CLASI activity score of 4 or greater at baseline. The CLASI is an instrument to assess the disease activity and damage caused to the skin for cutaneous lupus erythematosus participants with or without systemic involvement. The CLASI activity score ranges from 0-70 with lower score being improved. Activity is scored based on erythema, scale/hyperkeratosis, mucous membrane involvement, acute hair loss, and non-scarring alopecia. (NCT03517722)
Timeframe: Week 52

Interventionpercentage of participants (Number)
Placebo to Ustekinumab55.9
Ustekinumab40.7

Time to First Flare

Time to flare is defined as the time (in days) post baseline when the first flare occurs. It was calculated with flare defined as either 1 or more BILAG A (severe disease activity) or 2 or more new BILAG B (moderate disease activity) domain scores relative to baseline. BILAG was defined as a measure of alterations or intensification to therapy consisting of 97 questions in 9 domains. Each domain can range from A=new domain activity, B=worse domain activity, C=same domain activity, D=improving domain activity to E=absence of domain activity. BILAG A flare was defined as at least 1 new BILAG A scores. BILAG B flare was defined as at least 2 new BILAG B scores. (NCT03517722)
Timeframe: Up to Week 52

,
Interventiondays (Mean)
Time to First BILAG FlareTime to First BILAG A FlareTime to First BILAG B Flare
Placebo to Ustekinumab200.4201.4218.1
Ustekinumab204.7203.1208.7

Change From Baseline in Daily Prednisone Dose at Week 24

Participants' current use of steroid therapy was assessed at each study visit, and the amount of daily prednisone was documented. (NCT03978520)
Timeframe: From Baseline to Week 24

Interventionmg (Least Squares Mean)
Elsubrutinib Placebo/Upadacitinib Placebo-0.65
ABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg)-0.45
Elsubrutinib Placebo/Upadacitinib 30 mg-0.62

Percentage of Participants Achieving British Isles Lupus Assessment Group (BILAG) Based Combined Lupus Assessment (BICLA) Response at Week 24

BICLA is a composite responder index. Achievement of BICLA response is defined as improvement in all initial A and B BILAG scores, with no more than one new BILAG B score without worsening of the overall condition (no worsening in Physician's Global Assessment [PhGA], < 0.3 point increase) and no worsening of the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score. (NCT03978520)
Timeframe: Baseline, Week 24

Interventionpercentage of participants (Number)
Elsubrutinib Placebo/Upadacitinib Placebo42.7
ABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg)54.4
Elsubrutinib Placebo/Upadacitinib 30 mg58.1

Percentage of Participants Achieving Lupus Low Disease Activity State (LLDAS) at Week 24

LLDAS is a state of low disease activity based on Systemic Lupus Erythematosus Disease Activity Index 2000 score (SLEDAI-2K score ≤4 excluding SLEDAI-2K activity in major organ systems), absence of SLE disease activity in major organ systems and new disease activity, Physician's Global Assessment (PhGA ≤1), and concomitant medication usage (steroid dose ≤7.5 mg QD and toleration of immunosuppressive drugs at standard maintenance doses). (NCT03978520)
Timeframe: Baseline, Week 24

Interventionpercentage of participants (Number)
Elsubrutinib Placebo/Upadacitinib Placebo13.3
ABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg)30.9
Elsubrutinib Placebo/Upadacitinib 30 mg45.2

Percentage of Participants Achieving SLE Responder Index (SRI)-4 and Steroid Dose ≤ 10 mg Prednisone Equivalent Once a Day (QD) at Week 24

"SLE Responder Index (SRI)-4 is defined as follows with all criteria compared to Baseline:~≥ 4-point reduction in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score~No worsening of the overall condition (< 0.3 point increase in Physician's Global Assessment [PhGA])~No new British Isles Lupus Assessment Group (BILAG) A or more than 1 new BILAG B disease activity scores (i.e., no organ system changes from baseline B/C/D/E to A and no more than 1 organ system changes from baseline C/D/E to B). A letter score is assigned to each organ system with following indications: A = severe, B = moderate, C = mild, D = inactive with prior history, and E = inactive with no history." (NCT03978520)
Timeframe: Baseline, Week 24

Interventionpercentage of participants (Number)
Elsubrutinib Placebo/Upadacitinib Placebo37.3
ABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg)48.5
Elsubrutinib Placebo/Upadacitinib 30 mg54.8

Percentage of Participants Achieving SLE Responder Index (SRI)-4 at Week 24

"SLE Responder Index (SRI)-4 is defined as follows with all criteria compared to Baseline:~≥ 4-point reduction in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score~No worsening of the overall condition (< 0.3 point increase in Physician's Global Assessment [PhGA])~No new British Isles Lupus Assessment Group (BILAG) A or more than 1 new BILAG B disease activity scores (i.e., no organ system changes from baseline B/C/D/E to A and no more than 1 organ system changes from baseline C/D/E to B). A letter score is assigned to each organ system with following indications: A = severe, B = moderate, C = mild, D = inactive with prior history, and E = inactive with no history." (NCT03978520)
Timeframe: Baseline, Week 24

Interventionpercentage of participants (Number)
Elsubrutinib Placebo/Upadacitinib Placebo38.7
ABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg)54.4
Elsubrutinib Placebo/Upadacitinib 30 mg56.5

Number of Flares Per Patient-year by Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA) SLEDAI Flare Index Through Week 24

The SELENA SLEDAI flare index defines mild/moderate or severe SLE flares using the SLEDAI score, definitions of worsening signs and symptoms, treatment changes, and Physician's Global Assessment of Disease Activity. (NCT03978520)
Timeframe: From Baseline to Week 24

,,
InterventionEvents per patient-year (Number)
Mild/ModerateSevereOverall
ABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg)1.390.261.65
Elsubrutinib Placebo/Upadacitinib 30 mg1.760.101.87
Elsubrutinib Placebo/Upadacitinib Placebo2.450.362.81

Part A : Percentage of Participants With Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity- 50 (CLASI-50) Response at Week 24

CLASI-50 Response is defined as a 50% improvement from baseline in CLASI-A score at Week 24. The CLASI is a clinical tool that quantifies disease activity and damage in CLE. The activity scale (CLASI-A) includes measurements of erythema, scale and hypertrophy, and mucous membrane disease. Each part of the body is listed separately, from the scalp to the feet, in addition to sections focusing on mucous membrane involvement and alopecia. Points are given for the presence of erythema, scale, mucous membrane lesions, recent hair loss, and inflammatory alopecia. Composite scores are calculated by summing the individual component scores. CLASI-A scores of 0-9, 10-20, and 21-70 represent disease severity of mild, moderate, and severe, respectively. Higher scores indicate more disease activity. (NCT02847598)
Timeframe: Week 24

Interventionpercentage of participants (Number)
Part A: Placebo42.11
Part A: BIIB059 50 mg50
Part A: BIIB059 150 mg16.67
Part A: BIIB059 450 mg64.10

Part A: Change From Baseline in Active Joint Count (28-joint Assessment) to Week 24

An active joint is defined as a joint with pain and signs of inflammation (e.g., tenderness, swelling or effusion). The 28 Joint Count includes assessment of swelling and tenderness in the shoulders, elbows, wrists, metacarpophalangeal joints, proximal interphalangeal joints and knees. The investigator counts how many of the 28 joints are swollen or tender at the given week. (NCT02847598)
Timeframe: Baseline to Week 24

Interventionjoints (Mean)
Part A: Placebo-12.7
Part A: BIIB059 50 mg-9.0
Part A: BIIB059 150 mg-13.0
Part A: BIIB059 450 mg-14.5

Part A: Change From Baseline in Physician's Global Assessment (PGA) of SLE Visual Analog Scale (VAS) Score at Week 24

The PGA is used to quantify disease activity and is measured using an anchored VAS. The PGA asks the Investigator to assess the participants current disease activity from a score of 0 (none) to 3 (severe), where higher score means severe SLE disease activity. (NCT02847598)
Timeframe: Baseline to Week 24

Interventionscore on a scale (Mean)
Part A: Placebo-2.46
Part A: BIIB059 50 mg-2.05
Part A: BIIB059 150 mg-0.12
Part A: BIIB059 450 mg-2.45

Part A: Change From Baseline in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) Score at Week 24

The SLEDAI-2K is a reliable, valid, simple, 1-page activity index that measures disease activity and records features of active lupus as present or not. It uses a weighted checklist to assign a numeric score based on the presence or absence of 24 symptoms at the time of assessment or during the previous 28 days. Each symptom present is assigned between 1 and up to 8 points based on its usual clinical importance, yielding a total score that ranges from 0 points (no symptoms) to 105 points (presence of all defined symptoms), where higher scores representing increased disease activity. (NCT02847598)
Timeframe: Baseline to Week 24

Interventionscore on a scale (Mean)
Part A: Placebo-2.1
Part A: BIIB059 50 mg-3.0
Part A: BIIB059 150 mg-1.3
Part A: BIIB059 450 mg-4.4

Part A: Number of Participants With Clinically Significant 12-Lead Electrocardiograms (ECGs) Abnormalities

(NCT02847598)
Timeframe: Baseline up to Week 36

InterventionParticipants (Count of Participants)
Part A: Placebo0
Part A: BIIB059 50 mg0
Part A: BIIB059 150 mg0
Part A: BIIB059 450 mg0

Part A: Number of Participants With Clinically Significant Laboratory Assessment Abnormalities

(NCT02847598)
Timeframe: Baseline up to Week 36

InterventionParticipants (Count of Participants)
Part A: Placebo0
Part A: BIIB059 50 mg0
Part A: BIIB059 150 mg0
Part A: BIIB059 450 mg0

Part A: Number of Participants With Clinically Significant Vital Sign Abnormalities

(NCT02847598)
Timeframe: Baseline up to Week 36

InterventionParticipants (Count of Participants)
Part A: Placebo0
Part A: BIIB059 50 mg0
Part A: BIIB059 150 mg0
Part A: BIIB059 450 mg0

Part A: Number of Participants With Positive BIIB059 Antibodies

(NCT02847598)
Timeframe: Baseline up to Week 24

InterventionParticipants (Count of Participants)
Part A: Placebo1
Part A: BIIB059 50 mg0
Part A: BIIB059 150 mg0
Part A: BIIB059 450 mg5

Part A: Percentage of Participants Achieving a Systemic Lupus Erythematosus (SLE) Responder Index >=4 (SRI-4) at Week 24

An SRI-4 at Week 24 was a categorical response variable (Yes/No) incorporating the following criteria for achievement of responder status (i.e., all criteria must have been met to achieve responder status): A reduction from baseline of ≥4 points in SLEDAI-2K, No new organ system affected, as defined by no new BILAG-2004 Grade A and no more than 1 new BILAG-2004 Grade B, No worsening from baseline in participant's lupus disease activity, defined by a <1-point increase in the PGA (VAS) [on a scale of 0 to 10],No changes to protocol-specified medication rules,as follows (all criteria were required to be met): No initiation or increase of SLE standard of care therapy or other disallowed concomitant therapy; Concomitant corticosteroid dosage at Week 24 to be ≤10 mg/day;Concomitant corticosteroid dosage at Week 24 was no more than at Day 1;No increase in corticosteroid dose between Weeks 17 and 24. The percentage of participants who had responded to each of the 4 criteria was also reported. (NCT02847598)
Timeframe: Week 24

Interventionpercentage of participants (Number)
Part A: Placebo28.57
Part A: BIIB059 50 mg33.33
Part A: BIIB059 150 mg16.67
Part A: BIIB059 450 mg56.25

Part A: Percentage of Participants With a >=4-point Reduction From Baseline in Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) Score at Week 24

The CLASI is a clinical tool that quantifies disease activity and damage in CLE. The activity scale (CLASI-A) includes measurements of erythema, scale and hypertrophy, and mucous membrane disease. Each part of the body is listed separately, from the scalp to the feet, in addition to sections focusing on mucous membrane involvement and alopecia. Points are given for the presence of erythema, scale, mucous membrane lesions, recent hair loss, and inflammatory alopecia. Composite scores are calculated by summing the individual component scores. CLASI-A scores of 0-9, 10-20, and 21-70 represent disease severity of mild, moderate, and severe, respectively. Higher scores indicate more disease activity. The percentage of participants with a >=4-point reduction from baseline in CLASI-A score are reported here. (NCT02847598)
Timeframe: Week 24

Interventionpercentage of participants (Number)
Part A: Placebo57.89
Part A: BIIB059 50 mg83.66
Part A: BIIB059 150 mg16.67
Part A: BIIB059 450 mg71.79

Part A: Percentage of Participants With a >=7-point Change From Baseline in Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) Score at Week 24

The CLASI is a clinical tool that quantifies disease activity and damage in CLE. The activity scale (CLASI-A) includes measurements of erythema, scale and hypertrophy, and mucous membrane disease. Each part of the body is listed separately, from the scalp to the feet, in addition to sections focusing on mucous membrane involvement and alopecia. Points are given for the presence of erythema, scale, mucous membrane lesions, recent hair loss, and inflammatory alopecia. Composite scores are calculated by summing the individual component scores. CLASI-A scores of 0-9, 10-20, and 21-70 represent disease severity of mild, moderate, and severe, respectively. Higher scores indicate more disease activity. The percentage of participants with a >=7-point reduction from baseline in CLASI-A score are reported here. (NCT02847598)
Timeframe: Week 24

Interventionpercentage of participants (Number)
Part A: Placebo34.21
Part A: BIIB059 50 mg66.67
Part A: BIIB059 150 mg16.67
Part A: BIIB059 450 mg56.41

Part A: Percentage of Participants With no New Organ System Affected at Week 24

No new organ system affected, as defined by no new British Isles Lupus Activity Group (BILAG)-2004 A and no more than one new BILAG-2004 B. The BILAG-2004 index categorizes disease activity in each organ system into five different levels from A to E. Grade A represents very active disease, Grade B represents moderate disease activity, Grade C indicates mild stable disease, and grade D implies no disease activity, but suggests the organ system had previously been affected. Grade E indicates no current or previous disease activity. A score is applied to each grade of each organ system using coding scheme of A=12, B=8, C=1, and D/E=0 and is summarized as a total score ranging 0-108. Higher scores indicate more severe disease activity. (NCT02847598)
Timeframe: Week 24

Interventionpercentage of participants (Number)
Part A: Placebo82.14
Part A: BIIB059 50 mg100.00
Part A: BIIB059 150 mg50.00
Part A: BIIB059 450 mg85.94

Part B: Number of Participants With Clinically Significant 12-Lead Electrocardiograms (ECGs) Abnormalities

(NCT02847598)
Timeframe: Baseline up to Week 28

InterventionParticipants (Count of Participants)
Part B: Placebo0
Part B: BIIB059 50 mg0
Part B: BIIB059 150 mg0
Part B: BIIB059 450 mg0

Part B: Number of Participants With Clinically Significant Laboratory Assessment Abnormalities

(NCT02847598)
Timeframe: Baseline up to Week 28

InterventionParticipants (Count of Participants)
Part B: Placebo0
Part B: BIIB059 50 mg0
Part B: BIIB059 150 mg0
Part B: BIIB059 450 mg0

Part B: Number of Participants With Clinically Significant Vital Sign Abnormalities

(NCT02847598)
Timeframe: Baseline up to Week 28

InterventionParticipants (Count of Participants)
Part B: Placebo0
Part B: BIIB059 50 mg0
Part B: BIIB059 150 mg0
Part B: BIIB059 450 mg0

Part B: Number of Participants With Positive BIIB059 Antibodies

(NCT02847598)
Timeframe: Baseline up to Week 16

InterventionParticipants (Count of Participants)
Part B: Placebo0
Part B: BIIB059 50 mg5
Part B: BIIB059 150 mg4
Part B: BIIB059 450 mg5

Part B: Percent Change From Baseline in Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) Score at Week 12

The CLASI is a clinical tool that quantifies disease activity and damage in CLE. The activity scale (CLASI-A) includes measurements of erythema, scale and hypertrophy, and mucous membrane disease. Each part of the body is listed separately, from the scalp to the feet, in addition to sections focusing on mucous membrane involvement and alopecia. Points are given for the presence of erythema, scale, mucous membrane lesions, recent hair loss, and inflammatory alopecia. Composite scores are calculated by summing the individual component scores. CLASI-A scores of 0-9, 10-20, and 21-70 represent disease severity of mild, moderate, and severe, respectively. Higher scores indicate more disease activity. (NCT02847598)
Timeframe: Baseline, Week 12

Interventionpercent change (Mean)
Part B: Placebo-10.73
Part B: BIIB059 50 mg-38.72
Part B: BIIB059 150 mg-47.82
Part B: BIIB059 450 mg-35.25

Part B: Percent Change From Baseline in Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) Score to Week 16

The Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) is a clinical tool that quantifies disease activity and damage in cutaneous lupus erythematosus (CLE). The activity scale (CLASI-A) includes measurements of erythema, scale and hypertrophy, and mucous membrane disease. Each part of the body is listed separately, from the scalp to the feet, in addition to sections focusing on mucous membrane involvement and alopecia. Points are given for the presence of erythema, scale, mucous membrane lesions, recent hair loss, and inflammatory alopecia. Composite scores are calculated by summing the individual component scores. CLASI-A scores of 0-9, 10-20, and 21-70 represent disease severity of mild, moderate, and severe, respectively. Higher scores indicate more disease activity. (NCT02847598)
Timeframe: Baseline to Week 16

Interventionpercent change (Mean)
Part B: Placebo-15.03
Part B: BIIB059 50 mg-35.52
Part B: BIIB059 150 mg-47.11
Part B: BIIB059 450 mg-41.66

Part A: Absolute Change From Baseline in Vaccine Titers - Clostridium Tetani (C. Tetani) and Diphtheria at Week 24

Vaccine-related immunoglobulin titers for tetanus and diphtheria were analyzed using international units per milliliter (IU/mL). (NCT02847598)
Timeframe: Baseline to Week 24

,,,
InterventionIU/mL (Mean)
C. tetani IgG Antibody: BaselineC. tetani IgG Antibody: Change at Week 24Diphtheria IgG Antibody: BaselineDiphtheria IgG Antibody: Change at Week 24
Part A: BIIB059 150 mg2.521.070.170.07
Part A: BIIB059 450 mg3.30-0.700.33-0.07
Part A: BIIB059 50 mg1.730.070.10-0.03
Part A: Placebo2.46-0.070.33-0.06

Part A: Absolute Change From Baseline in Vaccine Titers - Streptococcus Pneumoniae (S. Pneumoniae) at Week 24

Vaccine-related immunoglobulin (Ig) titers for Pneumococcus (S. pneumoniae) were analyzed, including 23 types of serotypes (sero). AB = Antibody. (NCT02847598)
Timeframe: Baseline to Week 24

,,,
Interventionmilligrams per liter (mg/L) (Mean)
Sero 1 IgG AB: BaselineSero 1 IgG AB: Change at Week 24Sero 2 IgG AB: BaselineSero 2 IgG AB: Change at Week 24Sero 3 IgG AB: BaselineSero 3 IgG AB: Change at Week 24Sero 4 IgG AB: BaselineSero 4 IgG AB: Change at Week 24Sero 5 IgG AB: BaselineSero 5 IgG AB: Change at Week 24Sero 6 IgG AB: BaselineSero 6 IgG AB: Change at Week 24Sero 7 IgG AB: BaselineSero 7 IgG AB: Change at Week 24Sero 8 IgG AB: BaselineSero 8 IgG AB: Change at Week 24Sero 9N IgG AB: BaselineSero 9N IgG AB: Change at Week 24Sero 9V IgG AB: BaselineSero 9V IgG AB: Change at Week 24Sero 10A IgG AB: BaselineSero 10A IgG AB: Change at Week 24Sero 11A IgG AB: BaselineSero 11A IgG AB: Change at Week 24Sero 12F IgG AB: BaselineSero 12F IgG AB: Change at Week 24Sero 14 IgG AB: BaselineSero 14 IgG AB: Change at Week 24Sero 15B IgG AB: BaselineSero 15B IgG AB: Change at Week 24Sero 17F IgG AB: BaselineSero 17F IgG AB: Change at Week 24Sero 18C IgG AB: BaselineSero 18C IgG AB: Change at Week 24Sero 19A IgG AB: BaselineSero 19A IgG AB: Change at Week 24Sero 19F IgG AB: BaselineSero 19F IgG AB: Change at Week 24Sero 20 IgG AB: BaselineSero 20 IgG AB: Change at Week 24Sero 22F IgG AB: BaselineSero 22F IgG AB: Change at Week 24Sero 23F IgG AB: BaselineSero 23F IgG AB: Change at Week 24Sero 33F IgG AB: BaselineSero 33F IgG AB: Change at Week 24
Part A: BIIB059 150 mg2.705-0.5654.202-1.9751.2733-0.20671.317-0.79513.507-7.3224.458-3.0837.0033-2.89172.6183-1.54832.810-0.9071.5900-0.575014.0400.1004.095-0.7822.077-1.2208.167-0.7984.332-1.60711.952-5.8982.980-0.91550.3175-29.35588.353-3.67321.8742-13.09425.525-3.6570.6850.1905.630-3.740
Part A: BIIB059 450 mg1.4950.4751.626-0.0111.65790.81220.4290.0604.4420.3291.9570.0703.09830.30531.58900.12812.3370.4992.26960.67017.631-0.3842.308-0.2760.262-0.0725.1830.5973.690-0.3414.2771.3302.4850.05414.95544.09882.6091.1364.09021.24371.1380.0871.7970.1251.8000.066
Part A: BIIB059 50 mg3.8730.0555.715-1.6482.1450-0.20172.602-1.51010.693-4.6924.462-2.1688.5333-1.32833.1933-1.33002.710-1.3271.8300-0.076717.847-8.0623.203-1.6152.355-1.64813.982-7.0276.287-2.26211.422-6.1233.475-1.17235.2000-18.075010.857-6.44726.7958-21.44755.743-4.0001.897-0.1506.600-5.042
Part A: Placebo2.0170.4451.5620.0141.2607-0.08860.734-0.0254.9210.8133.348-0.4486.4300-1.03363.19780.09251.7810.2171.02740.39636.4430.5021.7680.2410.8520.0607.910-0.6353.9260.6034.8170.4273.229-0.09615.23722.24184.2030.6515.45060.04551.5630.2441.4010.0782.610-0.392

Part A: Absolute Change From Baseline Over Time in Immunoglobulin Levels

(NCT02847598)
Timeframe: Baseline up to Week 24

,
Interventiongrams per Liter (g/L) (Mean)
Immunoglobulin A (IgA): BaselineIgA: Change at Week 24Immunoglobulin G (IgG): BaselineIgG: Change at Week 24Immunoglobulin M (IgM): BaselineIgM: Change at Week 24
Part A: BIIB059 150 mg4.080-0.05717.620-0.7901.242-0.150
Part A: BIIB059 50 mg3.610-0.43315.723-0.4681.065-0.050

Part A: Absolute Change From Baseline Over Time in Immunoglobulin Levels

(NCT02847598)
Timeframe: Baseline up to Week 24

,
Interventiongrams per Liter (g/L) (Mean)
Immunoglobulin A (IgA): BaselineIgA: Change at Week 16IgA: Change at Week 24Immunoglobulin G (IgG): BaselineIgG: Change at Week 16IgG: Change at Week 24Immunoglobulin M (IgM): BaselineIgM: Change at Week 16IgM: Change at Week 24
Part A: BIIB059 450 mg3.116-0.0060.01214.7920.2330.7581.106-0.065-0.072
Part A: Placebo3.3500.033-0.09314.4231.0570.8741.0460.004-0.003

Part A: Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An SAE is any untoward medical occurrence that at any dose: Results in death; in the view of the Investigator, places the participant at immediate risk of death (a life-threatening event); however, this does not include an event that, had it occurred in a more severe form, might have caused death; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; results in a congenital anomaly/birth defect. (NCT02847598)
Timeframe: Baseline up to Week 36

,,,
InterventionParticipants (Count of Participants)
AEsSAEs
Part A: BIIB059 150 mg61
Part A: BIIB059 450 mg363
Part A: BIIB059 50 mg30
Part A: Placebo386

Part A: Percent Change From Baseline in Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) Score at Week 12, 16 and 24

The CLASI is a clinical tool that quantifies disease activity and damage in CLE. The activity scale (CLASI-A) includes measurements of erythema, scale and hypertrophy, and mucous membrane disease. Each part of the body is listed separately, from the scalp to the feet, in addition to sections focusing on mucous membrane involvement and alopecia. Points are given for the presence of erythema, scale, mucous membrane lesions, recent hair loss, and inflammatory alopecia. Composite scores are calculated by summing the individual component scores. CLASI-A scores of 0-9, 10-20, and 21-70 represent disease severity of mild, moderate, and severe, respectively. Higher scores indicate more disease activity. (NCT02847598)
Timeframe: Baseline, Week 12, 16 and 24

,,,
Interventionpercent change (Mean)
Change at Week 12Change at Week 16Change at Week 24
Part A: BIIB059 150 mg-8.39-6.19-17.92
Part A: BIIB059 450 mg-44.36-50.20-60.59
Part A: BIIB059 50 mg-29.32-41.76-58.61
Part A: Placebo-36.63-42.55-45.40

Part A: Percent Change From Baseline in Vaccine Titers at Week 24

Vaccine-related immunoglobulin (Ig) titers for Pneumococcus (S. pneumoniae) including 23 types of serotypes (sero), tetanus and diphtheria were analyzed. AB = Antibody (NCT02847598)
Timeframe: Baseline to Week 24

,,,
Interventionpercent change (Mean)
Sero 1 IgG AB: Change at Week 24Sero 2 IgG AB: Change at Week 24Sero 3 IgG AB: Change at Week 24Sero 4 IgG AB: Change at Week 24Sero 5 IgG AB: Change at Week 24Sero 6B IgG AB: Change at Week 24Sero 7F IgG AB: Change at Week 24Sero 8 IgG AB: Change at Week 24Sero 9N IgG AB: Change at Week 24Sero 9V IgG AB: Change at Week 24Sero 10A IgG AB: Change at Week 24Sero 11A IgG AB: Change at Week 24Sero 12F IgG AB: Change at Week 24Sero 14 IgG AB: Change at Week 24Sero 15B IgG AB: Change at Week 24Sero 17F IgG AB: Change at Week 24Sero 18C IgG AB: Change at Week 24Sero 19A IgG AB: Change at Week 24Sero 19F IgG AB: Change at Week 24Sero 20 IgG AB: Change at Week 24Sero 22F IgG AB: Change at Week 24Sero 23F IgG AB: Change at Week 24Sero 33F IgG AB: Change at Week 24C.tetani IgG Antibody: Change at Week24Diphtheria IgG Antibody: Change at Week 24
Part A: BIIB059 150 mg-10.403-26.08916.282-26.4352.937-40.573-27.272-19.9192.985-13.59111.36414.976-41.4162.213-5.380-29.346-30.608-16.275-20.778-53.328-27.15035.862-47.06929.88777.083
Part A: BIIB059 450 mg159.2982.20751.00026.48123.06434.20419.82713.55213.70356.44524.32118.956-11.44720.27869.30551.18743.45432.146101.39775.40720.04822.32923.533-11.895-8.842
Part A: BIIB059 50 mg2.99617.857530.405-15.38581.053-7.7611.928-14.91722.663-3.399101.031-16.656-5.463-31.37517.3531.009-14.82744.8145.412-37.64123.82818.204-3.34839.032-50.000
Part A: Placebo53.629-2.263-10.854-8.03913.293-8.215-7.56013.54013.30232.98319.72951.134-4.445-3.08711.20620.23814.72021.43354.69135.20211.4190.2152.24519.51715.310

Part A: Percent Change From Baseline Over Time in Immunoglobulin Levels

(NCT02847598)
Timeframe: Baseline up to Week 24

,
Interventionpercent change (Mean)
IgA: Change at Week 24IgG: Change at Week 24IgM: Change at Week 24
Part A: BIIB059 150 mg-0.10-5.88-14.99
Part A: BIIB059 50 mg-15.55-2.53-6.73

Part A: Percent Change From Baseline Over Time in Immunoglobulin Levels

(NCT02847598)
Timeframe: Baseline up to Week 24

,
Interventionpercent change (Mean)
IgA: Change at Week 16IgA: Change at Week 24IgG: Change at Week 16IgG: Change at Week 24IgM: Change at Week 16IgM: Change at Week 24
Part A: BIIB059 450 mg-0.53-0.482.636.07-0.730.87
Part A: Placebo1.50-1.517.306.860.961.86

Part A: Serum Concentration of BIIB059

(NCT02847598)
Timeframe: Part A: pre-dose on Days 1, 29, 85 and 113 and post-dose on Days 1, 8, 29, 85, 169, 197 and 253

Interventionnanogram per milliliter (ng/mL) (Mean)
Day 1: Pre-doseDay 1: Post-doseDay 8Day 29: Pre-doseDay 29: Post-doseDay 85: Pre-doseDay 113: Pre-doseDay 169Day 197Day 253
Part A: BIIB059 150 mg0.02.117.123.725.912.711.312.84.10.4

Part A: Serum Concentration of BIIB059

(NCT02847598)
Timeframe: Part A: pre-dose on Days 1, 29, 85 and 113 and post-dose on Days 1, 8, 29, 85, 169, 197 and 253

Interventionnanogram per milliliter (ng/mL) (Mean)
Day 1: Pre-doseDay 1: Post-doseDay 8Day 29: Pre-doseDay 29: Post-doseDay 85: Pre-doseDay 85: Post-doseDay 113: Pre-doseDay 169Day 197Day 253
Part A: BIIB059 450 mg0.01.945.553.652.534.736.134.632.012.62.8

Part A: Serum Concentration of BIIB059

(NCT02847598)
Timeframe: Part A: pre-dose on Days 1, 29, 85 and 113 and post-dose on Days 1, 8, 29, 85, 169, 197 and 253

Interventionnanogram per milliliter (ng/mL) (Mean)
Day 1: Pre-doseDay 1: Post-doseDay 8Day 29: Pre-doseDay 29: Post-doseDay 85: Pre-doseDay 113: Pre-doseDay 169Day 197
Part A: BIIB059 50 mg0.00.75.57.07.93.93.43.70.9

Part B: Absolute Change From Baseline in Vaccine Titers - Clostridium Tetani (C. Tetani) and Diphtheria at Week 12

Vaccine-related immunoglobulin titers for tetanus and diphtheria were analyzed. (NCT02847598)
Timeframe: Baseline to Week 12

InterventionIU/mL (Mean)
C. tetani IgG Antibody: BaselineDiphtheria IgG Antibody: Baseline
Part B: BIIB059 50 mg3.000.10

Part B: Absolute Change From Baseline in Vaccine Titers - Clostridium Tetani (C. Tetani) and Diphtheria at Week 12

Vaccine-related immunoglobulin titers for tetanus and diphtheria were analyzed. (NCT02847598)
Timeframe: Baseline to Week 12

,
InterventionIU/mL (Mean)
C. tetani IgG Antibody: BaselineC. tetani IgG Antibody: Change at Week 12Diphtheria IgG Antibody: BaselineDiphtheria IgG Antibody: Change at Week 12
Part B: BIIB059 450 mg5.041.200.740.06
Part B: Placebo4.41-0.610.46-0.01

Part B: Absolute Change From Baseline in Vaccine Titers - Streptococcus Pneumoniae (S. Pneumoniae) at Week 12

Vaccine-related immunoglobulin (Ig) titers for Pneumococcus (S. pneumoniae) were analyzed, including 23 types of serotypes (sero). AB = Antibody. (NCT02847598)
Timeframe: Baseline to Week 12

Interventionmg/L (Mean)
Sero 1 IgG AB: BaselineSero 2 IgG AB: BaselineSero 3 IgG AB: BaselineSero 4 IgG AB: BaselineSero 5 IgG AB: BaselineSero 6B IgG AB: BaselineSero 7F IgG AB: BaselineSero 8 IgG AB: BaselineSero 9N IgG AB: BaselineSero 9V IgG AB: BaselineSero 10A IgG AB: BaselineSero 11A IgG AB: BaselineSero 12F IgG AB: BaselineSero 14 IgG AB: BaselineSero 15B IgG AB: BaselineSero 17F IgG AB: BaselineSero 18C IgG AB: BaselineSero 19A IgG AB: BaselineSero 19F IgG AB: BaselineSero 20 IgG AB: BaselineSero 22F IgG AB: BaselineSero 23F IgG AB: BaselineSero 33F IgG AB: Baseline
Part B: BIIB059 50 mg0.2100.99000.4000.10003.35000.36000.6600.23000.13000.0702.1400.35000.27008.90001.43017.45000.14013.77002.05000.79000.67000.56000.220

Part B: Absolute Change From Baseline in Vaccine Titers - Streptococcus Pneumoniae (S. Pneumoniae) at Week 12

Vaccine-related immunoglobulin (Ig) titers for Pneumococcus (S. pneumoniae) were analyzed, including 23 types of serotypes (sero). AB = Antibody. (NCT02847598)
Timeframe: Baseline to Week 12

,
Interventionmg/L (Mean)
Sero 1 IgG AB: BaselineSero 1 IgG AB: Change at Week 12Sero 2 IgG AB: BaselineSero 2 IgG AB: Change at Week 12Sero 3 IgG AB: BaselineSero 3 IgG AB: Change at Week 12Sero 4 IgG AB: BaselineSero 4 IgG AB: Change at Week 12Sero 5 IgG AB: BaselineSero 5 IgG AB: Change at Week 12Sero 6B IgG AB: BaselineSero 6B IgG AB: Change at Week 12Sero 7F IgG AB: BaselineSero 7F IgG AB: Change at Week 12Sero 8 IgG AB: BaselineSero 8 IgG AB: Change at Week 12Sero 9N IgG AB: BaselineSero 9N IgG AB: Change at Week 12Sero 9V IgG AB: BaselineSero 9V IgG AB: Change at Week 12Sero 10A IgG AB: BaselineSero 10A IgG AB: Change at Week 12Sero 11A IgG AB: BaselineSero 11A IgG AB: Change at Week 12Sero 12F IgG AB: BaselineSero 12F IgG AB: Change at Week 12Sero 14 IgG AB: BaselineSero 14 IgG AB: Change at Week 12Sero 15B IgG AB: BaselineSero 15B IgG AB: Change at Week 12Sero 17F IgG AB: BaselineSero 17F IgG AB: Change at Week 12Sero 18C IgG AB: BaselineSero 18C IgG AB: Change at Week 12Sero 19A IgG AB: BaselineSero 19A IgG AB: Change at Week 12Sero 19F IgG AB: BaselineSero 19F IgG AB: Change at Week 12Sero 20 IgG AB: BaselineSero 20 IgG AB: Change at Week 12Sero 22F IgG AB: BaselineSero 22F IgG AB: Change at Week 12Sero 23F IgG AB: BaselineSero 23F IgG AB: Change at Week 12Sero 33F IgG AB: BaselineSero 33F IgG AB: Change at Week 12
Part B: BIIB059 450 mg1.9300.1163.9669-0.47341.1330.3071.23760.04505.01243.47942.92100.27383.0300.7962.66290.59312.08480.58751.520-0.1816.6004.6963.58310.64311.24240.363811.0210-1.03193.4100.6246.87521.45315.6300.07716.56245.35753.38001.22758.2971-1.66383.80021.84311.99570.27754.2450.203
Part B: Placebo3.5384.1934.7775-0.45863.881-1.8863.61850.05717.28454.444310.79650.29432.4824.3993.68201.53294.10903.34071.104-0.0016.7601.8332.18600.62932.16801.14295.64351.36864.7170.20916.0005-2.03574.0838.43924.54853.44574.10402.389311.5305-0.22715.9930-1.85001.69801.99645.500-0.281

Part B: Absolute Change From Baseline Over Time in Immunoglobulin Levels

(NCT02847598)
Timeframe: Baseline up to Week 16

,
Interventiong/L (Mean)
IgA: BaselineIgA: Change at Week 16IgG: BaselineIgG: Change at Week 16IgM: BaselineIgM: Change at Week 16
Part B: BIIB059 150 mg2.900-0.01613.700-0.0841.095-0.045
Part B: BIIB059 50 mg3.873-0.11714.087-0.7760.880-0.072

Part B: Absolute Change From Baseline Over Time in Immunoglobulin Levels

(NCT02847598)
Timeframe: Baseline up to Week 16

,
Interventiong/L (Mean)
IgA: BaselineIgA: Change at Week 12IgA: Change at Week 16IgG: BaselineIgG: Change at Week 12IgG: Change at Week 16IgM: BaselineIgM: Change at Week 12IgM: Change at Week 16
Part B: BIIB059 450 mg3.061-0.304-0.07614.874-1.961-0.0640.993-0.028-0.035
Part B: Placebo3.341-0.029-0.04513.4800.1200.4500.978-0.009-0.016

Part B: Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An SAE is any untoward medical occurrence that at any dose: Results in death; in the view of the Investigator, places the participant at immediate risk of death (a life-threatening event); however, this does not include an event that, had it occurred in a more severe form, might have caused death; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; results in a congenital anomaly/birth defect. (NCT02847598)
Timeframe: Baseline up to Week 28

,,,
InterventionParticipants (Count of Participants)
AEsSAEs
Part B: BIIB059 150 mg153
Part B: BIIB059 450 mg383
Part B: BIIB059 50 mg181
Part B: Placebo223

Part B: Percent Change From Baseline in Vaccine Titers at Week 12

Vaccine-related immunoglobulin (Ig) titers for Pneumococcus (S. pneumoniae) including 23 types of serotypes (sero), tetanus and diphtheria were analyzed. AB = Antibody. (NCT02847598)
Timeframe: Baseline to Week 12

,
Interventionpercent change (Mean)
Sero 1 IgG AB: Change at Week 12Sero 2 IgG AB: Change at Week 12Sero 3 IgG AB: Change at Week 12Sero 4 IgG AB: Change at Week 12Sero 5 IgG AB: Change at Week 12Sero 6B IgG AB: Change at Week 12Sero 7F IgG AB: Change at Week 12Sero 8 IgG AB: Change at Week 12Sero 9N IgG AB: Change at Week 12Sero 9V IgG AB: Change at Week 12Sero 10A IgG AB: Change at Week 12Sero 11A IgG AB: Change at Week 12Sero 12F IgG AB: Change at Week 12Sero 14 IgG AB: Change at Week 12Sero 15B IgG AB: Change at Week 12Sero 17F IgG AB: Change at Week 12Sero 18C IgG AB: Change at Week 12Sero 19A IgG AB: Change at Week 12Sero 19F IgG AB: Change at Week 12Sero 20 IgG AB: Change at Week 12Sero 22F IgG AB: Change at Week 12Sero 23F IgG AB: Change at Week 12Sero 33F IgG AB: Change at Week 12C. tetani IgG Antibody: Change at Week 12Diphtheria IgG Antibody: Change at Week 12
Part B: BIIB059 450 mg4.25715.43740.60432.03368.85043.75925.29741.62219.616-0.57360.43729.29562.76818.05927.18819.7128.88244.14046.9950.71438.97416.85926.24127.87228.845
Part B: Placebo16.835-20.725-3.3706.34939.57811.80067.78428.98118.274-7.70762.82412.39221.76877.55114.160-14.12836.97015.17954.7731.131-14.74852.2100.600-6.3870.000

Part B: Percent Change From Baseline Over Time in Immunoglobulin Levels

(NCT02847598)
Timeframe: Baseline up to Week 16

,
Interventionpercent change (Mean)
Ig A: Change at Week 16Ig G: Change at Week 16Ig M: Change at Week 16
Part B: BIIB059 150 mg0.191.05-1.25
Part B: BIIB059 50 mg-1.48-3.84-7.60

Part B: Percent Change From Baseline Over Time in Immunoglobulin Levels

(NCT02847598)
Timeframe: Baseline up to Week 16

,
Interventionpercent change (Mean)
Ig A: Change at Week 12Ig A: Change at Week 16Ig G: Change at Week 12Ig G: Change at Week 16Ig M: Change at Week 12Ig M: Change at Week 16
Part B: BIIB059 450 mg-5.11-2.98-8.40-0.39-1.22-0.57
Part B: Placebo-1.45-1.320.632.48-1.25-3.62

Part B: Percentage of Participants With a >=4-point Change From Baseline in Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) Score at Week 12 and 16

The CLASI is a clinical tool that quantifies disease activity and damage in CLE. The activity scale (CLASI-A) includes measurements of erythema, scale and hypertrophy, and mucous membrane disease. Each part of the body is listed separately, from the scalp to the feet, in addition to sections focusing on mucous membrane involvement and alopecia. Points are given for the presence of erythema, scale, mucous membrane lesions, recent hair loss, and inflammatory alopecia. Composite scores are calculated by summing the individual component scores. CLASI-A scores of 0-9, 10-20, and 21-70 represent disease severity of mild, moderate, and severe, respectively. Higher scores indicate more disease activity. The percentage of participants with a >=4-point reduction from baseline in CLASI-A score are reported here. (NCT02847598)
Timeframe: Week 12, Week 16

,,,
Interventionpercentage of participants (Number)
Week 12Week 16
Part B: BIIB059 150 mg76.0072.00
Part B: BIIB059 450 mg47.9255.81
Part B: BIIB059 50 mg50.0046.15
Part B: Placebo33.3337.50

Part B: Percentage of Participants With a >=7-point Change From Baseline in Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) Score at Week 12 and 16

The CLASI is a clinical tool that quantifies disease activity and damage in CLE. The activity scale (CLASI-A) includes measurements of erythema, scale and hypertrophy, and mucous membrane disease. Each part of the body is listed separately, from the scalp to the feet, in addition to sections focusing on mucous membrane involvement and alopecia. Points are given for the presence of erythema, scale, mucous membrane lesions, recent hair loss, and inflammatory alopecia. Composite scores are calculated by summing the individual component scores. CLASI-A scores of 0-9, 10-20, and 21-70 represent disease severity of mild, moderate, and severe, respectively. Higher scores indicate more disease activity. The percentage of participants with a >=7-point reduction from baseline in CLASI-A score are reported here. (NCT02847598)
Timeframe: Week 12, Week 16

,,,
Interventionpercentage of participants (Number)
Week 12Week 16
Part B: BIIB059 150 mg40.0048.00
Part B: BIIB059 450 mg33.3341.86
Part B: BIIB059 50 mg38.4630.77
Part B: Placebo18.1821.88

Part B: Percentage of Participants With Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity- 50 (CLASI-50) Response at Week 12 and 16

CLASI-50 Response is defined as a 50% improvement from baseline in CLASI-A score at Weeks 12 and 16. The CLASI is a clinical tool that quantifies disease activity and damage in CLE. The activity scale (CLASI-A) includes measurements of erythema, scale and hypertrophy, and mucous membrane disease. Each part of the body is listed separately, from the scalp to the feet, in addition to sections focusing on mucous membrane involvement and alopecia. Points are given for the presence of erythema, scale, mucous membrane lesions, recent hair loss, and inflammatory alopecia. Composite scores are calculated by summing the individual component scores. CLASI-A scores of 0-9, 10-20, and 21-70 represent disease severity of mild, moderate, and severe, respectively. Higher scores indicate more disease activity. (NCT02847598)
Timeframe: Week 12, Week 16

,,,
Interventionpercentage of participants (Number)
Week 12Week 16
Part B: BIIB059 150 mg48.0044.00
Part B: BIIB059 450 mg37.5046.51
Part B: BIIB059 50 mg38.4638.46
Part B: Placebo12.1221.88

Part B: Serum Concentration of BIIB059

(NCT02847598)
Timeframe: Part B: pre-dose on Days 1, 29, 85 and post-dose on Days 1, 29, 85, 113, 141, 169 and 197

,,
Interventionng/mL (Mean)
Day 1: Pre-doseDay 1: Post-doseDay 8Day 29: Pre-doseDay 29: Post-doseDay 85: Pre-doseDay 85: Post-doseDay 113Day 141Day 169Day 197
Part B: BIIB059 150 mg0.11.113.316.917.611.011.612.14.62.21.1
Part B: BIIB059 450 mg0.02.947.860.261.042.042.043.219.37.43.4
Part B: BIIB059 50 mg0.00.46.88.38.73.84.14.62.52.40.8

Number of Participants With Changes of Safety Parameters

Number of Participants with changes in vital signs, ECGs, Safety laboratory parameters (full blood count including white differential count, clinical chemistry, thyroid hormones, urinalysis, and faecal occult blood test), Development of anti-drug antibodies against BT063 (anti-BT063), Immunological status of potential viral and bacterial infections (HBV, HCV, HIV, tetanus, diphtheria tuberculosis), EBV / CMV Serology, Premature withdrawals. (NCT02554019)
Timeframe: Baseline through End of Trial Visit (Week 14)

InterventionParticipants (Count of Participants)
BT063 50 mg0
BT063 100 mg0
Placebo0

Number of Participants With Adverse Events

Number of Participants with Adverse Events (Including SAEs and AEs leading to discontinuation) from Baseline through End of Trial Visit (Week 14) (NCT02554019)
Timeframe: Baseline through End of Trial Visit (Week 14)

,,
InterventionParticipants (Count of Participants)
Subjects with TEAEsSubjects with TEAEs leading to early terminationSubjects with treatment-emergent SAEsSubjects with drug-related TEAEsSubjects with severe TEAEsSubjects with TEAEs leading to death
BT063 100 mg801200
BT063 50 mg511100
Placebo800000

Number of Participants With Improvement of Skin

"Number of Participants with 50% improvement in Cutaneous Lupus Erythematosus Disease Area and Sensitivity Index (CLASI) Activity score. The CLASI is an assessment over 13 body regions (scalp, ears, nose - including malar area, rest of the face, V-area neck - frontal, post. neck & shoulders, chest, abdomen, back and buttocks, arms, hands, legs, feet) and consists of 2 scores: total activity score and total damage score. Only the activity score was used in this study.~The minimum score possible on this scale is 0 and the maximum score is 70. The higher scores mean a worse outcome." (NCT02554019)
Timeframe: At week14 and week 28

,,
InterventionParticipants (Count of Participants)
50% improvement in CLASI Activity score at week 1450% improvement in CLASI Activity score at week 28
BT063 100 mg54
BT063 50 mg67
Placebo33

Number of Participants With Improvements of Joints

Number of Participants with 50% improvement of swollen/tender joints. A total of 66/68 joints was assessed for the swollen/tender joint count. A joint that is normal (no tenderness or swelling), without signs of inflammation will be graded as 0. A joint with tenderness will be graded as 1 for tender joint count and a joint with swelling will be graded as 1 for swollen joint count. Joints suspected or known to have ischemic osteonecrosis are not to be taken into consideration. Higher scores indicate more disease activity. (NCT02554019)
Timeframe: At week14 and week 28

,,
InterventionParticipants (Count of Participants)
50% improvement in swollen joints at week 1450% improvement in swollen joints at week 2850% improvement in tender joints at week 1450% improvement in tender joints at week 28
BT063 100 mg5476
BT063 50 mg8757
Placebo8766

Percent Changes in Systemic Lupus Erythematosus Disease Activity Index 2000

"Percent changes in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) scores from baseline SLEDAI-2K score.~The SLEDAI-2K is a global index that measures SLE disease activity. It includes 24 items for the 9 organs/systems. Scores range from 0 to 105; a score of 6 is considered clinically important. The index measures disease activity within the last 10 days. Higher scores mean worse outcome. Negative percent change means reduced disease activity." (NCT02554019)
Timeframe: Baseline to week 14 and at week 28

,,
Interventionpercentage of change (Mean)
Percent changes in SLEDAI-2K scores at week 14Percent changes in SLEDAI-2K scores at week 28
BT063 100 mg-18.0-24.4
BT063 50 mg-29.3-28.9
Placebo-18.2-13.5

Change From Baseline in Number of Joints With Pain and Signs of Inflammation at Week 24

Change from baseline in number of joints (active joint) with pain and signs of inflammation (tenderness, swelling or effusion) for participants with at least 2 affected joints at baseline were reported. An active joint is defined as a joint with pain and signs of inflammation (e.g., tenderness, swelling or effusion). (NCT02349061)
Timeframe: Baseline, Week 24

InterventionJoints (Mean)
Placebo-2.8
Ustekinumab-4.5

Change From Baseline in Physician's Global Assessment of Disease Activity (PGA) Score at Week 24

PGA was recorded on a visual analogue scale (VAS; 0.0 to 10.0 centimeter [cm]). The scale for the physician's assessment ranges for 'no lupus activity' (0.0) to 'extremely active lupus' (10.0). (NCT02349061)
Timeframe: Baseline, Week 24

InterventionUnits on a scale (Mean)
Placebo-1.93
Ustekinumab-2.17

Change From Baseline in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI 2K) Score at Week 24

The SLEDAI-2K is an established, validated SLE activity index. It is based on the presence of 24 features in 9 organ systems and measures disease activity in SLE patients in the previous 30 days. It is weighted according to the feature. Features are scored by the assessing physician if present within the last 30 days with more severe features having higher scores, and then simply added to determine the total SLEDAI 2K score, which ranges from 0 to 105, with higher scores representing increased disease activity. (NCT02349061)
Timeframe: Baseline, Week 24

InterventionUnits on a scale (Mean)
Placebo-3.8
Ustekinumab-4.4

Number of Participants With BILAG-based Combined Lupus Assessment (BICLA) Response at Week 24

BICLA response defined as participants meeting following criteria: 1. BILAG improvement (all BILAG A scores at baseline improved to either B, C or D and all BILAG B scores at baseline improved to C or D and no worsening in disease activity defined as no new BILAG A scores and <= 1 new BILAG B score) and 2. no worsening of total SLEDAI-2K from baseline 3. < 1 cm increase in PGA and 4. no treatment failure criteria met. BILAG: assesses disease extent, severity (range: A [severe] to E [no disease]). SLEDAI-2K: assesses improvement in disease activity (range: 0 to 105; higher score = higher severity). PGA: assesses worsening in participant's general health status (0.0= 'no lupus activity' to 10.0 = 'extremely active lupus'). (NCT02349061)
Timeframe: Week 24

InterventionParticipants (Count of Participants)
Placebo14
Ustekinumab21

Percentage of Participants With a Systemic Lupus Erythematosus Responder Index (SRI-4) Composite Response (CR) at Week 24

SRI-4 response was defined as greater than or equal to 4-point reduction in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) total score, no new British Isles Lupus Assessment Group (BILAG) A and no more than 1 new BILAG B domain score and no worsening (less than 10 percent increase) from baseline in Physician's Global Assessment of Disease Activity (PGA). Composite response is defined as SRI-4 response in participants who do not meet treatment failure criteria. SLEDAI-2K assessment consists of 24 items with total score of 0 to 105, with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system: A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. The PGA assess disease activity on a visual analogue scale = from very well (0)-very poor (10). (NCT02349061)
Timeframe: Week 24

InterventionPercentage of participants (Number)
Placebo33.3
Ustekinumab61.7

Area Under Curve of Belimumab at Steady State (AUC, ss)

The PK model was fitted to the observed serum concentration-time data. The AUC values reported in this table are model derived values at ss, assuming a 10 mg/kg dose administered once every 28 days. (NCT01649765)
Timeframe: 28-days dosing interval at steady state

InterventionMicrograms per milliliter (Geometric Mean)
Belimumab 10 mg/kg3012

Percent Change From Baseline in ParentGA at Week 52

ParentGA assesses the participant's overall well-being at the moment rated on a 21-numbered circle visual analog scale (VAS; 0 - very well, 10 - very poorly). Baseline was defined as measurements at Day 0. Percent change from Baseline was calculated by subtracting the Baseline value from value at Week 52 divided by the Baseline value X 100. Last Observation Carried Forward (LOCF) was used. Eight participants had a score of zero at Baseline and therefore, could not be included in the analysis. (NCT01649765)
Timeframe: Baseline (Day 0) and Week 52

InterventionPercent change (Median)
Placebo-23.61
Belimumab 10 mg/kg-53.85

Percent Change From Baseline in PedsQL Physical Functioning Domain Score at Week 52

The PedsQL is a generic quality of life scale validated for the pediatric population which consists of 23 items, encompassing 4 health domains: Physical Functioning (8 items), Emotional Functioning (5 items), Social Functioning (5 items), and School Functioning (5 items). From the raw scores of the 23 items, a total summary score and individual domain scores can be calculated. The total and domain scores are each transformed on a 0 to 100 score with higher scores indicating higher quality of life. For Physical Functioning Domain scale, score was from 0 to 100 where, 0 indicates lower quality of life and 100 indicates greater quality of life. Baseline was defined as measurements at Day 0. Percent change from Baseline was calculated by subtracting the Baseline value from value at Week 52 divided by the Baseline Value X 100. LOCF was used. (NCT01649765)
Timeframe: Baseline (Day 0) and Week 52

InterventionPercent change (Median)
Placebo12.5
Belimumab 10 mg/kg10.5

Percent Change From Baseline in PGA at Week 52

The PGA is a 10 centimeter (cm) visual analogue scale (VAS), anchored at 0 (none) and 3 (severe), designed for the physician to indicate the participant's overall disease activity at a particular visit as part of the validated SELENA SLEDAI index. Primary investigator or a subinvestigator scored the PGA for the participant, and same person evaluated the participant each time. Baseline was defined as measurements at Day 0. Percent change from Baseline was calculated by subtracting the Baseline value from value at Week 52 divided by the Baseline value X 100. LOCF was used. (NCT01649765)
Timeframe: Baseline (Day 0) and Week 52

InterventionPercent change (Mean)
Placebo-48.802
Belimumab 10 mg/kg-56.525

Percent Change From Baseline in Proteinuria at Week 52

Percent change from Baseline in proteinuria was calculated. The percent change from baseline to Week 52 in 24 hour proteinuria was analyzed using summary statistics and 95% confidence intervals, without any adjustment for covariates. Baseline was defined as measurements at Day 0. Percent change from Baseline was calculated by subtracting the Baseline value from value at Week 52 divided by the Baseline Value X 100. LOCF was used. (NCT01649765)
Timeframe: Baseline (Day 0) and Week 52

InterventionPercent Change (Median)
Placebo7.0920
Belimumab 10 mg/kg-2.1277

Percent Change From Baseline in SELENA SLEDAI at Week 52

The SELENA SLEDAI score is a weighted index for assessing SLE disease activity in which signs and symptoms, laboratory tests and physician's assessment for each of 9 organ system were given a weighted score and summed if present at the time of the visit or in the preceding 10 days. A SELENA SLEDAI score of 0 would suggest no lupus activity; while a score of 105 is the maximum calculable if all items were scored as being present from active lupus. A decrease of 4 points or more equates to a clinically meaningful improvement. Baseline was defined as measurements at Day 0. Percent change from Baseline was calculated by subtracting the Baseline value from value at Week 52 divided by the Baseline value X 100. One participant had missing data at Baseline and therefore, could not be included in the analysis. (NCT01649765)
Timeframe: Baseline (Day 0) and Week 52

InterventionPercent change (Mean)
Placebo-38.0
Belimumab 10 mg/kg-43.3

Percentage of Participants With a Sustained ParentGA Response

Sustained ParentGA response was defined as having >0.7 improvement at Weeks 44, 48, and 52 compared at Baseline. Data for percentage of participants with a sustained ParentGA response was presented. Thirteen participants had a score of <=0.7 at Baseline and therefore, could not be included in the analysis. (NCT01649765)
Timeframe: Up to 52 weeks

InterventionPercentage of Participants (Number)
Placebo33.3
Belimumab 10 mg/kg59.1

Percentage of Participants With a Sustained SRI Response

Sustained SRI response was defined as having a response on the primary efficacy endpoint at Weeks 44, 48, and 52. Data for percentage of participants with a sustained SRI response was presented. Drop Outs and Treatment Failures were considered Non-Responders. Only those participants with data available at specific time point were analyzed. (NCT01649765)
Timeframe: Up to 52 weeks

InterventionPercentage of participants (Number)
Placebo41.0
Belimumab 10 mg/kg43.4

Percentage of Participants With SLE Responder Index (SRI) Response at Week 52

SRI response is defined as >=4 point reduction, from Baseline in safety of estrogen in lupus national assessment (SELENA) systemic lupus erythematosus disease activity index (SLEDAI) score, no worsening (increase of <0.30 points from Baseline) in physician's global assessment (PGA) and no new British Isles Lupus Assessment Group of SLE clinics (BILAG) A organ domain score or 2 new BILAG B organ domain scores compared with Baseline. Analysis was performed using a logistic regression model for the comparison between belimumab and placebo with covariates treatment group, Baseline SELENA SLEDAI score (<=12 vs. >=13). Percentage of participants with SRI response at Week 52 of Part A were reported. Intent-to-Treat Population comprised of all participants who were randomized and treated with at least one dose of study agent in Part A. One participant had missing data at Baseline and therefore, could not be included in the analysis. (NCT01649765)
Timeframe: Week 52

InterventionPercentage of participants (Number)
Placebo43.6
Belimumab 10 mg/kg52.8

Maximum Concentration at Steady State (Cmax, ss) and Minimum Concentration at Steady State (Cmin, ss)

The pharmacokinetic (PK) population comprised all participants included in the As- Treated population for whom at least one post belimumab treatment PK sample was obtained and analyzed. The PK model was fitted to the observed serum concentration-time data. The maximum (Cmax) and minimum (Cmin) concentrations reported in this table are model derived values at ss, assuming a 10 mg/kg dose administered once every 28 days. (NCT01649765)
Timeframe: 28-days dosing interval at steady state

InterventionMicrograms per milliliter (Geometric Mean)
Cmax, ssCmin, ss
Belimumab 10 mg/kg31550

Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE is any untoward medical occurrence in a clinical investigation participant, temporarily associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment or all events of possible drug-induced liver injury with hyperbilirubinemia were categorized as SAE. Number of participants with AEs and SAEs have been reported. (NCT01649765)
Timeframe: Up to 60 weeks

,
InterventionParticipants (Count of Participants)
AEsSAEs
Belimumab 10 mg/kg429
Placebo3314

Percentage of Participants Meeting Pediatric Rheumatology International Trials Organization (PRINTO)/ American College of Rheumatology (ACR) Juvenile SLE Response Evaluation Criteria for Improvement in Juvenile SLE at Week 52 Using Definition 1 and 2

Percentage of participants meeting PRINTO/ACR Juvenile SLE Response Evaluation criteria for improvement in juvenile SLE using two different PRINTO/ACR Juvenile SLE Response Evaluation definitions of improvement that is Definition 1: At least 50% improvement in any 2 of 5 endpoints below and no more than 1 of the remaining worsening by more than 30% and Definition 2: At least 30% improvement in 3 of 5 endpoints below and no more than 1 of the remaining worsening more than 30%. Endpoints were: 1. Percent change in Parent's Global Assessment (ParentGA) at Week 52, 2. Percent change in PGA at Week 52, 3. Percent change in SELENA SLEDAI score at Week 52, 4. Percent change in Pediatric Quality of Life Inventory (PedsQL) physical functioning domain at Week 52, 5. Percent change in 24 hour proteinuria at Week 52 (gram/24hour equivalent by spot urine protein to creatinine ratio). (NCT01649765)
Timeframe: Week 52

,
InterventionPercentage of participants (Number)
Definition 1Definition 2
Belimumab 10 mg/kg60.452.8
Placebo35.027.5

Area Under the Plasma Concentration-Time Curve From Time 0 to the Last Measurable Concentration (AUCt) of Iberdomide

The area under the plasma concentration time curve (AUCt) was defined as area under the concentration-time curve from time zero to the last quantifiable time point, calculated by the linear trapezoidal rule when concentrations are increasing and the logarithmic trapezoidal method when concentrations are decreasing. Single and multiple-dose PK were collected in Part 1 of the study for all dose groups. Iberdomide reaches steady state within 7 days. PK collection on Day 29 was sufficient to understand PK once steady state was reached. As no dose adjustments were made in ATEP, further PK collection was not needed. (NCT02185040)
Timeframe: Pharmacokinetic (PK) blood samples were collected on Day 1 and Day 29 pre-dose (Time = 0 hours) and at 1, 2, 3, 4, between 6 and 8 hours and 24 hours after administration of IP.

,,,
Interventionng*h/mL (Geometric Mean)
Day 1Day 29
Part 1: Iberdomide 0.3 mg QD11.2915.55
Part 1: Iberdomide 0.3 mg QOD10.8213.34
Part 1: Iberdomide 0.6 mg QD38.7352.65
Part 1: Iberdomide 0.6 mg/0.3 mg ALT Days34.1524.85

Change From Baseline in Swollen Joint Count During the ATEP by Time Point

Joint swelling was noted as present or absent. Forty-four joints were assessed for swelling, including the sternoclavicular, acromioclavicular, shoulder, elbow, wrist, metacarpophalangeal (MCP), proximal interphalangeal (PIP), knee, ankle, and metatarsophalangeal (MTP) joints were included in this joint count. (NCT02185040)
Timeframe: Baseline to Weeks 1, 4, 12, 24, 36, 48, 60, 72, 84, 96 and follow-up at Week 100 during the ATEP.

,
InterventionJoints (Mean)
Week 1Week 4Week 12Week 24Week 36Week 48Week 60Week 72Week 84Week 96Week 100 Follow-Up
ATEP: Iberdomide 0.3 mg QD-1.2-1.8-2.6-2.1-3.9-3.6-2.6-4.0-4.2-3.7-3.6
ATEP: Iberdomide 0.6 mg/0.3 mg ALT Days-0.4-0.6-0.31.2-0.20.60.40.70.00.0-0.4

Change From Baseline in Tender Joint Count During the ATEP by Time Point

Joint tenderness was noted as present or absent. Forty-four joints were assessed for swelling, including the sternoclavicular, acromioclavicular, shoulder, elbow, wrist, metacarpophalangeal (MCP), proximal interphalangeal (PIP), knee, ankle, and metatarsophalangeal (MTP) joints were included in this joint count. (NCT02185040)
Timeframe: Baseline to Weeks 1, 4, 12, 24, 36, 48, 60, 72, 84, 96 and follow-up at Week 100 during the ATEP.

,
InterventionJoints (Mean)
Week 1Week 4Week 12Week 24Week 36Week 48Week 60Week 72Week 84Week 96Week 100 Follow-Up
ATEP: Iberdomide 0.3 mg QD-0.9-0.90.5-3.9-5.1-5.9-5.6-6.2-7.3-7.0-4.1
ATEP: Iberdomide 0.6 mg/0.3 mg ALT Days-2.5-2.0-3.7-3.6-3.8-3.0-4.4-6.70.00.0-1.4

Change From Baseline in the British Isles Lupus Assessment Group (BILAG) 2004 Global Score During the ATEP by Time Point

The BILAG-2004 index measures clinical disease activity in systemic lupus erythematosus (SLE). A single alphabetic score (A through E) is used to denote disease severity for each of the 9 domains (constitutional, mucocutaneous, neuropsychiatric, musculoskeletal, cardiorespiratory, gastrointestinal, ophthalmic, renal, and hematologic). BILAG A represents the most active disease or severe disease; BILAG B represents intermediate activity or moderate disease; BILAG C represents stable mild disease; BILAG D represents organ system previously affected but now inactive; and BILAG E represents organ system never involved. The global BILAG score is the sum of a converted numerical score (A=9, B=3, C=1, D=0, E=0) over 9 domains. The theoretical range spans from 0 (no activity) to 13 active or severe disease activity BILAG. A higher score means more severe disease activity while a lower score means lower disease activity (or no disease activity for score of zero). (NCT02185040)
Timeframe: Baseline to Weeks 1, 4, 12, 24, 36, 48, 60, 72, 84, 96 and follow-up at Week 100 during the ATEP.

,
InterventionUnits on a Scale (Mean)
Week 1Week 4Week 12Week 24Global Score Week 36Week 48Week 60Week 72Week 84Week 96Follow-Up Week 100
ATEP: Iberdomide 0.3 mg QD-0.52.0-2.2-6.3-7.3-6.1-6.3-7.5-7.8-0.52-6.3
ATEP: Iberdomide 0.6 mg/0.3 mg ALT Days3.30.72.03.01.61.40.44.3-1.0-0.20-3.9

Change From Baseline in the Cutaneous Lupus Area and Severity Index (CLASI) Damage Score During the ATEP by Time Point

The CLASI Activity Score ranges from 0 to 70. To generate the activity score erythema is scored on a scale of 0 (absent) to 3 (dark red; purple/violaceous/crusted/hemorrhagic) and scale/hypertrophy are scored on a scale of 0 (absent) to 2 (verrucous/hypertrophic). Both the erythema and scale/hypertrophy scores are assessed in 13 different anatomical locations. In addition, the presence of mucous membrane lesions is scored on a scale of 0 (absent) to 1 (lesion or ulceration), the occurrence of recent hair loss is captured (1=yes; 0=no) and nonscarring alopecia is scored on a scale of 0 (absent) to 3 (focal or patchy in more than one quadrant). To calculate the CLASI activity score, all scores for erythema, scale/hypertrophy, mucous membrane lesions and alopecia are added together. Composite scores are calculated by summing the individual component scores. The higher the score, the greater the cutaneous disease activity. (NCT02185040)
Timeframe: Baseline to Weeks 1, 4, 12, 24, 36, 48, 60, 72, 84, 96 and follow-up at Week 100 during the ATEP.

,
InterventionUnits on a Scale (Mean)
Week 1Week 4Week 12Week 24Week 36Week 48Week 60Week 72Week 84Week 96Follow-Up Week 100
ATEP: Iberdomide 0.3 mg QD-0.10.0-0.60.10.10.30.40.30.70.0-0.3
ATEP: Iberdomide 0.6 mg/0.3 mg ALT Days0.0-1.0-0.9-2.2-2.2-2.4-2.6-0.7-1.00.00.0

Change From Baseline in the Fatigue Visual Analog Scale (VAS) During the ATEP by Time Point

"The Fatigue VAS evaluates SLE-related fatigue using a 0 to 100 mm VAS scale. The Fatigue VAS allowed the participant to indicate the degree of SLE-related fatigue by placing an X representing how they feel, along a visual analog line that extends between two extremes (e.g., from not at all tired to extremely tired) over the previous week. A decrease in the fatigue VAS indicates improvement." (NCT02185040)
Timeframe: Baseline to Weeks 1, 4, 12, 24, 36, 48, 60, 72, 84, 96 and follow-up at Week 100 during the ATEP.

,
InterventionUnits on a Scale (Mean)
Week 1Week 4Week 12Week 24Week 36Week 48Week 60Week 72Week 84Week 96
ATEP: Iberdomide 0.3 mg QD-10.0-4.1-15.9-13.6-21.1-29.9-23.0-22.8-10.3-9.8
ATEP: Iberdomide 0.6 mg/0.3 mg ALT Days-4.0-3.7-8.0-4.0-17.2-12.8-12.6-25.7-14.0-20.0

Change From Baseline in the Hybrid Systemic Lupus Erythematosus Disease Activity Index (SELENA SLEDAI) During the ATEP by Time Point

The SELENA SLEDAI score measures SLE disease activity through assessment of 24 lupus descriptors/manifestations. Each descriptor (clinical or lab values) receives a positive score if it is present over the previous assessment period; a score of '0' indicates inactive disease while a positive score (from 1 to 8 based on the relative importance of each descriptor in the total scoring) indicates disease activity. The SELENA SLEDAI score is the sum of all 24 descriptors' scores for the assessment period. The SELENA SLEDAI score can range from '0' (no SLE disease activity) to a maximum theoretical score of 105 (maximum SLE disease activity). The higher the SELENA SLEDAI score the greater of SLE disease activity. (NCT02185040)
Timeframe: Baseline to Weeks 1, 4, 12, 24, 36, 48, 60, 72, 84, 96 and follow-up at Week 100 during the ATEP.

,
InterventionUnits on a Scale (Mean)
Week 1Week 4Week 12Week 24Week 36Week 48Week 60Week 72Week 84Week 96Week 100 Follow-Up
ATEP: Iberdomide 0.3 mg QD0.20.2-1.8-2.8-3.1-2.9-2.6-3.0-3.0-2.0-1.7
ATEP: Iberdomide 0.6 mg/0.3 mg ALT Days-1.0-1.7-0.9-1.20.3-1.0-1.8-1.3-1.00.00.3

Change From Baseline in the Pericardial/Pleuritic Pain Scale During ATEP by Time Poimt

The pericardial/pleuritic pain scale was scored using numerical values of 1 through 10 with 1 representing 'no pain' and 10 representing 'worst possible pain'. These were self-administered by the participants and gauged the severity of their SLE pain related to pericardial and pleuritic discomfort. Any indication from participants or study assessments, aside from pain, which indicated clinically significant pericardial or pleuritic manifestations of SLE was thoroughly investigated; if clinically significant SLE related complications were found, the participants was to be discontinued from the study and entered into the Observational Follow-up Period and treated appropriately. (NCT02185040)
Timeframe: Baseline to Weeks 1, 4, 12, 24, 36, 48, 60, 72, 84, 96 and follow-up at Week 100 during the ATEP.

,
InterventionUnits on a Scale (Mean)
Week 1Week 4Week 12Week 24Week 36Week 48Week 60Week 72Week 84Week 96Follow-Up Week 100
ATEP: Iberdomide 0.3 mg QD-1.0-0.8-1.1-1.0-0.7-1.4-1.10.20.2-0.2-0.6
ATEP: Iberdomide 0.6 mg/0.3 mg ALT Days0.80.91.30.60.70.91.10.00.00.00.2

Change From Baseline in the Physician's Global Assessment (PGA) Score During the ATEP by Time Point

"The physician's global assessment was administered by the treating physician and was used to gauge the participants overall state of health. The instrument uses a visual analogue scale with scores between 0 and 3 to indicate worsening of disease. The scoring is as follows:~0 = none~1 = mild disease~2 = moderate disease~3 = severe disease" (NCT02185040)
Timeframe: Baseline to Weeks 1, 4, 12, 24, 36, 48, 60, 72, 84, 96 and follow-up at Week 100 during the ATEP.

,
InterventionUnits on a Scale (Mean)
Week 1Week 4Week 12Week 24Week 36Week 48Week 60Week 72Week 84Week 96Follow-Up Week 100
ATEP: Iberdomide 0.3 mg QD-0.08-0.26-0.15-0.28-0.30-0.53-0.37-0.48-0.57-0.52-0.21
ATEP: Iberdomide 0.6 mg/0.3 mg ALT Days-0.10-0.17-0.31-0.20-0.36-0.26-0.24-0.23-0.30-0.200.10

Change From Baseline in the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Systemic Lupus Erythematosus (SLICC/ACR SLE) Damage Index Score During the ATEP by Time Point

SLICC/ACR score or damage index is a measure of cumulative damage due to Systemic Lupus Erythematosus (SLE). Damage is defined as nonreversible change (not related to active inflammation) occurring since onset of lupus, ascertained by clinical assessment and present for at least 6 months. Damage is defined for 12 separate organ systems: ocular (range 0-2), neuropsychiatric (0-6), renal (0-3), pulmonary (0-5), cardiovascular (0-6), peripheral vascular (0-5), gastrointestinal (0-6), musculoskeletal (0-7), skin (0-3), endocrine (diabetes) (0-1), gonadal (0-1) and malignancies (0-2). A score of 0=no damage, early damage is defined as ≥1. The total maximum score is 47, and increasing score indicates increasing disease damage severity. (NCT02185040)
Timeframe: Baseline to Weeks 1, 4, 12, 24, 36, 48, 60, 72, 84, 96 and follow-up at Week 100 during the ATEP.

,
InterventionUnits on a Scale (Mean)
Week 1Week 4Week 12Week 24Week 36Week 48Week 60Week 72Week 84Week 96Follow-Up Week 100
ATEP: Iberdomide 0.3 mg QD-0.1-0.1-0.1-0.10.00.00.00.00.00.00.6
ATEP: Iberdomide 0.6 mg/0.3 mg ALT Days0.0-0.1-0.1-0.2-0.2-0.2-0.20.00.00.00.0

Maximum Observed Concentration (Cmax) Of Iberdomide

Maximum observed plasma concentration, obtained directly from the observed concentration versus time data. Single and multiple-dose PK were collected in Part 1 of the study for all dose groups. Iberdomide reaches steady state within 7 days. PK collection on Day 29 was sufficient to understand PK once steady state was reached. As no dose adjustments were made in ATEP, further PK collection was not needed. (NCT02185040)
Timeframe: Pharmacokinetic blood samples were collected on Day 1 and Day 29 at pre-dose (Time = 0 hours) and at 1, 2, 3, 4, between 6 and 8 hours and 24 hours after administration of IP.

,,,
Interventionng/mL (Geometric Mean)
Day 1Day 29
Part 1: Iberdomide 0.3 mg QD0.641.09
Part 1: Iberdomide 0.3 mg QOD0.901.02
Part 1: Iberdomide 0.6 mg QD2.353.51
Part 1: Iberdomide 0.6 mg/0.3 mg ALT Days2.922.37

Number of Participants With Treatment Emergent Adverse Events (TEAEs) in Part 1 Treatment Phase

A TEAE was defined as any adverse event (AE) that began or worsened on or after the start of IP up to 28 days after the last dose of IP or IP discontinuation date, whichever was later. Each participant was counted once for each applicable category. An IP-related TEAE was defined as a TEAE that the investigator considered to be of suspected relationship to IP. The severity of each adverse event and serious AE (SAE) was assessed by the investigator and graded based on a scale from mild - mild symptoms to severe AEs (non-serious or serious). A serious adverse event (SAE) was any AE which: • Resulted in death • Was life-threatening • Required inpatient hospitalization or prolongation of existing hospitalization • Resulted in persistent or significant disability/incapacity • Was a congenital anomaly/birth defect • Constituted an important medical event. (NCT02185040)
Timeframe: From the start of the first dose of IP until 28 days after the last dose or study discontinuation in Part 1; median treatment duration = 12.0 weeks for the placebo, 0.3 mg QOD and 0.3 mg iberdomide QD arms, 11.9 weeks for the 0.6/0.3 ALT and 0.6 cohorts.

,,,,
InterventionParticipants (Count of Participants)
Any TEAEAny IP-related TEAEAny Severe TEAEAny Serious TEAEAny Serious IP-related TEAEAny TEAE Leading to IP InterruptionAny TEAE Leading to IP WithdrawalAny TEAE Leading to Death
Part 1: Iberdomide 0.3 mg QD72000100
Part 1: Iberdomide 0.3 mg QOD72000000
Part 1: Iberdomide 0.6 mg QD86211530
Part 1: Iberdomide 0.6 mg/0.3 mg ALT Days84110120
Part 1: Placebo51120010

Number of Participants With Treatment Emergent Adverse Events (TEAEs) in the Active Treatment Extension Phase

A TEAE was defined as any adverse event (AE) that began or worsened on or after the start of IP through 28 days after the last dose of IP or IP discontinuation date, whichever was later. Each participant was counted once for each applicable category. An IP-related TEAE was defined as a TEAE that the investigator considered to be of suspected relationship to IP. The severity of each adverse event and serious AE (SAE) was assessed by the investigator and graded based on a scale from mild - mild symptoms to severe AEs (non-serious or serious). A serious adverse event (SAE) was any AE which: • Resulted in death • Was life-threatening • Required inpatient hospitalization or prolongation of existing hospitalization • Resulted in persistent or significant disability/incapacity • Was a congenital anomaly/birth defect • Constituted an important medical event. (NCT02185040)
Timeframe: From the date of the first dose of IP in the ATEP until 28 days after the last dose in the ATEP or study discontinuation; median duration of IP was 95.86 weeks for the 0.3 mg iberdomide QD cohort and 60.64 weeks for the 0.6 mg/0.3 mg ALT QD cohorts.

,
InterventionParticipants (Count of Participants)
Any TEAEAny IP-related TEAEAny Severe TEAEAny Serious TEAEAny Serious IP-related TEAEAny TEAE Leading to IP InterruptionAny TEAE Leading to IP WithdrawalAny TEAE Leading to Death
ATEP: Iberdomide 0.3 mg QD92000210
ATEP: Iberdomide 0.6 mg/0.3 mg ALT Days75540540

Percent Change From Baseline in Cutaneous Lupus Area and Severity Index (CLASI) Activity Score During the ATEP by Time Point

The CLASI Activity Score ranges from 0 to 70. To generate the activity score erythema is scored on a scale of 0 (absent) to 3 (dark red; purple/violaceous/crusted/hemorrhagic) and scale/hypertrophy are scored on a scale of 0 (absent) to 2 (verrucous/hypertrophic). Both the erythema and scale/hypertrophy scores are assessed in 13 different anatomical locations. In addition, the presence of mucous membrane lesions is scored on a scale of 0 (absent) to 1 (lesion or ulceration), the occurrence of recent hair loss is captured (1=yes; 0=no) and nonscarring alopecia is scored on a scale of 0 (absent) to 3 (focal or patchy in more than one quadrant). To calculate the CLASI activity score, all scores for erythema, scale/hypertrophy, mucous membrane lesions and alopecia are added together. Composite scores are calculated by summing the individual component scores. The higher the score, the greater the cutaneous disease activity. (NCT02185040)
Timeframe: Baseline to Weeks 1, 4, 12, 24, 36, 48, 60, 72, 84, 96 and follow-up at Week 100 during the ATEP.

,
InterventionPercent Change (Mean)
Week 1Week 4Week 12Week 24Week 36Week 48Week 60Week 72Week 84Week 96Follow-Up Week 100
ATEP: Iberdomide 0.3 mg QD-21.40-32.13-18.4213.54-0.56-46.97-65.64-55.13-65.71-75.38-53.04
ATEP: Iberdomide 0.6 mg/0.3 mg ALT Days-13.35-18.32-36.46-44.69-43.98-46.00-47.51-40.35-32.46-26.32-18.82

Percentage of Participants Who Achieved ≥4 Points Reduction From Baseline in Hybrid Safety of Estrogens in Systemic Lupus Erythematosus National Assessment SLE Disease Activity Index Score (SELENA SLEDAI) During the ATEP by Time Point

The SELENA SLEDAI score measures SLE disease activity through assessment of 24 lupus descriptors/manifestations. Each descriptor (clinical or lab values) receives a positive score if it is present over the previous assessment period; a score of '0' indicates inactive disease while a positive score (from 1 to 8 based on the relative importance of each descriptor in the total scoring) indicates disease activity. The SELENA SLEDAI score is the sum of all 24 descriptors' scores for the assessment period. The SELENA SLEDAI score can range from '0' (no SLE disease activity) to a maximum theoretical score of 105 (maximum SLE disease activity). The higher the SELENA SLEDAI score the greater of SLE disease activity. (NCT02185040)
Timeframe: Baseline to Weeks 1, 4, 12, 24, 36, 48, 60, 72, 84, 96 and follow-up at Week 100 during the ATEP.

,
InterventionPercentage of Participants (Number)
Week 1Week 4Week 12Week 24Week 36Week 48Week 60Week 72Week 84Week 96Week 100 Follow-Up
ATEP: Iberdomide 0.3 mg QD0.00.066.783.366.750.033.380.080.040.040.0
ATEP: Iberdomide 0.6 mg/0.3 mg ALT Days12.514.30.020.00.020.020.00.00.00.00.0

Terminal Phase Half-Life (T1/2) Of Iberdomide

Terminal phase half-life in plasma, calculated as [(In 2)/λz]. T1/2 half was only calculated when a reliable estimate for λz could be obtained. Single and multiple-dose PK were collected in Part 1 of the study for all dose groups. Iberdomide reaches steady state within 7 days. PK collection on Day 29 was sufficient to understand PK once steady state was reached. As no dose adjustments were made in ATEP, further PK collection was not needed. (NCT02185040)
Timeframe: Pharmacokinetic blood samples were collected on Day 1 and Day 29 at pre-dose (Time = 0 hours) and at 1, 2, 3, 4, between 6 and 8 hours and 24 hours after administration of IP.

,,,
Interventiondays (Geometric Mean)
Day 1Day 29
Part 1: Iberdomide 0.3 mg QD10.2511.85
Part 1: Iberdomide 0.3 mg QOD7.508.46
Part 1: Iberdomide 0.6 mg QD9.5511.32
Part 1: Iberdomide 0.6 mg/0.3 mg ALT Days7.969.39

Time to Reach Maximum Concentration (Tmax) of Iberdomide

Time to Cmax, obtained directly from the observed concentration versus time data. Single and multiple-dose PK were collected in Part 1 of the study for all dose groups. Iberdomide reaches steady state within 7 days. PK collection on Day 29 was sufficient to understand PK once steady state was reached. As no dose adjustments were made in ATEP, further PK collection was not needed. (NCT02185040)
Timeframe: Pharmacokinetic blood samples were collected on Day 1 and Day 29 at pre-dose (Time = 0 hours) and at 1, 2, 3, 4, between 6 and 8 hours and 24 hours after administration of IP.

,,,
Interventiondays (Median)
Day 1Day 29
Part 1: Iberdomide 0.3 mg QD6.002.00
Part 1: Iberdomide 0.3 mg QOD4.004.00
Part 1: Iberdomide 0.6 mg QD4.012.02
Part 1: Iberdomide 0.6 mg/0.3 mg ALT Days1.923.00

Cutaneous Lupus Activity as Measured by the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) at Week 52

The CLASI consists of two scores the first summarizes the activity of the disease while the second is a measure of the damage done by the disease. Activity is scored on the basis of erythema, scale/hyperkeratosis, mucous membrane involvement, acute hair loss and non-scarring alopecia. The CLASI score ranges from 0 to 70, with higher scores indicating more severe skin disease. (NCT01753401)
Timeframe: at Week 52

Interventionscore on a scale (Mean)
Placebo/Acthar0.4
Acthar/Acthar1.3

Krupp Fatigue Severity Score (FSS) at Week 52

"The Krupp FSS is a scale to rate disability-related fatigue. Respondents use a scale ranging from 1 (completely disagree) to 7 (completely agree) to indicate their agreement with nine statements about fatigue. A visual analogue scale is also included with the scale; respondents are asked to denote the severity of their fatigue over the past 2 weeks by placing a mark on a line extending from no fatigue to fatigue as bad as could be. Higher scores on the scale are indicative of more severe fatigue.~This validated fatigue severity scale measures impact of fatigue with a 9-item questionnaire, with a 7-point Likert scale for each question. Total score ranges from 0 (best possible outcome) to 63 (worst possible fatigue)." (NCT01753401)
Timeframe: at Week 52

Interventionscore on a scale (Mean)
Placebo/Acthar4.523
Acthar/Acthar4.743

Mean Score on the Mental Component Scale (PCS) of the Short Form 36 Health Status Questionnaire (SF-36) at Week 52

The SF-36 determines participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 1-4 primarily contribute to the PCS score of the SF-36. Items 5-8 primarily contribute to the MCS score of the SF-36. Scores on each item are summed and averaged (range: 0=worst to 100=best). Higher scores indicate improvement. (NCT01753401)
Timeframe: at Week 52

Interventionscore on a scale (Mean)
Placebo/Acthar45.272
Acthar/Acthar39.700

Mean Score on the Physical Component Scale (PCS) of the Short Form 36 Health Status Questionnaire (SF-36) at Week 52

The SF-36 determines participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 1-4 primarily contribute to the PCS score of the SF-36. Items 5-8 primarily contribute to the MCS score of the SF-36. Scores on each item are summed and averaged (range: 0=worst to 100=best). Higher scores indicate improvement. (NCT01753401)
Timeframe: at Week 52

Interventionscore on a scale (Mean)
Placebo/Acthar43.618
Acthar/Acthar39.710

Number of Participants Who Meet the Definition of a Responder at Week 52

"Participants are counted as responders based on:~decrease in SELENA-SLEDAI score from 4 to 0 for arthritis and no worsening in other organ systems based on BILAG~OR~decrease in SELENA-SLEDAI score from 2 to 0 for rash and no worsening in other organ systems based on BILAG" (NCT01753401)
Timeframe: at Week 52

InterventionParticipants (Count of Participants)
Placebo/Acthar4
Acthar/Acthar3

Number of Participants Who Meet the Definition of a Responder Within 4 Weeks

"Participants are counted as responders based on two SLE indices: the Systemic Lupus Erythematosus Disease Activity Index amended by the SELENA group (SELENA-SLEDAI) and the British Isles Lupus Assessment Group (BILAG) Index.~decrease in SELENA-SLEDAI score from 4 to 0 for the arthritis descriptor (highest possible score is 4) and no worsening in other organ systems based on BILAG~OR~decrease in SELENA-SLEDAI score from 2 to 0 for rash (highest possible score is 2) and no worsening in other organ systems based on BILAG~The BILAG is a transitional index that captures changing severity of clinical manifestations. It has an ordinal scale scoring system by design that produces an overview of disease activity across eight systems. The individual system scores were not intended to be summated into a global score." (NCT01753401)
Timeframe: within 4 weeks

InterventionParticipants (Count of Participants)
Placebo3
Acthar4

Number of Participants Who Meet the Definition of a Responder Within 8 Weeks

"Participants are counted as responders based on:~decrease in SELENA-SLEDAI score from 4 to 0 for arthritis and no worsening in other organ systems based on BILAG~OR~decrease in SELENA-SLEDAI score from 2 to 0 for rash and no worsening in other organ systems based on BILAG" (NCT01753401)
Timeframe: within 8 weeks

InterventionParticipants (Count of Participants)
Placebo3
Acthar11

Number of Participants With a Relapse Within 52 Weeks

(NCT01753401)
Timeframe: within 52 weeks

InterventionParticipants (Count of Participants)
Placebo/Acthar1
Acthar/Acthar6

Number of Tender or Swollen Joints at Week 52

The doctor counted the number of tender or swollen joints at Week 52. (NCT01753401)
Timeframe: at Week 52

InterventionTender or Swollen Joints (Mean)
Placebo/Acthar1.1
Acthar/Acthar0.7

Score on the SELENA-SLEDAI at Week 52

"SLEDAI was modeled on the basis of clinician global judgment. A participant's SELENA-SLEDAI total score is the sum of all marked SLE-related descriptors on a checklist developed by the SELENA Group (also referred to as hybrid SLEDAI).~The scores of the descriptors range from 0 to 8. A total score can fall between 0 and 105, with a higher score representing a more significant degree of disease activity." (NCT01753401)
Timeframe: at Week 52

Interventionscore on a scale (Median)
Placebo/Acthar3
Acthar/Acthar4

BILAG Total Score Within 8 Weeks

"The BILAG is a transitional index that captures changing severity of clinical manifestations that produces an overview of disease activity across eight systems.~The 8 systems are scored on a scale from 0=not present to 4=worse, for the 4 week period before the assessment. The lowest possible score is 0, and the highest possible score is 32. A higher score means the symptoms are worse.~Rows: Baseline, Week 4, Week 8" (NCT01753401)
Timeframe: within 8 weeks

,
Interventionscore on a scale (Mean)
at Baselineat Week 4at Week 8
Acthar15.79.26.8
Placebo15.410.313.5

Cutaneous Lupus Activity as Measured by the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Within 8 Weeks

"The CLASI consists of two scores the first summarizes the activity of the disease while the second is a measure of the damage done by the disease. Activity is scored on the basis of erythema, scale/hyperkeratosis, mucous membrane involvement, acute hair loss and non-scarring alopecia. The CLASI score ranges from 0 to 70, with higher scores indicating more severe skin disease.~Rows: at Baseline, at Week 4, at Week 8" (NCT01753401)
Timeframe: at Baseline, Week 4 and Week 8 (within 8 weeks)

,
Interventionscore on a scale (Mean)
at Baselineat Week 4at Week 8
Acthar6.44.83.7
Placebo6.16.35.7

Krupp Fatigue Severity Score (FSS) Within 8 Weeks

"The Krupp FSS is a scale to rate disability-related fatigue. Respondents use a scale ranging from 1 (completely disagree) to 7 (completely agree) to indicate their agreement with nine statements about fatigue. A visual analogue scale is also included with the scale; respondents are asked to denote the severity of their fatigue over the past 2 weeks by placing a mark on a line extending from no fatigue to fatigue as bad as could be. Higher scores on the scale are indicative of more severe fatigue.~This validated fatigue severity scale measures impact of fatigue with a 9-item questionnaire, with a 7-point Likert scale for each question. Total score ranges from 0 (best possible outcome) to 63 (worst possible fatigue).~Rows: at Baseline, at Week 4, at Week 8" (NCT01753401)
Timeframe: at Baseline, Week 4 and Week 8 (within 8 weeks)

,
Interventionscore on a scale (Mean)
at Baselineat Week 4at Week 8
Acthar5.6485.2985.152
Placebo5.3745.3795.404

Mean Score on the Mental Component Scale (MCS) of the Short Form 36 Health Status Questionnaire (SF-36) Within 8 Weeks

The SF-36 determines participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 1-4 primarily contribute to the PCS score of the SF-36. Items 5-8 primarily contribute to the MCS score of the SF-36. Scores on each item are summed and averaged (range: 0=worst to 100=best). Higher scores indicate improvement. (NCT01753401)
Timeframe: at Baseline, Week 4 and Week 8 (within 8 weeks)

,
Interventionscore on a scale (Mean)
at Baselineat Week 4at Week 8
Acthar38.40640.28040.408
Placebo41.30438.74439.256

Mean Score on the Physical Component Scale (PCS) of the Short Form 36 Health Status Questionnaire (SF-36) Within 8 Weeks

"The SF-36 determines participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 1-4 primarily contribute to the PCS score of the SF-36. Items 5-8 primarily contribute to the MCS score of the SF-36. Scores on each item are summed and averaged (range: 0=worst to 100=best). Higher scores indicate improvement.~Rows: at Baseline, at Week 4, at Week 8" (NCT01753401)
Timeframe: at Baseline, Week 4 and Week 8 (within 8 weeks)

,
Interventionscore on a scale (Mean)
at Baselineat Week 4at Week 8
Acthar31.52635.31835.701
Placebo32.92732.83133.310

Number of Tender or Swollen Joints Within 8 Weeks

The doctor counted the number of tender or swollen joints at Baseline, at Week 4, and at Week 8 (NCT01753401)
Timeframe: at Baseline, Week 4, and Week 8 (within 8 weeks)

,
InterventionTender or Swollen Joints (Mean)
at Baselineat Week 4at Week 8
Acthar9.64.53.5
Placebo6.23.84.0

Score on the SELENA-SLEDAI Within 8 Weeks

"SLEDAI was modeled on the basis of clinician global judgment. A participant's SELENA-SLEDAI total score is the sum of all marked SLE-related descriptors on a checklist developed by the SELENA Group (also referred to as hybrid SLEDAI).~The scores of the descriptors range from 0 to 8. A total score can fall between 0 and 105, with a higher score representing a more significant degree of disease activity.~Rows: Week 2, Week 4, Week 6, Week 8" (NCT01753401)
Timeframe: within 8 weeks

,
Interventionscore on a scale (Median)
Week 2Week 4Week 6Week 8
Acthar8.08.06.06.0
Placebo10.09.08.09.0

Number of Days of Daily Prednisone Dose <=7.5 mg/Day and/or Reduced by 50 Percent From Baseline Over 52 Weeks for Double-blind Phase.

Number of days of daily prednisone dose <=7.5 mg/day and/or reduced by 50 percent over time through each scheduled visit during the blinded period were compared between belimumab and placebo using Rank ANCOVA model which was used for comparing belimumab and placebo. The independent variables in the model included treatment group, Baseline prednisone dose level, country, Baseline SELENA SLEDAI score (<=9 vs. >=10) and complement levels (low C3 and/or C4 vs. no low C3 or C4). This analysis was perfomed on the participants who used prednisone >7.5 mg/day at Baseline. (NCT01345253)
Timeframe: Week 52

InterventionDays (Median)
Placebo0.0
Belimumab 10 mg/kg0.0

Percent of Participants Achieving Systemic Lupus Erythematosus (SLE) Responder Index (SRI) Response Rate at Week 52 for Double-blind Phase.

SRI response is a composite index, defined as the percent of participants with >=4 point reduction from Baseline in safety of estrogen in lupus national assessment (SELENA) systemic lupus erythematosus disease activity index (SLEDAI) score and no worsening (increase of < 0.30 points from Baseline) in physicians global assessment (PGA) and no new British isles lupus assessment group (BILAG) A organ domain score or 2 new BILAG B organ domain scores compared with Baseline at the time of assessment (at Week 52 of the blinded period). A SELENA SLEDAI score of 0 would suggest no lupus activity; while a score of 105 is the maximum calculable if all items were scored as being present from active lupus. PGA ranges from 0 (no activity) to 3 (severe activity). BILAG has no range. The higher thresholds of SELENA SLEDAI improvement (i.e., SRI5, SRI6, and SRI7) indicates a higher response (SRI5 is a 5 point SELENA SLEDAI reduction, SRI6 is a 6 point reduction, and SRI7 is a 7 point reduction). (NCT01345253)
Timeframe: Week 52

InterventionPercentage of participants (Number)
Placebo40.1
Belimumab 10 mg/kg53.8

Percent of Participants With >=4 Point Reduction From Baseline in SELENA SLEDAI Score at Week 52 for Double-blind Phase.

The SELENA SLEDAI score is a weighted index for assessing SLE disease activity in which signs and symptoms, laboratory tests and physician's assessment for each of 9 organ system were given a weighted score and summed if present at the time of the visit or in the preceding 10 days. A SELENA SLEDAI score of 0 would suggest no lupus activity; while a score of 105 is the maximum calculable if all items were scored as being present from active lupus. A decrease of 4 points or more equates to a clinically meaningful improvement. The Baseline value of a variable is defined as the value of the variable measured at Day 0 prior to dosing. In case of multiple results on Day 0 prior to dosing, the latest result was used. If a Day 0 value was not available, the last available value prior to Day 0 was used. (NCT01345253)
Timeframe: Baseline (Day 0) and Week 52

InterventionPercentage of participants (Number)
Placebo42.2
Belimumab 10 mg/kg55.7

Percent of Participants With SRI7 Response at Week 52 for Double-blind Phase.

SRI7 response is defined as the percent of participants with >=7 point reduction from Baseline in SELENA SLEDAI score and no worsening (increase of < 0.30 points from Baseline) in PGA and no new BILAG A organ domain score or 2 new BILAG B organ domain scores compared with Baseline at the time of assessment (at Week 52 of the blinded period). A SELENA SLEDAI score of 0 would suggest no lupus activity; while a score of 105 is the maximum calculable if all items were scored as being present from active lupus. PGA ranges from 0 (no activity) to 3 (severe activity). BILAG has no range. The higher thresholds of SELENA SLEDAI improvement (i.e., SRI5, SRI6, and SRI7) indicates a higher response (SRI5 is a 5 point SELENA SLEDAI reduction, SRI6 is a 6 point reduction, and SRI7 is a 7 point reduction). (NCT01345253)
Timeframe: Baseline (Day 0) and Week 52

InterventionPercentage of participants (Number)
Placebo23.5
Belimumab 10 mg/kg32.4

Time to First Severe SLE Flare Index (SFI) Flare Over 52 Weeks for Double-blind Phase.

Time to first severe SLE flare is defined as the number of days from first treatment until the participant had an event (event date-treatement start date +1). If a participant had a severe SFI flare and received protocol restricted medication then the event date was the earliest of the first severe SFI flare date, and the treatment failure date. Analysis of severe SFI flare was performed on the modified SELENA SLEDAI SLE flare index in which the modification excluded severe flares that were triggered only by an increase in SELENA SLEDAI score to >12. Analysis was from Cox proportional hazards model for the comparison between belimumab and placebo adjusting for country, Baseline SELENA SLEDAI score (<=9 vs. >=10) and complement levels (low C3 and/or C4 vs. no low C3 or C4). (NCT01345253)
Timeframe: 52 weeks

InterventionDays (Median)
PlaceboNA
Belimumab 10 mg/kgNA

Percent of Participants Achieving SLE SRI Response Rate for Open-label (OL) Phase

SRI response is a composite index, defined as the percent of participants with >=4 point reduction from Baseline in SELENA SLEDAI score and no worsening (increase of < 0.30 points from Baseline) in PGA and no new BILAG A organ domain score or 2 new BILAG B organ domain scores compared with Baseline at time of assessment. Excludes participants with a SELENA SLEDAI score <4 at baseline. Participants randomized to belimumab in double-blinded (DB) phase, Baseline is last available value before first belimumab dose received in DB phase. Participants randomized to placebo in DB phase, Baseline is last available value before receiving first belimumab dose in OL phase. Observed case data are presented.Year 6 Week 48 is the Exit Visit obtained by slotting the Exit Visit to Week 48. A SELENA SLEDAI score of 0 (no lupus activity) and a score of 105 (maximum). PGA ranges from 0 (no activity) to 3 (severe activity). BILAG has no range. (NCT01345253)
Timeframe: Weeks 24 and 48 for Years 2, 3, 4, 5 and 6

InterventionPercentage of participants (Number)
Week 24, Year 2, n=326Week 48, Year 2, n=299Week 24, Year 3, n=271Week 48, Year 3, n=247Week 24, Year 4, n=233Week 48, Year 4, n=194Week 24, Year 5, n= 156Week 48, Year 5, n= 82Week 24, Year 6, n= 36Week 48, Year 6, n= 5
Belimumab 10mg/kg (Open-label Phase)66.069.672.370.971.776.881.480.586.160.0

British Isles Lupus Assessment Group Index-based Combined Lupus Assessment (BICLA)

This is a landmark measure of percentage of patients who meet response criteria. To meet the BICLA response measure a patient must, compared to baseline, have a decrease in all moderate or severe scores on the British Isles Lupus Assessment Group (BILAG) index by at least one severity grade (Severe disease (BILAG A score) must drop to at least moderate (B or better) and B must drop to at least mild (C or not present). Also, there must be no increase in any other BILAG organ scores, no increase in The Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score, and no increase in the physician's global assessment (PGA) by more than 10% of the scale. Furthermore, there may no off protocol medication increases. Note on all scales mentioned a higher score signifies greater disease activity. Ranges on BILAG could be 0-108 but are rarely greater than 36. SLEDAI could range 0-105 but is rarely greater than 20. PGA 0-100 but rarely greater than 76. (NCT01781611)
Timeframe: 24 weeks

InterventionParticipants (Count of Participants)
Extended Release Dipyridamole/Aspirin3
Aspirin2

SRI Component Analyses: 4 Point Drop in SLEDAI

This is a landmark analysis of percentage of patients who, compared to baseline, have a 4 point drop in the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI). A 4 point decrease signifies a clinically significant decrease in disease activity as reported in many studies and as commonly used as a clinical endpoint in trials. SLEDAI could range 0-105 but is rarely greater than 20. (NCT01781611)
Timeframe: 24 weeks

InterventionParticipants (Count of Participants)
Extended Release Dipyridamole/Aspirin4
Aspirin2

Systemic Lupus Erythematosus Responder Index (SRI) 4

This is a landmark analysis of percentage of patients who meet the following response criteria: Compared to baseline there must be a 4 point decrease in the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), no increase in The British Isles Lupus Assessment Group (BILAG) Index score and no more of an increase in Physician's Global Assessment (PGA) than 10% of the scale. As assessed here, there must also be no off protocol increase in medications. All scales signify worsening disease when scores increase. Ranges on BILAG could be 0-108 but are rarely greater than 36. SLEDAI could range 0-105 but is rarely greater than 20. PGA 0-100 but rarely greater than 76. (NCT01781611)
Timeframe: 24 weeks

InterventionParticipants (Count of Participants)
Extended Release Dipyridamole/Aspirin3
Aspirin2

Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Total Score

FACIT-Fatigue score calculated according to a 13-item questionnaire that assess self reported fatigue and its impact upon daily activities and function. It uses a 5-point Likert-type scale (0 = not at all; 1 = a little bit; 2 = somewhat; 3 = quite a bit; 4 = very much). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse possible score) to 52 (best score). A higher score reflected an improvement in the participant's health status. Least Squares (LS) mean was calculated using Mixed Model Repeated Measures (MMRM) analysis with treatment, baseline disease activity (total SLEDAI-2K <10; >=10), baseline corticosteroid dose (<10 mg/day; >= 10 mg/day prednisone or equivalent), region (North America, Central/South, America/Mexico, Europe, Asia Rest of World), visit (as categorical variable), baseline value, treatment-by-visit interaction, and baseline value-by-visit interaction. (NCT03616912)
Timeframe: Baseline, Week 52

Interventionscore on a scale (Least Squares Mean)
Placebo7.44
2 mg Baricitinib7.46
4 mg Baricitinib7.08

Change From Baseline in Swollen Joint Count

The number of swollen joints is determined by examination of 28 joints (14 on each side) which include: the 2 shoulders, the 2 elbows, the 2 wrists, the 10 metacarpophalangeal joints, the 2 interphalangeal joints of the thumb, the 8 proximal interphalangeal joints, and the 2 knees. The joints are assessed and classified as swollen or not swollen. LS mean was calculated using MMRM analysis with treatment, baseline disease activity (total SLEDAI-2K <10; >=10), baseline corticosteroid dose (<10 mg/day; >=10 mg/day prednisone or equivalent), region (North America, Central/South America/Mexico, Europe, Asia and Rest of World), visit (as categorical variable), baseline value, treatment-by-visit interaction, and baseline value-by-visit interaction. (NCT03616912)
Timeframe: Baseline, Week 52

Interventionswollen joint count (Least Squares Mean)
Placebo-5.37
2 mg Baricitinib-5.67
4 mg Baricitinib-5.81

Change From Baseline in Tender Joints Count

The number of tender and painful joints is determined by examination of 28 joints (14 on each side) which include: the 2 shoulders, the 2 elbows, the 2 wrists, the 10 metacarpophalangeal joints, the 2 interphalangeal joints of the thumb, the 8 proximal interphalangeal joints, and the 2 knees. The joints are assessed and classified as tender or not tender. LS mean was calculated using Mixed Model Repeated Measures (MMRM) analysis with treatment, baseline disease activity (total SLEDAI-2K <10; >=10), baseline corticosteroid dose (<10 mg/day; >=10 mg/day prednisone or equivalent), region (North America, Central/South America/Mexico, Europe, Asia and Rest of World), visit (as categorical variable), baseline value, treatment-by-visit interaction, and baseline value-by-visit interaction. (NCT03616912)
Timeframe: Baseline, Week 52

Interventiontender joint count (Least Squares Mean)
Placebo-7.50
2 mg Baricitinib-7.26
4 mg Baricitinib-7.94

Change From Baseline in Worst Pain Numeric Rating Scale (NRS)

Participants assessed their worst pain in the last 24 hours on an 11-point numeric rating scale (NRS) ranging from 0 (no pain) to 10 (pain as bad as you can imagine). The average worst daily pain score was calculated as the mean of the scores over the last 7 days prior to each assessment time point. Higher score indicated severe pain. Least Squares (LS) mean was calculated using Mixed Model Repeated Measures (MMRM) analysis with treatment, baseline disease activity (total SLEDAI-2K <10; >=10), baseline corticosteroid dose (<10 mg/day; >= 10 mg/day prednisone or equivalent), region (North America, Central/South, America/Mexico, Europe, Asia Rest of World), visit (as categorical variable), baseline value, treatment-by-visit interaction, and baseline value-by-visit interaction. (NCT03616912)
Timeframe: Baseline, Week 52

Interventionscore on a scale (Least Squares Mean)
Placebo-1.62
2 mg Baricitinib-1.73
4 mg Baricitinib-1.71

Percentage of Participants Achieving a Lupus Low Disease Activity State (LLDAS)

"The LLDAS is a composite measure designed to identify patients achieving a state of low disease activity. The LLDAS response criteria were: (1) SLEDAI-2K <=4, with no activity in major organ systems (CNS, vascular, renal, cardiorespiratory and constitutional); where no activity is defined as all items of SLEDAI-2K within these major organ systems equal to 0. (2) no new features of lupus disease activity compared to previous occurred visit, where the new feature is defined as any of the SLEDAI-2K 24 items changed from 0 to greater than 0; (3) PGA (scale 0-3), <=1; (4) current prednisolone (or equivalent) dose <=7.5 mg daily." (NCT03616912)
Timeframe: Week 52

Interventionpercentage of participants (Number)
Placebo26.2
2 mg Baricitinib25.7
4 mg Baricitinib29.7

Percentage of Participants Achieving a Systemic Lupus Erythematosus Responder Index 4 (SRI-4) Response (4 mg Baricitinib)

"SRI-4 response defined as 1)greater than or equal to (>=) 4-point reduction in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) total score 2)no new British Isles Lupus Assessment Group (BILAG) A and no more than 1 new BILAG B domain score and 3)no worsening in Physician Global Assessment (PGA) of Disease Activity (worsening defined as an increase of >=0.3 from baseline on a 0-3 visual analogue scale).~SLEDAI-2K assessment consists of 24 items with total score of 0(no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms,or laboratory parameters related to Systemic Lupus Erythematosus (SLE),divided into 9 organ systems. For each organ system A=severe disease,B=moderate disease,C=mild stable disease,D=inactive,but previously active,E=inactive and never affected. PGA assess disease activity on a visual analogue scale from 0 to 3 (1=mild, 2=moderate, 3=severe)." (NCT03616912)
Timeframe: Week 52

Interventionpercentage of participants (Number)
Placebo45.9
4 mg Baricitinib56.7

Percentage of Participants Achieving SRI-4 Response - 2 mg Baricitinib

"SRI-4 response defined as 1)greater than or equal to (>=) 4-point reduction in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) total score 2)no new British Isles Lupus Assessment Group (BILAG) A and no more than 1 new BILAG B domain score and 3)no worsening in Physician Global Assessment (PGA) of Disease Activity (worsening defined as an increase of >=0.3 from baseline on a 0-3 visual analogue scale).~SLEDAI-2K assessment consists of 24 items with total score of 0(no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms,or laboratory parameters related to Systemic Lupus Erythematosus (SLE),divided into 9 organ systems. For each organ system A=severe disease,B=moderate disease,C=mild stable disease,D=inactive,but previously active,E=inactive and never affected. PGA assess disease activity on a visual analogue scale from 0 to 3 (1=mild, 2=moderate, 3=severe)." (NCT03616912)
Timeframe: Week 52

Interventionpercentage of participants (Number)
Placebo45.9
2 mg Baricitinib49.8

Percentage of Participants Whose Average Prednisone Dose Had Been Reduced by >=25% From Baseline to <=7.5 mg/Day During Weeks 40 Through 52 in Participants Receiving Greater Than 7.5 mg/Day at Baseline

For the analysis of steroid use, steroid dosages were converted to a prednisone equivalent in mg. A responder was defined as having a prednisone reduction by >=25% from Baseline to <=7.5 mg/day during Weeks 40 through 52. (NCT03616912)
Timeframe: Baseline, Week 40 through Week 52

Interventionpercentage of participants (Number)
Placebo30.8
2 mg Baricitinib29.2
4 mg Baricitinib34.0

Percentage of Participants With Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Total Activity Score ≥10 at Baseline With ≥50% Reduction in CLASI Total Activity Score

The CLASI is a single-page tool that separately quantifies disease activity and damage. For the activity score, points are given for the presence of erythema, scale, mucous membrane lesions, recent hair loss, and inflammatory alopecia. The total score represents the sum of the individual scores and ranges from 0 to 70. Higher scores are awarded for more severe manifestations. (NCT03616912)
Timeframe: Week 52

Interventionpercentage of participants (Number)
Placebo49.0
2 mg Baricitinib54.3
4 mg Baricitinib55.8

Population Pharmacokinetics (PK): Area Under the Concentration-Time Curve of Baricitinib at Steady State (AUCτ, ss)

PK: Area Under the Concentration-Time Curve of Baricitinib at Steady State (AUCτ, ss) was evaluated using population PK approach. (NCT03616912)
Timeframe: Week 0 (Baseline): 15 minutes (min) and 60 min postdose; Week 4: 2 to 4 hours (hr) postdose; Week 8: 4 to 6 hr postdose; Week 12 and Week 16 predose

Interventionhour*nanograms per milliliter (h*ng/mL) (Geometric Mean)
2 mg Baricitinib256
4 mg Baricitinib502

Population PK: Maximum Observed Drug Concentration at Steady State (Cmax,ss)

Population PK: Maximum Observed Drug Concentration at Steady State (Cmax,ss) was evaluated using population PK approach. (NCT03616912)
Timeframe: Week 0 (Baseline): 15 minutes (min) and 60 min postdose; Week 4: 2 to 4 hours (hr) postdose; Week 8: 4 to 6 hr postdose; Week 12 and Week 16 predose

Interventionnanograms per milliliter (ng/mL) (Geometric Mean)
2 mg Baricitinib26.7
4 mg Baricitinib53.0

Time to First Severe Flare

Time to first severe flare was analyzed using a Cox proportional hazards model with treatment group, baseline disease activity (Systemic Lupus Erythematosus Disease Activity Index 2000 [SLEDAI-2K ] <10; SLEDAI-2K ≥10), baseline corticosteroid dose (<10 mg/day; ≥10 mg/day prednisone or equivalent), and region fitted as explanatory variables. Participants who did not have severe flare during the flare exposure time period were censored at the end of the flare exposure time. (NCT03616912)
Timeframe: Baseline to Week 52

Interventionweeks (Median)
PlaceboNA
2 mg BaricitinibNA
4 mg BaricitinibNA

Number of Participants With Electrocardiogram (ECG) Abnormalities Reported as Treatment-Emergent Adverse Events (TEAEs)

Any medically significant changes from the screening ECG was recorded as TEAEs. An abnormal ECG findings such as QT prolonged were reported as treatment emergent adverse events. (NCT01438489)
Timeframe: Day 1 (Baseline) to Day 422 (End of Study)

InterventionParticipants (Number)
Placebo0
Anifrolumab 300 mg0
Anifrolumab 1000 mg2

Percentage of Participants Achieving an Systemic Lupus Erythematosus (SLE) Responder Index [SRI (4)] Response With Oral Corticosteroids (OCS) Tapering at Day 169

An SRI (4) responder defined as a participant who had 1) a reduction in baseline Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score of greater than or equal to (>=) 4 points; 2) no worsening of disease from baseline as measured by the Physician Global Assessment (MDGA) (worsening was defined as an increase of >= 0.3 from baseline on a 0 to 3.0 visual analog scale); and 3) no new British Isles Lupus Assessment Group 2004 (BILAG-2004) Index 'A' organ system score and no more than one new or worsening BILAG-2004 Index 'B' organ system score. OCS tapering requires a sustained reduction of OCS from Day 85 through Day 169 [less than 10 milligram per day (mg/day) and less or equal to the dose received on Day 1]. SRI was analyzed by a logistic regression model. (NCT01438489)
Timeframe: Day 169

InterventionPercentage of Participants (Number)
Placebo17.6
Anifrolumab 300 mg34.3
Anifrolumab 1000 mg28.8

Percentage of Participants Achieving an Systemic Lupus Erythematosus (SLE) Responder Index [SRI (4)] Response With Oral Corticosteroids (OCS) Tapering at Day 365

An SRI (4) Responder was defined as a participant who had 1) a reduction in baseline SLEDAI-2K disease activity score of >= 4 points; 2) no worsening of disease from baseline as measured by the MDGA (worsening was defined as an increase of >= 0.3 from baseline on a 0 to 3.0 visual analog scale); and 3) no new British Isles Lupus Assessment Group 2004 (BILAG-2004) Index A organ system score and no more than one new or worsening BILAG-2004 Index B organ system score. OCS tapering requires a sustained reduction of OCS from Day 281 through Day 365 (less than 10 mg/day and less or equal to the dose received on Day 1). SRI was analyzed by a logistic regression model. (NCT01438489)
Timeframe: Day 365

InterventionPercentage of Participants (Number)
Placebo25.5
Anifrolumab 300 mg51.5
Anifrolumab 1000 mg38.5

Percentage of Participants on Oral Corticosteroids (OCS) >=10 mg/Day of Prednisone or Equivalent at Baseline Who Were Able to Taper to Less Than or Equal to (<=) 7.5 mg/Day at Day 365

Participants on OCS >=10 mg/day of prednisone or equivalent at baseline who were able to taper to <= 7.5 mg/day at Day 365 were evaluated. (NCT01438489)
Timeframe: Day 365

InterventionPercentage of Participants (Number)
Placebo26.6
Anifrolumab 300 mg56.4
Anifrolumab 1000 mg31.7

Percentage of Type I Interferon (IFN) Test High Participants Achieving an Systemic Lupus Erythematosus Responder Index (SRI) (4) Response With Oral Corticosteroids (OCS) Tapering at Day 169

Type I IFN signature in whole blood assessed by using a 4-gene diagnostic test. The blood samples collected were to be used to prospectively identify participants as IFN test-high or test-low. The results of this test were used to stratify participants. An SRI (4) Responder was defined as a participant who had 1) a reduction in baseline SLEDAI-2K disease activity score of >= 4 points; 2) no worsening of disease from baseline as measured by the Physician Global Assessment (MDGA) (worsening was defined as an increase of >= 0.3 from baseline on a 0 to 3.0 visual analog scale); and 3) no new British Isles Lupus Assessment Group 2004 (BILAG-2004) Index A organ system score and no more than one new or worsening BILAG-2004 Index B organ system score. OCS tapering requires a sustained reduction of OCS from Day 85 through Day 169 [less than 10 mg/day and less or equal to the dose received on Day 1]. SRI was analyzed by a logistic regression model. (NCT01438489)
Timeframe: Day 169

InterventionPercentage of Participants (Number)
Placebo13.2
Anifrolumab 300 mg36
Anifrolumab 1000 mg28.2

Accumulation Ratio of Maximum Observed Plasma Concentration (Cmax,AR) of Anifrolumab

Accumulation ratio for maximum plasma concentration (Cmax,AR) of anifrolumab after multiple administration at Day 169 and 337 was calculated. (NCT01438489)
Timeframe: Pre-infusion and 15 minutes post-infusion on Day 169 and 337

,
InterventionRatio (Median)
Day 169 (n=81,86)Day 337 (n=78,66)
Anifrolumab 1000 mg1.431.76
Anifrolumab 300 mg1.361.56

Accumulation Ratio of Trough Concentration (Ctrough,AR) of Anifrolumab at Day 169 and 365

Accumulation ratio for trough concentration (Ctrough,AR) of anifrolumab after multiple administration at Day 169 and 365 was calculated. (NCT01438489)
Timeframe: Pre-infusion and 15 minutes post-infusion on Day 169 and 365

,
InterventionRatio (Median)
Day 169 (n=82,86)Day 365 (n=79,70)
Anifrolumab 1000 mg2.293.02
Anifrolumab 300 mg2.493.06

Maximum Observed Plasma Concentration (Cmax) of Anifrolumab at Day 1, 169 and 337

Maximum plasma concentration (Cmax) was defined as the peak plasma level of anifrolumab, derived from plasma concentration -time data. (NCT01438489)
Timeframe: Pre-infusion and 15 minutes post-infusion on Day 1, 169 and 337

,
Interventionmicrograms/milliliter (mcg/mL) (Mean)
Day 1 (n=98,104)Day 169 (n=86,87)Day 337 (n=83,67)
Anifrolumab 1000 mg248375439
Anifrolumab 300 mg82.8110127

Neutralization Ratio of 21-Gene Type I Interferon (IFN) Signature for Participants With Positive Baseline Pharmacodynamic (PD) Gene Signature

The PD positive and negative gene signature was determined by comparing the expression of type I IFN-inducible genes in a 21-gene panel in study participants relative to pooled normal blood collected from healthy participants. (NCT01438489)
Timeframe: Days 29, 85, 141, 169, 253, 337 (treatment phase), on Days 365, 396, and 422 (follow up period)

,,
InterventionRatio (Mean)
Day 29 (n= 68, 66, 73)Day 85 (n= 63, 62, 72)Day 141 (n= 59, 64, 68)Day 169 (n= 56, 60, 66)Day 253 (n= 50, 60, 61)Day 337 (n= 49, 59, 53)Day 365 (n= 58, 66, 68)Day 396 (n= 56, 61, 64)Day 422 (n= 53, 57, 55)
Anifrolumab 1000 mg82.05679.35088.56988.12686.09987.81181.11572.29137.532
Anifrolumab 300 mg70.19472.63973.66277.36473.97279.36372.79611.510-0.836
Placebo-0.753-5.412-25.411-17.122-9.908-13.784-6.428-22.106-31.777

Number of Participants With Clinically Significant Laboratory Abnormalities in Investigations Reported as Treatment-Emergent Adverse Events

Any medically significant change in laboratory evaluations were recorded as Treatment emergent adverse events. (NCT01438489)
Timeframe: Day 1 (Baseline) to Day 422 (End of Study)

,,
InterventionParticipants (Number)
Neutrophil count increasedLeukocytosisLeukopeniaNeutropeniaAnaemiaIron deficiency anaemiaLymphopeniaMicrocytic anaemiaThrombocytosisWhite blood cell count increasedMonocyte count increasedHypochromic anaemiaHyperglycaemiaHypokalaemiaHepatic enzyme increasedHypocalcaemiaLipid metabolism disorderAlanine aminotransferase increasedAspartate aminotransferase increasedBlood creatine phosphokinase increasedHyperlipidaemiaHypertriglyceridaemiaHyponatraemiaBlood alkaline phosphatase increasedGamma-glutamyltransferase increasedGlomerular filtration rate decreasedTransaminases increasedDyslipidaemiaAlanine aminotransferase abnormalAspartate aminotransferase abnormalBlood triglycerides abnormalGlomerular filtration rate increased
Anifrolumab 1000 mg32332122011010311101101000100000
Anifrolumab 300 mg11000100100033011121010111000000
Placebo00200001000112100000120000111111

Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Adverse Events of Special Interest (AESIs) and Treatment-Emergent Serious Adverse Events (TESAEs)

An adverse event (AE) was any untoward medical occurrence in a study participant administered a pharmaceutical product and which does not necessarily have a causal relationship with treatment. A serious AE (SAE) was an AE resulting in any of following outcomes or deemed significant for any other reason: death; initial/prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly (in offspring of participant). AEs may be treatment emergent (TE) [that is, occurring after initial receipt of investigational product] or non-TE. An AESI is one of scientific and medical concern specific to understanding biologics and requires close monitoring and rapid communication by investigator to sponsor. (NCT01438489)
Timeframe: Day 1 (Baseline) to Day 422 (End of Study)

,,
InterventionParticipants (Number)
TEAEsTESAEsAESIs
Anifrolumab 1000 mg901815
Anifrolumab 300 mg841610
Placebo781912

Number of Participants With Vital Signs Abnormalities Reported as Treatment-Emergent Adverse Events (TEAEs)

Vital sign parameters are temperature, blood pressure, respiratory rate, heart rate and weight. Vital signs abnormalities were reported as TEAEs. (NCT01438489)
Timeframe: Day 1 (Baseline) to Day 422 (End of Study)

,,
InterventionParticipants (Number)
HypertensionPyrexiaBlood pressure increasedBlood pressure decreasedHypotensionSecondary hypertensionWeight increasedBlood pressure abnormalChillsHypertensive emergency
Anifrolumab 1000 mg2311011000
Anifrolumab 300 mg3020100000
Placebo7500000111

Percentage of SLE Participants With Positive Anti-drug Antibody (ADA)

Anti-drug antibody responses to anifrolumab in serum were evaluated. (NCT01438489)
Timeframe: Days 1, 85, 141, 169, 253, 337 (Treatment Phase), 365, 396, and 422 (Follow-up Period)

,,
InterventionPercentage of Participants (Number)
Day 1 (n=100,98,105)Day 85 (n=91,93,98)Day 141 (n=84,94,93)Day 169 (n=81,89,92)Day 253 (n=72,86,86)Day 337 (n=70,87,76)Day 365 (n=85,96,94)Day 396 (n=78,88,90)Day 422 (n=76,86,77)Any Visit Post Baseline (n= 99,98,102)
Anifrolumab 1000 mg1.90.02.21.10.00.01.10.00.02.0
Anifrolumab 300 mg1.00.00.00.01.21.11.02.35.85.1
Placebo1.01.12.42.50.00.00.00.01.33.0

Trough Concentration (Ctrough) of Anifrolumab at Day 29, 169 and 365

Trough concentration (Ctrough) of anifrolumab at Day 29, 169 and 365 were calculated. (NCT01438489)
Timeframe: Pre-infusion and 15 minutes post-infusion on Day 29, 169 and 365

,
Interventionmicrogram per milliliter (Mean)
Day 29 (n=95,99)Day 169 (n=87,87)Day 365 (n=83,71)
Anifrolumab 1000 mg46.8110154
Anifrolumab 300 mg7.9518.423.6

Change in HDL Cholesterol

(NCT00065806)
Timeframe: Change from baseline to 36 months

Interventionmg/dl (Mean)
1 Atorvastatin-0.43
2 Placebo0.89

Change in Homocysteine

(NCT00065806)
Timeframe: Change from baseline to 36 months

Interventionμmoles/liter (Mean)
1 Atorvastatin1.84
2 Placebo1.76

Change in LDL Cholesterol

(NCT00065806)
Timeframe: Change from baseline to 36 months

Interventionmg/dl (Mean)
1 Atorvastatin-27.63
2 Placebo-1.48

Change in Lipoprotein A

(NCT00065806)
Timeframe: Change from baseline to 36 months

Interventionmg/dl (Mean)
1 Atorvastatin2.00
2 Placebo6.34

Change in Mean-Max Bifurcation CIMT

For each side and wall of the bifurcation arterial segment, the maximum CIMT over the 4 angles of interrogation was selected to produce 4 summary variables (right bifurcation near wall max, right bifurcation far wall max, left bifurcation near wall max and left bifurcation far wall max). These summary variables were then averaged to estimate a single mean-max bifurcation CIMT for each participant visit. (NCT00065806)
Timeframe: Change from baseline to 36 months

Interventionmm (Mean)
1 Atorvastatin0.0033
2 Placebo0.0072

Change in Mean-Max CIMT

For each side, segment and wall, the maximum CIMT over the 4 angles of interrogation was selected to produce 12 summary variables (right common near wall max, right common far wall max, right bifurcation near wall max, right bifurcation far wall max, right internal near wall max, right internal far wall max, left common near wall max, left common far wall max, left bifurcation near wall max, left bifurcation far wall max, left internal near wall max and left internal far wall max). These 12 summary variables were then averaged to estimate a single mean-max CIMT for each participant visit. (NCT00065806)
Timeframe: Change from baseline to 36 months

Interventionmm (Mean)
1 Atorvastatin0.0037
2 Placebo0.0064

Change in Mean-Max Common CIMT

For each side and wall of the common carotid arterial segment, the maximum CIMT over the 4 angles of interrogation was selected to produce 4 summary variables (right common near wall max, right common far wall max, left common near wall max and left common far wall max). These summary variables were then averaged to estimate a single mean-max common CIMT for each participant visit. (NCT00065806)
Timeframe: Change from baseline to 36 months

Interventionmm (Mean)
1 Atorvastatin0.0006
2 Placebo0.0008

Change in Mean-Max Far Wall CIMT

For the far wall measurements for each side and segment, the maximum CIMT over the 4 angles of interrogation was selected to produce 6 summary variables (right common far wall max, right bifurcation far wall max, right internal far wall max, left common far wall max, left bifurcation far wall max, and left internal far wall max). These 6 summary variables were then averaged to estimate a single mean-max far wall CIMT for each participant visit. (NCT00065806)
Timeframe: Change from baseline to 36 months

Interventionmm (Mean)
1 Atorvastatin0.0045
2 Placebo0.0082

Change in Mean-Max Internal CIMT

For each side and wall of the internal carotid arterial segment, the maximum CIMT over the 4 angles of interrogation was selected to produce 4 summary variables (right internal near wall max, right internal far wall max, left internal near wall max and left internal far wall max). These summary variables were then averaged to estimate a single mean-max internal CIMT for each participant visit. (NCT00065806)
Timeframe: Change from baseline to 36 months

Interventionmm (Mean)
1 Atorvastatin0.0090
2 Placebo0.0144

Change in Mean-Max Near Wall CIMT

For the near wall measurements for each side and segment, the maximum CIMT over the 4 angles of interrogation was selected to produce 6 summary variables (right common near wall max, right bifurcation near wall max, right internal near wall max, left common near wall max, left bifurcation near wall max, and left internal near wall max). These 6 summary variables were then averaged to estimate a single mean-max near wall CIMT for each participant visit. (NCT00065806)
Timeframe: Change from baseline to 36 months

Interventionmm (Mean)
1 Atorvastatin0.0024
2 Placebo0.0038

Change in Mean-Mean Bifurcation CIMT

For the bifurcation arterial segment, mean CIMT values were averaged across angles by side and wall to produce 4 summary variables (right bifurcation near wall mean, right bifurcation far wall mean, left bifurcation near wall mean and left bifurcation far wall mean). These summary variables were then averaged to estimate a single mean-mean bifurcation CIMT for each participant visit. (NCT00065806)
Timeframe: Change from baseline to 36 months

Interventionmm (Mean)
1 Atorvastatin0.0030
2 Placebo0.0055

Change in Mean-Mean CIMT

For each side, segment and wall, mean CIMT values were averaged over the 4 angles of interrogation to produce 12 summary variables (right common near wall mean, right common far wall mean, right bifurcation near wall mean, right bifurcation far wall mean, right internal near wall mean, right internal far wall mean, left common near wall mean, left common far wall mean, left bifurcation near wall mean, left bifurcation far wall mean, left internal near wall mean and left internal far wall mean). These 12 summary variables were then averaged to estimate a single mean-mean CIMT for each participant visit. (NCT00065806)
Timeframe: Change from baseline to 36 months

Interventionmm (Mean)
1 Atorvastatin0.0033
2 Placebo0.0049

Change in Mean-Mean Common Carotid IMT (CIMT)

For the common carotid arterial segment, mean CIMT values were averaged across angles by side and wall to produce 4 summary variables (right common near wall mean, right common far wall mean, left common near wall mean and left common far wall mean). These summary variables were then averaged to estimate a single mean-mean common CIMT for each participant visit. (NCT00065806)
Timeframe: Change from baseline to 36 months

Interventionmm (Mean)
1 Atorvastatin0.0010
2 Placebo0.0024

Change in Mean-Mean Far Wall CIMT

For the far wall measurements for each side and segment, mean CIMT values were averaged over the 4 angles of interrogation to produce 6 summary variables (right common far wall mean, right bifurcation far wall mean, right internal far wall mean, left common far wall mean, left bifurcation far wall mean and left internal far wall mean). These 6 summary variables were then averaged to estimate a single mean-mean far wall CIMT for each participant visit. (NCT00065806)
Timeframe: Change from baseline to 36 months

Interventionmm (Mean)
1 Atorvastatin0.0042
2 Placebo0.0064

Change in Mean-Mean Internal CIMT

For the internal carotid arterial segment, mean CIMT values were averaged across angles by side and wall to produce 4 summary variables (right internal near wall mean, right internal far wall mean, left internal near wall mean and left internal far wall mean). These summary variables were then averaged to estimate a single mean-mean internal CIMT for each participant visit. (NCT00065806)
Timeframe: Change from baseline to 36 months

Interventionmm (Mean)
1 Atorvastatin0.0067
2 Placebo0.0082

Change in Mean-Mean Near Wall CIMT

For the near wall measurements for each side and segment, mean CIMT values were averaged over the 4 angles of interrogation to produce 6 summary variables (right common near wall mean, right bifurcation near wall mean, right internal near wall mean, left common near wall mean, left bifurcation wall mean and left internal far wall mean). These 6 summary variables were then averaged to estimate a single mean-mean far wall CIMT for each participant visit. (NCT00065806)
Timeframe: Change from baseline to 36 months

Interventionmm (Mean)
1 Atorvastatin0.0022
2 Placebo0.0028

Change in Natural Log of mg/L for hsCRP

(NCT00065806)
Timeframe: Change from baseline to 36 months

Interventionnatural log of mg/L (Mean)
1 Atorvastatin-0.13
2 Placebo0.27

Change in Total Cholesterol

(NCT00065806)
Timeframe: Change from baseline to 36 months

Interventionmg/dl (Mean)
1 Atorvastatin-30.30
2 Placebo-0.72

Change in Triglycerides

(NCT00065806)
Timeframe: Change from baseline to 36 months

Interventionmg/dl (Mean)
1 Atorvastatin-11.04
2 Placebo-5.62

Number of Adverse Events (AEs)Grade 3 or Higher Experienced by Participant During Treatment Phase of Study

"Number of adverse events (AEs) or serious adverse events (SAEs) Grade 3 or higher experienced by participant over the duration of the treatment period. [1]~[1] This study graded the severity of AEs experienced by the study participant according to the criteria set forth in the National Cancer Institute's Common Terminology Criteria for Adverse Events Version 3.0." (NCT00447265)
Timeframe: 24 Weeks

InterventionEvents (Number)
Etanercept0

Number of Participant Adverse Events (AEs) From Baseline to Early Study Withdrawal Visit

Number of participant AEs during the trial. This study graded the severity of AEs experienced by the study participant according to the criteria set forth in the National Cancer Institute's Common Terminology Criteria for Adverse Events Version 3.0. (NCT00447265)
Timeframe: 39 Weeks

InterventionEvents (Number)
Etanercept3

Number of Participants With a B to D Change From Baseline to Week 24 in the British Isles Lupus Assessment Group (BILAG) Musculoskeletal Score

Reported here is the number of participants with a change in their BILAG Musculoskeletal Score from B (at baseline) to D (at week 24). A single alphabetic score (A through E) is used to denote disease severity. The BILAG score is a converted numerical score (A=9, B=3, C=1, D=0, E=0).A maximum musculoskeletal score of 9 signifies higher disease activity and a score of 0 is indicative of inactive systematic lupus erythematosus (SLE) in the specified organ system. (NCT00447265)
Timeframe: Baseline, Week 24

InterventionParticipants (Number)
Etanercept1

Number of Participants With a C to B Score Change From Baseline to Week 24 in the British Isles Lupus Assessment Group (BILAG) Mucocutaneous Score

Reported here is the number of participants with a change in their BILAG Mucocutaneous Score from C (at baseline) to B (at week 24). A single alphabetic score (A through E) is used to denote disease severity. The BILAG score is a converted numerical score (A=9, B=3, C=1, D=0, E=0). A maximum mucocutaneous score of 9 signifies higher disease activity and a score of 0 is indicative of inactive systematic lupus erythematosus (SLE) in the specified organ system. (NCT00447265)
Timeframe: Baseline, Week 24

InterventionParticipants (Number)
Etanercept1

Number of Participants With an A to B Score Change From Baseline to Week 24 in the British Isles Lupus Assessment Group (BILAG) Renal Score

Reported here is the number of participants with a change in their BILAG Renal Score from A (at baseline) to B (at week 24). A single alphabetic score (A through E) is used to denote disease severity. The BILAG score is a converted numerical score (A=9, B=3, C=1, D=0, E=0).A maximum renal score of 9 signifies higher disease activity and a score of 0 is indicative of inactive systematic lupus erythematosus (SLE) in the specified organ system (NCT00447265)
Timeframe: Baseline, Week 24

InterventionParticipants (Number)
Etanercept1

Percent of Participants Who Achieved a Renal Response at Week 24

"Percent of study participants who achieved a renal response at 24 weeks.[1]~[1]A renal response is defined as: 1) 50% reduction in proteinuria compared to baseline as measured by urinary protein: creatinine ratio; and 2) stable or improving renal function as defined by the Glomerular filtration rate (GFR) calculated based on the Modification of Diet in Renal Disease equation (Levy, AS, Coresh J, Galk E et al, National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med, 139(2): 137-47, 2003)" (NCT00447265)
Timeframe: Week 24

InterventionPercent of Participants (Number)
Etanercept100

Time to Participant's Renal Response

"Time to when participant achieved a renal response[1]~[1]A renal response is defined as: 1) 50% reduction in proteinuria compared to baseline as measured by urinary protein: creatinine ratio; and 2) stable or improving renal function as defined by the Glomerular filtration rate (GFR) calculated based on the Modification of Diet in Renal Disease equation (Levy, AS, Coresh J, Galk E et al, National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med, 139(2): 137-47, 2003)" (NCT00447265)
Timeframe: First 24 Weeks of Study Period

InterventionWeeks (Number)
Etanercept24

Participant Medical Outcome Study Short Form 36 (SF-36) Mental Component Score at Baseline and Week 24

"Reported here are the participant SF-36 Mental Component scores at baseline and week 24. The SF-36 measures 8 domains: physical functioning, role limitations due to physical health, bodily pain, social functioning, mental health, role limitations due to emotional problems, vitality, and general health perceptions.[1] The Mental Component score of the SF-36 ranges from 0 to 100; 0 equals worst health state. Higher numbers reported here indicate more improvement in condition from baseline.~[1]Ref: Ware JE, Sherbourne CD. The MOS36-item short-form health survey. Med Care. 1992; 30:473-483" (NCT00447265)
Timeframe: Baseline, Week 24

InterventionScore on a scale (Number)
Baseline SF-36 Mental Component ScoreWeek 24 SF-36 Mental Component Score
Etanercept31.452.3

Participant Medical Outcome Study Short-Form 36 (SF-36) Physical Component Score at Baseline and Week 24

"Reported here is the participant baseline and week 24 SF-36 Physical Component scores. The SF-36 measures 8 domains: physical functioning, role limitations due to physical health, body pain, social functioning, mental health, role limitations due to emotional problems, vitality, and general health perceptions[1]. The Physical Component scores of the SF-36 range from 0 to 100; 0 equals worst health state. Higher numbers reported here indicate more improvement in condition from baseline.~[1]Ref: Ware JE, Sherbourne CD. The MOS36-item short-form health survey Med Care. 1992; 30:473-483." (NCT00447265)
Timeframe: Baseline, Week 24

InterventionScore on a scale (Number)
Baseline SF-36 Physical Component ScoreWeek 24 SF-36 Physical Component Score
Etanercept44.442.3

Participant Systematic Lupus Erythematosus Disease Activity Index (SLEDAI) Score at Baseline and at Early Study Withdrawal Visit

Reported here is the baseline and week 39 Systematic Lupus Erythematosus Disease Activity Index (SLEDAI) scores. The SLEDAI is a concise measure of lupus disease activity with excellent test-retest reliability and high responsiveness to clinically important changes in the disease. The total score is derived from ratings on 24 conditions plus the Physician's Global Assessment; 0 indicates inactive disease and the maximum theoretical score is 105, with higher scores representing increased disease activity. (NCT00447265)
Timeframe: Baseline, Week 39 (Early Study Withdrawal Visit)

InterventionPoints on a scale (Number)
Baseline SLEDAI ScoreWeek 39 SLEDAI score
Etanercept228

Serum Levels of Hydroxycloroquine

Serum levels of hydroxycloroquine by LCMS (NCT03122431)
Timeframe: 12 months

Interventionng/mL (Mean)
Inactive SLE With Standard Dose of HCQ991.6
Inactive SLE With Reduced Dose of HCQ569.0

Serum Levels of Thalidomide

Serum levels of thalidomide by liquid chromatography and tandem mass spectrometry (HPLC-MS/MS) (NCT03122431)
Timeframe: 12 months

Interventionng/mL (Mean)
SLE/Cutaneous Lupus With Thalidomide415.1

Reviews

95 reviews available for azathioprine and Libman-Sacks Disease

ArticleYear
Synthetic Pharmacotherapy for Systemic Lupus Erythematosus: Potential Mechanisms of Action, Efficacy, and Safety.
    Medicina (Kaunas, Lithuania), 2022, Dec-27, Volume: 59, Issue:1

    Topics: Azathioprine; Cyclophosphamide; Humans; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Myc

2022
B Cell Abnormalities in Systemic Lupus Erythematosus and Lupus Nephritis-Role in Pathogenesis and Effect of Immunosuppressive Treatments.
    International journal of molecular sciences, 2019, Dec-10, Volume: 20, Issue:24

    Topics: Antibodies, Monoclonal; Azathioprine; B-Lymphocytes; Clinical Trials as Topic; Cyclophosphamide; Hum

2019
Update οn the diagnosis and management of systemic lupus erythematosus.
    Annals of the rheumatic diseases, 2021, Volume: 80, Issue:1

    Topics: Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal, Humanized; Autoantibodies; Azathioprine; Calc

2021
Management of inflammatory neurologic and psychiatric manifestations of systemic lupus erythematosus: A systematic review.
    Seminars in arthritis and rheumatism, 2021, Volume: 51, Issue:1

    Topics: Azathioprine; Cyclophosphamide; Humans; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Lup

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Interventions for cutaneous disease in systemic lupus erythematosus.
    The Cochrane database of systematic reviews, 2021, 03-09, Volume: 3

    Topics: Age of Onset; Azathioprine; Bias; Biological Factors; Chloroquine; Cosmetic Techniques; Cyclosporine

2021
Research and therapeutics-traditional and emerging therapies in systemic lupus erythematosus.
    Rheumatology (Oxford, England), 2017, 04-01, Volume: 56, Issue:suppl_1

    Topics: Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Azathioprine; Cyclophosphamide; Drug Discov

2017
Current status of lupus nephritis.
    The Indian journal of medical research, 2017, Volume: 145, Issue:2

    Topics: Azathioprine; Cyclophosphamide; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Lupus E

2017
Corticosteroid-associated lupus pancreatitis: a case series and systematic review of the literature.
    Lupus, 2019, Volume: 28, Issue:6

    Topics: Acute Disease; Adolescent; Adrenal Cortex Hormones; Azathioprine; Cyclophosphamide; Dose-Response Re

2019
Amicrobial pustulosis of the folds associated with autoimmune disorders: systemic lupus erythematosus case series and first report on the association with autoimmune hepatitis.
    Dermatology (Basel, Switzerland), 2013, Volume: 226, Issue:1

    Topics: Adult; Antirheumatic Agents; Azathioprine; Chloroquine; Dapsone; Diagnosis, Differential; Drug Thera

2013
Aplastic anemia secondary to azathioprine in systemic lupus erythematosus: report of a case with normal thiopurine S-methyltransferase enzyme activity and review of the literature.
    Lupus, 2013, Volume: 22, Issue:14

    Topics: Anemia, Aplastic; Azathioprine; Fatal Outcome; Female; Humans; Immunosuppressive Agents; Lupus Eryth

2013
Intentional overdose of azathioprine in a patient with systemic lupus erythematosus.
    Scottish medical journal, 2013, Volume: 58, Issue:4

    Topics: Acetaminophen; Adolescent; Affective Disorders, Psychotic; Anti-Inflammatory Agents, Non-Steroidal;

2013
Ten common mistakes in the management of lupus nephritis.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2014, Volume: 63, Issue:4

    Topics: Adult; Antimalarials; Azathioprine; Bone Density; Cyclophosphamide; Female; Glucocorticoids; Humans;

2014
Hepatitis reactivation in patients with rheumatic diseases after immunosuppressive therapy--a report of long-term follow-up of serial cases and literature review.
    Clinical rheumatology, 2014, Volume: 33, Issue:4

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Arthritis, Rheumatoid; Azathioprine; Cohort Studies; Derm

2014
Systemic lupus erythematosus and pregnancy outcomes: an update and review of the literature.
    Current opinion in rheumatology, 2014, Volume: 26, Issue:2

    Topics: Antibodies, Monoclonal, Humanized; Azathioprine; Cohort Studies; Female; Heart Block; Humans; Hydrox

2014
Longitudinally extensive transverse myelitis.
    Current opinion in neurology, 2014, Volume: 27, Issue:3

    Topics: Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Aquaporin 4; Autoantibodi

2014
Optimizing the use of existing therapies in lupus.
    International journal of rheumatic diseases, 2015, Volume: 18, Issue:2

    Topics: Antimetabolites, Antineoplastic; Azathioprine; Cohort Studies; Cyclophosphamide; Dose-Response Relat

2015
Treatment Considerations of Lung Involvement in Rheumatologic Disease.
    Respiration; international review of thoracic diseases, 2015, Volume: 90, Issue:4

    Topics: Adrenal Cortex Hormones; Antirheumatic Agents; Arthritis, Rheumatoid; Azathioprine; Cyclophosphamide

2015
It hasn't gone away: the problem of glucocorticoid use in lupus remains.
    Rheumatology (Oxford, England), 2017, 04-01, Volume: 56, Issue:suppl_1

    Topics: Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Azathioprine; Cardiovascular Diseases; Cata

2017
[Treatment of proliferative glomerulonephritis of systemic lupus erythematosus. Recent development and current recommendations].
    La Revue de medecine interne, 2008, Volume: 29, Issue:9

    Topics: Azathioprine; Clinical Protocols; Cyclophosphamide; Glomerulonephritis; Humans; Lupus Erythematosus,

2008
Inosine triphosphate pyrophosphatase 94C>A polymorphism: clinical implications for patients with systemic lupus erythematosus treated with azathioprine.
    Expert opinion on drug safety, 2010, Volume: 9, Issue:3

    Topics: Asian People; Azathioprine; Clinical Trials as Topic; Humans; Lupus Erythematosus, Systemic; Pharmac

2010
Hypoparathyroidism in a patient with systemic lupus erythematosus coexisted with ankylosing spondylitis: a case report and review of literature.
    Joint bone spine, 2010, Volume: 77, Issue:6

    Topics: Adult; Azathioprine; Central Nervous System Diseases; Cyclophosphamide; Glucocorticoids; Humans; Hyp

2010
Lupus and pregnancy: integrating clues from the bench and bedside.
    European journal of clinical investigation, 2011, Volume: 41, Issue:6

    Topics: Abortion, Spontaneous; Antibodies, Antiphospholipid; Anticoagulants; Aspirin; Azathioprine; Counseli

2011
Clinical assessment and management of cytopenias in lupus patients.
    Current rheumatology reports, 2011, Volume: 13, Issue:4

    Topics: Anemia; Antibodies, Monoclonal, Murine-Derived; Azathioprine; Glucocorticoids; Humans; Immunoglobuli

2011
Mycophenolate mofetil in the treatment of systemic lupus erythematosus.
    Current opinion in rheumatology, 2011, Volume: 23, Issue:5

    Topics: Azathioprine; Clinical Trials as Topic; Drug Monitoring; Humans; Immunosuppressive Agents; Lupus Ery

2011
[Systemic autoimmune disorders and pregnancy].
    Orvosi hetilap, 2011, Oct-23, Volume: 152, Issue:43

    Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Antimalarials; Antiphospholipid Syndrome; Arthrit

2011
How to treat refractory arthritis in lupus?
    Joint bone spine, 2012, Volume: 79, Issue:4

    Topics: Abatacept; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal,

2012
Dutch guidelines for diagnosis and therapy of proliferative lupus nephritis.
    The Netherlands journal of medicine, 2012, Volume: 70, Issue:4

    Topics: Antirheumatic Agents; Azathioprine; Biopsy; Cyclophosphamide; Disease Progression; Humans; Immunosup

2012
[Association of systemic diseases and myelodysplastic syndromes. A retrospective study of 14 cases].
    Presse medicale (Paris, France : 1983), 2003, Mar-29, Volume: 32, Issue:12

    Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Azathioprine; Blood Transfusion; Cyclophosp

2003
Immunosuppressive drug use in pregnancy.
    Autoimmunity, 2003, Volume: 36, Issue:1

    Topics: Adrenal Cortex Hormones; Azathioprine; Breast Feeding; Cyclophosphamide; Cyclosporine; Female; Fetal

2003
[Systemic manifestations of Parvovirus B19 infections].
    La Revue de medecine interne, 2004, Volume: 25, Issue:10

    Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Antibodies, Viral; Arthritis, Infectious; Arthriti

2004
Systemic lupus erythematosus with simultaneous onset of Kikuchi-Fujimoto's disease complicated with antiphospholipid antibody syndrome: a case report and review of the literature.
    Rheumatology international, 2005, Volume: 25, Issue:4

    Topics: Administration, Oral; Adult; Anti-Inflammatory Agents; Anticoagulants; Antiphospholipid Syndrome; An

2005
Therapeutic options for refractory massive pleural effusion in systemic lupus erythematosus: a case study and review of the literature.
    Seminars in arthritis and rheumatism, 2005, Volume: 34, Issue:5

    Topics: Adult; Azathioprine; Biopsy, Needle; Combined Modality Therapy; Drainage; Female; Follow-Up Studies;

2005
[Pharmacotherapy of SLE].
    Nihon rinsho. Japanese journal of clinical medicine, 2005, Volume: 63 Suppl 5

    Topics: Adrenal Cortex Hormones; Anemia, Hemolytic; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; C

2005
Azathioprine induced hodgkin lymphoma: a case report and review of literature.
    American journal of clinical oncology, 2005, Volume: 28, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Azathioprine; Hodgkin Disease; Humans; Immunosuppres

2005
[Progress and perspectives in the treatment of systemic lupus erythematosus].
    Przeglad lekarski, 2005, Volume: 62, Issue:9

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Antimalarials; Antineoplastic Agents, Alkylating; Azathiopr

2005
Azathioprine and inhibition of the anticoagulant effect of warfarin: evidence from a case report and a literature review.
    The American journal of geriatric pharmacotherapy, 2006, Volume: 4, Issue:1

    Topics: Aged; Anticoagulants; Azathioprine; Drug Antagonism; Female; Humans; Immunosuppressive Agents; Inter

2006
[Risk of atherosclerosis development in patients with systemic lupus erythematosus].
    Polskie Archiwum Medycyny Wewnetrznej, 2005, Volume: 114, Issue:5

    Topics: Adrenal Cortex Hormones; Arteriosclerosis; Autoantibodies; Azathioprine; Blood Coagulation Disorders

2005
[Renal manifestations of systemic autoimmune disease: diagnosis and therapy].
    Nephrologie & therapeutique, 2006, Volume: 2, Issue:3

    Topics: Autoimmune Diseases; Azathioprine; Biopsy; Cyclophosphamide; Humans; Immunosuppressive Agents; Kidne

2006
Lupus activity in pregnancy.
    Rheumatic diseases clinics of North America, 2007, Volume: 33, Issue:2

    Topics: Adult; Animals; Azathioprine; Female; Glucocorticoids; Humans; Immunosuppressive Agents; Lupus Eryth

2007
Sensorineural hearing loss in systemic lupus erythematosus: case report and literature review.
    The Journal of laryngology and otology, 2008, Volume: 122, Issue:12

    Topics: Adult; Anticoagulants; Antimetabolites; Audiometry, Pure-Tone; Azathioprine; Drug Therapy, Combinati

2008
Systemic lupus erythematosus.
    Clinical obstetrics and gynecology, 1983, Volume: 26, Issue:3

    Topics: Abnormalities, Drug-Induced; Abortion, Therapeutic; Adrenal Cortex Hormones; Aspirin; Azathioprine;

1983
Immunosuppressive therapy in the treatment of autoimmune diseases.
    Springer seminars in immunopathology, 1984, Volume: 7, Issue:1

    Topics: Adolescent; Adrenal Cortex Hormones; Alkylating Agents; Anemia; Anemia, Aplastic; Anemia, Hemolytic,

1984
The application of plasmapheresis in systemic lupus erythematosus.
    Progress in clinical and biological research, 1982, Volume: 106

    Topics: Adrenal Cortex Hormones; Antigen-Antibody Complex; Azathioprine; Cyclophosphamide; Glomerulonephriti

1982
The natural history and response to therapy of lupus nephritis.
    Annual review of medicine, 1980, Volume: 31

    Topics: Animals; Azathioprine; Clinical Trials as Topic; Cyclophosphamide; Disease Models, Animal; Fluoresce

1980
Azathioprine.
    International journal of dermatology, 1981, Volume: 20, Issue:7

    Topics: Arthritis, Rheumatoid; Azathioprine; Behcet Syndrome; Bone Marrow; Colitis, Ulcerative; Crohn Diseas

1981
[Systemic diseases--the significance of early diagnosis exemplified by systemic lupus erythematosus and Wegener's granulomatosis].
    Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete, 1993, Volume: 48, Issue:12

    Topics: Adrenal Cortex Hormones; Azathioprine; Cyclophosphamide; Granulomatosis with Polyangiitis; Humans; L

1993
Immunosuppressive drug therapy of systemic lupus erythematosus.
    Rheumatic diseases clinics of North America, 1994, Volume: 20, Issue:1

    Topics: Azathioprine; Cyclophosphamide; Cyclosporine; Humans; Immunosuppressive Agents; Leukocyte Count; Lup

1994
Diagnosis and treatment of systemic lupus erythematosus.
    BMJ (Clinical research ed.), 1993, Sep-11, Volume: 307, Issue:6905

    Topics: Autoantibodies; Azathioprine; Cyclophosphamide; Humans; Lupus Erythematosus, Systemic; Prednisolone

1993
Transverse myelopathy in SLE: clinical features and functional outcomes.
    Lupus, 1996, Volume: 5, Issue:4

    Topics: Adult; Autoimmune Diseases; Azathioprine; Cyclophosphamide; Female; Humans; Immunosuppressive Agents

1996
What's new in the treatment of pediatric SLE.
    The Journal of rheumatology, 1996, Volume: 23, Issue:9

    Topics: Anticoagulants; Azathioprine; Child, Preschool; Cyclophosphamide; Humans; Lupus Erythematosus, Syste

1996
Immunosuppressant therapy during gestation.
    Seminars in perinatology, 1997, Volume: 21, Issue:2

    Topics: Arthritis, Rheumatoid; Azathioprine; Cyclosporine; Female; Humans; Immunosuppressive Agents; Infant,

1997
Update on immunosuppressive therapy.
    Current opinion in rheumatology, 1998, Volume: 10, Issue:3

    Topics: Adult; Arthritis, Juvenile; Azathioprine; Behcet Syndrome; Child; Cladribine; Cyclophosphamide; Cycl

1998
Indications for, and use of, cytotoxic agents in SLE.
    Bailliere's clinical rheumatology, 1998, Volume: 12, Issue:3

    Topics: Azathioprine; Cyclophosphamide; Humans; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Met

1998
Lupus erythematosus associated with erythema multiforme: does Rowell's syndrome exist?
    Journal of the American Academy of Dermatology, 1999, Volume: 40, Issue:5 Pt 1

    Topics: Adult; Azathioprine; Cathartics; Dermatologic Agents; Diagnosis, Differential; Erythema Multiforme;

1999
Optic neuropathy in systemic lupus erythematosus and antiphospholipid syndrome (APS): clinical features, pathogenesis, review of the literature and proposed ophthalmological criteria for APS diagnosis.
    Clinical rheumatology, 1999, Volume: 18, Issue:2

    Topics: Adult; Antibodies, Antinuclear; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Azathioprin

1999
Azathioprine therapy for patients with systemic lupus erythematosus.
    Lupus, 2001, Volume: 10, Issue:3

    Topics: Azathioprine; Humans; Immunosuppressive Agents; Lupus Erythematosus, Systemic

2001
Immunosuppressive therapy in rheumatic disease.
    The Medical clinics of North America, 1977, Volume: 61, Issue:2

    Topics: Arthritis, Rheumatoid; Azathioprine; Clinical Trials as Topic; Cyclophosphamide; Dermatomyositis; Gr

1977
Serologic abnormalities in spontaneous and drug-induced systemic lupus erythematosus.
    The Journal of rheumatology, 1975, Volume: 2, Issue:2

    Topics: Animals; Anti-Bacterial Agents; Antibodies, Anti-Idiotypic; Antibodies, Antinuclear; Anticonvulsants

1975
[Lupus erythematosus, modern aspects (author's transl)].
    Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis, 1977, May-10, Volume: 66, Issue:19

    Topics: Antacids; Antibodies, Antinuclear; Antigen-Antibody Complex; Azathioprine; Chlorambucil; Cyclophosph

1977
Glomerulonephritis in procainamide induced lupus erythematosus: report of a case and review of the literature.
    Journal of clinical & laboratory immunology, 1979, Volume: 2, Issue:1

    Topics: Azathioprine; Biopsy; Glomerulonephritis; Humans; Kidney Glomerulus; Lupus Erythematosus, Systemic;

1979
[Treatment of SLE-nephritis: literature review].
    Lakartidningen, 1978, May-31, Volume: 75, Issue:22

    Topics: Azathioprine; Cyclophosphamide; Drug Therapy, Combination; Glomerulonephritis; Humans; Kidney Glomer

1978
[Clinico-pathological correlations in lupus nephritis with reference to therapeutic and prognostic aspects (author's transl)].
    Immunitat und Infektion, 1979, Volume: 7, Issue:4

    Topics: Azathioprine; Female; Humans; Hypertension; Kidney; Lupus Erythematosus, Systemic; Male; Nephritis;

1979
Systemic lupus erythematosus: treatment and prognosis.
    British medical journal, 1979, Oct-27, Volume: 2, Issue:6197

    Topics: Adult; Azathioprine; Brain Diseases; Drug Therapy, Combination; Female; Glomerulonephritis; Glucocor

1979
Immunosuppressive agents in the treatment of the nephrotic syndrome and glomerulonephritis in children.
    Paediatrician, 1979, Volume: 8, Issue:5-6

    Topics: Azathioprine; Child; Chlorambucil; Cyclophosphamide; Glomerulonephritis; Humans; Immunosuppressive A

1979
[Myasthenia gravis and visceral lupus erythematosus].
    Schweizerische medizinische Wochenschrift, 1979, Dec-08, Volume: 109, Issue:47

    Topics: Acetylcholine; Adult; Antibodies, Antinuclear; Antigen-Antibody Complex; Azathioprine; Cell Membrane

1979
Immunosuppressive agents in lupus nephritis: a critical analysis.
    Medicine, 1976, Volume: 55, Issue:3

    Topics: Azathioprine; Cyclophosphamide; Glomerulonephritis; Humans; Immunosuppressive Agents; Kidney; Lupus

1976
[Immunovasculitis-- differential diagnosis and therapy of inflammatory systemic diseases].
    Die Medizinische Welt, 1976, Jun-25, Volume: 27, Issue:26

    Topics: Adult; Angiography; Arthritis, Rheumatoid; Autoimmune Diseases; Azathioprine; Diagnosis, Differentia

1976
Problems with immunosuppressive agents in renal disease.
    Journal of clinical pathology. Supplement (Royal College of Pathologists), 1975, Volume: 9

    Topics: Animals; Azathioprine; Cyclophosphamide; Granulomatosis with Polyangiitis; Humans; Immunosuppressive

1975
Recent observations on central nervous system lupus erythematosus.
    Seminars in arthritis and rheumatism, 1975, Volume: 4, Issue:3

    Topics: Animals; Antibodies, Viral; Autoantibodies; Azathioprine; Central Nervous System Diseases; Child; Co

1975
Laryngeal involvement in systemic lupus erythematosus.
    Seminars in arthritis and rheumatism, 1992, Volume: 22, Issue:3

    Topics: Adult; Azathioprine; Diagnosis, Differential; Female; Humans; Laryngeal Diseases; Laryngeal Edema; L

1992
[A case of systemic lupus erythematosus (SLE) developing pan-dysautonomia].
    Ryumachi. [Rheumatism], 1992, Volume: 32, Issue:1

    Topics: Adult; Antibodies, Antinuclear; Autonomic Nervous System Diseases; Azathioprine; Female; Humans; Lup

1992
Renal transplantation for systemic lupus erythematosus and recurrent lupus nephritis. A single-center experience and a review of the literature.
    Transplantation, 1991, Volume: 52, Issue:5

    Topics: Adult; Animals; Antibodies, Antinuclear; Antilymphocyte Serum; Azathioprine; Complement System Prote

1991
Azathioprine, cyclophosphamide and chlorambucil.
    Bailliere's clinical rheumatology, 1990, Volume: 4, Issue:3

    Topics: Arthritis, Rheumatoid; Azathioprine; Chlorambucil; Connective Tissue Diseases; Cyclophosphamide; Hum

1990
Immunologic and clinical effects of cytotoxic drugs used in the treatment of rheumatoid arthritis and systemic lupus erythematosus.
    Concepts in immunopathology, 1989, Volume: 7

    Topics: Arthritis, Rheumatoid; Autoimmune Diseases; Azathioprine; B-Lymphocytes; Cyclophosphamide; Humans; K

1989
Cytotoxic drugs: their clinical application to the rheumatic diseases.
    Seminars in arthritis and rheumatism, 1986, Volume: 15, Issue:4

    Topics: Arthritis; Arthritis, Rheumatoid; Azathioprine; Behcet Syndrome; Bone Marrow; Cell Division; Chemica

1986
Significance of the lupus anticoagulant.
    American journal of hematology, 1986, Volume: 22, Issue:3

    Topics: Adrenal Cortex Hormones; Autoantibodies; Azathioprine; Blood Coagulation Disorders; Blood Coagulatio

1986
Treatment of systemic lupus erythematosus.
    Springer seminars in immunopathology, 1986, Volume: 9, Issue:2-3

    Topics: Azathioprine; Cyclophosphamide; Cyclosporins; Drug Therapy, Combination; Humans; Hydroxychloroquine;

1986
Immunosuppressive agents and plasmapheresis in immunological disorders.
    Journal of immunopharmacology, 1985, Volume: 7, Issue:1

    Topics: Animals; Antigen-Antibody Complex; Autoantibodies; Azathioprine; Cyclophosphamide; Glucocorticoids;

1985
Mechanisms of action and clinical applications of cytotoxic drugs in rheumatic disorders.
    The Medical clinics of North America, 1985, Volume: 69, Issue:4

    Topics: Arthritis, Reactive; Arthritis, Rheumatoid; Azathioprine; Chlorambucil; Collagen Diseases; Cyclophos

1985
[Therapy of lupus-nephritis using corticosteroids and immunosuppressive agents].
    Deutsche medizinische Wochenschrift (1946), 1974, Jun-28, Volume: 99, Issue:26

    Topics: Adrenal Cortex Hormones; Antibodies, Antinuclear; Azathioprine; Beta-Globulins; Chlorambucil; Cyclop

1974
[Auto-immune diseases and immunodepressive therapy. II. Current clinical indications].
    Acta clinica Belgica, 1974, Volume: 29, Issue:6

    Topics: Adrenal Cortex Hormones; Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Arteritis; Autoimmune

1974
Cytotoxic drugs in treatment of nonmalignant diseases.
    Annals of internal medicine, 1972, Volume: 76, Issue:4

    Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Arthritis, Rheumatoid; Azathioprine; Chlor

1972
[Long-term therapy of immunologic diseases with special reference to the use of immunosuppressive agents].
    Deutsche medizinische Wochenschrift (1946), 1969, Nov-21, Volume: 94, Issue:47

    Topics: Adrenocorticotropic Hormone; Alkylating Agents; Anemia, Hemolytic, Autoimmune; Anti-Bacterial Agents

1969
Immunosuppressive therapy in neurological diseases.
    Annals of clinical research, 1974, Volume: 6, Issue:6

    Topics: Adrenocorticotropic Hormone; Azathioprine; Central Nervous System Diseases; Cyclophosphamide; Cytara

1974
Immunosuppressive therapy. 1.
    The New England journal of medicine, 1972, Aug-03, Volume: 287, Issue:5

    Topics: Alkylating Agents; Anemia, Hemolytic, Autoimmune; Antibodies; Antimetabolites; Arthritis, Rheumatoid

1972
Immunosuppressive therapy. 2.
    The New England journal of medicine, 1972, Aug-10, Volume: 287, Issue:6

    Topics: Abnormalities, Drug-Induced; Adrenal Cortex Hormones; Adult; Azathioprine; Child; Chlorambucil; Clin

1972
The effect of drugs on immunological renal disease.
    Progress in biochemical pharmacology, 1972, Volume: 7

    Topics: Adrenal Cortex Hormones; Antilymphocyte Serum; Azathioprine; Chlorambucil; Cyclophosphamide; Glomeru

1972
Drug therapy: immunosuppressive agents (second of two parts).
    The New England journal of medicine, 1973, Dec-06, Volume: 289, Issue:23

    Topics: Antimetabolites; Arthritis, Rheumatoid; Azathioprine; Child; Drug Therapy, Combination; Folic Acid A

1973
[The treatment of nephritis following disseminated lupus erythematosus with prednisone, azathioprine and cyclophosphamide].
    Nederlands tijdschrift voor geneeskunde, 1974, Sep-14, Volume: 118, Issue:37

    Topics: Azathioprine; Cyclophosphamide; Humans; Lupus Erythematosus, Systemic; Nephritis; Prednisone

1974
Chronic hepatitis.
    Gut, 1974, Volume: 15, Issue:7

    Topics: Adult; Animals; Autoimmune Diseases; Azathioprine; Chemical and Drug Induced Liver Injury; Child; Ch

1974
Acquired inhibitors in nonhemophilic patients.
    Haemostasis, 1974, Volume: 3, Issue:2

    Topics: Arthritis, Rheumatoid; Azathioprine; Blood Coagulation Disorders; Blood Coagulation Tests; Blood Pro

1974
[Pathophysiology of immunological processes. 3. Therapeutic influencing].
    Zeitschrift fur arztliche Fortbildung, 1968, Apr-15, Volume: 62, Issue:8

    Topics: Aged; Anemia, Hemolytic, Autoimmune; Antibody Formation; Antigen-Antibody Reactions; Arthritis, Rheu

1968
Therapeutics. XI. Immunosuppressive drugs.
    The British journal of dermatology, 1970, Volume: 83, Issue:2

    Topics: Adrenal Cortex Hormones; Animals; Antibody Formation; Autoimmune Diseases; Azathioprine; Cyclophosph

1970
Immunosuppressant agents in the treatment of glomerulonephritis. 2. Cytotoxic drugs.
    Journal of the Royal College of Physicians of London, 1971, Volume: 5, Issue:4

    Topics: Adult; Anti-Glomerular Basement Membrane Disease; Antilymphocyte Serum; Antineoplastic Agents; Azath

1971
[Treatment of chronic diseases of connective tissue by cytostatic drugs].
    Revista clinica espanola, 1970, Volume: 116, Issue:6

    Topics: Arthritis, Rheumatoid; Azathioprine; Chlorambucil; Collagen Diseases; Cyclophosphamide; Female; Huma

1970

Trials

50 trials available for azathioprine and Libman-Sacks Disease

ArticleYear
Weaning of maintenance immunosuppressive therapy in lupus nephritis (WIN-Lupus): results of a multicentre randomised controlled trial.
    Annals of the rheumatic diseases, 2022, Volume: 81, Issue:10

    Topics: Azathioprine; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Lupus Erythematosus, Syst

2022
Extrapolation of Adult Efficacy Data to Pediatric Systemic Lupus Erythematosus: Evaluating Similarities in Exposure-Response.
    Journal of clinical pharmacology, 2023, Volume: 63, Issue:1

    Topics: Adult; Azathioprine; Child; Cyclophosphamide; Enzyme Inhibitors; Humans; Hydroxychloroquine; Immunos

2023
Enteric-coated mycophenolate sodium versus azathioprine in patients with active systemic lupus erythematosus: a randomised clinical trial.
    Annals of the rheumatic diseases, 2017, Volume: 76, Issue:9

    Topics: Adult; Antimalarials; Azathioprine; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Immu

2017
Use of pharmacogenetics, enzymatic phenotyping, and metabolite monitoring to guide treatment with azathioprine in patients with systemic lupus erythematosus.
    The Journal of rheumatology, 2009, Volume: 36, Issue:1

    Topics: Adult; Aged; Azathioprine; Dose-Response Relationship, Drug; Drug Monitoring; Female; Heterozygote;

2009
Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients.
    Rheumatology (Oxford, England), 2009, Volume: 48, Issue:11

    Topics: Adult; Antibodies, Monoclonal; Antirheumatic Agents; Azathioprine; Drug Administration Schedule; Dru

2009
Very long-term outcome of pure lupus membranous nephropathy treated with glucocorticoid and azathioprine.
    Lupus, 2009, Volume: 18, Issue:12

    Topics: Adult; Azathioprine; Creatinine; Female; Glomerulonephritis, Membranous; Glucocorticoids; Humans; Im

2009
The BILAG multi-centre open randomized controlled trial comparing ciclosporin vs azathioprine in patients with severe SLE.
    Rheumatology (Oxford, England), 2010, Volume: 49, Issue:4

    Topics: Adrenal Cortex Hormones; Adult; Azathioprine; Cyclosporine; Dose-Response Relationship, Drug; Female

2010
Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents.
    Rheumatology (Oxford, England), 2002, Volume: 41, Issue:8

    Topics: Adult; Antibodies, Antinuclear; Azathioprine; Cyclophosphamide; Female; Follow-Up Studies; Humans; I

2002
Treatment of lupus psychosis with oral cyclophosphamide followed by azathioprine maintenance: an open-label study.
    The American journal of medicine, 2003, Volume: 115, Issue:1

    Topics: Administration, Oral; Adolescent; Adult; Anti-Inflammatory Agents; Antibodies, Antinuclear; Azathiop

2003
The reduction of serum B-lymphocyte activating factor levels following quinacrine add-on therapy in systemic lupus erythematosus.
    Scandinavian journal of immunology, 2006, Volume: 63, Issue:4

    Topics: Adult; Antibodies, Anticardiolipin; Antirheumatic Agents; Azathioprine; B-Cell Activating Factor; Ca

2006
Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus.
    Arthritis and rheumatism, 2007, Volume: 56, Issue:1

    Topics: Antibodies, Monoclonal; Apoptosis; Autoantibodies; Azathioprine; Dermatologic Agents; DNA; Drug Comb

2007
Controlled studies of oral immunosuppressive drugs in lupus nephritis. A long-term follow-up.
    Annals of internal medicine, 1983, Volume: 99, Issue:1

    Topics: Administration, Oral; Adolescent; Adult; Azathioprine; Child; Clinical Trials as Topic; Cyclophospha

1983
Systemic lupus erythematosus--immunoregulatory therapies.
    Clinics in rheumatic diseases, 1983, Volume: 9, Issue:3

    Topics: Animals; Azathioprine; Clinical Trials as Topic; Cyclophosphamide; Disease Models, Animal; Female; H

1983
Evidence for the superiority of immunosuppressive drugs and prednisone over prednisone alone in lupus nephritis. Results of a pooled analysis.
    The New England journal of medicine, 1984, Dec-13, Volume: 311, Issue:24

    Topics: Azathioprine; Clinical Trials as Topic; Cyclophosphamide; Drug Administration Schedule; Drug Therapy

1984
The natural history and response to therapy of lupus nephritis.
    Annual review of medicine, 1980, Volume: 31

    Topics: Animals; Azathioprine; Clinical Trials as Topic; Cyclophosphamide; Disease Models, Animal; Fluoresce

1980
Alternative modes of cyclophosphamide and azathioprine therapy in lupus nephritis.
    Annals of internal medicine, 1982, Volume: 96, Issue:6 Pt 1

    Topics: Administration, Oral; Adult; Azathioprine; Clinical Trials as Topic; Creatinine; Cyclophosphamide; D

1982
Prevention of relapses in systemic lupus erythematosus.
    Lancet (London, England), 1995, Jun-24, Volume: 345, Issue:8965

    Topics: Adult; Aged; Autoantibodies; Azathioprine; Cyclophosphamide; DNA; Female; Follow-Up Studies; Humans;

1995
[A clinico-immunological analysis of the efficacy of prospidin and azathioprine in systemic lupus erythematosus (the results of a 12-month observation)].
    Terapevticheskii arkhiv, 1993, Volume: 65, Issue:5

    Topics: Acute Disease; Adolescent; Adult; Azathioprine; Female; Follow-Up Studies; Humans; Lupus Erythematos

1993
Respiratory function in systemic lupus erythematosus: relation with activity and severity.
    Lupus, 1996, Volume: 5, Issue:1

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Female; Humans; Immunosuppressive Agen

1996
Correlation between CD29 density on CD8+ lymphocytes and serum IgG in systemic lupus erythematosus.
    Lupus, 1997, Volume: 6, Issue:4

    Topics: Antigens, CD; Azathioprine; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cohort Studies;

1997
Cyclosporine and therapeutic plasma exchange in treatment of progressive autoimmune diseases.
    Artificial organs, 1997, Volume: 21, Issue:9

    Topics: Adrenal Cortex Hormones; Adult; Aged; Antibody Formation; Azathioprine; Behcet Syndrome; Combined Mo

1997
A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group.
    Lupus, 1998, Volume: 7, Issue:2

    Topics: Adult; Antimalarials; Azathioprine; Cyclophosphamide; Female; Follow-Up Studies; Humans; Hydroxychlo

1998
A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group.
    Lupus, 1998, Volume: 7, Issue:2

    Topics: Adult; Antimalarials; Azathioprine; Cyclophosphamide; Female; Follow-Up Studies; Humans; Hydroxychlo

1998
A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group.
    Lupus, 1998, Volume: 7, Issue:2

    Topics: Adult; Antimalarials; Azathioprine; Cyclophosphamide; Female; Follow-Up Studies; Humans; Hydroxychlo

1998
A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group.
    Lupus, 1998, Volume: 7, Issue:2

    Topics: Adult; Antimalarials; Azathioprine; Cyclophosphamide; Female; Follow-Up Studies; Humans; Hydroxychlo

1998
Immunosuppressive therapy in rheumatic disease.
    The Medical clinics of North America, 1977, Volume: 61, Issue:2

    Topics: Arthritis, Rheumatoid; Azathioprine; Clinical Trials as Topic; Cyclophosphamide; Dermatomyositis; Gr

1977
Comparison of chlorambucil, azathioprine or cyclophosphamide combined with corticosteroids in the treatment of lupus nephritis.
    The British journal of dermatology, 1979, Volume: 100, Issue:2

    Topics: Adolescent; Adult; Azathioprine; Child; Chlorambucil; Clinical Trials as Topic; Cyclophosphamide; Dr

1979
[Evaluation of the effectiveness of the imuran treatment of lupus erythematosus].
    Vestnik dermatologii i venerologii, 1977, Issue:2

    Topics: Adult; Azathioprine; Chronic Disease; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Imm

1977
Longterm survival of lupus nephritis patients treated with azathioprine and prednisone.
    The Journal of rheumatology, 1978,Fall, Volume: 5, Issue:3

    Topics: Adolescent; Adult; Azathioprine; California; Clinical Trials as Topic; Drug Therapy, Combination; Fe

1978
Comparison of therapy in severe systemic lupus erythematosus employing stratification techniques.
    The Journal of rheumatology, 1978,Spring, Volume: 5, Issue:1

    Topics: Azathioprine; Creatinine; Drug Therapy, Combination; Evaluation Studies as Topic; Humans; Lupus Eryt

1978
Progression from minimal or focal to diffuse proliferative lupus nephritis.
    Laboratory investigation; a journal of technical methods and pathology, 1975, Volume: 32, Issue:5

    Topics: Adolescent; Adult; Azathioprine; Child; Clinical Trials as Topic; Cyclophosphamide; Female; Glomerul

1975
Azathioprine plus prednisone compared with prednisone alone in the treatment of systemic lupus erythematosus. Report of a prospective controlled trial in 24 patients.
    Annals of internal medicine, 1975, Volume: 83, Issue:5

    Topics: Adolescent; Adult; Antibodies, Antinuclear; Azathioprine; Clinical Trials as Topic; Drug Therapy, Co

1975
Cyclophosphamide or azathioprine in lupus glomerulonephritis. A controlled trial: results at 28 months.
    Annals of internal medicine, 1975, Volume: 83, Issue:5

    Topics: Adolescent; Adult; Amenorrhea; Azathioprine; Child; Clinical Trials as Topic; Complement C3; Cycloph

1975
[Multicenter cooperative study of immunosuppressive therapy of systemic lupus erythematosus--a report of Therapy Research Division of Research Committee for Autoimmune Diseases, the Ministry of Health and Welfare].
    Ryumachi. [Rheumatism], 1988, Volume: 28, Issue:4

    Topics: Adolescent; Adult; Azathioprine; Child; Child, Preschool; Cyclophosphamide; Female; Humans; Immunosu

1988
Immunosuppressive therapy in systemic lupus erythematosus.
    The Journal of rheumatology. Supplement, 1987, Volume: 14 Suppl 13

    Topics: Azathioprine; Clinical Trials as Topic; Cyclophosphamide; Double-Blind Method; Humans; Immune Tolera

1987
Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs.
    The New England journal of medicine, 1986, Mar-06, Volume: 314, Issue:10

    Topics: Administration, Oral; Adult; Azathioprine; Biopsy; Clinical Trials as Topic; Creatinine; Cyclophosph

1986
Chemotherapy of lupus nephropathy.
    Contributions to nephrology, 1985, Volume: 45

    Topics: Azathioprine; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combination; Humans; Lupus E

1985
[Drug treatment of chronic glomerulonephritis: contra].
    Klinische Wochenschrift, 1985, Sep-16, Volume: 63, Issue:18

    Topics: Azathioprine; Chlorambucil; Chronic Disease; Clinical Trials as Topic; Cyclophosphamide; Drug Therap

1985
"Lupoid" hepatitis, a nonentity in the spectrum of chronic active liver disease.
    Gastroenterology, 1972, Volume: 63, Issue:3

    Topics: Adolescent; Adult; Aged; Alkaline Phosphatase; Aspartate Aminotransferases; Azathioprine; Bilirubin;

1972
Anticomplementary hepatitis B antigen. Prognostic importance in chronic active liver disease.
    Archives of internal medicine, 1973, Volume: 132, Issue:4

    Topics: Antibodies; Azathioprine; Chronic Disease; Complement Fixation Tests; Drug Synergism; Hepatitis B An

1973
[Immuno-suppressive treatment in 15 patients with autoimmune affections or diseases of immunological pathogenesis].
    Acta clinica Belgica, 1966, Volume: 21, Issue:3

    Topics: Anemia, Hemolytic, Autoimmune; Azathioprine; Clinical Trials as Topic; Humans; Lupus Erythematosus,

1966
[Indomethacin in rheumatic diseases with special reference to ophthalmologic studies].
    Medizinische Klinik, 1972, Feb-25, Volume: 67, Issue:8

    Topics: Allopurinol; Arthritis, Rheumatoid; Azathioprine; Blood Cells; Capsules; Clinical Trials as Topic; E

1972
Immunosuppressive therapy. 1.
    The New England journal of medicine, 1972, Aug-03, Volume: 287, Issue:5

    Topics: Alkylating Agents; Anemia, Hemolytic, Autoimmune; Antibodies; Antimetabolites; Arthritis, Rheumatoid

1972
Immunosuppressive therapy. 2.
    The New England journal of medicine, 1972, Aug-10, Volume: 287, Issue:6

    Topics: Abnormalities, Drug-Induced; Adrenal Cortex Hormones; Adult; Azathioprine; Child; Chlorambucil; Clin

1972
Exacerbation of systemic lupus erythematosus after withdrawal of azathioprine therapy.
    The New England journal of medicine, 1973, Jan-18, Volume: 288, Issue:3

    Topics: Azathioprine; Blood Sedimentation; Clinical Trials as Topic; Follow-Up Studies; Humans; Kidney; Lupu

1973
[Treatment of chronic hepatitis with immunosuppressive agents and D-penicillamine].
    Wiener medizinische Wochenschrift (1946), 1973, Jun-23, Volume: 123, Issue:25

    Topics: Agranulocytosis; Azathioprine; Chronic Disease; Clinical Trials as Topic; Drug Hypersensitivity; Fem

1973
Psychopathology in systemic lupus erythematosus. II. Relation to clinical observations, corticosteroid administration, and cerebrospinal fluid C4.
    Seminars in arthritis and rheumatism, 1973, Volume: 3, Issue:2

    Topics: Adolescent; Adrenal Cortex Hormones; Adult; Affective Symptoms; Azathioprine; Brain Diseases; Centra

1973
Psychopathology in systemic lupus erythematosus. I. Psychiatric observations.
    Seminars in arthritis and rheumatism, 1973, Volume: 3, Issue:2

    Topics: Adolescent; Adult; Affective Symptoms; Aspirin; Azathioprine; Brain Diseases; Clinical Trials as Top

1973
Editorial: Diffuse proliferative lupus nephritis. Evaluation of therapy.
    Urology, 1973, Volume: 1, Issue:2

    Topics: Adrenal Cortex Hormones; Azathioprine; Child; Clinical Trials as Topic; Cyclophosphamide; Drug Evalu

1973
Comparison of azathioprine, prednisone, and heparin alone or combined in treating lupus nephritis.
    Nephron, 1973, Volume: 10, Issue:1

    Topics: Adolescent; Adult; Azathioprine; Child; Cushing Syndrome; Diabetes Mellitus; Drug Combinations; Fema

1973
Controlled study of azathioprine in lupus.
    The New England journal of medicine, 1968, May-02, Volume: 278, Issue:18

    Topics: Azathioprine; Clinical Trials as Topic; Humans; Lupus Erythematosus, Systemic; Nephritis; Prednisone

1968
Azathioprine and prednisone in the treatment of adults with lupus nephritis. Clinical, histological, and immunological changes with therapy.
    Medicine, 1970, Volume: 49, Issue:5

    Topics: Adult; Azathioprine; Clinical Trials as Topic; Female; Fluorescent Antibody Technique; Glomeruloneph

1970
[Effectiveness of immunosuppressive agents in systemic lupus erythematosus. Comparative study of a series of 13 cases and of a control series of 12 cases].
    La Nouvelle presse medicale, 1972, Jun-17, Volume: 1, Issue:25

    Topics: Adrenal Cortex Hormones; Azathioprine; Chlorambucil; Drug Combinations; Drug Interactions; Humans; I

1972

Other Studies

527 other studies available for azathioprine and Libman-Sacks Disease

ArticleYear
Remission or low disease activity at pregnancy onset are linked to improved foetal outcomes in women with systemic lupus erythematosus: results from a prospective observational study.
    Clinical and experimental rheumatology, 2022, Volume: 40, Issue:9

    Topics: Antibodies, Antiphospholipid; Azathioprine; Female; Glucocorticoids; Humans; Hydroxychloroquine; Inf

2022
Successful treatment of bullous lupus with corticosteroids and belimumab: A case report.
    Modern rheumatology case reports, 2023, 01-03, Volume: 7, Issue:1

    Topics: Adrenal Cortex Hormones; Adult; Antibodies, Monoclonal, Humanized; Azathioprine; Female; Humans; Lup

2023
Intravenous immunoglobulin in the management of refractory lupus profundus.
    Lupus, 2022, Volume: 31, Issue:8

    Topics: Adult; Azathioprine; Female; Humans; Immunoglobulins, Intravenous; Lupus Erythematosus, Cutaneous; L

2022
Outcomes of children born to mothers with systemic lupus erythematosus exposed to hydroxychloroquine or azathioprine.
    Rheumatology (Oxford, England), 2023, 03-01, Volume: 62, Issue:3

    Topics: Adolescent; Antirheumatic Agents; Azathioprine; Child; Female; Humans; Hydroxychloroquine; Lupus Ery

2023
Azathioprine-induced hypersensitivity reaction mimicking sepsis in a patient with systemic lupus erythematosus.
    Modern rheumatology case reports, 2023, 01-03, Volume: 7, Issue:1

    Topics: Abdominal Pain; Adult; Azathioprine; Female; Humans; Immunosuppressive Agents; Lupus Erythematosus,

2023
Association of mycophenolate and azathioprine use with cognitive function in systemic lupus.
    Rheumatology (Oxford, England), 2023, 05-02, Volume: 62, Issue:5

    Topics: Adult; Azathioprine; Cognition; Enzyme Inhibitors; Humans; Immunosuppressive Agents; Lupus Erythemat

2023
Fibrillar glomerulonephritis in a patient with systemic lupus erythematosus with no evidence of lupus nephritis.
    BMJ case reports, 2023, Feb-21, Volume: 16, Issue:2

    Topics: Azathioprine; Female; Glomerulonephritis; HSP40 Heat-Shock Proteins; Humans; Lupus Erythematosus, Sy

2023
Azathioprine-induced vanishing bile duct syndrome: The value of early thiopurine metabolism assessment.
    British journal of clinical pharmacology, 2023, Volume: 89, Issue:8

    Topics: Adult; Azathioprine; Bile Ducts; Female; Guanine Nucleotides; Humans; Immunosuppressive Agents; Lupu

2023
Real-world treatment patterns of immunosuppressants in Adults with systemic lupus erythematosus: A claims database analysis in the United States.
    Lupus, 2023, Volume: 32, Issue:7

    Topics: Adult; Azathioprine; Humans; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Methotrexate;

2023
Comparative Risks of Infection With Belimumab Versus Oral Immunosuppressants in Patients With Nonrenal Systemic Lupus Erythematosus.
    Arthritis & rheumatology (Hoboken, N.J.), 2023, Volume: 75, Issue:11

    Topics: Azathioprine; Female; Humans; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Male; Methotr

2023
Association of patient copayment and medication adherence in systemic lupus erythematosus.
    Lupus science & medicine, 2023, Volume: 10, Issue:2

    Topics: Adult; Aged; Azathioprine; Female; Humans; Hydroxychloroquine; Immunosuppressive Agents; Lupus Eryth

2023
Antimalarial agents diminish while methotrexate, azathioprine and mycophenolic acid increase BAFF levels in systemic lupus erythematosus.
    Autoimmunity reviews, 2019, Volume: 18, Issue:10

    Topics: Antimalarials; Azathioprine; B-Cell Activating Factor; Humans; Immunosuppressive Agents; Lupus Eryth

2019
EBV-positive mucocutaneous ulcer in a patient with systemic lupus erythematosus.
    Rheumatology (Oxford, England), 2020, 04-01, Volume: 59, Issue:4

    Topics: Azathioprine; Conservative Treatment; Deprescriptions; Epstein-Barr Virus Infections; Facial Dermato

2020
Prevalence and predictors of flare after immunosuppressant discontinuation in patients with systemic lupus erythematosus in remission.
    Rheumatology (Oxford, England), 2020, 07-01, Volume: 59, Issue:7

    Topics: Adult; Antimalarials; Antirheumatic Agents; Azathioprine; Cyclosporine; Deprescriptions; Female; Hum

2020
Comparison of lupus patients with early and late onset nephritis: a study in 71 patients from a single referral center.
    Advances in rheumatology (London, England), 2020, 01-03, Volume: 60, Issue:1

    Topics: Adult; Azathioprine; Biopsy; Complement C3; Complement C4; Creatinine; Cyclophosphamide; Delayed Dia

2020
A Long-Term Follow-up of Retinal Vasculitis - Do They Develop Systemic Disease?
    Ocular immunology and inflammation, 2020, Nov-16, Volume: 28, Issue:8

    Topics: Adolescent; Adult; Aged; Antitubercular Agents; Azathioprine; Colitis, Ulcerative; Cyclosporine; Dru

2020
A novel long-acting azathioprine polyhydroxyalkanoate nanoparticle enhances treatment efficacy for systemic lupus erythematosus with reduced side effects.
    Nanoscale, 2020, May-21, Volume: 12, Issue:19

    Topics: Animals; Azathioprine; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Mice; Nanoparticles;

2020
COVID-19 infection in a northern-Italian cohort of systemic lupus erythematosus assessed by telemedicine.
    Annals of the rheumatic diseases, 2020, Volume: 79, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Azathioprine; Betacoronavirus; Clinical Labora

2020
Incidence, Clinical Features, and Outcomes of Late-Onset Neutropenia From Rituximab for Autoimmune Disease.
    Arthritis & rheumatology (Hoboken, N.J.), 2021, Volume: 73, Issue:2

    Topics: Adult; Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Asymptomatic Diseases; Auto

2021
Comparative risks of cardiovascular disease events among SLE patients receiving immunosuppressive medications.
    Rheumatology (Oxford, England), 2021, 08-02, Volume: 60, Issue:8

    Topics: Adult; Azathioprine; Cardiovascular Diseases; Cause of Death; Coronary Artery Bypass; Cyclophosphami

2021
Analysis of trends and causes of death in SLE patients over a 40-years period in a cohort of patients in the United Kingdom.
    Lupus, 2021, Volume: 30, Issue:5

    Topics: Adult; Antirheumatic Agents; Azathioprine; Cardiovascular Diseases; Cause of Death; Cohort Studies;

2021
Barriers to Taking Medications for Systemic Lupus Erythematosus: A Qualitative Study of Racial Minority Patients, Lupus Providers, and Clinic Staff.
    Arthritis care & research, 2022, Volume: 74, Issue:9

    Topics: Azathioprine; Ethnic and Racial Minorities; Humans; Immunosuppressive Agents; Lupus Erythematosus, S

2022
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies.
    CNS drugs, 2021, Volume: 35, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alemtuzumab; Azathioprine; Black or African American; Cl

2021
Personalised therapy during preconception and gestation in SLE: usefulness of 6-mercaptopurine metabolite levelswith azathioprine.
    Lupus science & medicine, 2021, Volume: 8, Issue:1

    Topics: Antirheumatic Agents; Azathioprine; Female; Humans; Immunosuppressive Agents; Lupus Erythematosus, S

2021
Rowell syndrome: targeting a true definition.
    Cutis, 2017, Volume: 100, Issue:1

    Topics: Adult; Azathioprine; Diagnosis, Differential; Drug Therapy, Combination; Erythema Multiforme; Female

2017
Azathioprine Hypersensitivity Syndrome.
    The Journal of rheumatology, 2017, Volume: 44, Issue:12

    Topics: Adult; Azathioprine; Drug Hypersensitivity Syndrome; Female; Humans; Lupus Erythematosus, Systemic

2017
Natural history of longitudinally extensive transverse myelitis in 35 Hispanic patients with systemic lupus erythematosus: good short-term functional outcome and paradoxical increase in long-term mortality.
    Lupus, 2018, Volume: 27, Issue:8

    Topics: Adult; Azathioprine; Female; Humans; Lupus Erythematosus, Systemic; Magnetic Resonance Imaging; Male

2018
Clinical and immunological pattern and outcome of Egyptian systemic lupus erythematosus patients: a single center experience.
    Lupus, 2018, Volume: 27, Issue:9

    Topics: Adolescent; Adult; Antimalarials; Azathioprine; Child; Child, Preschool; Egypt; Female; Glucocortico

2018
Invasive aspergillosis in patients with systemic lupus erythematosus: a retrospective study on clinical characteristics and risk factors for mortality.
    Lupus, 2018, Volume: 27, Issue:12

    Topics: Adult; Aspergillosis; Azathioprine; Bacteremia; Cytomegalovirus Infections; Female; Humans; Logistic

2018
Generalized anhidrosis as first clinical presentation of systemic lupus erythematosus.
    Lupus, 2018, Volume: 27, Issue:14

    Topics: Azathioprine; Female; Humans; Hypohidrosis; Lupus Erythematosus, Systemic; Methylprednisolone; Middl

2018
Azathioprine and Mycophenolate Mofetil Adherence Patterns and Predictors Among Medicaid Beneficiaries With Systemic Lupus Erythematosus.
    Arthritis care & research, 2019, Volume: 71, Issue:11

    Topics: Adult; Azathioprine; Female; Humans; Immunosuppressive Agents; Logistic Models; Longitudinal Studies

2019
Commonly used medication for Lupus.
    Lupus, 2018, Volume: 27, Issue:1_suppl

    Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Disease Management;

2018
Recurrent Abdominal Pain in Systemic Lupus Erythematosus: Concurrent Lupus Enteritis and Lupus Cystitis.
    The American journal of medicine, 2019, Volume: 132, Issue:5

    Topics: Abdominal Pain; Adult; Azathioprine; Cyclophosphamide; Cystitis; Enteritis; Female; Humans; Immunosu

2019
Spontaneous intracranial hypotension associated with pachymeningeal enhancement in a patient with systemic lupus erythematosus (SLE): an extremely rare presenting feature.
    BMJ case reports, 2019, Feb-07, Volume: 12, Issue:2

    Topics: Adolescent; Azathioprine; Female; Fever; Headache; Humans; Immunosuppressive Agents; Intracranial Hy

2019
Novel multiple heterozygous NUDT15 variants cause an azathioprine-induced severe leukopenia in a patient with systemic lupus erythematosus.
    Clinical immunology (Orlando, Fla.), 2019, Volume: 200

    Topics: Azathioprine; Heterozygote; Humans; Immunosuppressive Agents; Leukopenia; Lupus Erythematosus, Syste

2019
Belimumab in refractory organizing pneumonia associated with systemic lupus erythematosus: a case report.
    Lupus, 2019, Volume: 28, Issue:4

    Topics: Antibodies, Antinuclear; Antibodies, Monoclonal, Humanized; Azathioprine; Bronchiolitis Obliterans;

2019
Successful conception in a 34-year-old lupus patient following spontaneous pregnancy after autotransplantation of cryopreserved ovarian tissue.
    Lupus, 2019, Volume: 28, Issue:5

    Topics: Adult; Antibodies, Monoclonal, Humanized; Azathioprine; Cryopreservation; Cyclophosphamide; Female;

2019
Spontaneous recovery from suppressed B cell production and proliferation caused by intrauterine azathioprine exposure in the fetal period.
    Lupus, 2019, Volume: 28, Issue:8

    Topics: Adult; Azathioprine; B-Lymphocytes; Cell Proliferation; Female; Humans; Immunosuppressive Agents; In

2019
Balancing immunosuppression and infection: recurrent enterovirus encephalitis in SLE.
    Practical neurology, 2019, Volume: 19, Issue:6

    Topics: Azathioprine; Encephalitis, Viral; Enterovirus Infections; Female; Humans; Immunocompromised Host; I

2019
Systemic Lupus Erythematosus-associated Acute Acalculous Cholecystitis Successfully Treated by a Corticosteroid Combined with Azathioprine.
    Internal medicine (Tokyo, Japan), 2019, Oct-01, Volume: 58, Issue:19

    Topics: Acalculous Cholecystitis; Acute Disease; Aged; Azathioprine; Conservative Treatment; Drug Therapy, C

2019
Longterm outcomes and damage accrual in patients with childhood systemic lupus erythematosus with psychosis and severe cognitive dysfunction.
    The Journal of rheumatology, 2013, Volume: 40, Issue:4

    Topics: Azathioprine; Cognition Disorders; Cohort Studies; Cyclophosphamide; Humans; Immunosuppressive Agent

2013
Two cases of refractory thrombocytopenia in systemic lupus erythematosus that responded to intravenous low-dose cyclophosphamide.
    Journal of Korean medical science, 2013, Volume: 28, Issue:3

    Topics: Azathioprine; Bone Marrow; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Immunosuppre

2013
Intractable vomiting as an initial presentation of lupus-related neuromyelitis optica.
    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2013, Volume: 19, Issue:3

    Topics: Adult; Azathioprine; Cyclophosphamide; Female; Glucocorticoids; Humans; Immunosuppressive Agents; Lu

2013
Invasive fungal infections in Argentine patients with systemic lupus erythematosus.
    Lupus, 2013, Volume: 22, Issue:9

    Topics: Adult; Argentina; Azathioprine; Case-Control Studies; Female; Hospitalization; Humans; Immunosuppres

2013
Painless ascites and elevated CA125: initial presentation of lupus-associated protein-losing enteropathy.
    Lupus, 2013, Volume: 22, Issue:11

    Topics: Ascites; Azathioprine; CA-125 Antigen; Cyclophosphamide; Female; Humans; Lupus Erythematosus, System

2013
Thyroid nodules in Hispanic patients with systemic lupus erythematosus.
    Lupus, 2013, Volume: 22, Issue:14

    Topics: Adult; Azathioprine; Female; Humans; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Male;

2013
Association of thiopurine methyltransferase status with azathioprine side effects in Chinese patients with systemic lupus erythematosus.
    Clinical rheumatology, 2014, Volume: 33, Issue:4

    Topics: Adult; Alleles; Alopecia; Asian People; Azathioprine; Chemical and Drug Induced Liver Injury; Cohort

2014
Coexistence of systemic lupus erythematosus and multiple sclerosis: prevalence, clinical characteristics, and natural history.
    Seminars in arthritis and rheumatism, 2014, Volume: 43, Issue:6

    Topics: Adrenal Cortex Hormones; Adult; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-De

2014
Switching treatment between mycophenolate mofetil and azathioprine in lupus patients: indications and outcomes.
    Arthritis care & research, 2014, Volume: 66, Issue:12

    Topics: Adolescent; Adult; Azathioprine; Female; Humans; Immunosuppressive Agents; Lupus Erythematosus, Syst

2014
A study of Thai patients with systemic lupus erythematosus in the medical intensive care unit: epidemiology and predictors of mortality.
    Lupus, 2015, Volume: 24, Issue:1

    Topics: Adult; APACHE; Azathioprine; Female; Glucocorticoids; Hospital Mortality; Humans; Immunosuppressive

2015
The influence of therapy on CD4+CD25(high)FOXP3+ regulatory T cells in systemic lupus erythematosus patients: a prospective study.
    Scandinavian journal of rheumatology, 2015, Volume: 44, Issue:1

    Topics: Adult; Azathioprine; CD4 Antigens; Cyclophosphamide; Female; Flow Cytometry; Forkhead Transcription

2015
Recurrent spontaneous subdural hematoma secondary to immune thrombocytopenia in a patient with overlap syndrome.
    Lupus, 2015, Volume: 24, Issue:1

    Topics: Anti-Inflammatory Agents; Azathioprine; Cyclophosphamide; Female; Hematoma, Subdural; Humans; Immuno

2015
Celebrating the ACP centennial: from the Annals archive.
    Annals of internal medicine, 2015, Jan-06, Volume: 162, Issue:1

    Topics: Azathioprine; Cyclophosphamide; Female; Glomerulonephritis; Glucocorticoids; Humans; Immunosuppressi

2015
Characteristics and outcome of autoimmune liver disease in Asian children.
    Hepatology international, 2015, Volume: 9, Issue:2

    Topics: Adolescent; Anti-Inflammatory Agents; Asian People; Azathioprine; Child; Child, Preschool; Cholangit

2015
Specific systemic lupus erythematosus disease manifestations in the six months prior to conception are associated with similar disease manifestations during pregnancy.
    Lupus, 2015, Volume: 24, Issue:12

    Topics: Adult; Antirheumatic Agents; Azathioprine; Female; Humans; Hydroxychloroquine; Logistic Models; Lupu

2015
Azathioprine during pregnancy in systemic lupus erythematosus patients is not associated with poor fetal outcome.
    Clinical rheumatology, 2015, Volume: 34, Issue:7

    Topics: Abortion, Spontaneous; Adult; Azathioprine; Female; Humans; Immunosuppressive Agents; Infant, Newbor

2015
[Recurrent lupus enteritis improved by Azathioprine].
    The Pan African medical journal, 2015, Volume: 20

    Topics: Adult; Azathioprine; Enteritis; Female; Humans; Immunosuppressive Agents; Lupus Erythematosus, Syste

2015
Liver injury correlates with biomarkers of autoimmunity and disease activity and represents an organ system involvement in patients with systemic lupus erythematosus.
    Clinical immunology (Orlando, Fla.), 2015, Volume: 160, Issue:2

    Topics: Acetylcysteine; Adult; Alanine Transaminase; Antibodies, Antinuclear; Aspartate Aminotransferases; A

2015
Efficacy of intravenous immunoglobulins in a patient with systemic lupus erythematosus presenting with Stevens-Johnson syndrome.
    BMJ case reports, 2015, Jul-22, Volume: 2015

    Topics: Adult; Azathioprine; Female; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Lupus E

2015
First report of multi-drug resistant tuberculosis in a systemic lupus erythematosus patient.
    BMC research notes, 2015, Aug-06, Volume: 8

    Topics: Adrenal Cortex Hormones; Antitubercular Agents; Azathioprine; Female; Femur Head Necrosis; Humans; I

2015
The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies.
    American journal of obstetrics and gynecology, 2016, Volume: 214, Issue:2

    Topics: Adolescent; Adult; Antibodies, Antinuclear; Antibodies, Antiphospholipid; Antiphospholipid Syndrome;

2016
The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies.
    American journal of obstetrics and gynecology, 2016, Volume: 214, Issue:2

    Topics: Adolescent; Adult; Antibodies, Antinuclear; Antibodies, Antiphospholipid; Antiphospholipid Syndrome;

2016
The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies.
    American journal of obstetrics and gynecology, 2016, Volume: 214, Issue:2

    Topics: Adolescent; Adult; Antibodies, Antinuclear; Antibodies, Antiphospholipid; Antiphospholipid Syndrome;

2016
The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies.
    American journal of obstetrics and gynecology, 2016, Volume: 214, Issue:2

    Topics: Adolescent; Adult; Antibodies, Antinuclear; Antibodies, Antiphospholipid; Antiphospholipid Syndrome;

2016
Increased binding of circulating systemic lupus erythematosus autoantibodies to recombinant interferon alpha 2b.
    APMIS : acta pathologica, microbiologica, et immunologica Scandinavica, 2015, Volume: 123, Issue:12

    Topics: Antibody Affinity; Autoantibodies; Azathioprine; Cloning, Molecular; Enzyme-Linked Immunosorbent Ass

2015
Features associated with hematologic abnormalities and their impact in patients with systemic lupus erythematosus: Data from a multiethnic Latin American cohort.
    Seminars in arthritis and rheumatism, 2016, Volume: 45, Issue:6

    Topics: Adolescent; Adult; Age Factors; Anemia, Hemolytic; Antibodies, Antinuclear; Antibodies, Antiphosphol

2016
Drugs used in incident systemic lupus erythematosus - results from the Finnish nationwide register 2000-2007.
    Lupus, 2016, Volume: 25, Issue:6

    Topics: Adult; Aged; Antirheumatic Agents; Azathioprine; Chronic Disease; Female; Finland; Humans; Hydroxych

2016
Cytomegalovirus-induced Colon Perforation in Systemic Lupus Erythematosus.
    The Journal of rheumatology, 2016, Volume: 43, Issue:2

    Topics: Azathioprine; Colon; Cytomegalovirus; Cytomegalovirus Infections; Female; Humans; Immunocompromised

2016
Breastfeeding in mothers with systemic lupus erythematosus.
    Lupus, 2016, Volume: 25, Issue:9

    Topics: Adult; Azathioprine; Breast Feeding; Databases, Factual; Decision Making; Female; Humans; Hydroxychl

2016
Immunosuppressive medication use and risk of herpes zoster (HZ) in patients with systemic lupus erythematosus (SLE): A nationwide case-control study.
    Journal of the American Academy of Dermatology, 2016, Volume: 75, Issue:1

    Topics: Administration, Intravenous; Administration, Oral; Adrenal Cortex Hormones; Adult; Azathioprine; Cas

2016
Severe transaminitis in a paediatric patient with systemic lupus erythaematosus and a discussion of the literature.
    BMJ case reports, 2016, Apr-18, Volume: 2016

    Topics: Adolescent; Azathioprine; Biopsy; Female; Hepatitis, Autoimmune; Humans; Immunosuppressive Agents; L

2016
Comparative Rates of Serious Infections Among Patients With Systemic Lupus Erythematosus Receiving Immunosuppressive Medications.
    Arthritis & rheumatology (Hoboken, N.J.), 2017, Volume: 69, Issue:2

    Topics: Adult; Azathioprine; Cohort Studies; Cyclophosphamide; Female; Humans; Immunosuppressive Agents; Inf

2017
Diabetic Ketoacidosis Without Diabetes.
    The Journal of clinical endocrinology and metabolism, 2016, Volume: 101, Issue:11

    Topics: Adult; Antigens, CD; Autoantibodies; Azathioprine; Dexamethasone; Diabetes Mellitus; Diabetic Ketoac

2016
Juvenile systemic lupus erythematosus in Nigeria.
    Lupus, 2017, Volume: 26, Issue:3

    Topics: Adolescent; Antibodies, Antinuclear; Antirheumatic Agents; Azathioprine; Child; Female; Hospitals, T

2017
New onset of lupus nephritis in two patients with SLE shortly after initiation of treatment with belimumab.
    Seminars in arthritis and rheumatism, 2017, Volume: 46, Issue:6

    Topics: Adult; Antibodies, Monoclonal, Humanized; Azathioprine; Disease Progression; Drug Therapy, Combinati

2017
Association of Therapy for Autoimmune Disease With Myelodysplastic Syndromes and Acute Myeloid Leukemia.
    JAMA oncology, 2017, Jul-01, Volume: 3, Issue:7

    Topics: Aged; Aged, 80 and over; Arthritis, Rheumatoid; Autoimmune Diseases; Azathioprine; Case-Control Stud

2017
Psoriasis in systemic lupus erythematosus: a single-center experience.
    Clinical rheumatology, 2017, Volume: 36, Issue:4

    Topics: Adolescent; Adult; Antirheumatic Agents; Azathioprine; Cohort Studies; Female; Humans; Hydroxychloro

2017
Interstitial granulomatous dermatitis: a misdiagnosed cutaneous form of systemic lupus erythematosus?
    Clinical and experimental dermatology, 2008, Volume: 33, Issue:6

    Topics: Adult; Azathioprine; Dermatitis; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Lupus E

2008
An unusual case of testicular pain.
    Clinical rheumatology, 2009, Volume: 28, Issue:3

    Topics: Administration, Oral; Adult; Azathioprine; Diagnosis, Differential; Diuretics; Drug Therapy, Combina

2009
Pro32Thr polymorphism of inosine triphosphate pyrophosphatase gene predicts efficacy of low-dose azathioprine for patients with systemic lupus erythematosus.
    Clinical pharmacology and therapeutics, 2009, Volume: 85, Issue:5

    Topics: Adolescent; Adult; Aged; Alleles; Asian People; Azathioprine; Female; Glutathione Transferase; Human

2009
Acute renal failure in paediatric systemic lupus erythematosus: treatment and outcome.
    Rheumatology (Oxford, England), 2009, Volume: 48, Issue:2

    Topics: Acute Kidney Injury; Adolescent; Adult; Area Under Curve; Azathioprine; Child; Child, Preschool; Cyc

2009
Do immunosuppressives upregulate antiphospholid antibodies?
    The Journal of rheumatology, 2009, Volume: 36, Issue:2

    Topics: Antiphospholipid Syndrome; Autoantibodies; Autoimmune Diseases; Azathioprine; Biomarkers; Cardiolipi

2009
Clinical image: Lupus erythematosus cells in ascites fluid.
    Arthritis and rheumatism, 2009, Volume: 60, Issue:3

    Topics: Ascitic Fluid; Azathioprine; Felty Syndrome; Female; Granulocytes; Humans; Immunosuppressive Agents;

2009
Lupus nephritis among 624 cases of systemic lupus erythematosus in Riyadh, Saudi Arabia.
    Rheumatology international, 2009, Volume: 29, Issue:9

    Topics: Adolescent; Adult; Age of Onset; Azathioprine; Child; Cohort Studies; Cyclophosphamide; Drug Therapy

2009
Premature atherosclerosis in pediatric systemic lupus erythematosus: risk factors for increased carotid intima-media thickness in the atherosclerosis prevention in pediatric lupus erythematosus cohort.
    Arthritis and rheumatism, 2009, Volume: 60, Issue:5

    Topics: Adolescent; Atherosclerosis; Azathioprine; Body Mass Index; Carotid Artery, Common; Child; Creatinin

2009
Rapidly fatal HTLV-1-associated T-cell leukemia/lymphoma in a patient with SLE.
    Nature reviews. Rheumatology, 2009, Volume: 5, Issue:5

    Topics: Azathioprine; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Fatal Outcome; Female; Gluco

2009
Autoimmune hypothyroidism and lupus-like syndrome.
    Rheumatology international, 2010, Volume: 30, Issue:4

    Topics: Adult; Arthritis; Azathioprine; Biphenyl Compounds; Complement C3; Complement C4; Complement System

2010
Systemic lupus erythematosus and hyper-eosinophilic syndrome: an unusual association.
    The West Indian medical journal, 2009, Volume: 58, Issue:1

    Topics: Adrenal Cortex Hormones; Adult; Anticoagulants; Antirheumatic Agents; Azathioprine; Diagnosis, Diffe

2009
Third cranial nerve palsy or pseudo 3rd nerve palsy of myasthenia gravis? A challenging diagnosis in systemic lupus erythematosus.
    Lupus, 2009, Volume: 18, Issue:9

    Topics: Adrenal Cortex Hormones; Aged; Azathioprine; Diagnosis, Differential; Diplopia; Female; Humans; Immu

2009
Increased plasma myeloperoxidase levels in systemic lupus erythematosus.
    Rheumatology international, 2010, Volume: 30, Issue:6

    Topics: Adult; Age of Onset; Antimalarials; Arthritis; Azathioprine; Biomarkers; Cross-Sectional Studies; Cy

2010
Acute generalized exanthematous pustulosis and toxic epidermal necrolysis induced by hydroxychloroquine.
    Clinical rheumatology, 2009, Volume: 28, Issue:12

    Topics: Aged; Antirheumatic Agents; Azathioprine; Cyclosporine; Dose-Response Relationship, Drug; Drug Thera

2009
Heart failure as presenting manifestation of cardiac involvement in systemic lupus erythematosus.
    The Netherlands journal of medicine, 2009, Volume: 67, Issue:9

    Topics: Adult; Azathioprine; Cyclophosphamide; Female; Glucocorticoids; Heart Failure; Humans; Immunosuppres

2009
Serum BLC/CXCL13 concentrations and renal expression of CXCL13/CXCR5 in patients with systemic lupus erythematosus and lupus nephritis.
    The Journal of rheumatology, 2010, Volume: 37, Issue:1

    Topics: Adolescent; Adult; Aged; Animals; Antigens, CD19; Antirheumatic Agents; Azathioprine; B-Lymphocytes;

2010
Experience with mycophenolate mofetil as maintenance therapy in five pediatric patients with severe systemic lupus erythematosus.
    Klinische Padiatrie, 2009, Volume: 221, Issue:7

    Topics: Adolescent; Azathioprine; Child; Disease Progression; Dose-Response Relationship, Drug; Drug Therapy

2009
Mucormycosis complications in systemic lupus erythematosus.
    Lupus, 2010, Volume: 19, Issue:8

    Topics: Aged; Azathioprine; Central Nervous System Fungal Infections; Female; Humans; Immunosuppressive Agen

2010
Enhanced adhesive properties of endothelial progenitor cells (EPCs) in patients with SLE.
    Rheumatology international, 2011, Volume: 31, Issue:6

    Topics: Adult; Antirheumatic Agents; Azathioprine; Cell Adhesion; Cells, Cultured; Colony-Forming Units Assa

2011
OCT follow-up of systemic lupus erythematosus choroidopathy.
    Ocular immunology and inflammation, 2010, Volume: 18, Issue:2

    Topics: 4-Hydroxycoumarins; Adolescent; Adrenal Cortex Hormones; Angiography; Antibodies, Antinuclear; Aspir

2010
[A wolf in sheep's clothing: atypical systemic lupus erythematosus (SLE) presenting as cardiovascular disease].
    Medizinische Klinik (Munich, Germany : 1983), 2010, Volume: 105, Issue:4

    Topics: Antiphospholipid Syndrome; Azathioprine; Biopsy; Diagnosis, Differential; Female; Heart Failure; Hea

2010
Innovative management of lupus erythematosus.
    Dermatologic clinics, 2010, Volume: 28, Issue:3

    Topics: Administration, Topical; Adolescent; Adult; Anti-Inflammatory Agents; Antimalarials; Azathioprine; C

2010
An unusual case of ANA negative systemic lupus erythematosus presented with vasculitis, long-standing serositis and full-house nephropathy.
    Rheumatology international, 2013, Volume: 33, Issue:1

    Topics: Administration, Oral; Adolescent; Antibodies, Antinuclear; Azathioprine; Cyclophosphamide; Dipyridam

2013
Rituximab treatment in a child with rosai-dorfman disease and systemic lupus erythematosus.
    The Journal of rheumatology, 2010, Aug-01, Volume: 37, Issue:8

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antirheumatic Agents; Azathioprine;

2010
[Gastric neuroendocrine tumors in a woman with systemic lupus erythematosus].
    Deutsche medizinische Wochenschrift (1946), 2010, Volume: 135, Issue:36

    Topics: Antibodies, Antinuclear; Azathioprine; DNA; Female; Gastroscopy; Humans; Immunosuppressive Agents; L

2010
Devic's syndrome and SLE: challenges in diagnosis and therapeutic possibilities based on two overlapping cases.
    Autoimmunity reviews, 2011, Volume: 10, Issue:3

    Topics: Aquaporin 4; Autoantibodies; Azathioprine; Cyclophosphamide; Female; Humans; Immunosuppressive Agent

2011
Fatal rhabdomyolysis in systemic lupus erythematosus.
    Rheumatology international, 2011, Volume: 31, Issue:9

    Topics: Acute Kidney Injury; Adult; Anti-Bacterial Agents; Antibodies, Antinuclear; Arthritis; Azathioprine;

2011
Quantitative and functional profiles of CD4+ lymphocyte subsets in systemic lupus erythematosus patients with lymphopenia.
    Clinical and experimental immunology, 2011, Volume: 164, Issue:1

    Topics: Adult; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Azathioprine; CD4-Positive T-Lymphocyt

2011
[Protein-losing enteropathy: a cause of hypoalbuminaemia in patients with systemic lupus erythematosus].
    Zeitschrift fur Rheumatologie, 2011, Volume: 70, Issue:3

    Topics: Adult; Anti-Inflammatory Agents; Antimetabolites; Azathioprine; Female; Humans; Hypoalbuminemia; Lup

2011
Autoimmune liver disease in patients with systemic lupus erythematosus: a retrospective analysis of 147 cases.
    Scandinavian journal of gastroenterology, 2011, Volume: 46, Issue:6

    Topics: Adult; Antibodies, Antinuclear; Azathioprine; Biopsy; Enzyme-Linked Immunosorbent Assay; Female; Hep

2011
Exercise in a child with systemic lupus erythematosus and antiphospholipid syndrome.
    Medicine and science in sports and exercise, 2011, Volume: 43, Issue:12

    Topics: Adolescent; Anaerobic Threshold; Antiphospholipid Syndrome; Azathioprine; Drug Therapy, Combination;

2011
Protein-losing enteropathy as initial manifestation of systemic lupus erythematosus.
    Lupus, 2012, Volume: 21, Issue:4

    Topics: Adolescent; Antibodies, Antinuclear; Azathioprine; Biomarkers; Complement C3; Diarrhea; Drug Therapy

2012
[Cutaneous involvement in systemic Chagas disease in immunocompromised patient].
    Medicina clinica, 2012, May-19, Volume: 138, Issue:14

    Topics: Adult; Azathioprine; Chagas Disease; Female; Humans; Immunocompromised Host; Immunosuppressive Agent

2012
Early treatment with rituximab in newly diagnosed systemic lupus erythematosus patients: a steroid-sparing regimen.
    Rheumatology (Oxford, England), 2012, Volume: 51, Issue:3

    Topics: Adrenal Cortex Hormones; Adult; Antibodies, Anti-Idiotypic; Antibodies, Monoclonal, Murine-Derived;

2012
Three siblings with systemic lupus erythematosus.
    The Journal of dermatology, 2012, Volume: 39, Issue:2

    Topics: Adult; Antibodies, Antinuclear; Azathioprine; Dermatologic Agents; Exanthema; Female; HLA Antigens;

2012
Prevalence and risk factors for liver biochemical abnormalities in Canadian patients with systemic lupus erythematosus.
    The Journal of rheumatology, 2012, Volume: 39, Issue:2

    Topics: Adult; Alanine Transaminase; Antibodies, Neutralizing; Antiphospholipid Syndrome; Aspartate Aminotra

2012
[Allergo-immunology. Clinical immunology].
    Revue medicale suisse, 2012, Jan-11, Volume: 8, Issue:323

    Topics: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Monoclonal; Antibodies, Mono

2012
Acute lymphoblastic leukaemia in a child with systemic lupus erythematosus.
    Lupus, 2012, Volume: 21, Issue:8

    Topics: Antimetabolites; Azathioprine; Child; Fatal Outcome; Female; Humans; Lupus Erythematosus, Systemic;

2012
The clinical characteristics of lupus related protein-losing enteropathy in Hong Kong Chinese population: 10 years of experience from a regional hospital.
    Lupus, 2012, Volume: 21, Issue:8

    Topics: Adolescent; Adult; Aged; Analysis of Variance; Anti-Inflammatory Agents; Azathioprine; Blood Sedimen

2012
[Successful completed pregnancies in patients with systemic lupus erythematosus].
    Orvosi hetilap, 2012, Mar-25, Volume: 153, Issue:12

    Topics: Adrenal Cortex Hormones; Adult; Aspirin; Azathioprine; Birth Weight; Female; Follow-Up Studies; Gest

2012
Hepatosplenic αβ T-cell lymphoma associated with azathioprine therapy.
    International journal of hematology, 2012, Volume: 95, Issue:5

    Topics: Azathioprine; Female; Humans; Immunosuppressive Agents; Liver Neoplasms; Lupus Erythematosus, System

2012
Mycophenolic acid counteracts B cell proliferation and plasmablast formation in patients with systemic lupus erythematosus.
    Arthritis research & therapy, 2012, Volume: 14, Issue:3

    Topics: Adolescent; Adult; Aged; Azathioprine; B-Lymphocytes; Cell Proliferation; Female; Flow Cytometry; Hu

2012
Reactivation of Chagas disease by immunosuppressive therapy in a patient with systemic lupus erythematosus: report of an exceptional case.
    The American Journal of dermatopathology, 2012, Volume: 34, Issue:6

    Topics: Adult; Azathioprine; Biopsy; Chagas Disease; Female; Humans; Immunosuppressive Agents; Lupus Erythem

2012
Bordetella holmesii endocarditis in a patient with systemic lupus erythematous treated with immunosuppressive agents.
    Journal of chemotherapy (Florence, Italy), 2012, Volume: 24, Issue:4

    Topics: Azathioprine; Bordetella; Bordetella Infections; Drug Therapy, Combination; Endocarditis, Bacterial;

2012
In utero azathioprine exposure and increased utilization of special educational services in children born to mothers with systemic lupus erythematosus.
    Arthritis care & research, 2013, Volume: 65, Issue:5

    Topics: Adolescent; Adult; Azathioprine; Child; Child, Preschool; Cohort Studies; Developmental Disabilities

2013
Effect of genetic polymorphisms on effectiveness of low-dose azathioprine in Japanese patients with systemic lupus erythematosus.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2012, Dec-01, Volume: 69, Issue:23

    Topics: Adolescent; Adult; Aged; Asian People; Azathioprine; Female; Genotype; Humans; Immunosuppressive Age

2012
Lymphoma risk in systemic lupus: effects of disease activity versus treatment.
    Annals of the rheumatic diseases, 2014, Volume: 73, Issue:1

    Topics: Adult; Antimalarials; Azathioprine; Case-Control Studies; Cyclophosphamide; Female; Glucocorticoids;

2014
Lupus enteritis: an uncommon manifestation of systemic lupus erythematosus.
    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2013, Volume: 19, Issue:2

    Topics: Adult; Azathioprine; Colonoscopy; Cyclophosphamide; Endoscopy, Gastrointestinal; Enteritis; Female;

2013
Autoimmune hyperlipidemia in a child with autoimmune hepatitis.
    Journal of clinical gastroenterology, 2002, Volume: 35, Issue:2

    Topics: Adolescent; Autoimmune Diseases; Azathioprine; Child; Drug Therapy, Combination; Female; Hepatitis,

2002
The apoptotic ligands TRAIL, TWEAK, and Fas ligand mediate monocyte death induced by autologous lupus T cells.
    Journal of immunology (Baltimore, Md. : 1950), 2002, Nov-15, Volume: 169, Issue:10

    Topics: Adult; Apoptosis; Apoptosis Regulatory Proteins; Azathioprine; Carrier Proteins; Cells, Cultured; Ch

2002
Practical pharmacogenetics: the cost effectiveness of screening for thiopurine s-methyltransferase polymorphisms in patients with rheumatological conditions treated with azathioprine.
    The Journal of rheumatology, 2002, Volume: 29, Issue:12

    Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Azathioprine; Cost-Benefit Analysis; Decision Support T

2002
Long-term effectiveness of danazol corticosteroids and cytotoxic drugs in the treatment of hematologic manifestations of systemic lupus erythematosus.
    Lupus, 2003, Volume: 12, Issue:1

    Topics: Adult; Anemia, Hemolytic; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Azathio

2003
44-year-old woman with fatigue and dyspnea.
    Mayo Clinic proceedings, 2003, Volume: 78, Issue:3

    Topics: Adult; Anti-Inflammatory Agents; Azathioprine; Dyspnea; Fatigue; Female; Humans; Immunosuppressive A

2003
[Psoriasis and systemic lupus erythematosus: a rare association with specific therapeutic problems].
    Annales de medecine interne, 2003, Volume: 154, Issue:1

    Topics: Adrenal Cortex Hormones; Adult; Aged; Antirheumatic Agents; Azathioprine; Dermatologic Agents; Femal

2003
[Drug alternatives in therapy of neuropsychiatric systemic lupus erythematosus (NPSLE)].
    Medizinische Klinik (Munich, Germany : 1983), 2003, Jun-15, Volume: 98, Issue:6

    Topics: Antibodies, Antiphospholipid; Anticoagulants; Antirheumatic Agents; Azathioprine; Coumarins; Cycloph

2003
Pharmacoeconomic analysis of thiopurine methyltransferase polymorphism screening by polymerase chain reaction for treatment with azathioprine in Korea.
    Rheumatology (Oxford, England), 2004, Volume: 43, Issue:2

    Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Azathioprine; Cost-Benefit Analysis; Decision Trees; Di

2004
TREATMENT OF ACTIVE CHRONIC HEPATITIS AND LUPOID HEPATITIS WITH 6-MERCAPTOPURINE AND AZOTHIOPRINE.
    Lancet (London, England), 1964, Apr-25, Volume: 1, Issue:7339

    Topics: Adolescent; Anemia; Anemia, Pernicious; Antineoplastic Agents; Autoimmune Diseases; Azathioprine; Cl

1964
SYSTEMIC LUPUS ERYTHEMATOSUS AND RENAL TRANSPLANTATION: REPORT OF TWO CASES.
    Archives of dermatology, 1965, Volume: 92

    Topics: Adolescent; Azathioprine; Humans; Kidney; Kidney Transplantation; Kidneys, Artificial; Leukopenia; L

1965
Cavernous hemangioma. Reversible posterior leukoencephalopathy syndrome.
    Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2003, Volume: 10, Issue:6

    Topics: Adult; Azathioprine; Diabetes Mellitus, Type 1; Diffusion Magnetic Resonance Imaging; Female; Hemang

2003
Bilateral cytomegalovirus retinitis in a patient with systemic lupus erythematosus and end-stage renal disease.
    Mayo Clinic proceedings, 2003, Volume: 78, Issue:11

    Topics: Adult; Antirheumatic Agents; Azathioprine; Cytomegalovirus Retinitis; Female; HIV Seronegativity; Hu

2003
CMV enteritis causing ileal perforation in underlying lupus enteritis.
    Clinical rheumatology, 2004, Volume: 23, Issue:1

    Topics: Adult; Anti-Inflammatory Agents; Antiviral Agents; Azathioprine; Cytomegalovirus; Cytomegalovirus In

2004
Does long term treatment with azathioprine predispose to malignancy and death in patients with systemic lupus erythematosus?
    Annals of the rheumatic diseases, 2004, Volume: 63, Issue:3

    Topics: Adult; Azathioprine; Female; Humans; Lupus Erythematosus, Systemic; Male; Neoplasms; Time Factors; T

2004
[Bullous systemic lupus erythematosus].
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2004, Volume: 55, Issue:4

    Topics: Adult; Anti-Inflammatory Agents; Azathioprine; Dermatologic Agents; Fluorescent Antibody Technique,

2004
Maximum tolerable dose of cyclophosphamide and azathioprine in Pakistani patients with primary renal disease.
    JPMA. The Journal of the Pakistan Medical Association, 2004, Volume: 54, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Azathioprine; Chi-Square Distribution; Child; Cyclophosp

2004
Increased incidence of cervical intraepithelial neoplasia in women with systemic lupus erythematosus treated with intravenous cyclophosphamide.
    The Journal of rheumatology, 2004, Volume: 31, Issue:9

    Topics: Adult; Anti-Inflammatory Agents; Antirheumatic Agents; Azathioprine; Cyclophosphamide; Female; Follo

2004
Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study.
    Arthritis and rheumatism, 2004, Volume: 50, Issue:10

    Topics: Adult; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis; Autoantibodies; Azathioprine; Bacter

2004
Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study.
    Arthritis and rheumatism, 2004, Volume: 50, Issue:10

    Topics: Adult; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis; Autoantibodies; Azathioprine; Bacter

2004
Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study.
    Arthritis and rheumatism, 2004, Volume: 50, Issue:10

    Topics: Adult; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis; Autoantibodies; Azathioprine; Bacter

2004
Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study.
    Arthritis and rheumatism, 2004, Volume: 50, Issue:10

    Topics: Adult; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis; Autoantibodies; Azathioprine; Bacter

2004
[Panzytopenia from combination therapy with azathioprin and allopurinol].
    Zeitschrift fur Rheumatologie, 2004, Volume: 63, Issue:5

    Topics: Aged; Allopurinol; Antirheumatic Agents; Autoantibodies; Azathioprine; Blood Cell Count; Diabetes Me

2004
Late puerperal thrombohemorrhagic complications in a patient with antiphospholipid syndrome.
    European journal of haematology, 2004, Volume: 73, Issue:6

    Topics: Abortion, Habitual; Activated Protein C Resistance; Adult; Anticoagulants; Antiphospholipid Syndrome

2004
The effect of intravenous zoledronic acid on glucocorticoid-induced multiple vertebral fractures in juvenile systemic lupus erythematosus.
    Revista do Hospital das Clinicas, 2004, Volume: 59, Issue:5

    Topics: Adolescent; Azathioprine; Bone Density; Bone Density Conservation Agents; Cervical Vertebrae; Diphos

2004
Lupus cystitis in association with severe gastrointestinal manifestations in an adolescent.
    The Journal of rheumatology, 2005, Volume: 32, Issue:1

    Topics: Adolescent; Antirheumatic Agents; Azathioprine; Cystitis, Interstitial; Drug Therapy, Combination; F

2005
IgG immunoadsorption reduces systemic lupus erythematosus activity and proteinuria: a long term observational study.
    Annals of the rheumatic diseases, 2005, Volume: 64, Issue:7

    Topics: Adult; Analysis of Variance; Azathioprine; Combined Modality Therapy; Female; Follow-Up Studies; Hum

2005
Tuberculosis in systemic lupus erythematosus in an endemic area and the role of isoniazid prophylaxis during corticosteroid therapy.
    The Journal of rheumatology, 2005, Volume: 32, Issue:4

    Topics: Adult; Antibiotic Prophylaxis; Antitubercular Agents; Azathioprine; Endemic Diseases; Female; Glucoc

2005
Isaacs' syndrome (autoimmune neuromyotonia) in a patient with systemic lupus erythematosus.
    The Journal of rheumatology, 2005, Volume: 32, Issue:4

    Topics: Amines; Anticonvulsants; Autoantibodies; Azathioprine; Clonazepam; Cyclohexanecarboxylic Acids; Drug

2005
Mycophenolate mofetil: a magic bullet for lupus?
    The Journal of rheumatology, 2005, Volume: 32, Issue:6

    Topics: Azathioprine; Cyclophosphamide; Humans; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Myc

2005
Natural killer cell activity in families of patients with systemic lupus erythematosus: demonstration of a killing defect in patients.
    Clinical and experimental immunology, 2005, Volume: 141, Issue:1

    Topics: Adolescent; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Azathioprine; Cells, Cultured;

2005
Azathioprine induced hepatic veno-occlusive disease in systemic lupus erythematosus.
    Lupus, 2005, Volume: 14, Issue:6

    Topics: Adult; Azathioprine; Female; Hepatic Veno-Occlusive Disease; Humans; Immunosuppressive Agents; Lupus

2005
Successful preventive treatment of congenital heart block during pregnancy in a woman with systemic lupus erythematosus and anti-Sjögren's syndrome A/Ro antibody.
    Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi, 2005, Volume: 38, Issue:5

    Topics: Adult; Antibodies, Antinuclear; Azathioprine; Dexamethasone; Female; Heart Block; Humans; Immunosupp

2005
Outcome of protein-losing gastroenteropathy in systemic lupus erythematosus treated with prednisolone and azathioprine.
    Rheumatology (Oxford, England), 2006, Volume: 45, Issue:4

    Topics: Administration, Oral; Adult; Anti-Inflammatory Agents; Antirheumatic Agents; Azathioprine; Diarrhea;

2006
Thiopurine methyltransferase genotype and phenotype status in Japanese patients with systemic lupus erythematosus.
    Biological & pharmaceutical bulletin, 2005, Volume: 28, Issue:11

    Topics: Adolescent; Adult; Aged; Alleles; Azathioprine; DNA; Female; Gene Frequency; Genotype; Heterozygote;

2005
Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease.
    Annals of the rheumatic diseases, 2006, Volume: 65, Issue:7

    Topics: Adult; Aged; Antibodies, Viral; Azathioprine; Case-Control Studies; Female; Hemagglutination Inhibit

2006
Fatal varicella infection in a girl with systemic lupus erythematosus after oral acyclovir prophylaxis.
    European journal of pediatrics, 2006, Volume: 165, Issue:4

    Topics: Acyclovir; Adolescent; Antiviral Agents; Aspergillosis; Azathioprine; Brain; Chickenpox; Disseminate

2006
Lupus and leg ulcers--a diagnostic quandary.
    Clinical rheumatology, 2007, Volume: 26, Issue:7

    Topics: Adult; Azathioprine; Drug Therapy, Combination; Glucocorticoids; Humans; Immunosuppressive Agents; L

2007
The dynamism of cutaneous lupus erythematosus: mild discoid lupus erythematosus evolving into SLE with SCLE and treatment-resistant lupus panniculitis.
    Clinical rheumatology, 2007, Volume: 26, Issue:7

    Topics: Antimalarials; Azathioprine; Cyclophosphamide; Cyclosporine; Disease Progression; Drug Therapy, Comb

2007
Reversible posterior leukoencephalopathy caused by azathioprine in systemic lupus erythematosus.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2006, Volume: 89, Issue:7

    Topics: Adult; Azathioprine; Brain Diseases; Female; Humans; Immunosuppressive Agents; Lupus Erythematosus,

2006
Thromboembolism complicating the treatment of lupus anticoagulant hypoprothrombinemia syndrome.
    The Journal of rheumatology, 2006, Volume: 33, Issue:10

    Topics: Adrenal Cortex Hormones; Antiphospholipid Syndrome; Azathioprine; Central Nervous System Diseases; C

2006
Chylothorax as the initial presentation of systemic lupus erythematosus: a case report.
    Clinical rheumatology, 2007, Volume: 26, Issue:8

    Topics: Adult; Antibodies, Antinuclear; Antirheumatic Agents; Azathioprine; Chylothorax; Female; Humans; Lup

2007
A case of systemic lupus erythematosus presenting with protein-losing enteropathy.
    The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2006, Volume: 17, Issue:3

    Topics: Adrenal Cortex Hormones; Adult; Azathioprine; Cyclophosphamide; Drug Therapy, Combination; Female; H

2006
Hypocomplementemic urticarial vasculitis: a rare presentation of systemic lupus erythematosus.
    International journal of dermatology, 2006, Volume: 45, Issue:9

    Topics: Adrenal Cortex Hormones; Azathioprine; Complement C3c; Complement C4; Fatal Outcome; Female; Humans;

2006
Expression of messenger RNA for transforming growth factor-beta1 and for transforming growth factor-beta receptors in peripheral blood of systemic lupus erythematosus patients treated with low doses of quinagolide.
    Autoimmunity, 2007, Volume: 40, Issue:1

    Topics: Adolescent; Adult; Aminoquinolines; Azathioprine; Cyclosporine; Dopamine Agonists; Dose-Response Rel

2007
Current use of pharmacogenetic testing: a national survey of thiopurine methyltransferase testing prior to azathioprine prescription.
    Journal of clinical pharmacy and therapeutics, 2007, Volume: 32, Issue:2

    Topics: Attitude of Health Personnel; Azathioprine; Crohn Disease; Dermatology; Dose-Response Relationship,

2007
[The occurrence of malignancies in a Hungarian lupus population].
    Orvosi hetilap, 2006, Nov-19, Volume: 147, Issue:46

    Topics: Adult; Aged; Azathioprine; Breast Neoplasms; Bronchial Neoplasms; Cyclophosphamide; Female; Gastroin

2006
The relationship between cancer and medication exposures in systemic lupus erythaematosus: a case-cohort study.
    Annals of the rheumatic diseases, 2008, Volume: 67, Issue:1

    Topics: Adult; Azathioprine; Case-Control Studies; Cyclophosphamide; Dose-Response Relationship, Drug; Femal

2008
[Chloroquine/hydroxychloroquine: variability of retinotoxic cumulative doses].
    Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft, 2007, Volume: 104, Issue:10

    Topics: Adolescent; Adult; Aged; Antirheumatic Agents; Azathioprine; Child; Chloroquine; Dose-Response Relat

2007
Immune function in children born to mothers with autoimmune diseases and exposed in utero to immunosuppressants.
    Lupus, 2007, Volume: 16, Issue:8

    Topics: Antigens, CD; Autoimmune Diseases; Azathioprine; Cyclosporine; Cytokines; Dexamethasone; Female; Hum

2007
Life-threatening systemic flare-up of systemic lupus erythematosus following influenza vaccination.
    Lupus, 2008, Volume: 17, Issue:1

    Topics: Anemia, Hemolytic, Autoimmune; Azathioprine; Female; Humans; Immunosuppressive Agents; Influenza Vac

2008
Azathioprine-induced fatal myelosuppression in systemic lupus erythematosus patient carrying TPMT*3C polymorphism.
    Lupus, 2008, Volume: 17, Issue:2

    Topics: Adult; Alleles; Azathioprine; Fatal Outcome; Female; Humans; Immunosuppressive Agents; Leukopenia; L

2008
Bleeding and thrombosis in a patient with secondary antiphospholipid syndrome.
    Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 2008, Volume: 19, Issue:2

    Topics: Adrenal Cortex Hormones; Adult; Anticoagulants; Antiphospholipid Syndrome; Azathioprine; Female; Hem

2008
Clinical and laboratory characteristics and long-term outcome of pediatric systemic lupus erythematosus: a longitudinal study.
    The Journal of pediatrics, 2008, Volume: 152, Issue:4

    Topics: Adolescent; Age of Onset; Antimalarials; Autoantibodies; Azathioprine; Central Nervous System Diseas

2008
Reversible Hodgkin's lymphoma associated with Epstein-Barr virus occurring during azathioprine therapy for SLE.
    Rheumatology (Oxford, England), 2008, Volume: 47, Issue:7

    Topics: Azathioprine; Epstein-Barr Virus Infections; Female; Hodgkin Disease; Humans; Immunosuppressive Agen

2008
[The immunosuppressive agents. 3. The immunosuppressive agents in hematology].
    La Presse medicale, 1967, Jul-01, Volume: 75, Issue:32

    Topics: Anemia, Hemolytic, Autoimmune; Autoimmune Diseases; Azathioprine; Cyclophosphamide; Humans; Immunosu

1967
Azathioprine treatment of immunological renal disease.
    JAMA, 1967, Feb-13, Volume: 199, Issue:7

    Topics: Adolescent; Adult; Azathioprine; Chlorambucil; Cortisone; Female; Glomerulonephritis; Humans; Lupus

1967
Intensive immunosuppression versus prednisolone in the treatment of connective tissue diseases.
    Annals of the rheumatic diseases, 1982, Volume: 41, Issue:6

    Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Azathioprine; Connective Tissue Diseases; Dermatomyos

1982
Cytostatic drugs in the treatment of severe vasculitides. Indications, results and risks.
    European neurology, 1984, Volume: 23, Issue:6

    Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Azathioprine; Cyclophosphamide; Drug Therapy, Combin

1984
Acute pancreatitis in systemic lupus erythematosus: report of twenty cases and a review of the literature.
    Medicine, 1982, Volume: 61, Issue:1

    Topics: Acute Disease; Adolescent; Adult; Aged; Amylases; Azathioprine; Female; Humans; Lupus Erythematosus,

1982
Interferon production of vitro by leucocytes from patients with systemic lupus erythematosus and rheumatoid arthritis.
    Clinical and experimental immunology, 1981, Volume: 45, Issue:3

    Topics: Adult; Arthritis, Rheumatoid; Azathioprine; Cells, Cultured; Female; Humans; Interferon Inducers; In

1981
Multiple mononeuropathy as the initial presentation of systemic lupus erythematosus--nerve biopsy and response to plasma exchange.
    Journal of neurology, 1982, Volume: 228, Issue:4

    Topics: Azathioprine; Biopsy; Diagnosis, Differential; Extremities; Female; Humans; Lupus Erythematosus, Sys

1982
T lymphocyte subpopulations defined by two sets of monoclonal antibodies in chronic active hepatitis and systemic lupus erythematosus.
    Clinical and experimental immunology, 1982, Volume: 50, Issue:1

    Topics: Adult; Aged; Antibodies, Monoclonal; Azathioprine; Female; Hepatitis, Chronic; Humans; Leukocyte Cou

1982
[Lupus erythematosus and the central nervous system].
    Der Nervenarzt, 1984, Volume: 55, Issue:4

    Topics: Azathioprine; Blood-Brain Barrier; Brain; Brain Diseases; Cyclophosphamide; Diagnosis, Differential;

1984
Azathioprine in the treatment of systemic lupus erythematosus. A three-year prospective study.
    Clinical rheumatology, 1984, Volume: 3, Issue:3

    Topics: Adult; Aged; Antibodies, Antinuclear; Azathioprine; DNA; Female; Humans; Lupus Erythematosus, System

1984
[Treatment of subacute cutaneous lupus erythematosus with thalidomide].
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 1983, Volume: 34, Issue:4

    Topics: Azathioprine; Biopsy; Fluorescent Antibody Technique; Humans; Immunoglobulin G; Immunoglobulin M; Ki

1983
A critical analysis of the use of azathioprine in clinical medicine.
    The Netherlands journal of medicine, 1983, Volume: 26, Issue:6

    Topics: Animals; Antibody Formation; Autoimmune Diseases; Azathioprine; Crohn Disease; Dogs; Humans; Immunit

1983
Prognostic significance of subepidermal immune deposits in uninvolved skin of patients with systemic lupus erythematosus: a 10-year longitudinal study.
    The Journal of investigative dermatology, 1984, Volume: 83, Issue:4

    Topics: Adolescent; Adult; Azathioprine; Biopsy; Child; Chlorambucil; Cyclophosphamide; Female; Fluorescent

1984
Acute tuberculous lymphadenopathy in an immunosuppressed patient.
    British medical journal (Clinical research ed.), 1983, Jan-01, Volume: 286, Issue:6358

    Topics: Acute Disease; Azathioprine; Female; Humans; Lupus Erythematosus, Systemic; Middle Aged; Tuberculosi

1983
Supressor monocytes in patients with systemic lupus erythematosus. Evidence of suppressor activity associated with a cell-free soluble product of monocytes.
    The Journal of laboratory and clinical medicine, 1980, Volume: 95, Issue:1

    Topics: Adult; Azathioprine; Cells, Cultured; Female; Humans; Indomethacin; Lectins; Lupus Erythematosus, Sy

1980
Myocardial perfusion abnormalities in asymptomatic patients with systemic lupus erythematosus.
    The American journal of medicine, 1984, Volume: 77, Issue:2

    Topics: Adolescent; Adult; Azathioprine; Cicatrix; Coronary Disease; Exercise Test; Female; Heart; Humans; L

1984
Course of renal pathology in patients with systemic lupus erythematosus.
    The American journal of medicine, 1984, Volume: 77, Issue:4

    Topics: Adult; Azathioprine; Biopsy; Blood Pressure; Creatinine; Cyclophosphamide; Female; Follow-Up Studies

1984
Azathioprine.
    Clinics in rheumatic diseases, 1984, Volume: 10, Issue:2

    Topics: Arthritis; Arthritis, Rheumatoid; Azathioprine; Female; Gastrointestinal Diseases; Humans; Leukopeni

1984
Severe thoracic systemic lupus erythematosus.
    Australian and New Zealand journal of medicine, 1984, Volume: 14, Issue:3

    Topics: Adult; Aged; Azathioprine; Female; Humans; Lung Diseases; Lupus Erythematosus, Systemic; Middle Aged

1984
Systemic lupus erythematosus and lymphoma. A family study.
    Scandinavian journal of rheumatology, 1983, Volume: 12, Issue:3

    Topics: Adult; Autoimmune Diseases; Azathioprine; Child; Drug Therapy, Combination; Female; Humans; Killer C

1983
Systemic lupus erythematosus with paraproteinemia.
    Arthritis and rheumatism, 1984, Volume: 27, Issue:6

    Topics: Adult; Aged; Antibodies, Antinuclear; Azathioprine; Female; Glomerulonephritis; Glycoproteins; HLA A

1984
[Systemic lupus erythematosus. Brown-Sequard syndrome, spinal ataxia and peripheral polyneuropathy as the sole manifestations].
    Deutsche medizinische Wochenschrift (1946), 1984, Jun-29, Volume: 109, Issue:26

    Topics: Aged; Antibodies, Antinuclear; Ataxia; Autoantibodies; Azathioprine; DNA; Female; Humans; Liver Cirr

1984
Murine lupus nephritis: effect of azathioprine on glomerular permeability and localization of immunoreactants.
    Clinical and experimental immunology, 1983, Volume: 53, Issue:3

    Topics: Animals; Azathioprine; Basement Membrane; Complement C3; Female; Glomerular Filtration Rate; Glomeru

1983
Azathioprine and urinary bladder tumor.
    Annals of internal medicine, 1983, Volume: 99, Issue:5

    Topics: Adult; Azathioprine; Carcinoma, Transitional Cell; Humans; Lupus Erythematosus, Systemic; Male; Urin

1983
[Extracorporeal hemosorption in the complex treatment of systemic lupus erythematosus in children].
    Pediatriia, 1983, Issue:11

    Topics: Adolescent; Azathioprine; Combined Modality Therapy; Female; Hemoperfusion; Humans; Lupus Erythemato

1983
[Changes in the cellular-humoral immune reactivity of patients with lupus nephritis and chronic glomerulonephritis treated with corticosteroids or corticosteroids and imuran].
    Vutreshni bolesti, 1983, Volume: 22, Issue:5

    Topics: Adrenal Cortex Hormones; Antibody Formation; Azathioprine; Chronic Disease; Drug Therapy, Combinatio

1983
Azathioprine and the liver. Evidence favoring idiosyncratic, mixed cholestatic-hepatocellular injury in humans.
    Gastroenterology, 1984, Volume: 86, Issue:1

    Topics: Adult; Alkaline Phosphatase; Azathioprine; Bilirubin; Cholestasis; Humans; Liver Function Tests; Lup

1984
Lupus erythematosus and panhypogammaglobulinemia.
    Annals of internal medicine, 1984, Volume: 100, Issue:1

    Topics: Adult; Agammaglobulinemia; Azathioprine; Female; Humans; Lupus Erythematosus, Systemic

1984
Two chromosome aberrations in the child of a woman with systemic lupus erythematosus treated with azathioprine and prednisone.
    American journal of medical genetics, 1984, Volume: 17, Issue:3

    Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Adult; Azathioprine; Chromosome Aberrations; C

1984
Renal involvement in systemic lupus erythematosus.
    The Medical journal of Australia, 1984, Jun-23, Volume: 140, Issue:13

    Topics: Acute Kidney Injury; Adolescent; Adult; Aged; Azathioprine; Drug Therapy, Combination; Female; Glome

1984
IgG therapy in systemic lupus erythematosus--two case reports.
    Blut, 1984, Volume: 48, Issue:6

    Topics: Azathioprine; Child; Cushing Syndrome; Female; Humans; Immunoglobulin G; Lupus Erythematosus, System

1984
Effect of treatment on the evolution of renal abnormalities in lupus nephritis.
    The New England journal of medicine, 1984, Aug-23, Volume: 311, Issue:8

    Topics: Adult; Azathioprine; Cyclophosphamide; Female; Humans; Kidney; Lupus Erythematosus, Systemic; Male;

1984
Cytotoxic-drug treatment of lupus nephritis.
    The New England journal of medicine, 1984, Aug-23, Volume: 311, Issue:8

    Topics: Adult; Azathioprine; Cyclophosphamide; Female; Humans; Lupus Erythematosus, Systemic; Male; Nephriti

1984
[Therapy of acute pulmonary hemorrhage in systemic lupus erythematosus].
    MMW, Munchener medizinische Wochenschrift, 1980, Mar-21, Volume: 122, Issue:12

    Topics: Azathioprine; Child; Hematuria; Hemorrhage; Humans; Lung; Lupus Erythematosus, Systemic; Male; Predn

1980
[Azathioprine in the treatment of disseminated lupus erythematosus].
    MMW, Munchener medizinische Wochenschrift, 1982, May-14, Volume: 124, Issue:19

    Topics: Adrenal Cortex Hormones; Azathioprine; Drug Administration Schedule; Humans; Kidney; Lupus Erythemat

1982
Transition from systemic lupus erythematosus to common variable hypogammaglobulinemia.
    Annals of internal medicine, 1983, Volume: 99, Issue:1

    Topics: Adolescent; Adult; Agammaglobulinemia; Azathioprine; Complement System Proteins; Female; Humans; Imm

1983
Childhood systemic lupus erythematosus. Association with pancreatitis, subcutaneous fat necrosis, and calcinosis cutis.
    Archives of dermatology, 1983, Volume: 119, Issue:6

    Topics: Adipose Tissue; Azathioprine; Calcinosis; Child; Female; Humans; Hydrochlorothiazide; Lupus Erythema

1983
[Therapy of lupus nephritis in childhood].
    Padiatrie und Grenzgebiete, 1983, Volume: 22, Issue:2-3

    Topics: Adolescent; Autoimmune Diseases; Azathioprine; Cyclophosphamide; Humans; Immunosuppression Therapy;

1983
Azathioprine and subacute myelomonocytic leukemia.
    Acta medica Scandinavica, 1980, Volume: 207, Issue:4

    Topics: Adult; Azathioprine; Bone Marrow; Female; Humans; Leukemia, Myeloid; Lupus Erythematosus, Systemic

1980
The effects of azathioprine and prednisolone on T- and B-lymphocytes in patients with lupus nephritis and chronic glomerulonephritis.
    Clinical nephrology, 1980, Volume: 14, Issue:5

    Topics: Adolescent; Adult; Azathioprine; B-Lymphocytes; Chronic Disease; Glomerulonephritis; Humans; Lupus E

1980
Therapeutic plasmapheresis in systemic lupus erythematosus. Effect on immune complexes and antibodies to DNA.
    Arthritis and rheumatism, 1981, Volume: 24, Issue:9

    Topics: Adolescent; Adult; Antibodies, Antinuclear; Antigen-Antibody Complex; Arthritis; Azathioprine; Chlor

1981
Immunologic and genetic aspects of systemic lupus erythematosus.
    Kidney international, 1981, Volume: 19, Issue:3

    Topics: Adult; Antibodies, Antinuclear; Azathioprine; Biopsy; Diseases in Twins; Female; Fluorescent Antibod

1981
[Lupus nephritis. 3: Therapeutic approach].
    L'union medicale du Canada, 1982, Volume: 111, Issue:2

    Topics: Azathioprine; Cyclophosphamide; Glomerulonephritis; Humans; Lupus Erythematosus, Systemic; Nephritis

1982
Bone marrow megakaryocytes and platelet kinetics in systemic lupus erythematosus. With special reference to corticosteroid and azathioprine therapy.
    Acta medica Scandinavica, 1982, Volume: 211, Issue:4

    Topics: Adrenal Cortex Hormones; Adult; Aged; Azathioprine; Blood Platelets; Cell Count; Female; Humans; Lup

1982
Cytotoxic drug treatment of lupus nephritis.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 1982, Volume: 2, Issue:1 Suppl 1

    Topics: Antibiotics, Antineoplastic; Azathioprine; Cyclophosphamide; Drug Therapy, Combination; Glomerulonep

1982
Overview of treatment of lupus nephropathy.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 1982, Volume: 2, Issue:1 Suppl 1

    Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Azathioprine; Biopsy; Cyclophosphamide; Drug Therapy

1982
The management of systemic lupus erythematosus.
    Arthritis and rheumatism, 1982, Volume: 25, Issue:7

    Topics: Adrenal Cortex Hormones; Azathioprine; Cyclophosphamide; Humans; Lupus Erythematosus, Systemic; Plas

1982
Retinopathy in a patient with systemic lupus erythematosus.
    Annals of ophthalmology, 1982, Volume: 14, Issue:5

    Topics: Adult; Azathioprine; Communicable Diseases; Female; Humans; Lupus Erythematosus, Systemic; Prednison

1982
[Effect of treatment with enkorton and cytostatics on selected immunologic indicators in patients with systemic lupus erythematosus].
    Reumatologia, 1982, Volume: 20, Issue:1-2

    Topics: Adolescent; Adult; Antigen-Antibody Complex; Autoantibodies; Azathioprine; Child; Complement System

1982
[Possibilities of combined treatment of diffuse collagenous glomerulonephritis].
    Vutreshni bolesti, 1982, Volume: 21, Issue:5

    Topics: Acenocoumarol; Adolescent; Adult; Azathioprine; Drug Therapy, Combination; Female; Glomerulonephriti

1982
Azathioprine teratogenicity: review of the literature and case report.
    Obstetrics and gynecology, 1981, Volume: 58, Issue:2

    Topics: Abnormalities, Drug-Induced; Adult; Animals; Azathioprine; Female; Fingers; Humans; Infant, Newborn;

1981
Increased incidence of cervical atypia in women with systemic lupus erythematosus treated with chemotherapy.
    Arthritis and rheumatism, 1981, Volume: 24, Issue:5

    Topics: Adult; Aged; Azathioprine; Cervix Uteri; Female; Humans; Lupus Erythematosus, Systemic; Middle Aged;

1981
Chronic plasma exchange therapy in SLE nephritis.
    Clinical nephrology, 1981, Volume: 16, Issue:1

    Topics: Azathioprine; Female; Humans; Kidney Function Tests; Lupus Erythematosus, Systemic; Male; Nephritis;

1981
Platelet-bound IgG in systemic lupus erythematosus with and without thrombocytopenia.
    Journal of immunological methods, 1981, Volume: 45, Issue:3

    Topics: Antigen-Antibody Complex; Azathioprine; Binding Sites, Antibody; Blood Platelets; Humans; Immunoglob

1981
[Plasma exchange in rapidly progressive glomerulonephritis (author's transl)].
    Deutsche medizinische Wochenschrift (1946), 1981, Nov-27, Volume: 106, Issue:48

    Topics: Adolescent; Adult; Aged; Anti-Glomerular Basement Membrane Disease; Antigen-Antibody Complex; Azathi

1981
Platelet kinetics in systemic lupus erythematosus (SLE), with special reference to corticosteroid and azathioprine therapy.
    Scandinavian journal of rheumatology, 1981, Volume: 10, Issue:4

    Topics: Adult; Aged; Azathioprine; Blood Platelets; Cell Survival; Female; Humans; Kinetics; Lupus Erythemat

1981
Regimens for treatment of lupus nephritis.
    Annals of internal medicine, 1980, Volume: 92, Issue:3

    Topics: Azathioprine; Cyclophosphamide; Drug Therapy, Combination; Humans; Lupus Erythematosus, Systemic; Ne

1980
[Plasmapheresis in the treatment of extracapillary glomerulonephritis (author's transl)].
    Medicina clinica, 1980, May-10, Volume: 74, Issue:9

    Topics: Arteritis; Azathioprine; Blood Proteins; Cyclophosphamide; Glomerulonephritis; Humans; IgA Vasculiti

1980
[Comparative effectiveness of different therapeutic regimens in lupus nephritis in children and adolescents].
    Pediatriia, 1980, Issue:4

    Topics: Adolescent; Azathioprine; Child; Child, Preschool; Dipyridamole; Drug Therapy, Combination; Evaluati

1980
[Treatment of lupus nephritis].
    Terapevticheskii arkhiv, 1980, Volume: 52, Issue:4

    Topics: Azathioprine; Humans; Lupus Erythematosus, Systemic; Nephritis; Plasmapheresis; Prednisolone; Renal

1980
[Effect of cytotoxic immunosuppressive agents on the level of urinary seromucoids and cathepsins in lupus nephritis].
    Terapevticheskii arkhiv, 1980, Volume: 52, Issue:6

    Topics: Azathioprine; Cathepsins; Chlorambucil; Cyclophosphamide; Drug Therapy, Combination; Humans; Immunos

1980
Platelet survival and platelet production in systemic lupus erythematosus (SLE).
    Scandinavian journal of rheumatology, 1980, Volume: 9, Issue:4

    Topics: Adrenal Cortex Hormones; Adult; Aged; Azathioprine; Blood Platelets; Cell Survival; Female; Humans;

1980
Azathioprine-induced pancytopenia. Occurrence in two patients with connective-tissue diseases.
    Archives of internal medicine, 1981, Volume: 141, Issue:2

    Topics: Adult; Arthritis, Juvenile; Azathioprine; Blood Cell Count; Bone Marrow; Connective Tissue Diseases;

1981
Longitudinal study on the production of and cellular response to interleukin-2 in patients with systemic lupus erythematosus.
    Rheumatology international, 1995, Volume: 15, Issue:2

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Cells, Cultured; Cyclophosphamide; Fem

1995
Improved outcome of systemic lupus erythematosus among children in Durban, South Africa.
    Annals of tropical paediatrics, 1994, Volume: 14, Issue:2

    Topics: Azathioprine; Child; Chloroquine; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Lupu

1994
Autoimmune multiorgan involvement in elderly men is it SLE?
    Clinical rheumatology, 1994, Volume: 13, Issue:4

    Topics: Aged; Aged, 80 and over; Azathioprine; Diagnosis, Differential; Humans; Immunoglobulins, Intravenous

1994
[A case report: cryptococcal meningitis and fluconazole therapy].
    Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases, 1994, Volume: 68, Issue:11

    Topics: Adolescent; Azathioprine; Female; Fluconazole; Humans; Immunocompromised Host; Lupus Erythematosus,

1994
Development of panhypogammaglobulinaemia in a patient with systemic lupus erythematosus.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 1994, Volume: 9, Issue:6

    Topics: Administration, Oral; Adult; Agammaglobulinemia; Azathioprine; Bacterial Infections; Cyclophosphamid

1994
Post-infantile giant cell hepatitis in an elderly female patient with systemic lupus erythematosus.
    Journal of gastroenterology, 1994, Volume: 29, Issue:3

    Topics: Aged; Azathioprine; Cyclosporine; Female; Giant Cells; Hepatitis, Viral, Human; Humans; Liver; Lupus

1994
Assessment of clinical parameters associated with increased frequency of mutant T cells in patients with systemic lupus erythematosus.
    Arthritis and rheumatism, 1994, Volume: 37, Issue:2

    Topics: Adult; Azathioprine; Cell Division; Clone Cells; Cyclophosphamide; Female; Humans; Lupus Erythematos

1994
[Bilateral kidney enlargement with kidney failure. Manifestation of primary extranodal B-cell lymphoma after long-term immunosuppression].
    Medizinische Klinik (Munich, Germany : 1983), 1994, Feb-15, Volume: 89, Issue:2

    Topics: Azathioprine; Female; Humans; Hypertrophy; Kidney; Kidney Failure, Chronic; Kidney Neoplasms; Lupus

1994
Fetal salvage in maternal systemic lupus erythematosus.
    Annals of the Academy of Medicine, Singapore, 1993, Volume: 22, Issue:4

    Topics: Abortion, Spontaneous; Adult; Azathioprine; Female; Fetal Death; Humans; Infant, Newborn; Kidney Fun

1993
Lupus and its management.
    Journal of the South Carolina Medical Association (1975), 1993, Volume: 89, Issue:11

    Topics: Adolescent; Antibiotics, Antineoplastic; Autoantibodies; Azathioprine; Cyclophosphamide; Dose-Respon

1993
Limitations of randomized clinical trials to recognize possible advantages of combination therapies in rheumatic diseases.
    Seminars in arthritis and rheumatism, 1993, Volume: 23, Issue:2 Suppl 1

    Topics: Arthritis, Rheumatoid; Auranofin; Azathioprine; Drug Combinations; Humans; Lupus Erythematosus, Syst

1993
Pregnancy outcome in women with systemic lupus erythematosus treated with immunosuppressive drugs.
    The Journal of rheumatology, 1993, Volume: 20, Issue:7

    Topics: Abortion, Spontaneous; Adolescent; Adult; Azathioprine; Cyclophosphamide; Female; Fetal Death; Human

1993
Association of interstitial lupus cystitis with systemic lupus erythematosus.
    Clinical nephrology, 1993, Volume: 39, Issue:5

    Topics: Adult; Azathioprine; Cystitis; Humans; Hydronephrosis; Lupus Erythematosus, Systemic; Male; Methylpr

1993
Increased rate of lupus flare during pregnancy and the puerperium: a prospective study of 78 pregnancies.
    British journal of rheumatology, 1996, Volume: 35, Issue:2

    Topics: Adult; Anti-Inflammatory Agents; Antirheumatic Agents; Azathioprine; Cyclophosphamide; Female; Follo

1996
Incidence of ovarian failure in systemic lupus erythematosus after treatment with pulse cyclophosphamide.
    Annals of the rheumatic diseases, 1996, Volume: 55, Issue:4

    Topics: Adolescent; Adult; Age Factors; Azathioprine; Cohort Studies; Cyclophosphamide; Drug Administration

1996
Factors associated with fetal losses in severe systemic lupus erythematosus.
    Lupus, 1996, Volume: 5, Issue:2

    Topics: Adult; Analysis of Variance; Azathioprine; Case-Control Studies; Chloroquine; Cohort Studies; Congen

1996
Predictors of flares and long-term outcome of systemic lupus erythematosus during combined treatment with azathioprine and low-dose prednisolone.
    Rheumatology international, 1996, Volume: 16, Issue:4

    Topics: Adolescent; Adult; Antirheumatic Agents; Azathioprine; Child; Drug Therapy, Combination; Female; Hum

1996
Systemic lupus erythematosus [clinical inference].
    BMJ (Clinical research ed.), 1997, Jan-25, Volume: 314, Issue:7076

    Topics: Adult; Antiphospholipid Syndrome; Azathioprine; Cyclophosphamide; Female; Humans; Lupus Erythematosu

1997
Systemic lupus erythematosus and bone marrow necrosis in a dog.
    The Canadian veterinary journal = La revue veterinaire canadienne, 1996, Volume: 37, Issue:12

    Topics: Animals; Anti-Inflammatory Agents; Antibodies, Antinuclear; Antirheumatic Agents; Arthritis; Azathio

1996
Azathioprine hypersensitivity in a patient affected by systemic lupus erythematosus.
    Lupus, 1997, Volume: 6, Issue:7

    Topics: Adult; Azathioprine; Drug Hypersensitivity; Female; Humans; Immunosuppressive Agents; Lupus Erythema

1997
Clinically important interaction between azathioprine (Imurel) and phenprocoumon (Marcoumar)
    European journal of clinical pharmacology, 1997, Volume: 52, Issue:6

    Topics: Adult; Anticoagulants; Azathioprine; Drug Antagonism; Female; Humans; Immunosuppressive Agents; Lupu

1997
Azathioprine treatment and thiopurine metabolism in rheumatic diseases. Introduction and first results of investigation.
    Advances in experimental medicine and biology, 1998, Volume: 431

    Topics: 5'-Nucleotidase; Antirheumatic Agents; Arthritis, Rheumatoid; Azathioprine; Cross-Sectional Studies;

1998
Acute myeloid leukemia after azathioprine treatment for autoimmune diseases: association with -7/7q-.
    Cancer genetics and cytogenetics, 1998, Jul-15, Volume: 104, Issue:2

    Topics: Acute Disease; Adult; Aged; Arthritis, Rheumatoid; Azathioprine; Chromosomes, Human, Pair 7; Female;

1998
Antigen-specific antibody responses in lupus patients following immunization.
    Arthritis and rheumatism, 1998, Volume: 41, Issue:10

    Topics: Adolescent; Adult; Aged; Antibody Formation; Azathioprine; Bacterial Vaccines; Cyclophosphamide; Epi

1998
[Case of systemic erythematodes on long-term care with repeated development of severe cytomegalovirus infection].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 1998, Aug-10, Volume: 87, Issue:8

    Topics: Azathioprine; Cytomegalovirus Infections; Female; Humans; Immunocompromised Host; Immunosuppressive

1998
Identification of thiopurine methyltransferase (TPMT) polymorphisms cannot predict myelosuppression in systemic lupus erythematosus patients taking azathioprine.
    Rheumatology (Oxford, England), 1999, Volume: 38, Issue:7

    Topics: Azathioprine; Genotype; Humans; Immunosuppressive Agents; Inflammatory Bowel Diseases; Lupus Erythem

1999
Diarrhoea secondary to azathioprine in two patients with SLE.
    Lupus, 1999, Volume: 8, Issue:7

    Topics: Adult; Azathioprine; Diarrhea; Female; Humans; Immunosuppressive Agents; Lupus Erythematosus, System

1999
Dramatic improvement of left ventricular function after cytotoxic therapy in lupus patients with acute cardiomyopathy: report of 6 cases.
    The Journal of rheumatology, 1999, Volume: 26, Issue:10

    Topics: Acute Disease; Adult; Anti-Inflammatory Agents; Azathioprine; Cardiomyopathies; Cyclophosphamide; Fe

1999
A meningioma-mimicking tumor caused by Mycobacterium avium complex in an immunocompromised patient.
    The American journal of surgical pathology, 2000, Volume: 24, Issue:1

    Topics: Anti-Inflammatory Agents; Azathioprine; Female; Humans; Immunocompromised Host; Immunohistochemistry

2000
Relationship between red cell mean corpuscular volume and 6-thioguanine nucleotides in patients treated with azathioprine.
    The Journal of laboratory and clinical medicine, 2000, Volume: 135, Issue:3

    Topics: Adult; Azathioprine; Biological Availability; Churg-Strauss Syndrome; Erythrocyte Indices; Erythrocy

2000
Sensitivity to change of the MOS SF-36 quality of life assessment questionnaire in patients with systemic lupus erythematosus taking immunosuppressive therapy.
    The Journal of rheumatology, 2000, Volume: 27, Issue:8

    Topics: Adult; Azathioprine; Cyclophosphamide; Humans; Immunosuppressive Agents; Lupus Erythematosus, System

2000
[Spontaneous infrapatellar tendon rupture in a patient with systemic lupus erythematosus].
    Ugeskrift for laeger, 2000, Sep-18, Volume: 162, Issue:38

    Topics: Adult; Azathioprine; Drug Therapy, Combination; Female; Glomerulonephritis; Glucocorticoids; Humans;

2000
An unusual case of systemic lupus erythematosus, lupus nephritis, and transient monoclonal gammopathy.
    Rheumatology international, 2000, Volume: 19, Issue:6

    Topics: Adult; Antirheumatic Agents; Azathioprine; Cyclophosphamide; Female; Humans; Immunosuppressive Agent

2000
Cyclosporin A and therapeutic plasma exchange in the treatment of severe systemic lupus erythematosus.
    Artificial organs, 2000, Volume: 24, Issue:11

    Topics: Adrenal Cortex Hormones; Adult; Antibodies, Antinuclear; Antigen-Antibody Complex; Azathioprine; Chi

2000
Severe hypercalcemia and systemic lupus erythematosus.
    Joint bone spine, 2000, Volume: 67, Issue:5

    Topics: Adult; Azathioprine; Blood Sedimentation; Clodronic Acid; Female; Humans; Hypercalcemia; Lupus Eryth

2000
Excellent effect of steroid plus azathioprine in a young woman with pernicious anaemia and systemic lupus erythematosus.
    Clinical rheumatology, 2000, Volume: 19, Issue:6

    Topics: Adult; Anemia, Pernicious; Azathioprine; Bone Marrow Examination; Disease Progression; Drug Therapy,

2000
Remission of precapillary pulmonary hypertension in systemic lupus erythematosus.
    Journal of the Royal Society of Medicine, 2001, Volume: 94, Issue:1

    Topics: Adult; Anti-Inflammatory Agents; Azathioprine; Female; Humans; Hypertension, Pulmonary; Immunosuppre

2001
Development of severe longitudinal atrophy of thoracic spinal cord following lupus-related myelitis.
    Internal medicine (Tokyo, Japan), 2001, Volume: 40, Issue:4

    Topics: Adult; Atrophy; Azathioprine; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Lupus Ery

2001
Systemic lupus erythematosus.
    Lancet (London, England), 2001, Aug-18, Volume: 358, Issue:9281

    Topics: Antiphospholipid Syndrome; Azathioprine; Cyclophosphamide; Female; Glucocorticoids; Humans; Immunogl

2001
Primary protein-losing enteropathy in anti-double-stranded DNA disease: the initial and sole clinical manifestation of occult systemic lupus erythematosus?
    Journal of clinical gastroenterology, 2001, Volume: 33, Issue:4

    Topics: Adult; Antibodies, Antinuclear; Azathioprine; Biopsy, Needle; Diet Therapy; DNA; Drug Therapy, Combi

2001
Warfarin and azathioprine: clinically significant drug interaction.
    The Journal of rheumatology, 2002, Volume: 29, Issue:2

    Topics: Adult; Anticoagulants; Azathioprine; Drug Antagonism; Drug Therapy, Combination; Female; Humans; Imm

2002
Pulmonary silicosis and systemic lupus erythematosus in men: a report of two cases.
    Joint bone spine, 2002, Volume: 69, Issue:1

    Topics: Adult; Azathioprine; Cyclophosphamide; Drug Therapy, Combination; Humans; Immunosuppressive Agents;

2002
Systemic lupus erythematosus related transverse myelitis presenting longitudinal involvement of the spinal cord.
    Internal medicine (Tokyo, Japan), 2002, Volume: 41, Issue:2

    Topics: Adult; Autoimmune Diseases; Azathioprine; Brain; Cyclophosphamide; Drug Resistance; Facial Nerve Dis

2002
Systemic lupus erythematosus complicated by cytomegalovirus-induced hemophagocytic syndrome and colitis.
    Internal medicine (Tokyo, Japan), 2002, Volume: 41, Issue:2

    Topics: Autoimmune Diseases; Azathioprine; Colitis; Cyclophosphamide; Cytokines; Cytomegalovirus Infections;

2002
Progressive multifocal leucoencephalopathy isolated to the posterior fossa in a patient with systemic lupus erythematosus.
    Rheumatology (Oxford, England), 2002, Volume: 41, Issue:7

    Topics: Adult; Azathioprine; Cranial Fossa, Posterior; Humans; Immunocompromised Host; Immunosuppressive Age

2002
[Hyperergic collagenoses. Clinical aspects, differential diagnosis and therapy (author's transl)].
    MMW, Munchener medizinische Wochenschrift, 1977, Oct-21, Volume: 119, Issue:42

    Topics: Adolescent; Adult; Age Factors; Aged; Azathioprine; Child; Collagen Diseases; Cyclophosphamide; Derm

1977
[Azathioprine in rheumatology].
    Fortschritte der Medizin, 1979, Dec-20, Volume: 97, Issue:48

    Topics: Arthritis, Rheumatoid; Azathioprine; Chromosome Aberrations; Humans; Immunosuppression Therapy; Lupu

1979
Noninfectious canine arthritis: the inflammatory, nonerosive arthritides.
    Journal of the American Veterinary Medical Association, 1976, Aug-01, Volume: 169, Issue:3

    Topics: Animals; Arthritis; Arthritis, Infectious; Azathioprine; Cyclophosphamide; Dog Diseases; Dogs; Femal

1976
Pulmonary manifestations of systemic lupus erythematosus: review of twelve cases of acute lupus pneumonitis.
    Medicine, 1975, Volume: 54, Issue:5

    Topics: Acute Disease; Adolescent; Adult; Aged; Azathioprine; Cardiomegaly; Female; Humans; Lung Volume Meas

1975
Correlation between the results of the migration inhibitory factor production test with DNA and the severity of the disease in the systemic lupus erythematosus patients.
    Zeitschrift fur Immunitatsforschung, experimentelle und klinische Immunologie, 1975, Volume: 150, Issue:1

    Topics: Antigens; Azathioprine; Cyclophosphamide; DNA; Female; Humans; Immunosuppression Therapy; Lupus Eryt

1975
The course of lupus nephritis: contribution of serial renal biopsies.
    Advances in nephrology from the Necker Hospital, 1976, Volume: 6

    Topics: Adolescent; Adrenal Cortex Hormones; Adult; Azathioprine; Biopsy; Child; Female; Glomerulonephritis;

1976
Maternal immunosuppression and cytomegalovirus infection of the fetus.
    Australian and New Zealand journal of medicine, 1979, Volume: 9, Issue:4

    Topics: Adult; Antibodies, Bacterial; Azathioprine; Brain Damage, Chronic; Cytomegalovirus Infections; Femal

1979
Lymphocytotoxic antibodies in systemic lupus erythematosus: their clinical significance.
    Journal of clinical pathology. Supplement (Royal College of Pathologists), 1979, Volume: 13

    Topics: Antilymphocyte Serum; Azathioprine; Binding Sites, Antibody; Central Nervous System Diseases; Comple

1979
[Effect of prednisolone and azathioprine on T- and B-lymphocyte number in peripheral blood of patients with glomerulonephritis and systemic lupus erythematosus].
    Terapevticheskii arkhiv, 1978, Volume: 50, Issue:6

    Topics: Adolescent; Adult; Azathioprine; B-Lymphocytes; Glomerulonephritis; Humans; Leukocyte Count; Lupus E

1978
Treatment of systemic lupus erythematosus in childhood.
    Arthritis and rheumatism, 1977, Volume: 20, Issue:2 Suppl

    Topics: Antibodies, Antinuclear; Azathioprine; Child; Complement System Proteins; DNA; Drug Administration S

1977
Fetal immunoglobulin synthesis following maternal immunosuppression.
    American journal of obstetrics and gynecology, 1977, Nov-15, Volume: 129, Issue:6

    Topics: Adult; Azathioprine; Female; Fetus; Graft Rejection; Humans; Immunity; Immunoglobulins; Immunosuppre

1977
Experience of a platelet factor 3 immunoinjury technique in the detection of antiplatelet antibody in systemic lupus erythematosus and other clinical disorders.
    Scandinavian journal of rheumatology, 1978, Volume: 7, Issue:1

    Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Antimalarials; Azathioprine; Blood Cell Count; Blo

1978
Reticulum cell sarcoma in azathioprine-treated systemic lupus erythematosus.
    Annals of the rheumatic diseases, 1979, Volume: 38, Issue:1

    Topics: Adult; Azathioprine; Female; Humans; Immunosuppression Therapy; Lung Neoplasms; Lupus Erythematosus,

1979
[Cavitary multiple pulmonary nodules in disseminated lupus erythematosus].
    Revista clinica espanola, 1979, Jan-15, Volume: 152, Issue:1

    Topics: Azathioprine; Female; Humans; Lupus Erythematosus, Systemic; Middle Aged; Prednisone; Radiography; S

1979
Acute pancreatitis associated with long-term azathioprine therapy. Occurrence in a patient with systemic lupus erythematosus.
    Archives of dermatology, 1979, Volume: 115, Issue:2

    Topics: Acute Disease; Adult; Azathioprine; Female; Humans; Lupus Erythematosus, Systemic; Pancreatitis; Pre

1979
Cryptococcal meningitis and internal ophthalmoplegia.
    American journal of ophthalmology, 1979, Volume: 87, Issue:5

    Topics: Adolescent; Adult; Aged; Amphotericin B; Azathioprine; Child; Child, Preschool; Cryptococcosis; Fema

1979
Grand rounds: the treatment of lupus nephritis.
    Virginia medical, 1979, Volume: 106, Issue:5

    Topics: Adult; Azathioprine; Child; Cyclophosphamide; Humans; Kidney; Lupus Erythematosus, Systemic; Nephrit

1979
Adrenocortical carcinoma in a patient with systemic lupus erythematosus treated with azathioprine.
    Arthritis and rheumatism, 1979, Volume: 22, Issue:8

    Topics: Adrenal Cortex Neoplasms; Azathioprine; Humans; Lupus Erythematosus, Systemic; Male; Middle Aged; Ne

1979
Systemic lupus erythematosus in pregnancy.
    American journal of obstetrics and gynecology, 1979, Oct-15, Volume: 135, Issue:4

    Topics: Abortion, Induced; Abortion, Missed; Azathioprine; Female; Humans; Infant, Newborn; Lupus Erythemato

1979
[Puerperal systemic lupus erythematosus. Personal studies].
    Minerva medica, 1979, Oct-06, Volume: 70, Issue:43

    Topics: Adrenal Cortex Hormones; Adult; Alopecia; Anuria; Azathioprine; Female; Fever; Glomerulonephritis; H

1979
[Comparative evaluation of the effectiveness of corticosteroids and cytostatics in hypertensive variants of systemic nephritis].
    Klinicheskaia meditsina, 1979, Volume: 57, Issue:8

    Topics: Adolescent; Adrenal Cortex Hormones; Adult; Antineoplastic Agents; Azathioprine; Drug Evaluation; Dr

1979
[Remote results of combined immunosuppressive treatment of systemic lupus erythematosus (1969-1978)].
    Wiadomosci lekarskie (Warsaw, Poland : 1960), 1979, Nov-15, Volume: 32, Issue:22

    Topics: Adolescent; Adult; Aged; Azathioprine; Cyclophosphamide; Drug Therapy, Combination; Female; Follow-U

1979
[Systemic lupus erythematosus in twins (author's transl)].
    Klinische Padiatrie, 1978, Volume: 190, Issue:4

    Topics: Adolescent; Anemia, Hemolytic; Azathioprine; Child; Diseases in Twins; Female; Humans; Lupus Erythem

1978
Development of a lymphocytic lymphoma during immunosuppressive therapy with azathioprine for systemic lupus erythematosus with renal involvement induced by phenylbutazone.
    Clinical nephrology, 1977, Volume: 8, Issue:1

    Topics: Azathioprine; Female; Humans; Kidney Diseases; Lupus Erythematosus, Systemic; Lymphoma, Non-Hodgkin;

1977
Myocardial infarction and systemic lupus erythematosus: beneficial response to treatment with azathioprine.
    Irish journal of medical science, 1977, Volume: 146, Issue:12

    Topics: Adult; Azathioprine; Female; Humans; Lupus Erythematosus, Systemic; Myocardial Infarction

1977
The effect of normalization of serum complement and anti-DNA antibody on the course of lupus nephritis: a two year prospective study.
    The American journal of medicine, 1978, Volume: 64, Issue:2

    Topics: Antibodies; Azathioprine; Complement System Proteins; DNA; Humans; Kidney Glomerulus; Lupus Erythema

1978
Azathioprine-induced meningitis in systemic lupus erythematosus.
    JAMA, 1978, Aug-11, Volume: 240, Issue:6

    Topics: Azathioprine; Humans; Lupus Erythematosus, Systemic; Meningitis; Meningitis, Aseptic

1978
[Problems of disseminated lupus erythematosus in infants and children].
    Verhandlungen der Deutschen Gesellschaft fur Rheumatologie, 1978, Volume: 5

    Topics: Arthritis, Rheumatoid; Azathioprine; Child; Child, Preschool; Chloroquine; Dermatomyositis; Female;

1978
[Therapy of systemic lupus erythematosus and of pseudo-le-syndrome].
    Deutsche medizinische Wochenschrift (1946), 1978, Nov-17, Volume: 103, Issue:46

    Topics: Aged; Azathioprine; Chloroquine; Cyclophosphamide; Diagnosis, Differential; Female; Glucocorticoids;

1978
Treatment of lupus nephritis.
    Advances in nephrology from the Necker Hospital, 1976, Volume: 6

    Topics: Adrenal Cortex Hormones; Adult; Animals; Antibody Formation; Azathioprine; Chlorambucil; Cyclophosph

1976
Systemic lupus erythematosus within the first two decades of life.
    The American journal of medicine, 1977, Volume: 62, Issue:1

    Topics: Adolescent; Azathioprine; Central Nervous System Diseases; Child; Child, Preschool; Female; Follow-U

1977
Current concepts in management of lupus nephritis.
    Hospital practice, 1977, Volume: 12, Issue:5

    Topics: Animals; Azathioprine; Cyclophosphamide; Humans; Kidney Glomerulus; Lupus Erythematosus, Systemic; M

1977
[Prednisone and azathioprine therapy in systemic lupus erythematosus nephropathy (author's transl)].
    Lijecnicki vjesnik, 1977, Volume: 99, Issue:4

    Topics: Azathioprine; Drug Synergism; Humans; Kidney Diseases; Lupus Erythematosus, Systemic; Prednisone

1977
Treatment of lupus nephritis.
    Nephron, 1977, Volume: 19, Issue:4

    Topics: Adrenal Cortex Hormones; Azathioprine; Cyclophosphamide; Humans; Immunosuppressive Agents; Lupus Ery

1977
[Objective evaluation of remote results of treatment of systemic lupus erythematosus].
    Terapevticheskii arkhiv, 1977, Volume: 49, Issue:9

    Topics: Adolescent; Adult; Azathioprine; Drug Evaluation; Drug Therapy, Combination; Female; Follow-Up Studi

1977
The prognosis of childhood systemic lupus erythematosus.
    American journal of diseases of children (1960), 1976, Volume: 130, Issue:9

    Topics: Adolescent; Antimetabolites; Azathioprine; Child; Child, Preschool; Chloroquine; Female; Humans; Inf

1976
[Iatrogenic causes of death in systemic lupus erythematosus].
    Revista clinica espanola, 1976, Aug-15, Volume: 142, Issue:3

    Topics: Adult; Azathioprine; Drug Therapy, Combination; Female; Humans; Iatrogenic Disease; Lupus Erythemato

1976
The treatment of connective tissue diseases with antilymphocyte globulin.
    Postgraduate medical journal, 1976, Volume: 52, Issue:5 Suppl

    Topics: Aged; Antilymphocyte Serum; Azathioprine; Collagen Diseases; Dermatomyositis; Drug Therapy, Combinat

1976
Isolation, biochemical characteristics, and biological activity of a circulating thymic hormone in the mouse and in the human.
    Annals of the New York Academy of Sciences, 1975, Feb-28, Volume: 249

    Topics: Aging; Animals; Antilymphocyte Serum; Arthritis, Rheumatoid; Autoantibodies; Azathioprine; Cell-Free

1975
[Haemodialysis for renal failure in a case of systemic lupus erythematosus (author's transl)].
    Deutsche medizinische Wochenschrift (1946), 1975, Jun-13, Volume: 100, Issue:24

    Topics: Acute Kidney Injury; Adult; Antibodies, Antinuclear; Anuria; Azathioprine; Blood Urea Nitrogen; Comp

1975
[Effect of combined immunosuppressive treatment with Imuran and prednisone on the concentration of selected immune proteins in the serum of patients with lupus erythematosus].
    Polski tygodnik lekarski (Warsaw, Poland : 1960), 1976, May-19, Volume: 31, Issue:16

    Topics: alpha 1-Antitrypsin; Azathioprine; Complement C3; Complement System Proteins; Drug Therapy, Combinat

1976
Central nervous system disease in systemic lupus erythematosus. Therapy and prognosis.
    The American journal of medicine, 1975, Volume: 58, Issue:5

    Topics: Adolescent; Adult; Azathioprine; Central Nervous System Diseases; Female; Humans; Lupus Erythematosu

1975
Clinical features of chorea associated with systemic lupus erythematosus.
    The American journal of medicine, 1975, Volume: 58, Issue:6

    Topics: Adult; Azathioprine; Blood Sedimentation; Chlorpromazine; Chorea; Female; Haloperidol; Humans; Lupus

1975
Editorials: Immunosuppressive therapy in lupus erythematosus.
    Annals of internal medicine, 1975, Volume: 83, Issue:5

    Topics: Azathioprine; Cyclophosphamide; Humans; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Nep

1975
Clinical conference: lupus erythematosus.
    Archives of internal medicine, 1975, Volume: 135, Issue:12

    Topics: Adult; Anticonvulsants; Azathioprine; Central Nervous System Diseases; Cyclophosphamide; Female; Hum

1975
Blastic transformation of lymphocytes in in vitro cultures during immunosuppressive therapy in patients with glomerulonephritis.
    Archivum immunologiae et therapiae experimentalis, 1975, Volume: 23, Issue:3

    Topics: Adolescent; Adult; Azathioprine; Chronic Disease; Cyclophosphamide; Female; Glomerulonephritis; Huma

1975
[Differential indications in rheumatism therapy on the basis of well-known drug side effects].
    Acta medica Austriaca, 1975, Volume: 2, Issue:4

    Topics: Arthritis, Rheumatoid; Azathioprine; Chloroquine; Glucocorticoids; Gold; Humans; Lupus Erythematosus

1975
Strategy for lupus nephritis.
    Proceedings of the Clinical Dialysis and Transplant Forum, 1975, Volume: 5

    Topics: Azathioprine; Biopsy; Cyclophosphamide; Drug Therapy, Combination; Humans; Kidney; Lupus Erythematos

1975
Prognostic indices in lupus nephritis.
    Medicine, 1976, Volume: 55, Issue:2

    Topics: Adolescent; Adult; Azathioprine; Child; Female; Humans; Immunosuppression Therapy; Kidney; Lupus Ery

1976
Letter: Treatment of lupus erythematosus.
    Annals of internal medicine, 1976, Volume: 84, Issue:3

    Topics: Azathioprine; Cyclophosphamide; Drug Therapy, Combination; Humans; Lupus Erythematosus, Systemic; Ne

1976
Letter: Immunosuppressive drugs in lupus nephritis.
    Annals of internal medicine, 1976, Volume: 84, Issue:4

    Topics: Azathioprine; Humans; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Prednisone

1976
Editorial: Immunosuppressive therapy in SLE-a reappraisal.
    British medical journal, 1976, Apr-10, Volume: 1, Issue:6014

    Topics: Azathioprine; Cyclophosphamide; Humans; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Pre

1976
Long-term azathioprine-corticosteroid therapy in lupus nephritis and idiopathic nephrotic syndrome.
    Journal of chronic diseases, 1976, Volume: 29, Issue:3

    Topics: Adolescent; Adrenal Cortex Hormones; Adult; Azathioprine; Child; Drug Administration Schedule; Femal

1976
Thrombokinetics in systemic lupus erythematosus A preliminary report.
    Pahlavi medical journal, 1976, Volume: 7, Issue:2

    Topics: Adult; Aged; Azathioprine; Blood Cell Count; Blood Platelets; Cell Survival; Female; Glucocorticoids

1976
Letter: Lupus erythematosus: immunosuppressive therapy.
    Annals of internal medicine, 1976, Volume: 84, Issue:5

    Topics: Adrenal Cortex Hormones; Azathioprine; Drug Therapy, Combination; Humans; Lupus Erythematosus, Syste

1976
[Systemic lupus erythematosus in puerperium].
    Zentralblatt fur Gynakologie, 1992, Volume: 114, Issue:12

    Topics: Adult; Autoantibodies; Azathioprine; Blood Component Removal; Cyclophosphamide; Diagnosis, Different

1992
Crescentic glomerulonephritis in children.
    Pediatric nephrology (Berlin, Germany), 1992, Volume: 6, Issue:3

    Topics: Adolescent; Adrenal Cortex Hormones; Anticoagulants; Azathioprine; Child; Child, Preschool; Cyclopho

1992
Exocrine pancreatic function in children with systemic lupus erythematosus.
    The Journal of rheumatology, 1992, Volume: 19, Issue:6

    Topics: Adolescent; Adult; Azathioprine; Biomarkers; Child; Female; Humans; Lupus Erythematosus, Systemic; M

1992
Systemic lupus erythematosus presenting with myelofibrosis.
    The Journal of rheumatology, 1992, Volume: 19, Issue:8

    Topics: Adrenal Cortex Hormones; Adult; Azathioprine; Biopsy; Bone Marrow; Diagnosis, Differential; Dose-Res

1992
Magnetic resonance imaging findings in lupus ataxia.
    Acta neurologica Scandinavica, 1992, Volume: 86, Issue:4

    Topics: Azathioprine; Cerebellar Ataxia; Cerebellum; Drug Therapy, Combination; Female; Functional Lateralit

1992
Acute nonlymphocytic leukemia after treatment of systemic lupus erythematosus with immunosuppressive agents.
    The Journal of rheumatology, 1992, Volume: 19, Issue:10

    Topics: Adult; Azathioprine; Chromosomes, Human, Pair 16; Cyclophosphamide; Female; Humans; Immunosuppressiv

1992
Extracorporeal photochemotherapy and the psychological effects of new procedures.
    Arthritis and rheumatism, 1992, Volume: 35, Issue:12

    Topics: Azathioprine; Humans; Lupus Erythematosus, Systemic; Photochemotherapy

1992
Neuropsychiatric systemic lupus erythematosus in elderly people: a case series.
    Journal of neurology, neurosurgery, and psychiatry, 1992, Volume: 55, Issue:12

    Topics: Aged; Aged, 80 and over; Azathioprine; Confusion; Dementia; Diagnosis, Differential; Drug Therapy, C

1992
[Blood purification therapy of systemic lupus erythematosus].
    Nihon rinsho. Japanese journal of clinical medicine, 1992, Volume: 50 Suppl

    Topics: Adult; Azathioprine; Cyclophosphamide; Female; Humans; Leukapheresis; Lupus Erythematosus, Systemic;

1992
[Cryptococcal meningoencephalitis following immunosuppressive therapy].
    Zeitschrift fur arztliche Fortbildung, 1992, May-11, Volume: 86, Issue:9

    Topics: Adult; Azathioprine; Brain; Cryptococcus neoformans; Female; Humans; Immune Tolerance; Lupus Erythem

1992
Antiphospholipid antibody syndrome of systemic lupus erythematosus presenting as deep vein thrombosis.
    The Journal of the Association of Physicians of India, 1992, Volume: 40, Issue:2

    Topics: Adolescent; Adrenal Cortex Hormones; Anticoagulants; Antiphospholipid Syndrome; Azathioprine; Female

1992
Systemic lupus erythematosus in pregnancy.
    Lancet (London, England), 1991, Jul-13, Volume: 338, Issue:8759

    Topics: Antibodies, Anti-Idiotypic; Azathioprine; Female; Humans; Infant, Newborn; Lupus Erythematosus, Syst

1991
Cryptococcal meningitis in a child with systemic lupus erythematosus.
    Annals of tropical paediatrics, 1990, Volume: 10, Issue:3

    Topics: Amphotericin B; Azathioprine; Cerebrospinal Fluid; Child; Cryptococcosis; Diagnosis, Differential; F

1990
[Lupus myopathy refractory to steroid treatment].
    Anales de medicina interna (Madrid, Spain : 1984), 1991, Volume: 8, Issue:10

    Topics: Azathioprine; Biopsy; Drug Resistance; Female; Humans; Lupus Erythematosus, Systemic; Middle Aged; M

1991
Salmonella arizona arthritis and septicemia associated with rattlesnake ingestion by patients with connective tissue diseases. A dangerous complication of folk medicine.
    The Journal of rheumatology, 1991, Volume: 18, Issue:9

    Topics: Adolescent; Adult; Animals; Arthritis, Infectious; Azathioprine; Connective Tissue Diseases; Drug Th

1991
Study of DNA repair in the peripheral blood lymphocytes of patients with rheumatic diseases under going treatment.
    Advances in experimental medicine and biology, 1991, Volume: 309A

    Topics: Adolescent; Adult; Arthritis, Rheumatoid; Azathioprine; DNA Repair; Humans; Lupus Erythematosus, Sys

1991
[T-helper cell subsets in patients with inflammatory rheumatic diseases undergoing immunosuppressive therapy].
    Immunitat und Infektion, 1991, Volume: 19, Issue:1

    Topics: Antineoplastic Agents; Arthritis, Rheumatoid; Azathioprine; Cyclophosphamide; Flow Cytometry; Humans

1991
Brown-Séquard and SLE.
    Neurology, 1991, Volume: 41, Issue:5

    Topics: Aged; Azathioprine; Female; Humans; Lupus Erythematosus, Systemic; Prednisolone; Spinal Cord Injurie

1991
Chronic lupus peritonitis with ascites.
    Annals of the rheumatic diseases, 1991, Volume: 50, Issue:3

    Topics: Adult; Ascites; Azathioprine; Chronic Disease; Drug Therapy, Combination; Female; Humans; Lupus Eryt

1991
[Bronchoalveolar lavage in patients with systemic scleroderma and systemic lupus erythematosus: characterization of cell activity by cytofluorometry, chemiluminescence and differential cell count].
    Zeitschrift fur Erkrankungen der Atmungsorgane, 1991, Volume: 176, Issue:1

    Topics: Adult; Azathioprine; B-Lymphocyte Subsets; Bronchoalveolar Lavage Fluid; Female; Flow Cytometry; Hum

1991
Renal transplantation in patients with systemic lupus erythematosus: increased risk of early graft loss.
    Scandinavian journal of urology and nephrology, 1990, Volume: 24, Issue:4

    Topics: Adolescent; Adult; Azathioprine; Cyclosporins; Female; Follow-Up Studies; Graft Rejection; Graft Sur

1990
Pancytopenia in systemic lupus erythematosus related to azathioprine.
    Journal of internal medicine, 1990, Volume: 227, Issue:1

    Topics: Adult; Azathioprine; Female; Humans; Lupus Erythematosus, Systemic; Pancytopenia

1990
Annular pustular psoriasis and systemic lupus erythematosus.
    International journal of dermatology, 1990, Volume: 29, Issue:4

    Topics: Adult; Azathioprine; Female; Humans; Lupus Erythematosus, Systemic; Prednisone; Psoriasis

1990
[Systemic lupus erythematosus and pregnancy. Clinical aspects, serology and management].
    Geburtshilfe und Frauenheilkunde, 1990, Volume: 50, Issue:7

    Topics: Antibodies, Antinuclear; Azathioprine; Female; Fetal Death; Humans; Infant, Newborn; Lupus Erythemat

1990
[Reactivation of the alpha 1-fetoprotein synthesis in systemic lupus erythematosus].
    Zeitschrift fur Hautkrankheiten, 1985, Jun-01, Volume: 60, Issue:11

    Topics: Alanine Transaminase; alpha-Fetoproteins; Antibodies; Arthritis, Rheumatoid; Aspartate Aminotransfer

1985
Multiple lesions of molluscum contagiosum with metaplastic ossification.
    The American Journal of dermatopathology, 1989, Volume: 11, Issue:3

    Topics: Adult; Azathioprine; Female; Humans; Lupus Erythematosus, Systemic; Metaplasia; Methylprednisolone;

1989
Murine chronic graft-versus-host disease as a model of systemic lupus erythematosus: effect of immunosuppressive drugs on disease development.
    Clinical and experimental immunology, 1989, Volume: 78, Issue:3

    Topics: Animals; Azathioprine; Cyclophosphamide; Cyclosporins; Deoxyguanosine; Dexamethasone; Disease Models

1989
Lupus pneumonitis and anti-SSA(Ro) antibodies.
    The Journal of rheumatology, 1989, Volume: 16, Issue:4

    Topics: Adolescent; Adult; Antibodies, Antinuclear; Azathioprine; Cyclophosphamide; Female; Fluorescent Anti

1989
[Systemic lupus erythematosus and end-stage chronic renal insufficiency. Therapeutic perspectives].
    Medicina clinica, 1989, Apr-22, Volume: 92, Issue:15

    Topics: Adrenal Cortex Hormones; Azathioprine; Cyclophosphamide; Humans; Immunosuppressive Agents; Kidney Fa

1989
[Immunodepressive agents in neurology].
    La Revue du praticien, 1986, Jan-21, Volume: 36, Issue:5

    Topics: Adrenal Cortex Hormones; Antilymphocyte Serum; Azathioprine; Cyclophosphamide; Dermatomyositis; Huma

1986
Endometrial carcinoma following chronic anovulation in a premenopausal woman with systemic lupus erythematosus.
    Acta obstetricia et gynecologica Scandinavica, 1988, Volume: 67, Issue:6

    Topics: Adenocarcinoma; Adult; Anovulation; Azathioprine; Endometrium; Female; Humans; Hyperplasia; Lupus Er

1988
Bullous eruption in a woman with lupus erythematosus. Bullous systemic lupus erythematosus (SLE)
    Archives of dermatology, 1988, Volume: 124, Issue:4

    Topics: Adult; Azathioprine; Dapsone; Drug Therapy, Combination; Female; Fluorescent Antibody Technique; Hum

1988
Danazol for the treatment of refractory autoimmune thrombocytopenia in systemic lupus erythematosus.
    Annals of internal medicine, 1988, Volume: 108, Issue:5

    Topics: Adult; Aged; Antigen-Antibody Complex; Autoimmune Diseases; Azathioprine; Blood Platelets; Combined

1988
Malignant transformation during immunosuppressive therapy (azathioprine) of rheumatoid arthritis and systemic lupus erythematosus. A retrospective study.
    Scandinavian journal of rheumatology. Supplement, 1987, Volume: 67

    Topics: Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Azathioprine; Cell Transformation, Neoplastic

1987
Clonality of the spontaneous immune response to DNA in murine lupus.
    Journal of clinical & laboratory immunology, 1986, Volume: 20, Issue:2

    Topics: Animals; Antibodies, Antinuclear; Antibody Formation; Azathioprine; Clone Cells; Cyclophosphamide; D

1986
[Plasma exchange therapy in children and adolescents with systemic lupus erythematosus (SLE)].
    Monatsschrift Kinderheilkunde : Organ der Deutschen Gesellschaft fur Kinderheilkunde, 1987, Volume: 135, Issue:1

    Topics: Adolescent; Antibodies, Antinuclear; Azathioprine; Child; Combined Modality Therapy; Cyclophosphamid

1987
Pregnancy among patients with systemic lupus erythematosus receiving immunosuppressive therapy.
    The Journal of rheumatology, 1987, Volume: 14, Issue:2

    Topics: Azathioprine; Creatine; Female; Fertilization; Humans; Immunosuppression Therapy; Lupus Erythematosu

1987
Lupus catatonia: a case report.
    Pharmatherapeutica, 1987, Volume: 5, Issue:2

    Topics: Adult; Azathioprine; Catatonia; Electroencephalography; Female; Humans; Lupus Erythematosus, Systemi

1987
Cerebral vasculopathy: an analysis of sixteen cases.
    Seminars in arthritis and rheumatism, 1986, Volume: 15, Issue:4

    Topics: Adrenal Cortex Hormones; Adult; Aged; Azathioprine; Blood Sedimentation; Cerebral Angiography; Cereb

1986
Total lymphoid irradiation in refractory systemic lupus erythematosus.
    Annals of internal medicine, 1986, Volume: 105, Issue:1

    Topics: Adult; Azathioprine; Drug Resistance; Female; Humans; Immunosuppression Therapy; Lupus Erythematosus

1986
Treatment of intractable lupus nephritis with total lymphoid irradiation.
    Annals of internal medicine, 1985, Volume: 102, Issue:4

    Topics: Adult; Antibodies, Antinuclear; Azathioprine; Combined Modality Therapy; DNA; Female; Glomerulonephr

1985
Pathogenic role of anti-DNA antibodies in murine lupus nephritis.
    Journal of clinical & laboratory immunology, 1985, Volume: 18, Issue:3

    Topics: Animals; Antibodies, Antinuclear; Antigen-Antibody Complex; Azathioprine; Cyclophosphamide; DNA; DNA

1985
A renal biopsy study of lupus nephropathy in the United States and Korea.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 1985, Volume: 5, Issue:5

    Topics: Adolescent; Adult; Aged; Asian People; Azathioprine; Biopsy; Black People; Child; Female; Fluorescen

1985
Livedoid vasculitis and central nervous system involvement in systemic lupus erythematosus.
    Archives of dermatology, 1986, Volume: 122, Issue:1

    Topics: Adult; Azathioprine; Betamethasone; Blood Vessels; Central Nervous System Diseases; Cyclophosphamide

1986
Psychogenic unresponsiveness in a patient with lupus cerebritis.
    Southern medical journal, 1986, Volume: 79, Issue:2

    Topics: Adult; Azathioprine; Coma; Drug Therapy, Combination; Encephalitis; Humans; Lupus Erythematosus, Sys

1986
Splenectomy does not cure the thrombocytopenia of systemic lupus erythematosus.
    Annals of internal medicine, 1985, Volume: 102, Issue:3

    Topics: Adult; Aged; Autoimmune Diseases; Azathioprine; Female; Humans; Immunosuppressive Agents; Lupus Eryt

1985
Influence of avidity of circulating anti-DNA antibodies on murine lupus nephritis.
    Journal of clinical & laboratory immunology, 1985, Volume: 16, Issue:4

    Topics: Animals; Antibody Affinity; Autoantibodies; Azathioprine; Cyclophosphamide; DNA; Female; Immunosuppr

1985
Successful treatment of generalized discoid skin lesions with azathioprine. Its use in a patient with systemic lupus erythematosus.
    Archives of dermatology, 1985, Volume: 121, Issue:10

    Topics: Adult; Azathioprine; Female; Humans; Lupus Erythematosus, Discoid; Lupus Erythematosus, Systemic; Sy

1985
[Circulating immune complexes, immunoglobulins and phagocytic activity of neutrophils in the evaluation of the activity and effectiveness of treatment of systemic lupus erythematosus].
    Terapevticheskii arkhiv, 1985, Volume: 57, Issue:8

    Topics: Antigen-Antibody Complex; Azathioprine; Cyclophosphamide; Dipyridamole; Follow-Up Studies; Heparin;

1985
Association of glycoprotein gp70 with progression or attenuation of murine lupus nephritis.
    Journal of clinical & laboratory immunology, 1985, Volume: 18, Issue:2

    Topics: Animals; Antigen-Antibody Complex; Azathioprine; Cyclophosphamide; Female; Glomerulonephritis; Glyco

1985
Treatment of lupus nephritis with cyclophosphamide.
    Lancet (London, England), 1970, Oct-24, Volume: 2, Issue:7678

    Topics: Adolescent; Adult; Age Factors; Azathioprine; Biopsy; Chlorambucil; Cortisone; Cyclophosphamide; Fem

1970
Systemic lupus erythematosus with fibrosing alveolitis.
    Proceedings of the Royal Society of Medicine, 1971, Volume: 64, Issue:1

    Topics: Azathioprine; Humans; Lupus Erythematosus, Systemic; Male; Neutrophils; Prednisolone; Pulmonary Fibr

1971
The effect of azathioprine on lupus glomerulonephritis.
    Medicine, 1972, Volume: 51, Issue:5

    Topics: Adolescent; Adult; Antibodies, Antinuclear; Azathioprine; Biopsy; Blood Proteins; Blood Urea Nitroge

1972
[Recommendations for immunosuppressive therapy in systemic lupus erythematosus].
    Monatsschrift fur Kinderheilkunde, 1972, Volume: 120, Issue:6

    Topics: Adrenocorticotropic Hormone; Antibodies, Antinuclear; Arthritis, Juvenile; Azathioprine; Bone Marrow

1972
Azathioprine in systemic lupus erythematosus.
    Lancet (London, England), 1973, Mar-31, Volume: 1, Issue:7805

    Topics: Acute Disease; Adrenal Cortex Hormones; Adult; Age Factors; Antimetabolites; Azathioprine; Humans; K

1973
Immunopathological changes during immunosuppressive treatment of glomerulonephritis in systemic lupus erythematosus.
    Acta medica Scandinavica, 1974, Volume: 196, Issue:4

    Topics: Adult; Animals; Antibodies; Antigens; Azathioprine; Biopsy; Complement System Proteins; Drug Therapy

1974
[Complications of immunosuppressive therapy using cytostatics in autoaggression diseases with special reference to cholestatic hepatosis].
    Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete, 1973, Jun-01, Volume: 28, Issue:11

    Topics: Adrenal Cortex Hormones; Autoimmune Diseases; Azathioprine; Chemical and Drug Induced Liver Injury;

1973
[Immunosuppressive agents].
    Revue medicale de Liege, 1974, Feb-15, Volume: 29, Issue:4

    Topics: Adrenal Cortex Hormones; Alkylating Agents; Anemia, Hemolytic, Autoimmune; Antibodies; Azathioprine;

1974
[Effects of immunosuppressive agents on renal and other changes in (NZBX NZW)F1 hybrid New Zealand mice].
    Ryumachi. [Rheumatism], 1974, Volume: 14, Issue:1

    Topics: Animals; Azathioprine; Cyclophosphamide; Dexamethasone; Immunosuppressive Agents; Kidney Diseases; L

1974
[DNA-synthesizing lymphocytes in the blood of patients with disseminated lupus erythematosus, rheumatoid arthritis, and panarteritis nodosa (author's transl)].
    Wiener klinische Wochenschrift, 1973, Feb-09, Volume: 85, Issue:6

    Topics: Adult; Aged; Arthritis, Rheumatoid; Azathioprine; Chloroquine; DNA; Female; Gold; Humans; Indomethac

1973
Treatment of collagen diseases with cytostatics.
    Lancet (London, England), 1965, Sep-18, Volume: 2, Issue:7412

    Topics: Adrenal Cortex Hormones; Adult; Aged; Anemia, Hemolytic, Autoimmune; Arthritis, Rheumatoid; Asthma;

1965
Treatment of rheumatoid arthritis with immunosuppressive drugs. I. Clinical study.
    Acta rheumatologica Scandinavica, 1965, Volume: 11, Issue:3

    Topics: Arthritis, Rheumatoid; Azathioprine; Blood Sedimentation; Dactinomycin; Humans; Immunosuppressive Ag

1965
[Rheumatoid arthritis treated by administration of imuran and actinomycin-c].
    Archives of interamerican rheumatology : A.I.R, 1965, Volume: 8, Issue:4

    Topics: Adult; Aged; Arthritis, Rheumatoid; Azathioprine; Dactinomycin; Female; Humans; Lupus Erythematosus,

1965
Systemic lupus erythematosus and multiple sclerosis in identical twins.
    Archives of internal medicine, 1967, Volume: 119, Issue:3

    Topics: Adult; Azathioprine; Diseases in Twins; Female; gamma-Globulins; Humans; Hydrocortisone; Immunoassay

1967
Immunosuppressive therapy. The relation between clinical response and immunologic competence.
    The New England journal of medicine, 1967, Jul-27, Volume: 277, Issue:4

    Topics: Adolescent; Adult; Anemia, Hemolytic, Autoimmune; Antibody Formation; Azathioprine; Chronic Disease;

1967
Treatment of systemic lupus erythematosus (SLE) with immunosuppressive drugs 1: An analysis of immunologic data.
    Helvetica medica acta, 1967, Volume: 34, Issue:1

    Topics: Adult; Aged; Antibodies, Antinuclear; Antibody Formation; Autoantibodies; Autoimmune Diseases; Azath

1967
Chronic hepatitis: effect of prolonged suppressive treatment and comparison of azathioprine with prednisolone.
    The Quarterly journal of medicine, 1968, Volume: 37, Issue:147

    Topics: Adolescent; Adult; Autoimmune Diseases; Azathioprine; Female; gamma-Globulins; Hepatitis; Humans; Im

1968
The coagulation abnormalities in systemic lupus erythematosus.
    Thrombosis et diathesis haemorrhagica, 1968, Dec-31, Volume: 20, Issue:3

    Topics: Antibodies; Anticoagulants; Azathioprine; Blood Cell Count; Blood Coagulation Disorders; Blood Coagu

1968
[Immunopathological examinations in lupus erythematodes disseminatus (subacutus and acutus)].
    Archiv fur klinische und experimentelle Dermatologie, 1968, Volume: 233, Issue:2

    Topics: Acute Disease; Adrenal Cortex Hormones; Azathioprine; Fluorescent Antibody Technique; gamma-Globulin

1968
[On the effect of azathioprine on the course of 3 cases of lupoid hepatitis].
    Verhandlungen der Deutschen Gesellschaft fur Innere Medizin, 1968, Volume: 74

    Topics: Adolescent; Adult; Azathioprine; Chronic Disease; Female; Hepatitis; Humans; Lupus Erythematosus, Sy

1968
Generalized cytomegalovirus infection in a patient with lupoid hepatitis.
    Australasian annals of medicine, 1969, Volume: 18, Issue:2

    Topics: Adult; Autoantibodies; Azathioprine; Cytomegalovirus Infections; Edema; Esophagus; Female; Hemorrhag

1969
Diagnostic aspects of lupus erythematosus cells and antinuclear factors in disease states.
    Mayo Clinic proceedings, 1969, Volume: 44, Issue:9

    Topics: Antibodies, Antinuclear; Arthritis, Rheumatoid; Autoantibodies; Azathioprine; Fluorescent Antibody T

1969
[Immunosuppressive long term therapy of visceral lupus erythematosus].
    Deutsche medizinische Wochenschrift (1946), 1970, Aug-28, Volume: 95, Issue:35

    Topics: Adult; Amides; Antibodies, Antinuclear; Azathioprine; Dactinomycin; Female; Fluorescent Antibody Tec

1970
Plasma C3 and C4 concentrations in management of glomerulonephritis.
    British medical journal, 1973, Sep-29, Volume: 3, Issue:5882

    Topics: Antibodies, Antinuclear; Azathioprine; Biopsy; Complement System Proteins; Glomerulonephritis; Human

1973
[Meningitis due to Listeria monocytogenes. Presentation of a case and literature review].
    L'union medicale du Canada, 1973, Volume: 103, Issue:8

    Topics: Adult; Amphotericin B; Ampicillin; Azathioprine; Cephaloridine; Cyclophosphamide; Female; Humans; Is

1973
[Detection of antibodies to soluble nucleoprotein and to deoxyribonucleic acid using a radioimmunologic method].
    L'union medicale du Canada, 1974, Volume: 103, Issue:4

    Topics: Antibodies; Antibodies, Antinuclear; Arthritis, Rheumatoid; Azathioprine; Collagen Diseases; Dermato

1974
Lupus nephritis: long-term follow-up.
    Perspectives in nephrology and hypertension, 1973, Volume: 1 Pt 2, Issue:0

    Topics: Adolescent; Adrenal Cortex Hormones; Adult; Azathioprine; Child; Complement System Proteins; Cycloph

1973
Disseminated toxoplasmosis in the compromised host. A report of five cases.
    Archives of internal medicine, 1974, Volume: 134, Issue:6

    Topics: Adult; Aged; Anemia, Hemolytic, Autoimmune; Autopsy; Azathioprine; Brain; Breast Neoplasms; Female;

1974
Preliminary results of azathioprine treatment in severe rheumatic disease.
    Annals of physical medicine, 1969, Volume: 10, Issue:3

    Topics: Adrenocorticotropic Hormone; Adult; Aged; Arthritis; Arthritis, Rheumatoid; Azathioprine; Blood Cell

1969
[Treatment of systemic lupus erythematosus with immunosupressive agents. Results of our experience and review of the literature].
    La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris, 1971, Feb-08, Volume: 47, Issue:7

    Topics: Adult; Aged; Animals; Azathioprine; Chlorambucil; Female; Humans; Immunosuppressive Agents; Lupus Er

1971
Skin grafting in systemic lupus erythematosus patients who are on steroids.
    Plastic and reconstructive surgery, 1972, Volume: 50, Issue:4

    Topics: Adult; Azathioprine; Chlorothiazide; Debridement; Female; Guanethidine; Humans; Leg Injuries; Lupus

1972
[Prerequisites and first results of the therapeutic use of azathioprine (imuran) in chronic progressive rheumatic arthritis and in so-called collagen diseases].
    Die Medizinische Welt, 1967, Jan-21, Volume: 3

    Topics: Adult; Arthritis, Rheumatoid; Azathioprine; Female; Humans; Lupus Erythematosus, Systemic; Male; Mid

1967
[Current problems of immunology and immunosuppressive therapy in rheumatic diseases].
    La Clinica terapeutica, 1967, Jul-15, Volume: 42, Issue:1

    Topics: Antibodies; Arthritis, Rheumatoid; Azathioprine; Humans; Immunoglobulin G; Lupus Erythematosus, Syst

1967
[Theoretical basis of immunosuppression in autoimmune diseases].
    Dermatologische Monatschrift, 1972, Volume: 158, Issue:8

    Topics: Antigens; Autoimmune Diseases; Azathioprine; Drug Synergism; Glucocorticoids; Humans; Immune Toleran

1972
Relative macrocytosis in cyclophosphamide and azathioprine therapy.
    JAMA, 1974, Jul-08, Volume: 229, Issue:2

    Topics: Anemia, Macrocytic; Arthritis, Rheumatoid; Azathioprine; Bone Marrow Examination; Cyclophosphamide;

1974
Acute renal failure in systemic lupus erythematosus.
    British medical journal, 1974, Sep-21, Volume: 3, Issue:5933

    Topics: Acute Kidney Injury; Adult; Azathioprine; Biopsy; Creatinine; Cyclophosphamide; Female; Furosemide;

1974
Kaposi Sarcoma complicating systemic lupus erythematosus treated with immunosuppression.
    Archives of dermatology, 1974, Volume: 110, Issue:4

    Topics: Adult; Azathioprine; Biopsy; Female; Fingers; Humans; Immunosuppressive Agents; Lupus Erythematosus,

1974
[Combined immunosuppressive treatment of systemic lupus erythematosus].
    Polskie Archiwum Medycyny Wewnetrznej, 1974, Volume: 52, Issue:3

    Topics: Adolescent; Adrenal Cortex Hormones; Adult; Azathioprine; Cyclophosphamide; Drug Evaluation; Drug Th

1974
Lupus nephritis: response to azathioprine.
    Proceedings of the Royal Society of Medicine, 1974, Volume: 67, Issue:8

    Topics: Adolescent; Azathioprine; Edema; Female; Glomerular Filtration Rate; Glomerulonephritis; Hematuria;

1974
A vascular necrosis of the femoral head in childhood systemic lupus erythematosus.
    Canadian Medical Association journal, 1974, Oct-19, Volume: 111, Issue:8

    Topics: Adolescent; Azathioprine; Child; Corticosterone; Female; Femur Head; Femur Head Necrosis; Glomerulon

1974
Brain scan findings in central nervous system involvement by lupus erythematosus.
    Annals of internal medicine, 1974, Volume: 81, Issue:6

    Topics: Adolescent; Adult; Azathioprine; Brain Diseases; Evaluation Studies as Topic; Female; Humans; Lupus

1974
[Antimetabolites in complex treatment of systemic lupus erythematosus in children].
    Pediatriia, 1974, Issue:11

    Topics: Adolescent; Antimetabolites; Azathioprine; Child; Child, Preschool; Drug Therapy, Combination; Femal

1974
[Indications for immunosuppressive agents in glomerular nephropathies].
    Annales de medecine interne, 1974, Volume: 125, Issue:11

    Topics: Adrenal Cortex Hormones; Anti-Glomerular Basement Membrane Disease; Azathioprine; Chlorambucil; Cycl

1974
Treatment of lupus nephritis.
    Proceedings of the Clinical Dialysis and Transplant Forum, 1974, Issue:4

    Topics: Adrenal Cortex Hormones; Animals; Antineoplastic Agents; Azathioprine; Cyclophosphamide; Hip; Humans

1974
Platelet survival and sequestration patterns in thrombocytopenic disorders.
    Radiology, 1972, Volume: 102, Issue:1

    Topics: Adult; Aged; Azathioprine; Blood Platelets; Cell Survival; Chloramphenicol; Chromium Isotopes; Dexam

1972
Azathioprine administration to NZB X NZW hybrid mice with lupus nephritis: beneficial effect complicated by development of malignant lymphomas.
    The New Zealand medical journal, 1973, Oct-10, Volume: 79, Issue:500

    Topics: Animals; Autoantibodies; Autoimmune Diseases; Azathioprine; Body Weight; Female; Hodgkin Disease; Ki

1973
A sequential trial comparing cyclophosphamide and azathioprine as adjuncts in the treatment of systemic lupus erythematosus.
    Australian and New Zealand journal of medicine, 1974, Volume: 4, Issue:2

    Topics: Azathioprine; Cyclophosphamide; Drug Therapy, Combination; Female; Hospitalization; Humans; Lupus Er

1974
Pattern recognition in medicine--a place for the use of principal component analysis and factor analysis.
    Australian and New Zealand journal of medicine, 1974, Volume: 4, Issue:5

    Topics: Azathioprine; Body Height; Body Weight; Child; Computers; Cyclophosphamide; Diagnosis, Differential;

1974
[Immunosuppressive therapy in systemic lupus erythematosus].
    Monatsschrift fur Kinderheilkunde, 1972, Volume: 120, Issue:6

    Topics: Antibodies, Antinuclear; Autoantibodies; Azathioprine; Child; Collagen Diseases; Cyclophosphamide; E

1972
Presence of hepatitis-associated antigen in systemic lupus erythematosus.
    Clinical and experimental immunology, 1972, Volume: 12, Issue:1

    Topics: Adrenal Cortex Hormones; Agammaglobulinemia; Antibodies, Antinuclear; Azathioprine; Bacterial Infect

1972
[Course of nephropathy in systemic lupus erythematosus . Influence of the treatment on clinical symptoms, renal function and histology].
    Journal d'urologie et de nephrologie, 1972, Volume: 78, Issue:12

    Topics: Adolescent; Adult; Aged; Antibodies, Antinuclear; Antimalarials; Azathioprine; Biopsy; Chlorambucil;

1972
The complement system in renal homograft recipents.
    Surgery, 1972, Volume: 72, Issue:4

    Topics: Adolescent; Adult; Antilymphocyte Serum; Azathioprine; Child; Complement System Proteins; Graft Reje

1972
Results of outpatient treatment of 100 cases of systemic lupus erythematosus.
    Polish medical journal, 1972, Volume: 11, Issue:2

    Topics: Adolescent; Adult; Aged; Antibodies, Antinuclear; Azathioprine; Female; Fluorescent Antibody Techniq

1972
Treatment of lupus nephritis with prednisone and combined prednisone and azathioprine.
    Annals of internal medicine, 1972, Volume: 77, Issue:6

    Topics: Adolescent; Adult; Aged; Antibodies, Antinuclear; Azathioprine; Biopsy; Complement Fixation Tests; C

1972
Azathioprine.
    Annals of internal medicine, 1973, Volume: 79, Issue:5

    Topics: Arthritis, Rheumatoid; Asthma; Autoimmune Diseases; Azathioprine; Colitis, Ulcerative; Glomeruloneph

1973
Surgical treatment of Staphylococcus aureus endarteritis in a hemodialysis arteriovenous fistula.
    Archives of surgery (Chicago, Ill. : 1960), 1974, Volume: 108, Issue:5

    Topics: Adrenal Cortex Hormones; Adult; Arteriovenous Shunt, Surgical; Azathioprine; Cadaver; Cephalexin; Cl

1974
[Immunosuppressive long-term therapy of autoimmune diseases in hematology].
    Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete, 1972, Jun-01, Volume: 27, Issue:11

    Topics: Adolescent; Adult; Aged; Anemia, Hemolytic, Autoimmune; Antimetabolites; Arthritis, Rheumatoid; Auto

1972
[Treatment of systemic lupus and other collagenoses with antilymphocyte globulins. Apropos of 10 cases].
    La Nouvelle presse medicale, 1972, Sep-09, Volume: 1, Issue:31

    Topics: Adult; Angioedema; Antibodies; Antilymphocyte Serum; Azathioprine; Collagen Diseases; Epistaxis; Fem

1972
The effect of azathioprine on gammaglobulin synthesis in man.
    The Journal of clinical investigation, 1972, Volume: 51, Issue:9

    Topics: Antibodies, Antinuclear; Arthritis; Arthritis, Rheumatoid; Azathioprine; Chromatography, DEAE-Cellul

1972
[Absence of thymus hormone in the serum of NZB and NZBXNZW mice and patients with systemic lupus erythematosus].
    Journal d'urologie et de nephrologie, 1972, Volume: 78, Issue:12

    Topics: Adolescent; Adult; Animals; Azathioprine; Female; Humans; Hybridization, Genetic; Immune Adherence R

1972
Lupus nephritis.
    Verhandlungen der Deutschen Gesellschaft fur Innere Medizin, 1972, Volume: 78

    Topics: Azathioprine; Humans; Lupus Erythematosus, Systemic; Nephritis

1972
Acute lupus pneumonitis: response to azathioprine therapy.
    Chest, 1973, Volume: 63, Issue:1

    Topics: Adolescent; Azathioprine; Female; Humans; Lung Diseases; Lupus Erythematosus, Systemic; Prednisone;

1973
[Lupus erythematosus in childhood].
    Wiener klinische Wochenschrift, 1973, Feb-02, Volume: 85, Issue:5

    Topics: Anemia, Hemolytic, Autoimmune; Autoantibodies; Azathioprine; Child; Chloroquine; Female; Humans; Lup

1973
[Treatment of lupus nephropathy].
    Revista clinica espanola, 1973, Jan-15, Volume: 128, Issue:1

    Topics: Adolescent; Adult; Aged; Azathioprine; Evaluation Studies as Topic; Female; Humans; Lupus Erythemato

1973
Treatment of patients with systemic lupus erythematosus including nephritis with chlorambucil.
    British medical journal, 1973, Apr-28, Volume: 2, Issue:5860

    Topics: Adult; Alopecia; Amenorrhea; Azathioprine; Biopsy; Bone Marrow; Chlorambucil; Cyclophosphamide; Cyst

1973
Treatment of S.L.E. nephritis.
    British medical journal, 1973, May-19, Volume: 2, Issue:5863

    Topics: Azathioprine; Cyclophosphamide; Female; Humans; Kidney Diseases; Lupus Erythematosus, Systemic; Male

1973
[Purine analogues in autoimmune diseases--results of studies lasting several years].
    Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete, 1973, Mar-01, Volume: 28, Issue:5

    Topics: Anemia, Hemolytic, Autoimmune; Autoimmune Diseases; Azathioprine; Humans; Lupus Erythematosus, Syste

1973
Cytostatic treatment of glomerular diseases. I. Effect of azathioprine on serum creatinine and proteinuria. Report from a Copenhagen Study Group of Renal Diseases.
    Acta medica Scandinavica, 1973, Volume: 193, Issue:6

    Topics: Adolescent; Adult; Age Factors; Aged; Azathioprine; Child; Child, Preschool; Creatinine; Female; Glo

1973
Cytostatic treatment of glomerular diseases. II. Effect of azathioprine on serum and urine proteins. Report from a Copenhagen Study Group of Renal Diseases.
    Acta medica Scandinavica, 1973, Volume: 193, Issue:6

    Topics: Adolescent; Adult; Aged; Albuminuria; Azathioprine; Blood Proteins; Child; Child, Preschool; Female;

1973
Evaluation of azathioprine in autoimmune thrombocytopenia and lupus erythematosus.
    Scandinavian journal of haematology, 1973, Volume: 10, Issue:1

    Topics: Adult; Autoimmune Diseases; Azathioprine; Blood Cell Count; Female; Humans; Immunity, Cellular; Immu

1973
Editorial: Cytotoxic drugs and lupus nephritis.
    British medical journal, 1973, Oct-06, Volume: 4, Issue:5883

    Topics: Antineoplastic Agents; Azathioprine; Biopsy; Cyclophosphamide; Heparin; Humans; Kidney; Kidney Disea

1973
[Systemic lupus erythematosus. Etiopathogenesis and immunosuppressive therapy].
    Schweizerische medizinische Wochenschrift, 1973, Oct-06, Volume: 103, Issue:40

    Topics: Adolescent; Adult; Antibody Formation; Azathioprine; Drug Therapy, Combination; Female; Humans; Immu

1973
[Treatment of "collagen and autoimmune" diseases (author's transl)].
    Wiener klinische Wochenschrift, 1973, Nov-23, Volume: 85, Issue:47

    Topics: Adolescent; Adult; Aminobenzoates; Azathioprine; Chloroquine; Cyclophosphamide; Dermatomyositis; Dex

1973
Multiple dermatofibromas in patients with systemic lupus erythematosus on immunosuppressive therapy.
    The New England journal of medicine, 1973, Oct-18, Volume: 289, Issue:16

    Topics: Adult; Azathioprine; Female; Fibroma; Humans; Lupus Erythematosus, Systemic; Neoplasms, Multiple Pri

1973
The course of lupus nephritis: a clinical-pathological correlation of fifty patients.
    Perspectives in nephrology and hypertension, 1973, Volume: 1 Pt 2, Issue:0

    Topics: Adolescent; Adult; Azathioprine; Basement Membrane; Biopsy; Chloroquine; Cyclophosphamide; Female; F

1973
Lupus nephritis: clinical course in relation to treatment.
    Perspectives in nephrology and hypertension, 1973, Volume: 1 Pt 2, Issue:0

    Topics: Adolescent; Adult; Aged; Azathioprine; Child; Creatinine; Cyclophosphamide; Female; Follow-Up Studie

1973
Pregnancy and azathioprine in systemic lupus erythrmatosus.
    American journal of obstetrics and gynecology, 1974, Jan-01, Volume: 118, Issue:1

    Topics: Abnormalities, Drug-Induced; Adult; Azathioprine; Birth Weight; Female; Fetus; Humans; Lupus Erythem

1974
Esophageal motility in systemic lupus erythematosus.
    The American journal of digestive diseases, 1974, Volume: 19, Issue:2

    Topics: Adolescent; Adult; Aged; Aspirin; Azathioprine; Chloroquine; Deglutition Disorders; Dilatation; Drug

1974
Immunosuppression and plasmocytoma of the cervix.
    The Journal of obstetrics and gynaecology of the British Commonwealth, 1974, Volume: 81, Issue:2

    Topics: Adult; Azathioprine; Diabetes Complications; Female; Furosemide; Humans; Immunosuppression Therapy;

1974
Evaluation of clearance studies in lupus nephritis.
    Clinical nephrology, 1974, Volume: 2, Issue:2

    Topics: Adolescent; Adult; Aminohippuric Acids; Azathioprine; Biopsy; Blood Sedimentation; Creatinine; Femal

1974
[Immunosuppressive therapy of collagen diseases. Case report].
    Minerva medica, 1974, Mar-31, Volume: 65, Issue:24

    Topics: Adult; Aged; Arthritis, Rheumatoid; Azathioprine; Collagen Diseases; Female; Humans; Immunosuppressi

1974
[Editorial: Treatment of systemic lupus erythematosus with azathioprine].
    Harefuah, 1974, Apr-01, Volume: 86, Issue:7

    Topics: Azathioprine; Humans; Lupus Erythematosus, Systemic

1974
Vincristine therapy of idiopathic and secondary thrombocytopenias.
    The New England journal of medicine, 1974, Aug-22, Volume: 291, Issue:8

    Topics: Adult; Aged; Azathioprine; Blood Cell Count; Blood Platelets; Bone Marrow Diseases; Child; Cyclophos

1974
Avascular necrosis of bone in systemic lupus erythematosus.
    The Journal of pediatrics, 1974, Volume: 85, Issue:1

    Topics: Adolescent; Adult; Azathioprine; Blood Vessels; Bone and Bones; Bone Diseases; Child; Female; Femur;

1974
Letter: Treatment of acute lupus pneumonitis with azathioprine.
    Chest, 1974, Volume: 66, Issue:2

    Topics: Adult; Azathioprine; Carbon Dioxide; Female; Humans; Lupus Erythematosus, Systemic; Oxygen; Pneumoni

1974
Autoimmune disease.
    The Medical journal of Australia, 1969, Mar-29, Volume: 1, Issue:13

    Topics: Adolescent; Antibodies, Antinuclear; Antigen-Antibody Reactions; Autoantibodies; Autoimmune Diseases

1969
Reactions between anti-nuclear factors and the nuclei of azathioprine-treated subjects.
    International archives of allergy and applied immunology, 1969, Volume: 35, Issue:6

    Topics: Antibodies, Antinuclear; Autoantibodies; Azathioprine; Cell Nucleus; Fluorescent Antibody Technique;

1969
Immunosuppressive therapy of proliferative glomerulonephritis in children.
    American journal of diseases of children (1960), 1969, Volume: 118, Issue:3

    Topics: Adolescent; Autoantibodies; Azathioprine; Child; Complement System Proteins; Creatinine; Female; Flu

1969
Lymphocyte transformation tests in patients under treatment with immunosuppressive drugs.
    Helvetica medica acta, 1969, Volume: 35, Issue:2

    Topics: Adolescent; Adult; Aged; Anemia, Hemolytic, Autoimmune; Arthritis, Rheumatoid; Azathioprine; Female;

1969
[Treatment of chronic connective tissue diseases with cytostatics].
    Minerva medica, 1970, Jul-11, Volume: 61, Issue:55

    Topics: Antineoplastic Agents; Arthritis, Rheumatoid; Azathioprine; Chlorambucil; Chronic Disease; Collagen

1970
Reactivities to horse anti-lymphocyte globulin. II. Serum sickness nephritis with complement alterations in man.
    International archives of allergy and applied immunology, 1970, Volume: 39, Issue:2-3

    Topics: Antilymphocyte Serum; Azathioprine; Complement System Proteins; Fever; Glomerulonephritis; Hemagglut

1970
[Serologic studies of patients under treatment with xenogenous antilymphocyte globulin].
    Klinische Wochenschrift, 1970, Aug-01, Volume: 48, Issue:15

    Topics: Adrenal Cortex Hormones; Agglutination Tests; Animals; Antibodies; Antibody Formation; Antilymphocyt

1970
Azathioprine in steroid-insensitive nephropathy.
    The American journal of medicine, 1970, Volume: 49, Issue:6

    Topics: Adolescent; Adult; Azathioprine; Complement C3; Drug Therapy, Combination; Female; Glomerulonephriti

1970
Azathioprine in connective tissue disorders.
    British medical journal, 1972, Mar-11, Volume: 1, Issue:5801

    Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Azathioprine; Humans; Immunosuppressive Agents; Lup

1972
Effect of azathioprine.
    Archives of internal medicine, 1972, Volume: 129, Issue:3

    Topics: Azathioprine; Drug Combinations; Humans; Kidney Diseases; Lupus Erythematosus, Systemic; Prednisone

1972
Hazard of immunosuppressive therapy.
    British medical journal, 1972, Apr-29, Volume: 2, Issue:5808

    Topics: Adult; Azathioprine; Female; Humans; Lupus Erythematosus, Systemic; Melanoma; Prednisone

1972
Meningitic reactions after azathioprine.
    The New England journal of medicine, 1972, Jun-15, Volume: 286, Issue:24

    Topics: Adult; Azathioprine; Central Nervous System Diseases; Diagnosis, Differential; Female; Humans; Lupus

1972
[Immunosuppressive agents or splenectomy in hematologic autoaggressive diseases? Clinical experiment report].
    Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete, 1972, Mar-15, Volume: 27, Issue:6

    Topics: Adrenal Cortex Hormones; Anemia, Hemolytic, Autoimmune; Anemia, Myelophthisic; Autoimmune Diseases;

1972
Steroid-resistant idiopathic nephrotic syndrome. Results of azathioprine treatment in adults.
    Archives of internal medicine, 1972, Volume: 130, Issue:6

    Topics: Adolescent; Adult; Azathioprine; Female; Glomerulonephritis; Humans; Kidney Diseases; Lupus Erythema

1972
[Case report on the treatment with azathioprine of collagen diseases].
    Das Deutsche Gesundheitswesen, 1971, Jan-01, Volume: 26, Issue:1

    Topics: Adult; Arthritis; Autoimmune Diseases; Azathioprine; Chronic Disease; Collagen Diseases; Dermatomyos

1971
Haloperidol treatment of chorea associated with systemic lupus erythematosus.
    Neurology, 1971, Volume: 21, Issue:9

    Topics: Adult; Azathioprine; Chorea; Female; Haloperidol; Humans; Lupus Erythematosus, Systemic

1971
Effect of azathioprine on renal histology and function in lupus nephritis.
    Archives of internal medicine, 1971, Volume: 128, Issue:4

    Topics: Adolescent; Adult; Azathioprine; Child; Female; Glomerular Filtration Rate; Glomerulonephritis; Huma

1971
[Immunosuppressive therapy of systemic lupus erythematosus].
    Therapeutische Umschau. Revue therapeutique, 1971, Volume: 28, Issue:9

    Topics: Azathioprine; Complement System Proteins; Cyclophosphamide; Female; Humans; Immunosuppressive Agents

1971
When to stop treating lupoid hepatitis.
    Postgraduate medicine, 1971, Volume: 50, Issue:6

    Topics: Azathioprine; Biopsy; Female; Follow-Up Studies; Hepatitis; Humans; Liver Function Tests; Lupus Eryt

1971
Therapy of autoimmune nephropathy with steroids and cytostatics. A follow-up study of 80 patients and of 16 years.
    Acta medica Academiae Scientiarum Hungaricae, 1971, Volume: 28, Issue:1

    Topics: Adolescent; Adult; Aged; Antimalarials; Autoimmune Diseases; Azathioprine; Chlorambucil; Cyclophosph

1971
[Hair changes in immunosuppressive therapy].
    Zeitschrift fur Haut- und Geschlechtskrankheiten, 1971, Volume: 46, Issue:19

    Topics: Antineoplastic Agents; Azathioprine; Chlorambucil; Cyclophosphamide; Hair; Humans; Immunosuppression

1971
Measurement of antibody-producing capacity to flagellin in man. IV. Studies in autoimmune disease, allergy and after azathioprine treatment.
    Clinical and experimental immunology, 1971, Volume: 9, Issue:4

    Topics: Animals; Antibody Formation; Antigens, Bacterial; Arthritis, Rheumatoid; Asthma; Autoimmune Diseases

1971
[Long-term studies on indomethacin in rheumatology with special reference to its use in combination with azathioprine].
    Arzneimittel-Forschung, 1971, Volume: 21, Issue:11

    Topics: Administration, Oral; Arthritis; Arthritis, Rheumatoid; Azathioprine; Chronic Disease; Drug Combinat

1971
[Treatment of systemic lupus erythematosus with antimetabolites. Relations between the clinical course and immunological reactions].
    Helvetica medica acta, 1967, Volume: 34, Issue:1

    Topics: Antibodies, Antinuclear; Autoantibodies; Azathioprine; Complement System Proteins; Humans; Lupus Ery

1967
[Treatment of systemic lupus erythematosus with antimetabolites. Relations between the clinical course and immunological reactions].
    Helvetica medica acta. Supplementum, 1967, May-28, Volume: 47

    Topics: Antibodies, Antinuclear; Antigen-Antibody Reactions; Antimetabolites; Azathioprine; Humans; Immunogl

1967
[Immunodepressive therapy in nephropathies].
    Studii si cercetari de medicina interna, 1969, Volume: 10, Issue:2

    Topics: Azathioprine; Chlorambucil; Collagen Diseases; Diabetic Nephropathies; Glomerulonephritis; Humans; I

1969
[Treatment with immunosuppressive agents in disseminated lupus erythematosus and in some evolutive nephropathies].
    Studii si cercetari de medicina interna, 1969, Volume: 10, Issue:2

    Topics: Azathioprine; Cortisone; Cyclophosphamide; Glomerulonephritis; Humans; Immunosuppressive Agents; Lup

1969
[Research on the effects of azathioprine (Imuran) in rheumatoid arthritis and lupic diseases].
    Medicina interna, 1969, Volume: 21, Issue:5

    Topics: Adult; Arthritis, Rheumatoid; Azathioprine; Humans; Lupus Erythematosus, Systemic; Middle Aged; Pred

1969
Systemic lupus erythematosus with nodular lesions.
    Archives of dermatology, 1969, Volume: 100, Issue:5

    Topics: Adult; Azathioprine; Electrophoresis; Humans; Lupus Erythematosus, Systemic; Male; Prednisone; Prote

1969
Systemic lupus erythematosus.
    California medicine, 1969, Volume: 111, Issue:6

    Topics: Adolescent; Aged; Animals; Antigen-Antibody Reactions; Arthritis, Rheumatoid; Azathioprine; Cortison

1969
[Results of immunosuppressive treatment of visceral lupus erythematosus].
    Polski tygodnik lekarski (Warsaw, Poland : 1960), 1969, Oct-06, Volume: 24, Issue:40

    Topics: Adolescent; Adult; Aged; Azathioprine; Drug Hypersensitivity; Female; Humans; Immunosuppressive Agen

1969
[Multiple vascular disorders in a patient with visceral lupus erythematosus].
    Bulletin de la Societe francaise de dermatologie et de syphiligraphie, 1969, Volume: 76, Issue:4

    Topics: Adult; Azathioprine; Female; Humans; Lupus Erythematosus, Systemic; Phlebitis; Raynaud Disease; Rena

1969
[New treatment possibilities of nephritis in generalized lupus erythematosus].
    Monatsschrift fur Kinderheilkunde, 1969, Volume: 117, Issue:4

    Topics: Adolescent; Azathioprine; Female; Humans; Lupus Erythematosus, Systemic; Nephritis; Prednisone

1969
[Immunosuppressive treatment of collagen diseases].
    Therapeutische Umschau. Revue therapeutique, 1969, Volume: 26, Issue:12

    Topics: Arthritis, Rheumatoid; Azathioprine; Chlorambucil; Collagen Diseases; Cyclophosphamide; Dermatomyosi

1969
Antilymphocyte antisera in immunologically mediated renal disease.
    JAMA, 1969, Nov-10, Volume: 210, Issue:6

    Topics: Adolescent; Adrenal Cortex Hormones; Animals; Anti-Glomerular Basement Membrane Disease; Antilymphoc

1969
[Lymphocyte transformation during immunosuppressive therapy of lupus erythematosus visceralis].
    Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete, 1969, Jan-01, Volume: 24, Issue:1

    Topics: Adult; Arthritis, Rheumatoid; Azathioprine; Humans; Immunosuppressive Agents; Lupus Erythematosus, S

1969
Treatment of lupus nephritis with azathioprine.
    Archives of internal medicine, 1970, Volume: 125, Issue:2

    Topics: Adolescent; Adult; Autoimmune Diseases; Azathioprine; Female; Humans; Lupus Erythematosus, Systemic;

1970
Preliminary results of azathioprine therapy in severe rheumatic disease.
    Annals of the rheumatic diseases, 1970, Volume: 29, Issue:2

    Topics: Adult; Aged; Anemia; Arthritis, Rheumatoid; Azathioprine; Female; Humans; Lupus Erythematosus, Syste

1970
[Practical use of immunosuppressive and cytostatic drugs in dermatological diseases].
    Minerva medica, 1970, Jul-11, Volume: 61, Issue:55

    Topics: Antineoplastic Agents; Azathioprine; Condylomata Acuminata; Fluorouracil; Humans; Immunosuppressive

1970
[Systemic lupus erythematosus and glomerulonephritis treated with Imuran (azathioprine) in 2 children].
    Ceskoslovenska pediatrie, 1970, Volume: 25, Issue:5

    Topics: Adolescent; Azathioprine; Child; Female; Glomerulonephritis; Humans; Lupus Erythematosus, Systemic;

1970
[Lupoid hepatitis in elderly women treated with imuran and 6-mercaptopurine].
    Terapevticheskii arkhiv, 1970, Volume: 42, Issue:1

    Topics: Azathioprine; Female; Humans; Liver Cirrhosis; Liver Diseases; Lupus Erythematosus, Systemic; Menopa

1970
Endothelial cytoplasmic inclusions.
    Archives of pathology, 1970, Volume: 90, Issue:3

    Topics: Azathioprine; Biopsy; Capillaries; Epithelium; Humans; Inclusion Bodies, Viral; Kidney Glomerulus; L

1970
[Collagen diseases].
    Nihon rinsho. Japanese journal of clinical medicine, 1970, Volume: 28, Issue:7

    Topics: Arthritis, Rheumatoid; Azathioprine; Collagen Diseases; Humans; Immunosuppressive Agents; Lupus Eryt

1970
[Immunological indices in diffuse glomerulonephritis during immunodepressive therapy].
    Sovetskaia meditsina, 1970, Volume: 33, Issue:7

    Topics: Adolescent; Adult; Antistreptolysin; Autoantibodies; Autoimmune Diseases; Azathioprine; Child; Chlor

1970
[2 cases of systemic lupus erythematosus treated with immunosuppressive agents].
    Bulletin de la Societe francaise de dermatologie et de syphiligraphie, 1970, Volume: 77, Issue:3

    Topics: Azathioprine; Female; Glucocorticoids; Humans; Immunosuppressive Agents; Lupus Erythematosus, System

1970
[So-called immunosuppressive cytotoxic medication in acute disseminated lupus erythematosus and scleroderma].
    Bulletin de la Societe francaise de dermatologie et de syphiligraphie, 1970, Volume: 77, Issue:3

    Topics: Acute Disease; Adult; Azathioprine; Cyclophosphamide; Female; Glucocorticoids; Humans; Immunosuppres

1970
[Our experiences with Imuran treatment].
    Polski tygodnik lekarski (Warsaw, Poland : 1960), 1971, Mar-08, Volume: 26, Issue:10

    Topics: Aged; Anemia, Hemolytic; Antibody Formation; Arthritis, Rheumatoid; Autoimmune Diseases; Azathioprin

1971
[Rheumatoid arthritis and circulating antifactor 8 anticoagulant of immunoglobulin (IgG) nature. Apropos of a case treated with azathioprine].
    Revue du rhumatisme et des maladies osteo-articulaires, 1971, Volume: 38, Issue:3

    Topics: Aged; Antibodies; Anticoagulants; Arthritis, Rheumatoid; Autoimmune Diseases; Azathioprine; Factor V

1971
[Immunosuppressive therapy in autoimmune diseases].
    Das Deutsche Gesundheitswesen, 1971, Mar-25, Volume: 26, Issue:13

    Topics: Anemia, Hemolytic; Antineoplastic Agents; Autoimmune Diseases; Azathioprine; Collagen Diseases; Huma

1971
Antibodies to DNA in childhood systemic lupus erythematosus.
    The Journal of pediatrics, 1971, Volume: 78, Issue:6

    Topics: Adolescent; Antibodies; Arthritis, Juvenile; Azathioprine; Carbon Isotopes; Child; Child, Preschool;

1971
Identical 3-year-old twins with disseminated lupus erythematosus: one with nephrosis and one with nephritis.
    Arthritis and rheumatism, 1968, Volume: 11, Issue:1

    Topics: Azathioprine; Biopsy; Child, Preschool; Chloroquine; Diseases in Twins; Female; Humans; Kidney; Late

1968
The development of lymphomas in mice with autoimmune disorders treated with azathioprine.
    Blood, 1968, Volume: 31, Issue:3

    Topics: Animals; Autoimmune Diseases; Azathioprine; Female; Injections, Intramuscular; Lupus Erythematosus,

1968
Chromosomes in patients treated with Imuran.
    Humangenetik, 1968, Volume: 6, Issue:1

    Topics: Azathioprine; Chromosome Aberrations; Female; Glomerulonephritis; Hepatitis; Humans; Lupus Erythemat

1968
Thymic size in systemic lupus erythematosus. Roentgenological assessment.
    Archives of internal medicine, 1969, Volume: 124, Issue:1

    Topics: Adolescent; Adult; Age Factors; Azathioprine; Female; Humans; Lupus Erythematosus, Systemic; Male; M

1969
[Transformation of lymphocytes during immunosuppressive therapy in lupus erythematosus visceralis].
    Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete, 1969, May-15, Volume: 24, Issue:10

    Topics: Adult; Aged; Arthritis, Rheumatoid; Azathioprine; Culture Techniques; Humans; Immunosuppressive Agen

1969
Systemic lupus erythematosus in pregnancy treated with azathioprine.
    Proceedings of the Royal Society of Medicine, 1966, Volume: 59, Issue:9

    Topics: Adult; Azathioprine; Bone Marrow; Female; Humans; Lupus Erythematosus, Systemic; Pregnancy; Pregnanc

1966